assay_id,assay_organism,tid,chembl_id,variant_id,src_id,bao_format,assay_type,assay_tax_id,relationship_type,curated_by,doc_id,description,assay_test_type,assay_category,assay_strain,assay_tissue
1,,12052,CHEMBL615117,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,
2,,22226,CHEMBL615118,,1,BAO_0000219,F,,U,Autocuration,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,
3,,22226,CHEMBL615119,,1,BAO_0000019,B,,U,Autocuration,15453,,,,,
4,Bos taurus,104729,CHEMBL615120,,1,BAO_0000249,B,9913.0,H,Autocuration,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,,
5,Homo sapiens,80001,CHEMBL615121,,1,BAO_0000219,F,9606.0,N,Intermediate,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,,
6,Homo sapiens,80001,CHEMBL615122,,1,BAO_0000219,F,9606.0,N,Intermediate,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,,,
7,Mus musculus,80001,CHEMBL615123,,1,BAO_0000219,F,10090.0,N,Intermediate,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,,,
8,Homo sapiens,80001,CHEMBL615124,,1,BAO_0000219,F,9606.0,N,Expert,17774,In vitro cell cytotoxicity was determined against 143B cell line,,,,
9,Homo sapiens,80001,CHEMBL615125,,1,BAO_0000219,F,9606.0,N,Intermediate,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,,,
10,Homo sapiens,80001,CHEMBL615126,,1,BAO_0000219,F,9606.0,N,Intermediate,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,,
11,Homo sapiens,80001,CHEMBL615127,,1,BAO_0000219,F,9606.0,N,Intermediate,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,,,
12,Homo sapiens,80001,CHEMBL615128,,1,BAO_0000219,F,9606.0,N,Expert,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,,,
13,Staphylococcus aureus,50185,CHEMBL857900,,1,BAO_0000218,F,1280.0,N,Intermediate,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,
14,Staphylococcus aureus,50185,CHEMBL615129,,1,BAO_0000218,F,1280.0,N,Intermediate,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,
15,Staphylococcus aureus,50185,CHEMBL615130,,1,BAO_0000218,F,1280.0,N,Intermediate,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,
16,Staphylococcus aureus,50185,CHEMBL615131,,1,BAO_0000218,F,1280.0,N,Intermediate,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,
17,Rattus norvegicus,100122,CHEMBL884521,,1,BAO_0000357,A,10116.0,D,Expert,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,,
18,,12054,CHEMBL615132,,1,BAO_0000357,B,,H,Autocuration,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,
19,,12054,CHEMBL615133,,1,BAO_0000019,B,,H,Autocuration,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,
20,,12054,CHEMBL615134,,1,BAO_0000357,B,,H,Autocuration,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,
21,,12054,CHEMBL615135,,1,BAO_0000357,B,,H,Autocuration,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,
22,,12054,CHEMBL615136,,1,BAO_0000357,B,,H,Autocuration,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,
23,,12054,CHEMBL615137,,1,BAO_0000357,B,,H,Autocuration,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,
24,,12054,CHEMBL615138,,1,BAO_0000357,B,,H,Autocuration,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,
25,,22226,CHEMBL836324,,1,BAO_0000219,B,,U,Autocuration,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,
26,Oryctolagus cuniculus,12054,CHEMBL615139,,1,BAO_0000357,B,9986.0,H,Autocuration,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,,
27,Oryctolagus cuniculus,12054,CHEMBL615140,,1,BAO_0000357,B,9986.0,H,Autocuration,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,,
28,,12426,CHEMBL615141,,1,BAO_0000219,B,,H,Autocuration,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,
29,soya bean,12054,CHEMBL615142,,1,BAO_0000357,B,3847.0,H,Autocuration,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,,
30,Glycine max,12054,CHEMBL615143,,1,BAO_0000357,B,3847.0,H,Autocuration,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,,
31,Glycine max,12054,CHEMBL615144,,1,BAO_0000357,B,3847.0,H,Autocuration,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,,
32,Glycine max,12054,CHEMBL872867,,1,BAO_0000357,B,3847.0,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,,
33,Glycine max,12054,CHEMBL615145,,1,BAO_0000357,B,3847.0,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,,
34,Glycine max,12054,CHEMBL615146,,1,BAO_0000357,B,3847.0,H,Autocuration,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,,
35,Glycine max,12054,CHEMBL615147,,1,BAO_0000357,B,3847.0,H,Autocuration,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,,
36,Rattus norvegicus,22226,CHEMBL615148,,1,BAO_0000019,A,10116.0,U,Autocuration,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,,
37,Escherichia coli,22226,CHEMBL615149,,1,BAO_0000019,B,562.0,U,Autocuration,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,,
38,,22226,CHEMBL615150,,1,BAO_0000019,B,,U,Autocuration,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,
39,,22222,CHEMBL615151,,1,BAO_0000225,B,,M,Intermediate,3782,Dissociation constant towards 16S rRNA construct A,,,,
40,,22222,CHEMBL615152,,1,BAO_0000225,B,,M,Intermediate,3782,Dissociation constant towards 16S rRNA construct B,,,,
41,Escherichia coli,100263,CHEMBL615153,,1,BAO_0000225,B,562.0,M,Expert,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,,
42,Escherichia coli,100263,CHEMBL615154,,1,BAO_0000225,B,562.0,M,Expert,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,,
43,,13053,CHEMBL615155,,1,BAO_0000019,B,,H,Autocuration,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,
44,,13053,CHEMBL615156,,1,BAO_0000019,B,,H,Autocuration,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,
45,Homo sapiens,20001,CHEMBL615157,,1,BAO_0000019,B,9606.0,H,Autocuration,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,,
46,Homo sapiens,20001,CHEMBL615158,,1,BAO_0000019,B,9606.0,H,Autocuration,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,,
47,Rattus norvegicus,12971,CHEMBL615159,,1,BAO_0000019,B,10116.0,D,Expert,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,,
48,Rattus norvegicus,12971,CHEMBL615172,,1,BAO_0000019,B,10116.0,D,Expert,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,,
49,Rattus norvegicus,12971,CHEMBL615173,,1,BAO_0000019,B,10116.0,D,Expert,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,,
50,Rattus norvegicus,12971,CHEMBL615174,,1,BAO_0000019,B,10116.0,D,Expert,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,,
51,,13053,CHEMBL884518,,1,BAO_0000019,B,,H,Autocuration,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,
52,,11512,CHEMBL615175,,1,BAO_0000357,B,,H,Autocuration,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,
53,,11512,CHEMBL615176,,1,BAO_0000357,B,,H,Autocuration,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,
54,,11512,CHEMBL615177,,1,BAO_0000357,B,,H,Autocuration,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,
55,Rattus norvegicus,104740,CHEMBL615178,,1,BAO_0000249,B,10116.0,D,Autocuration,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,,
56,Homo sapiens,80002,CHEMBL615179,,1,BAO_0000219,F,9606.0,N,Intermediate,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,,,
57,Rattus norvegicus,104835,CHEMBL615180,,1,BAO_0000219,F,10116.0,D,Autocuration,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,,
58,Rattus norvegicus,104821,CHEMBL615181,,1,BAO_0000219,F,10116.0,D,Autocuration,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,,
59,Rattus norvegicus,104848,CHEMBL615182,,1,BAO_0000219,F,10116.0,D,Autocuration,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,,
60,Homo sapiens,80002,CHEMBL615183,,1,BAO_0000219,F,9606.0,N,Expert,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,,,
61,Homo sapiens,80002,CHEMBL615184,,1,BAO_0000219,F,9606.0,N,Intermediate,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,,,
62,Homo sapiens,80002,CHEMBL615185,,1,BAO_0000219,F,9606.0,N,Intermediate,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,,,,
63,Homo sapiens,80002,CHEMBL615186,,1,BAO_0000219,F,9606.0,N,Intermediate,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,,,
64,Homo sapiens,80002,CHEMBL615187,,1,BAO_0000219,F,9606.0,N,Intermediate,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,,,,
65,Homo sapiens,80002,CHEMBL885343,,1,BAO_0000219,F,9606.0,N,Expert,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,,,
66,Homo sapiens,80002,CHEMBL615188,,1,BAO_0000219,F,9606.0,N,Intermediate,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,,,
67,Homo sapiens,80002,CHEMBL615189,,1,BAO_0000219,F,9606.0,N,Intermediate,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,,,
68,Homo sapiens,80002,CHEMBL615190,,1,BAO_0000219,F,9606.0,N,Intermediate,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,,,
69,Homo sapiens,80002,CHEMBL615191,,1,BAO_0000219,F,9606.0,N,Intermediate,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,,,,
70,Homo sapiens,80002,CHEMBL615192,,1,BAO_0000219,F,9606.0,N,Expert,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,,,
71,Homo sapiens,80002,CHEMBL827083,,1,BAO_0000219,F,9606.0,N,Expert,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,,,
72,Homo sapiens,80002,CHEMBL615193,,1,BAO_0000219,F,9606.0,N,Expert,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,,,
73,Homo sapiens,80002,CHEMBL615194,,1,BAO_0000219,F,9606.0,N,Intermediate,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,,,
74,Homo sapiens,80002,CHEMBL615195,,1,BAO_0000219,F,9606.0,N,Intermediate,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,,,
75,Homo sapiens,80002,CHEMBL615196,,1,BAO_0000219,F,9606.0,N,Intermediate,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,,,
76,Homo sapiens,81072,CHEMBL615197,,1,BAO_0000219,F,9606.0,N,Intermediate,17721,Inhibitory concentration against Jurkat cells,,,,
77,,22226,CHEMBL615198,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,
78,Rattus norvegicus,100121,CHEMBL615199,,1,BAO_0000357,A,10116.0,D,Expert,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,,
79,,11231,CHEMBL615200,,1,BAO_0000357,B,,H,Expert,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,
80,,11231,CHEMBL615201,,1,BAO_0000357,B,,H,Expert,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,
81,,11231,CHEMBL615202,,1,BAO_0000357,B,,H,Expert,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,
82,Candida albicans,11231,CHEMBL615203,,1,BAO_0000251,B,5476.0,H,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,,
83,Candida albicans,11231,CHEMBL615204,,1,BAO_0000251,B,5476.0,H,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,,
84,Saccharomyces cerevisiae,11231,CHEMBL615205,,1,BAO_0000251,B,4932.0,H,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,,
85,Saccharomyces cerevisiae,11231,CHEMBL615206,,1,BAO_0000251,B,4932.0,H,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,,
86,Sus scrofa,12083,CHEMBL615207,,1,BAO_0000251,B,9823.0,H,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,,Liver
87,Rattus norvegicus,11231,CHEMBL827084,,1,BAO_0000019,B,10116.0,H,Autocuration,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,,
88,Rattus norvegicus,11231,CHEMBL615208,,1,BAO_0000019,B,10116.0,H,Autocuration,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,,
89,Rattus norvegicus,11231,CHEMBL615209,,1,BAO_0000019,B,10116.0,H,Autocuration,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,,
90,Rattus norvegicus,12083,CHEMBL615210,,1,BAO_0000251,B,10116.0,D,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,,Liver
91,Rattus norvegicus,12083,CHEMBL615211,,1,BAO_0000251,B,10116.0,D,Autocuration,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,,Liver
92,Rattus norvegicus,12083,CHEMBL615212,,1,BAO_0000251,B,10116.0,D,Autocuration,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,,Liver
93,,11377,CHEMBL615213,,1,BAO_0000357,B,,H,Expert,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,
94,,11377,CHEMBL615273,,1,BAO_0000357,B,,H,Expert,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,
95,Homo sapiens,81020,CHEMBL615274,,1,BAO_0000219,F,9606.0,N,Expert,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,,
96,Homo sapiens,81020,CHEMBL615275,,1,BAO_0000219,F,9606.0,N,Intermediate,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,,,
97,Homo sapiens,81020,CHEMBL615276,,1,BAO_0000219,F,9606.0,N,Intermediate,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,,,
98,Homo sapiens,81020,CHEMBL615277,,1,BAO_0000219,F,9606.0,N,Intermediate,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,,,
99,Homo sapiens,81020,CHEMBL615326,,1,BAO_0000219,F,9606.0,N,Intermediate,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,,,
100,Hepatitis B virus,50606,CHEMBL883130,,1,BAO_0000218,F,10407.0,N,Expert,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,,
101,Homo sapiens,81020,CHEMBL884519,,1,BAO_0000219,F,9606.0,N,Intermediate,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,,,
102,Homo sapiens,81020,CHEMBL615327,,1,BAO_0000219,F,9606.0,N,Intermediate,1717,Concentration required to inhibit 50% of 2.2.15 cell line,,,,
103,Homo sapiens,81020,CHEMBL615328,,1,BAO_0000219,A,9606.0,N,Intermediate,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,,,
104,Homo sapiens,50587,CHEMBL615329,,1,BAO_0000218,F,9606.0,N,Intermediate,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,,
105,Homo sapiens,50587,CHEMBL615330,,1,BAO_0000218,F,9606.0,N,Intermediate,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,,
106,Hepatitis B virus,50606,CHEMBL615331,,1,BAO_0000218,F,10407.0,N,Expert,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,,
107,Homo sapiens,50587,CHEMBL615332,,1,BAO_0000218,F,9606.0,N,Intermediate,1593,In vitro anti-HBV activity in 2.2.15 cells,,,,
108,Homo sapiens,50587,CHEMBL615333,,1,BAO_0000218,F,9606.0,N,Intermediate,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,,
109,Homo sapiens,50587,CHEMBL615334,,1,BAO_0000218,F,9606.0,N,Intermediate,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,,
110,Homo sapiens,50587,CHEMBL615335,,1,BAO_0000218,F,9606.0,N,Intermediate,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,,
111,Homo sapiens,50587,CHEMBL615336,,1,BAO_0000218,F,9606.0,N,Intermediate,1593,Cytotoxicity in 2.2.15 cells,,,,
112,Homo sapiens,50587,CHEMBL615337,,1,BAO_0000218,F,9606.0,N,Intermediate,1593,Cytotoxicity in 2.2.15 cells; Not determined,,,,
113,Homo sapiens,50587,CHEMBL615338,,1,BAO_0000218,F,9606.0,N,Intermediate,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,,
114,Homo sapiens,50587,CHEMBL615339,,1,BAO_0000218,F,9606.0,N,Intermediate,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,,
115,Homo sapiens,50587,CHEMBL615340,,1,BAO_0000218,F,9606.0,N,Intermediate,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,,
116,Homo sapiens,81020,CHEMBL615341,,1,BAO_0000219,F,9606.0,N,Intermediate,14764,Antiviral activity against HBV was determined in 2.215 cell line,,,,
117,Homo sapiens,22226,CHEMBL615342,,1,BAO_0000251,B,9606.0,U,Autocuration,6531,Inhibition of 20-HETE synthesis in human renal microsomes,,,,
118,,22226,CHEMBL615343,,1,BAO_0000019,B,,U,Autocuration,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,
119,Homo sapiens,80612,CHEMBL615344,,1,BAO_0000219,F,9606.0,N,Intermediate,17072,Inhibitory concentration against 2008 (ovarian) cells,,,,
120,Homo sapiens,80612,CHEMBL615345,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,,,
121,Homo sapiens,80612,CHEMBL615346,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,,,
122,Homo sapiens,80612,CHEMBL615347,,1,BAO_0000219,F,9606.0,N,Intermediate,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,,,
123,Homo sapiens,80612,CHEMBL615348,,1,BAO_0000219,F,9606.0,N,Intermediate,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,,,
124,Homo sapiens,80613,CHEMBL827085,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 2008/R ovarian cancer cell line,,,,
125,Homo sapiens,80613,CHEMBL615349,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,,,
126,Homo sapiens,80614,CHEMBL615350,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 2008/S ovarian cancer cell line,,,,
127,Homo sapiens,80614,CHEMBL615351,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,,,
128,Homo sapiens,100256,CHEMBL615352,,1,BAO_0000220,B,9606.0,S,Expert,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,,
129,Homo sapiens,100256,CHEMBL615353,,1,BAO_0000220,B,9606.0,S,Intermediate,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,,
130,,100256,CHEMBL615354,,1,BAO_0000220,B,,S,Expert,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,
131,,100256,CHEMBL615355,,1,BAO_0000220,B,,S,Expert,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,
132,,100256,CHEMBL615356,,1,BAO_0000220,B,,S,Intermediate,3260,Inhibitory activity against 20S proteosome,,,,
133,Homo sapiens,22226,CHEMBL615357,,1,BAO_0000019,B,9606.0,U,Autocuration,3451,Compound was tested for inhibitory activity against tryptase,,,,
134,Homo sapiens,81020,CHEMBL615358,,1,BAO_0000219,F,9606.0,N,Intermediate,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,,,
135,Homo sapiens,81020,CHEMBL827086,,1,BAO_0000219,F,9606.0,N,Intermediate,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,,,
136,,22226,CHEMBL615359,,1,BAO_0000019,B,,U,Autocuration,3676,Compound was tested for the inhibition of Alpha-glucosidase,,,,
137,,235,CHEMBL615360,,1,BAO_0000357,B,,H,Autocuration,6043,Inhibitory concentration against human neutrophil elastase (HNE),,,,
138,Rattus norvegicus,22226,CHEMBL615361,,1,BAO_0000218,F,10116.0,U,Autocuration,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,,Heart
139,,19640,CHEMBL615362,,1,BAO_0000019,F,,H,Autocuration,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
140,,19640,CHEMBL615363,,1,BAO_0000019,F,,H,Expert,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
141,,19640,CHEMBL615364,,1,BAO_0000357,B,,H,Autocuration,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
142,,19640,CHEMBL615365,,1,BAO_0000019,F,,H,Expert,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,
143,Mus musculus,80360,CHEMBL615366,,1,BAO_0000219,F,10090.0,N,Intermediate,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,,,
144,Mus musculus,80360,CHEMBL615367,,1,BAO_0000219,F,10090.0,N,Intermediate,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,,,
145,Homo sapiens,80384,CHEMBL615368,,1,BAO_0000219,F,9606.0,N,Intermediate,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,,,
146,Ovis aries,22226,CHEMBL615369,,1,BAO_0000019,F,9940.0,U,Autocuration,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,,
147,Ovis aries,22226,CHEMBL615370,,1,BAO_0000019,F,9940.0,U,Autocuration,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,,
148,,191,CHEMBL615673,,1,BAO_0000357,B,,H,Autocuration,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,
149,Homo sapiens,22226,CHEMBL615674,,1,BAO_0000019,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,,
150,Homo sapiens,22226,CHEMBL615675,,1,BAO_0000019,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,,
151,Homo sapiens,22226,CHEMBL615676,,1,BAO_0000219,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,,,
152,Homo sapiens,22226,CHEMBL615677,,1,BAO_0000219,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,,,
153,Homo sapiens,22226,CHEMBL615678,,1,BAO_0000219,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,,,
154,Homo sapiens,22226,CHEMBL615679,,1,BAO_0000219,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,,,
155,Homo sapiens,22226,CHEMBL615680,,1,BAO_0000019,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,,
156,Homo sapiens,22226,CHEMBL615681,,1,BAO_0000019,F,9606.0,U,Autocuration,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,,
157,,104290,CHEMBL857972,,1,BAO_0000249,B,,H,Autocuration,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,
158,Streptococcus pyogenes,50264,CHEMBL857899,,1,BAO_0000218,F,1314.0,N,Intermediate,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,,
159,Human herpesvirus 3,50527,CHEMBL615371,,1,BAO_0000218,F,10335.0,N,Intermediate,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,,
160,vericilla zoster virus,50527,CHEMBL615372,,1,BAO_0000218,F,10335.0,N,Expert,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,,,
161,vericilla zoster virus,50527,CHEMBL615373,,1,BAO_0000218,F,10335.0,N,Intermediate,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,,,,
162,vericilla zoster virus,50527,CHEMBL615374,,1,BAO_0000218,F,10335.0,N,Intermediate,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,,,,
163,escherichia cloac,50145,CHEMBL615375,,1,BAO_0000218,F,561.0,N,Intermediate,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,,
164,,22226,CHEMBL615376,,1,BAO_0000019,B,,U,Autocuration,9707,Ratio of Ki at A2 to Ki at A1 receptors,,,,
165,Candida albicans,11143,CHEMBL615377,,1,BAO_0000249,B,5476.0,H,Expert,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,,
166,Candida glabrata CBS 138,18077,CHEMBL615378,,1,BAO_0000357,B,284593.0,H,Expert,2205,"Inhibition of 1,3-beta-glucan synthase",,,,
167,Homo sapiens,80609,CHEMBL615379,,1,BAO_0000219,F,9606.0,N,Intermediate,11900,Inhibition of growth of 1-87 human tumor cell line,,,,
168,Rattus norvegicus,12166,CHEMBL615380,,1,BAO_0000219,B,10116.0,D,Expert,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,,
169,Glycine max,100171,CHEMBL615381,,1,BAO_0000357,B,3847.0,D,Autocuration,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,,
170,Glycine max,100171,CHEMBL615382,,1,BAO_0000357,B,3847.0,D,Autocuration,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,,
171,Glycine max,100171,CHEMBL615383,,1,BAO_0000357,B,3847.0,D,Autocuration,16474,% inhibition against soybean 1-lipoxygenase (SLO),,,,
172,Glycine max,100171,CHEMBL615384,,1,BAO_0000357,B,3847.0,D,Autocuration,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,,
173,Glycine max,100171,CHEMBL615385,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,,
174,Glycine max,100171,CHEMBL615386,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,,
175,Glycine max,100171,CHEMBL615387,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,,
176,Glycine max,100171,CHEMBL615388,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,,
177,Glycine max,100171,CHEMBL615214,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,,
178,Glycine max,100171,CHEMBL827087,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,,
179,Glycine max,100171,CHEMBL615215,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,,
180,Glycine max,100171,CHEMBL615216,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,,
181,Glycine max,100171,CHEMBL615217,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,,
182,Glycine max,100171,CHEMBL615218,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,,
183,Glycine max,100171,CHEMBL615219,,1,BAO_0000357,B,3847.0,D,Autocuration,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,,
184,Mus musculus,22226,CHEMBL615220,,1,BAO_0000019,B,10090.0,U,Autocuration,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,,
185,Mus musculus,80049,CHEMBL615221,,1,BAO_0000219,F,10090.0,N,Intermediate,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,,,
186,,22226,CHEMBL615222,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,
187,,11489,CHEMBL615223,,1,BAO_0000357,B,,H,Autocuration,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,
188,,11862,CHEMBL615224,,1,BAO_0000357,B,,H,Autocuration,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,
189,,11862,CHEMBL615225,,1,BAO_0000357,B,,H,Autocuration,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,
190,,11489,CHEMBL615226,,1,BAO_0000357,B,,H,Autocuration,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,
191,,11862,CHEMBL615227,,1,BAO_0000357,B,,H,Autocuration,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,
192,Bos taurus,12347,CHEMBL615228,,1,BAO_0000019,F,9913.0,D,Expert,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,,
193,Rattus norvegicus,100120,CHEMBL615229,,1,BAO_0000357,B,10116.0,D,Expert,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,,
194,Rattus norvegicus,100120,CHEMBL615230,,1,BAO_0000357,B,10116.0,D,Expert,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,,Adrenal gland
195,Rattus norvegicus,100120,CHEMBL615231,,1,BAO_0000357,B,10116.0,D,Expert,9066,Inhibition of rat adrenal 11-beta-hydroxylase,,,,
196,Rattus norvegicus,100120,CHEMBL884520,,1,BAO_0000357,B,10116.0,D,Expert,8394,Inhibition of rat adrenal 11-beta-hydroxylase,,,,
197,Rattus norvegicus,100120,CHEMBL615232,,1,BAO_0000357,B,10116.0,D,Expert,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,,
198,,10328,CHEMBL615233,,1,BAO_0000019,B,,H,Autocuration,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,
199,,11490,CHEMBL827088,,1,BAO_0000357,B,,H,Autocuration,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,
200,,11490,CHEMBL615234,,1,BAO_0000357,B,,H,Autocuration,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,
201,,11134,CHEMBL615235,,1,BAO_0000019,F,,H,Autocuration,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,
202,,12052,CHEMBL615236,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,
203,,11134,CHEMBL615237,,1,BAO_0000019,B,,H,Autocuration,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,
204,,11134,CHEMBL615238,,1,BAO_0000019,F,,H,Autocuration,12079,Inhibitory concentration against human platelet 12-lipoxygenase,,,,
205,,11134,CHEMBL615239,,1,BAO_0000019,B,,H,Autocuration,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,
206,Homo sapiens,11134,CHEMBL615240,,1,BAO_0000019,F,9606.0,D,Autocuration,12079,Inhibitory concentration against human platelet 12-lipoxygenase,,,,
207,,11835,CHEMBL615241,,1,BAO_0000019,B,,H,Expert,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,
208,,11601,CHEMBL615242,,1,BAO_0000357,B,,H,Expert,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,
209,,11134,CHEMBL615243,,1,BAO_0000019,B,,H,Autocuration,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,
210,,11134,CHEMBL615244,,1,BAO_0000019,B,,H,Autocuration,1630,Inhibitory activity against human platelet 12-lipoxygenase,,,,
211,,11134,CHEMBL615245,,1,BAO_0000019,B,,H,Autocuration,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,
212,,11134,CHEMBL615246,,1,BAO_0000019,B,,H,Autocuration,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,
213,,11134,CHEMBL615247,,1,BAO_0000019,B,,H,Autocuration,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,
214,,11134,CHEMBL615248,,1,BAO_0000019,B,,H,Autocuration,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,
215,,11601,CHEMBL615249,,1,BAO_0000357,B,,H,Autocuration,10091,Inhibitory activity towards porcine 12-lipoxygenase,,,,
216,,11601,CHEMBL615250,,1,BAO_0000357,B,,H,Autocuration,11966,Tested for inhibition against porcine 12-LO,,,,
217,,12052,CHEMBL615251,,1,BAO_0000019,B,,H,Autocuration,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,
218,,12052,CHEMBL615252,,1,BAO_0000019,B,,H,Autocuration,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,
219,,12052,CHEMBL828340,,1,BAO_0000019,B,,H,Expert,10193,In vitro inhibition of rat platelet 12-lipoxygenase,,,,
220,,12052,CHEMBL615253,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,
221,,12052,CHEMBL615254,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,
222,,12052,CHEMBL615255,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,
223,,12052,CHEMBL615256,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,
224,,12052,CHEMBL615257,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,
225,,12052,CHEMBL615258,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,
226,Homo sapiens,80007,CHEMBL615259,,1,BAO_0000219,F,9606.0,N,Intermediate,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,,,
227,Homo sapiens,80007,CHEMBL615260,,1,BAO_0000219,F,9606.0,N,Expert,12989,In vitro antitumor activity against 41M cell line.,,,,
228,Homo sapiens,80007,CHEMBL615261,,1,BAO_0000219,F,9606.0,N,Intermediate,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,,,
229,Homo sapiens,80007,CHEMBL615262,,1,BAO_0000219,F,9606.0,N,Intermediate,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,,,
230,Homo sapiens,80007,CHEMBL615263,,1,BAO_0000219,F,9606.0,N,Expert,12989,In vitro antitumor activity against 41McisR cell line.,,,,
231,Homo sapiens,80007,CHEMBL838393,,1,BAO_0000219,F,9606.0,N,Expert,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,,,
232,Homo sapiens,80007,CHEMBL615264,,1,BAO_0000219,F,9606.0,N,Intermediate,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,,,
233,Homo sapiens,84,CHEMBL615265,,1,BAO_0000357,B,9606.0,D,Expert,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,,
234,Homo sapiens,68,CHEMBL615266,,1,BAO_0000357,B,9606.0,D,Expert,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,
235,,68,CHEMBL615267,,1,BAO_0000357,B,,H,Expert,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,
236,,10201,CHEMBL615268,,1,BAO_0000357,B,,H,Expert,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,
237,,10201,CHEMBL615269,,1,BAO_0000357,B,,H,Expert,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,
238,,10201,CHEMBL615270,,1,BAO_0000357,B,,H,Expert,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,
239,,12220,CHEMBL615271,,1,BAO_0000357,B,,H,Autocuration,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,
240,Escherichia coli,11303,CHEMBL615272,,1,BAO_0000357,B,562.0,H,Autocuration,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,,
241,Escherichia coli,11303,CHEMBL615103,,1,BAO_0000357,B,562.0,H,Autocuration,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,,
242,Escherichia coli,11303,CHEMBL615104,,1,BAO_0000357,B,562.0,H,Autocuration,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,,
243,,12220,CHEMBL615105,,1,BAO_0000357,B,,H,Autocuration,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,
244,,12220,CHEMBL872866,,1,BAO_0000357,B,,H,Autocuration,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,
245,Sus scrofa,11303,CHEMBL615106,,1,BAO_0000357,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,,
246,Sus scrofa,11303,CHEMBL615107,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,,
247,Sus scrofa,11303,CHEMBL615108,,1,BAO_0000357,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,,
248,Sus scrofa,11303,CHEMBL615109,,1,BAO_0000357,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,,
249,Sus scrofa,11303,CHEMBL615110,,1,BAO_0000357,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,,
250,Sus scrofa,11303,CHEMBL840105,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,,
251,Sus scrofa,11303,CHEMBL615111,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,,
252,Sus scrofa,11303,CHEMBL615112,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,,
253,Sus scrofa,11303,CHEMBL615113,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,,
254,Sus scrofa,11303,CHEMBL615114,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,,
255,Sus scrofa,11303,CHEMBL615115,,1,BAO_0000357,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,,
256,Sus scrofa,11303,CHEMBL615116,,1,BAO_0000019,B,9823.0,H,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,,
257,,11303,CHEMBL615698,,1,BAO_0000357,B,,H,Autocuration,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,
258,Sus scrofa,22226,CHEMBL615699,,1,BAO_0000019,B,9823.0,U,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,,
259,Sus scrofa,22226,CHEMBL615700,,1,BAO_0000019,B,9823.0,U,Autocuration,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,,
260,Saccharomyces cerevisiae,100249,CHEMBL615701,,1,BAO_0000357,B,4932.0,H,Expert,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,,
261,Rattus norvegicus,22226,CHEMBL615702,,1,BAO_0000019,B,10116.0,U,Autocuration,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,,
262,Rattus norvegicus,22226,CHEMBL615703,,1,BAO_0000019,B,10116.0,U,Autocuration,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,,
263,Rattus norvegicus,22226,CHEMBL615704,,1,BAO_0000019,B,10116.0,U,Autocuration,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,,
264,,104698,CHEMBL615705,,1,BAO_0000019,F,,H,Autocuration,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,
265,,104698,CHEMBL615706,,1,BAO_0000019,F,,H,Autocuration,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,
266,Cavia porcellus,20033,CHEMBL615707,,1,BAO_0000221,F,10141.0,D,Intermediate,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,,Ileum
267,,10623,CHEMBL615708,,1,BAO_0000019,F,,H,Expert,12211,Stimulatory activity of intragastric pressure was tested in the rat,,,,
268,,121,CHEMBL615709,,1,BAO_0000357,B,,H,Autocuration,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,
269,Rattus norvegicus,22226,CHEMBL615710,,1,BAO_0000218,F,10116.0,U,Autocuration,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,,
270,,12688,CHEMBL615711,,1,BAO_0000019,F,,H,Autocuration,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,
271,Homo sapiens,121,CHEMBL615712,,1,BAO_0000357,B,9606.0,D,Expert,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,,
272,Homo sapiens,121,CHEMBL836325,,1,BAO_0000357,B,9606.0,D,Expert,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,,
273,,12198,CHEMBL615713,,1,BAO_0000019,F,,H,Autocuration,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,
274,,12198,CHEMBL615714,,1,BAO_0000357,B,,H,Autocuration,11863,Inhibition constant of high-affinity 5-HT uptake,,,,
275,,12198,CHEMBL615715,,1,BAO_0000019,F,,H,Autocuration,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,
276,,12198,CHEMBL615716,,1,BAO_0000019,F,,H,Autocuration,11863,Maximum rate was determined for high affinity transport of 5-HT,,,,
277,,104714,CHEMBL615717,,1,BAO_0000019,F,,H,Autocuration,4639,Compound was tested for agonistic activity against 5-HT uptake,,,,
278,,10577,CHEMBL881818,,1,BAO_0000019,B,,H,Expert,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,
279,Bos taurus,105,CHEMBL884540,,1,BAO_0000357,B,9913.0,H,Expert,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,,
280,Rattus norvegicus,104744,CHEMBL615718,,1,BAO_0000224,B,10116.0,D,Autocuration,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,
281,,104744,CHEMBL615719,,1,BAO_0000224,B,,H,Autocuration,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,
282,,104744,CHEMBL615720,,1,BAO_0000249,B,,H,Autocuration,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,
283,,104744,CHEMBL615721,,1,BAO_0000249,B,,H,Autocuration,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,
284,,104744,CHEMBL615722,,1,BAO_0000019,B,,H,Autocuration,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
285,,51,CHEMBL615723,,1,BAO_0000019,F,,H,Autocuration,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,
286,,51,CHEMBL615724,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
287,,51,CHEMBL615725,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
288,,51,CHEMBL615726,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
289,,10576,CHEMBL615727,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),In vivo,,,
290,Cavia porcellus,105570,CHEMBL615728,,1,BAO_0000019,F,10141.0,D,Intermediate,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,,
291,,279,CHEMBL857971,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
292,,107,CHEMBL615729,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,
293,Rattus norvegicus,12687,CHEMBL615730,,1,BAO_0000019,F,10116.0,D,Expert,15363,Efficacy against 5-hydroxytryptamine 2A receptor,,,,
294,,12687,CHEMBL615731,,1,BAO_0000019,F,,H,Expert,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,
295,,12687,CHEMBL615732,,1,BAO_0000019,F,,H,Expert,15329,Relative potency towards 5-HT2A receptor of rat tail artery,,,,
296,,12687,CHEMBL615733,,1,BAO_0000019,F,,H,Expert,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,
297,,12687,CHEMBL615734,,1,BAO_0000019,F,,H,Expert,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,
298,,12687,CHEMBL615735,,1,BAO_0000019,F,,H,Autocuration,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,
299,,12687,CHEMBL615736,,1,BAO_0000019,F,,H,Expert,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,
300,Cavia porcellus,20033,CHEMBL615737,,1,BAO_0000221,F,10141.0,D,Intermediate,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,,Ileum
301,Cavia porcellus,20033,CHEMBL615738,,1,BAO_0000221,F,10141.0,D,Intermediate,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,,Ileum
302,Cavia porcellus,20033,CHEMBL615739,,1,BAO_0000221,F,10141.0,D,Intermediate,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,,Ileum
303,,10623,CHEMBL615278,,1,BAO_0000357,B,,H,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,
304,Rattus norvegicus,10623,CHEMBL615279,,1,BAO_0000019,F,10116.0,D,Expert,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,
305,,168,CHEMBL615280,,1,BAO_0000357,B,,H,Expert,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,
306,Gallus gallus,22226,CHEMBL615281,,1,BAO_0000019,B,9031.0,U,Autocuration,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,,
307,Homo sapiens,22226,CHEMBL615282,,1,BAO_0000019,F,9606.0,U,Autocuration,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,,
308,Homo sapiens,22226,CHEMBL615283,,1,BAO_0000019,F,9606.0,U,Autocuration,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,,
309,Homo sapiens,80156,CHEMBL615284,,1,BAO_0000219,B,9606.0,N,Autocuration,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,,,
310,Homo sapiens,22226,CHEMBL615285,,1,BAO_0000019,B,9606.0,U,Autocuration,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,,
311,Homo sapiens,22226,CHEMBL615286,,1,BAO_0000019,B,9606.0,U,Autocuration,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,,
312,Homo sapiens,104703,CHEMBL615287,,1,BAO_0000219,B,9606.0,D,Autocuration,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,,
313,,100256,CHEMBL615288,,1,BAO_0000220,F,,S,Intermediate,16575,Chymotryptic inhibitory activity against 26S proteasome,,,,
314,,100256,CHEMBL615289,,1,BAO_0000220,B,,S,Intermediate,15407,Inhibitory activity against 26S proteasome degradation of IkB,,,,
315,Homo sapiens,81034,CHEMBL615290,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,,,,
316,Homo sapiens,81034,CHEMBL884522,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 2780/S ovarian cancer cell line,,,,
317,Homo sapiens,22226,CHEMBL615291,,1,BAO_0000019,F,9606.0,U,Autocuration,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,,
318,,22222,CHEMBL615292,,1,BAO_0000225,B,,M,Intermediate,16037,Association constant for binding to AATT 28-mer AATT hairpin,,,,
319,,22222,CHEMBL615293,,1,BAO_0000225,B,,M,Intermediate,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,
320,,22222,CHEMBL615294,,1,BAO_0000225,B,,M,Intermediate,16037,Reaction Rate Parameter for 28-mer AATT hairpin,,,,
321,,22222,CHEMBL615295,,1,BAO_0000225,B,,M,Intermediate,16037,Reaction Rate Parameter for 28-mer AATT hairpin,,,,
322,Homo sapiens,22226,CHEMBL825021,,1,BAO_0000019,F,9606.0,U,Autocuration,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,,
323,Homo sapiens,22226,CHEMBL615296,,1,BAO_0000019,F,9606.0,U,Autocuration,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,,
324,Homo sapiens,22226,CHEMBL615297,,1,BAO_0000019,F,9606.0,U,Autocuration,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,,
325,Cricetulus griseus,22226,CHEMBL615298,,1,BAO_0000019,F,10029.0,U,Autocuration,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,,
326,Cricetulus griseus,22226,CHEMBL615299,,1,BAO_0000019,F,10029.0,U,Autocuration,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,,
327,Cricetulus griseus,22226,CHEMBL615300,,1,BAO_0000019,F,10029.0,U,Autocuration,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,,
328,,241,CHEMBL615301,,1,BAO_0000357,B,,H,Autocuration,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,
329,Homo sapiens,241,CHEMBL615302,,1,BAO_0000357,B,9606.0,D,Expert,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,,
330,Rattus norvegicus,22226,CHEMBL615303,,1,BAO_0000019,B,10116.0,U,Autocuration,9964,Selectivity ratio of ID50 in liver and heart,,,,
331,,12132,CHEMBL615304,,1,BAO_0000019,B,,H,Autocuration,9964,"Selectivity, ratio of relative ID50 in liver and heart",,,,
332,,12132,CHEMBL615305,,1,BAO_0000019,B,,H,Autocuration,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,
333,,12132,CHEMBL615306,,1,BAO_0000218,B,,H,Autocuration,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,
334,,12132,CHEMBL615307,,1,BAO_0000218,B,,H,Autocuration,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,
335,,12132,CHEMBL615308,,1,BAO_0000218,B,,H,Autocuration,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,
336,,12132,CHEMBL615309,,1,BAO_0000218,F,,H,Autocuration,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",In vivo,,,
337,,22226,CHEMBL615310,,1,BAO_0000019,B,,U,Autocuration,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,
338,,12132,CHEMBL615311,,1,BAO_0000019,B,,H,Autocuration,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,
339,Homo sapiens,22226,CHEMBL615312,,1,BAO_0000019,B,9606.0,U,Autocuration,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,,
340,,12132,CHEMBL615313,,1,BAO_0000019,B,,H,Autocuration,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,
341,,12132,CHEMBL615314,,1,BAO_0000019,F,,H,Autocuration,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,
342,,12132,CHEMBL615315,,1,BAO_0000019,B,,H,Autocuration,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,
343,Rattus norvegicus,22226,CHEMBL615316,,1,BAO_0000218,B,10116.0,U,Autocuration,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,,
344,,12132,CHEMBL615317,,1,BAO_0000218,B,,H,Autocuration,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,In vivo,,,
345,,12132,CHEMBL615318,,1,BAO_0000218,B,,H,Autocuration,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,
346,Rattus norvegicus,22226,CHEMBL615319,,1,BAO_0000218,B,10116.0,U,Autocuration,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,,
347,,12132,CHEMBL615320,,1,BAO_0000019,B,,H,Autocuration,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,
348,,12132,CHEMBL615321,,1,BAO_0000019,F,,H,Autocuration,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,
349,Rattus norvegicus,22226,CHEMBL615322,,1,BAO_0000019,B,10116.0,U,Autocuration,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,,
350,Escherichia coli,19690,CHEMBL615323,,1,BAO_0000357,B,562.0,H,Autocuration,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,,
351,Escherichia coli,19690,CHEMBL615407,,1,BAO_0000357,B,562.0,H,Autocuration,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,,
352,Escherichia coli,19690,CHEMBL857267,,1,BAO_0000357,B,562.0,H,Autocuration,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,,
353,Escherichia coli,19690,CHEMBL615408,,1,BAO_0000357,B,562.0,H,Autocuration,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,,
354,,19690,CHEMBL615409,,1,BAO_0000357,B,,H,Autocuration,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,
355,,19690,CHEMBL615410,,1,BAO_0000357,B,,H,Autocuration,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,
356,,19690,CHEMBL615411,,1,BAO_0000357,B,,H,Autocuration,166,Inhibition constant against 3-dehydroquinate synthase,,,,
357,,19690,CHEMBL615412,,1,BAO_0000357,B,,H,Autocuration,166,Association rate constant against 3-dehydroquinate synthase,,,,
358,,19690,CHEMBL615413,,1,BAO_0000357,B,,H,Autocuration,166,Rate constant against 3-dehydroquinate synthase,,,,
359,,22226,CHEMBL615414,,1,BAO_0000019,B,,U,Autocuration,3548,Inhibitory activity against fuc-TVII,,,,
360,Rattus norvegicus,12236,CHEMBL615415,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,,Liver
361,Rattus norvegicus,12236,CHEMBL615416,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,,Liver
362,Rattus norvegicus,12236,CHEMBL615417,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,,Liver
363,Rattus norvegicus,12236,CHEMBL615418,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,,Liver
364,Rattus norvegicus,12236,CHEMBL615419,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,,Liver
365,Rattus norvegicus,12236,CHEMBL615420,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,,Liver
366,Rattus norvegicus,12236,CHEMBL615421,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,,Liver
367,Rattus norvegicus,12236,CHEMBL615422,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,,Liver
368,Rattus norvegicus,12236,CHEMBL615423,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,,Liver
369,Rattus norvegicus,12236,CHEMBL872868,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,,Liver
370,Rattus norvegicus,12236,CHEMBL615424,,1,BAO_0000251,B,10116.0,D,Autocuration,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,,Liver
371,,104832,CHEMBL825022,,1,BAO_0000224,B,,H,Autocuration,3003,Inhibitory activity against 3-phosphoglycerate kinase.,,,,
372,,104832,CHEMBL615425,,1,BAO_0000224,B,,H,Autocuration,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,
373,,104832,CHEMBL615426,,1,BAO_0000224,B,,H,Autocuration,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,
374,Homo sapiens,10612,CHEMBL615427,,1,BAO_0000357,B,9606.0,D,Expert,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,,
375,Homo sapiens,80616,CHEMBL615428,,1,BAO_0000219,F,9606.0,N,Intermediate,6072,Cytotoxicity on 3677 melanoma cells,,,,
376,Homo sapiens,80616,CHEMBL615429,,1,BAO_0000219,F,9606.0,N,Intermediate,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,,,
377,Mus musculus,80617,CHEMBL615430,,1,BAO_0000219,F,10090.0,N,Intermediate,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,,,
378,Homo sapiens,22226,CHEMBL615431,,1,BAO_0000019,F,9606.0,U,Intermediate,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,,
379,,22226,CHEMBL615432,,1,BAO_0000218,F,,U,Autocuration,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,,
380,,22226,CHEMBL615433,,1,BAO_0000218,F,,U,Autocuration,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,,
381,Human rhinovirus 14,12464,CHEMBL615434,,1,BAO_0000019,F,12131.0,D,Expert,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,,
382,Human rhinovirus sp.,50085,CHEMBL615435,,1,BAO_0000218,F,169066.0,N,Intermediate,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,,
383,human rhinovirus type 14,50679,CHEMBL615436,,1,BAO_0000218,F,169066.0,N,Intermediate,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,,
384,human rhinovirus type 14,50679,CHEMBL615437,,1,BAO_0000218,F,169066.0,N,Intermediate,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,,
385,Human rhinovirus 14,12464,CHEMBL615438,,1,BAO_0000019,F,12131.0,D,Expert,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,,
386,Human rhinovirus 14,12464,CHEMBL615439,,1,BAO_0000019,F,12131.0,D,Expert,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,,
387,Human rhinovirus 14,12464,CHEMBL615440,,1,BAO_0000019,F,12131.0,D,Expert,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,,
388,Human rhinovirus 14,12464,CHEMBL615441,,1,BAO_0000019,F,12131.0,D,Expert,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,,
389,Enterovirus,50665,CHEMBL615641,,1,BAO_0000218,F,12059.0,N,Intermediate,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,,
390,Enterovirus,50665,CHEMBL872065,,1,BAO_0000218,F,12059.0,N,Intermediate,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,,
391,Enterovirus,50665,CHEMBL825023,,1,BAO_0000218,F,12059.0,N,Intermediate,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,,
392,Enterovirus,50665,CHEMBL615642,,1,BAO_0000218,F,12059.0,N,Intermediate,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,,
393,Human rhinovirus B,12464,CHEMBL615643,,1,BAO_0000357,B,147712.0,H,Expert,13748,Inhibition of human rhinovirus 3C protease,,,,
394,Homo sapiens,22226,CHEMBL615644,,1,BAO_0000019,B,9606.0,U,Autocuration,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,,
395,Mus musculus,80619,CHEMBL615645,,1,BAO_0000218,F,10090.0,N,Intermediate,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,,,
396,Mus musculus,80619,CHEMBL615646,,1,BAO_0000218,F,10090.0,N,Intermediate,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,,,
397,Mus musculus,80619,CHEMBL615647,,1,BAO_0000218,F,10090.0,N,Intermediate,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,,,
398,Mus musculus,80619,CHEMBL615648,,1,BAO_0000218,F,10090.0,N,Intermediate,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,,,
399,Mus musculus,80619,CHEMBL615649,,1,BAO_0000218,F,10090.0,N,Intermediate,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,,,
400,Mus musculus,80619,CHEMBL615650,,1,BAO_0000218,F,10090.0,N,Intermediate,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,,,
401,Mus musculus,80620,CHEMBL615651,,1,BAO_0000218,F,10090.0,N,Intermediate,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,,
402,Mus musculus,80620,CHEMBL615652,,1,BAO_0000218,F,10090.0,N,Intermediate,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,,,
403,Mus musculus,80620,CHEMBL615653,,1,BAO_0000218,F,10090.0,N,Expert,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,,,
404,Mus musculus,80620,CHEMBL615654,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,,,
405,Mus musculus,80620,CHEMBL615655,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,,,
406,Mus musculus,80620,CHEMBL825024,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,,,
407,Mus musculus,80620,CHEMBL615656,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,,,
408,Mus musculus,80620,CHEMBL615657,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,,,
409,Mus musculus,80620,CHEMBL615658,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,,,
410,Mus musculus,80620,CHEMBL615659,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,,,
411,Mus musculus,80620,CHEMBL615660,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,,,
412,Mus musculus,80620,CHEMBL615661,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,,
413,Mus musculus,80620,CHEMBL615662,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,,,
414,Mus musculus,80620,CHEMBL615663,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,,,
415,Mus musculus,80620,CHEMBL615664,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,,,
416,Mus musculus,80620,CHEMBL615665,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,,,
417,Mus musculus,80620,CHEMBL615666,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,,,
418,Mus musculus,80620,CHEMBL615667,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,,,
419,Mus musculus,80620,CHEMBL615668,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,,,
420,Mus musculus,80620,CHEMBL615669,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,,,
421,Mus musculus,80620,CHEMBL615670,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,,,
422,Mus musculus,80620,CHEMBL836739,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,,,
423,Mus musculus,80620,CHEMBL615671,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,,,
424,Mus musculus,80620,CHEMBL615672,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,,,
425,Mus musculus,80620,CHEMBL615791,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,,,
426,Mus musculus,80620,CHEMBL615792,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,,,
427,Mus musculus,80620,CHEMBL615793,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,,,
428,Mus musculus,80620,CHEMBL615794,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,,,
429,Mus musculus,80620,CHEMBL615795,,1,BAO_0000219,F,10090.0,N,Intermediate,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,,,
430,Homo sapiens,80621,CHEMBL615590,,1,BAO_0000219,F,9606.0,N,Intermediate,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,,,
431,,22226,CHEMBL615591,,1,BAO_0000218,F,,U,Autocuration,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,
432,,22226,CHEMBL615592,,1,BAO_0000218,F,,U,Autocuration,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,
433,,22226,CHEMBL615593,,1,BAO_0000218,F,,U,Autocuration,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,
434,,22226,CHEMBL615594,,1,BAO_0000218,F,,U,Autocuration,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,
435,Mus musculus,80951,CHEMBL615595,,1,BAO_0000219,F,10090.0,N,Intermediate,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,,
436,Mus musculus,80951,CHEMBL615596,,1,BAO_0000219,F,10090.0,N,Intermediate,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,,,
437,,11169,CHEMBL615597,,1,BAO_0000219,F,,H,Expert,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,,
438,Mus musculus,80951,CHEMBL615598,,1,BAO_0000219,F,10090.0,N,Intermediate,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,,,
439,Mus musculus,80951,CHEMBL615599,,1,BAO_0000219,F,10090.0,N,Intermediate,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,,,
440,Mus musculus,80951,CHEMBL615600,,1,BAO_0000219,F,10090.0,N,Expert,17642,Effective dose against murine 3T3 fibroblasts cells,,,,
441,Mus musculus,80951,CHEMBL615601,,1,BAO_0000219,F,10090.0,N,Expert,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,,,
442,Mus musculus,80951,CHEMBL615602,,1,BAO_0000219,F,10090.0,N,Expert,12340,Cytotoxic effect on 3T3 cells,,,,
443,Mus musculus,80951,CHEMBL615603,,1,BAO_0000219,F,10090.0,N,Expert,12340,Cytotoxic effect on 3T3 cells,,,,
444,Mus musculus,80951,CHEMBL615604,,1,BAO_0000219,F,10090.0,N,Intermediate,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,,,
445,Mus musculus,80951,CHEMBL615605,,1,BAO_0000219,F,10090.0,N,Intermediate,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,,
446,Mus musculus,80951,CHEMBL615606,,1,BAO_0000219,F,10090.0,N,Intermediate,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,,,
447,Mus musculus,80951,CHEMBL884526,,1,BAO_0000219,F,10090.0,N,Expert,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,,,
448,Mus musculus,80951,CHEMBL615607,,1,BAO_0000219,F,10090.0,N,Expert,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,,,
449,Mus musculus,80951,CHEMBL615608,,1,BAO_0000219,F,10090.0,N,Intermediate,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,,,
450,Mus musculus,80951,CHEMBL615609,,1,BAO_0000219,F,10090.0,N,Expert,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,,,
451,Mus musculus,80951,CHEMBL615682,,1,BAO_0000219,F,10090.0,N,Expert,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,,,
452,Mus musculus,80951,CHEMBL615683,,1,BAO_0000219,F,10090.0,N,Intermediate,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,,,
453,Mus musculus,80951,CHEMBL615684,,1,BAO_0000218,F,10090.0,N,Expert,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,,,
454,Mus musculus,104860,CHEMBL615685,,1,BAO_0000219,F,10090.0,D,Autocuration,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,,
455,Mus musculus,80951,CHEMBL615686,,1,BAO_0000219,F,10090.0,N,Expert,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,,,
456,Mus musculus,80951,CHEMBL615687,,1,BAO_0000219,F,10090.0,N,Intermediate,14892,Inhibitory activity against 3T3 cell line,,,,
457,Mus musculus,80951,CHEMBL884523,,1,BAO_0000219,F,10090.0,N,Intermediate,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,,,
458,,11169,CHEMBL615688,,1,BAO_0000019,F,,H,Expert,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,
459,Mus musculus,80951,CHEMBL615689,,1,BAO_0000219,F,10090.0,N,Intermediate,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,,,
460,Mus musculus,80951,CHEMBL615690,,1,BAO_0000219,F,10090.0,N,Intermediate,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,,,
461,,11169,CHEMBL615691,,1,BAO_0000019,F,,H,Expert,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,
462,,11169,CHEMBL615692,,1,BAO_0000019,F,,H,Expert,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,
463,Mus musculus,80951,CHEMBL615693,,1,BAO_0000219,F,10090.0,N,Intermediate,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,,,
464,Mus musculus,80951,CHEMBL615324,,1,BAO_0000219,F,10090.0,N,Expert,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,,,
465,Homo sapiens,9,CHEMBL615325,,1,BAO_0000219,F,9606.0,D,Expert,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,,,
466,Homo sapiens,9,CHEMBL615490,,1,BAO_0000219,F,9606.0,D,Expert,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,,,
467,Homo sapiens,188,CHEMBL615491,,1,BAO_0000219,F,9606.0,D,Expert,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,,,
468,Homo sapiens,188,CHEMBL615492,,1,BAO_0000219,F,9606.0,D,Expert,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,,,
469,Mus musculus,80951,CHEMBL615493,,1,BAO_0000219,F,10090.0,N,Intermediate,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,,,
470,Mus musculus,80951,CHEMBL615494,,1,BAO_0000219,F,10090.0,N,Intermediate,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,,,
471,Mus musculus,80951,CHEMBL615495,,1,BAO_0000219,F,10090.0,N,Intermediate,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,,,
472,Mus musculus,80951,CHEMBL615496,,1,BAO_0000219,F,10090.0,N,Intermediate,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,,,
473,Mus musculus,80951,CHEMBL615497,,1,BAO_0000219,F,10090.0,N,Intermediate,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,,,
474,Mus musculus,80951,CHEMBL615498,,1,BAO_0000219,F,10090.0,N,Expert,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,,,
475,Mus musculus,80951,CHEMBL615499,,1,BAO_0000219,A,10090.0,N,Intermediate,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,,,
476,Mus musculus,80951,CHEMBL835522,,1,BAO_0000219,F,10090.0,N,Expert,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,,,
477,Mus musculus,80951,CHEMBL615500,,1,BAO_0000219,F,10090.0,N,Intermediate,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,,,
478,Mus musculus,80951,CHEMBL615501,,1,BAO_0000219,F,10090.0,N,Intermediate,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,,
479,Mus musculus,80951,CHEMBL615502,,1,BAO_0000219,F,10090.0,N,Intermediate,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,,
480,Mus musculus,80951,CHEMBL615503,,1,BAO_0000219,F,10090.0,N,Intermediate,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,,
481,Mus musculus,80951,CHEMBL615504,,1,BAO_0000219,F,10090.0,N,Intermediate,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,,
482,Mus musculus,80951,CHEMBL615505,,1,BAO_0000219,F,10090.0,N,Intermediate,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,,,
483,Mus musculus,80951,CHEMBL615506,,1,BAO_0000219,F,10090.0,N,Expert,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,,,,
484,Mus musculus,80951,CHEMBL615507,,1,BAO_0000219,F,10090.0,N,Intermediate,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,,,
485,,80006,CHEMBL615508,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,
486,Mus musculus,80006,CHEMBL615509,,1,BAO_0000219,F,10090.0,N,Intermediate,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,,,
487,Mus musculus,80006,CHEMBL615510,,1,BAO_0000219,F,10090.0,N,Intermediate,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,,,
488,Mus musculus,80006,CHEMBL615511,,1,BAO_0000219,F,10090.0,N,Intermediate,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,,,
489,Mus musculus,80006,CHEMBL615512,,1,BAO_0000219,F,10090.0,N,Intermediate,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,,,
490,Mus musculus,80006,CHEMBL615513,,1,BAO_0000218,F,10090.0,N,Intermediate,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,,,
491,Mus musculus,80006,CHEMBL615514,,1,BAO_0000218,F,10090.0,N,Intermediate,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,,,
492,,80006,CHEMBL615515,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,,
493,,80006,CHEMBL615516,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,
494,,80006,CHEMBL615517,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,
495,,80006,CHEMBL615518,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,
496,,80006,CHEMBL615519,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,
497,,80006,CHEMBL615520,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,,
498,,80006,CHEMBL615521,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,,
499,,80006,CHEMBL615522,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,
500,,80006,CHEMBL615523,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,
501,,80006,CHEMBL615524,,1,BAO_0000218,F,,N,Expert,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,
502,,80006,CHEMBL615525,,1,BAO_0000218,F,,N,Expert,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,
503,,80006,CHEMBL615526,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,
504,,80006,CHEMBL615527,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,
505,,80006,CHEMBL615528,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,,
506,,80006,CHEMBL615529,,1,BAO_0000218,F,,N,Expert,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,
507,,80006,CHEMBL615530,,1,BAO_0000218,F,,N,Expert,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,
508,,80006,CHEMBL615531,,1,BAO_0000218,F,,N,Expert,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,
509,,80006,CHEMBL615532,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,
510,,80006,CHEMBL615533,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,
511,,80006,CHEMBL615534,,1,BAO_0000219,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,
512,,80006,CHEMBL615535,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,
513,,80006,CHEMBL615536,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,
514,,80006,CHEMBL615537,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,
515,,80006,CHEMBL615538,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,
516,,80006,CHEMBL836166,,1,BAO_0000218,F,,N,Intermediate,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,
517,,11214,CHEMBL615539,,1,BAO_0000219,F,,H,Expert,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,,
518,Mus musculus,80006,CHEMBL615540,,1,BAO_0000219,F,10090.0,N,Intermediate,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,,,
519,,11214,CHEMBL615541,,1,BAO_0000219,F,,H,Expert,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,,
520,Mus musculus,80006,CHEMBL615542,,1,BAO_0000219,F,10090.0,N,Expert,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,,,
521,Mus musculus,80006,CHEMBL615543,,1,BAO_0000219,F,10090.0,N,Intermediate,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,,,
522,Mus musculus,80006,CHEMBL615544,,1,BAO_0000219,F,10090.0,N,Expert,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,,,
523,Mus musculus,80006,CHEMBL615545,,1,BAO_0000219,F,10090.0,N,Expert,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,,
524,Mus musculus,80006,CHEMBL615546,,1,BAO_0000219,F,10090.0,N,Expert,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,,,
525,Mus musculus,80006,CHEMBL615547,,1,BAO_0000219,F,10090.0,N,Expert,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,,,
526,Mus musculus,80006,CHEMBL615548,,1,BAO_0000219,F,10090.0,N,Expert,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,,,
527,Mus musculus,80006,CHEMBL615549,,1,BAO_0000219,F,10090.0,N,Expert,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,,,
528,Mus musculus,80006,CHEMBL615550,,1,BAO_0000219,F,10090.0,N,Expert,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,,,
529,Rattus norvegicus,80622,CHEMBL615551,,1,BAO_0000219,F,10116.0,N,Intermediate,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,,,,
530,Rattus norvegicus,80622,CHEMBL615552,,1,BAO_0000219,F,10116.0,N,Expert,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,,,
531,Rattus norvegicus,80622,CHEMBL615553,,1,BAO_0000219,F,10116.0,N,Expert,15899,Cytotoxicity in 3Y1 cells.,,,,
532,Rattus norvegicus,80622,CHEMBL615554,,1,BAO_0000219,F,10116.0,N,Expert,15899,Cytostatic effect in 3Y1 cells.,,,,
533,Rattus norvegicus,80622,CHEMBL615555,,1,BAO_0000219,F,10116.0,N,Intermediate,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,,,
534,Rattus norvegicus,80622,CHEMBL615556,,1,BAO_0000219,F,10116.0,N,Expert,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,,,
535,,22226,CHEMBL615557,,1,BAO_0000019,B,,U,Autocuration,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,
536,,22226,CHEMBL615558,,1,BAO_0000019,B,,U,Autocuration,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,
537,,22226,CHEMBL872066,,1,BAO_0000019,B,,U,Autocuration,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,
538,Sus scrofa,11607,CHEMBL615559,,1,BAO_0000019,B,9823.0,D,Expert,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,,
539,,11607,CHEMBL615560,,1,BAO_0000019,B,,H,Autocuration,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,
540,,11607,CHEMBL615561,,1,BAO_0000019,B,,H,Autocuration,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,
541,,11607,CHEMBL857062,,1,BAO_0000019,B,,H,Expert,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,
542,,11607,CHEMBL615562,,1,BAO_0000019,B,,H,Expert,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,
543,,11607,CHEMBL615563,,1,BAO_0000019,B,,H,Autocuration,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,
544,,11607,CHEMBL615564,,1,BAO_0000357,B,,H,Autocuration,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,
545,,11607,CHEMBL615565,,1,BAO_0000019,B,,H,Autocuration,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,
546,,11607,CHEMBL615566,,1,BAO_0000019,B,,H,Autocuration,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,
547,Sus scrofa,11607,CHEMBL615567,,1,BAO_0000019,B,9823.0,D,Expert,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,,
548,,11607,CHEMBL615568,,1,BAO_0000019,B,,H,Autocuration,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,
549,,11607,CHEMBL615569,,1,BAO_0000357,B,,H,Autocuration,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,
550,,11607,CHEMBL615570,,1,BAO_0000019,B,,H,Autocuration,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,
551,,11607,CHEMBL615571,,1,BAO_0000019,B,,H,Autocuration,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,
552,,104733,CHEMBL615572,,1,BAO_0000224,B,,H,Autocuration,6455,Binding affinity against melatonin (MT1) receptor (pC1),,,,
553,,22226,CHEMBL615573,,1,BAO_0000019,B,,U,Autocuration,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,
554,,22226,CHEMBL615574,,1,BAO_0000019,B,,U,Autocuration,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,
555,,22226,CHEMBL615575,,1,BAO_0000019,B,,U,Autocuration,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,
556,,10619,CHEMBL615576,,1,BAO_0000357,B,,H,Autocuration,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,
557,,10619,CHEMBL615577,,1,BAO_0000357,B,,H,Autocuration,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,
558,,51,CHEMBL615578,,1,BAO_0000221,B,,H,Autocuration,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,,Hippocampus
559,,51,CHEMBL615579,,1,BAO_0000357,B,,H,Expert,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,
560,,51,CHEMBL615580,,1,BAO_0000357,B,,H,Expert,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,
561,,51,CHEMBL615581,,1,BAO_0000019,B,,H,Expert,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,
562,,51,CHEMBL615582,,1,BAO_0000221,B,,H,Autocuration,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus
563,,51,CHEMBL615583,,1,BAO_0000221,B,,H,Autocuration,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus
564,,51,CHEMBL615584,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
565,,51,CHEMBL833691,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
566,,51,CHEMBL615585,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
567,,51,CHEMBL615586,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
568,,51,CHEMBL884524,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
569,,51,CHEMBL615587,,1,BAO_0000221,B,,H,Autocuration,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus
570,,51,CHEMBL615588,,1,BAO_0000221,B,,H,Autocuration,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,Hippocampus
571,Rattus norvegicus,10576,CHEMBL615589,,1,BAO_0000249,B,10116.0,D,Expert,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,,
572,Bos taurus,51,CHEMBL615442,,1,BAO_0000221,B,9913.0,H,Expert,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,,Hippocampus
573,,51,CHEMBL615443,,1,BAO_0000221,B,,H,Autocuration,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,,Hippocampus
574,,51,CHEMBL615444,,1,BAO_0000221,B,,H,Autocuration,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,,Hippocampus
575,,51,CHEMBL615445,,1,BAO_0000221,B,,H,Expert,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,,Hippocampus
576,,51,CHEMBL615446,,1,BAO_0000221,B,,H,Autocuration,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,,Hippocampus
577,,51,CHEMBL615447,,1,BAO_0000219,B,,H,Autocuration,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,,
578,,51,CHEMBL615448,,1,BAO_0000221,B,,H,Expert,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus
579,,51,CHEMBL615449,,1,BAO_0000221,B,,H,Expert,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus
580,,51,CHEMBL615450,,1,BAO_0000219,B,,H,Autocuration,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
581,,51,CHEMBL615451,,1,BAO_0000221,B,,H,Expert,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,Hippocampus
582,,51,CHEMBL615452,,1,BAO_0000357,B,,H,Autocuration,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,
583,,51,CHEMBL615453,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
584,,51,CHEMBL615454,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
585,,51,CHEMBL615455,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
586,,51,CHEMBL615456,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
587,,51,CHEMBL615457,,1,BAO_0000221,B,,H,Autocuration,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus
588,,51,CHEMBL615458,,1,BAO_0000218,B,,H,Expert,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,,Hippocampus
589,,51,CHEMBL615459,,1,BAO_0000221,B,,H,Expert,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
590,Homo sapiens,51,CHEMBL615460,,1,BAO_0000219,B,9606.0,D,Expert,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,,,
591,Cavia porcellus,51,CHEMBL615461,,1,BAO_0000019,F,10141.0,H,Autocuration,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,,
592,Cavia porcellus,51,CHEMBL615462,,1,BAO_0000019,F,10141.0,H,Autocuration,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,,
593,Cavia porcellus,51,CHEMBL615463,,1,BAO_0000221,F,10141.0,H,Autocuration,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,,Hippocampus
594,Cavia porcellus,51,CHEMBL615464,,1,BAO_0000221,B,10141.0,H,Autocuration,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,,Ileum
595,Cavia porcellus,51,CHEMBL615465,,1,BAO_0000221,B,10141.0,H,Autocuration,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,,Ileum
596,Cavia porcellus,51,CHEMBL615466,,1,BAO_0000221,B,10141.0,H,Autocuration,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,,Ileum
597,Cavia porcellus,51,CHEMBL615467,,1,BAO_0000221,B,10141.0,H,Autocuration,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,,Ileum
598,Cavia porcellus,51,CHEMBL615468,,1,BAO_0000221,B,10141.0,H,Autocuration,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,,Ileum
599,Cavia porcellus,51,CHEMBL615469,,1,BAO_0000221,B,10141.0,H,Autocuration,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,,Ileum
600,Cavia porcellus,51,CHEMBL615470,,1,BAO_0000357,B,10141.0,H,Autocuration,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
601,Cavia porcellus,51,CHEMBL615471,,1,BAO_0000357,B,10141.0,H,Autocuration,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,,
602,Cavia porcellus,51,CHEMBL615472,,1,BAO_0000357,B,10141.0,H,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,,
603,Cavia porcellus,106,CHEMBL883242,,1,BAO_0000221,B,10141.0,H,Autocuration,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,,Hippocampus
604,Cavia porcellus,106,CHEMBL615473,,1,BAO_0000221,F,10141.0,H,Autocuration,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,,Hippocampus
605,Cricetulus griseus,11863,CHEMBL615474,,1,BAO_0000218,B,10029.0,H,Autocuration,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,
606,,51,CHEMBL615475,,1,BAO_0000357,B,,H,Autocuration,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,
607,,51,CHEMBL615476,,1,BAO_0000219,F,,H,Autocuration,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,,
608,,51,CHEMBL615477,,1,BAO_0000219,F,,H,Autocuration,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,,
609,,51,CHEMBL615478,,1,BAO_0000019,F,,H,Autocuration,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,
610,,51,CHEMBL615160,,1,BAO_0000219,F,,H,Autocuration,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,
611,,51,CHEMBL615161,,1,BAO_0000219,F,,H,Expert,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,
612,,51,CHEMBL615162,,1,BAO_0000219,F,,H,Autocuration,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,,
613,,51,CHEMBL615163,,1,BAO_0000219,F,,H,Autocuration,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,,
614,,51,CHEMBL615164,,1,BAO_0000219,B,,H,Expert,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
615,,51,CHEMBL615165,,1,BAO_0000219,B,,H,Expert,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
616,,51,CHEMBL615166,,1,BAO_0000219,B,,H,Autocuration,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,,
617,,51,CHEMBL615167,,1,BAO_0000219,F,,H,Autocuration,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,
618,Homo sapiens,51,CHEMBL615168,,1,BAO_0000219,B,9606.0,D,Expert,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,,
619,Homo sapiens,51,CHEMBL615169,,1,BAO_0000219,B,9606.0,D,Expert,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,,,
620,Homo sapiens,51,CHEMBL615170,,1,BAO_0000219,B,9606.0,D,Expert,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,,,
621,Homo sapiens,51,CHEMBL615171,,1,BAO_0000219,B,9606.0,D,Expert,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,
622,,51,CHEMBL615694,,1,BAO_0000019,F,,H,Autocuration,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,
623,,51,CHEMBL615695,,1,BAO_0000019,F,,H,Autocuration,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,
624,,51,CHEMBL615696,,1,BAO_0000019,F,,H,Autocuration,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,
625,,51,CHEMBL615697,,1,BAO_0000219,F,,H,Autocuration,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,
626,Homo sapiens,51,CHEMBL859410,,1,BAO_0000219,F,9606.0,D,Expert,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,,
627,,51,CHEMBL615841,,1,BAO_0000219,F,,H,Autocuration,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,
628,Homo sapiens,51,CHEMBL615842,,1,BAO_0000219,F,9606.0,D,Expert,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,,
629,,51,CHEMBL835003,,1,BAO_0000219,F,,H,Autocuration,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,
630,,51,CHEMBL615843,,1,BAO_0000219,F,,H,Autocuration,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,,
631,Homo sapiens,51,CHEMBL615979,,1,BAO_0000219,F,9606.0,D,Expert,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,,,
632,,51,CHEMBL615980,,1,BAO_0000219,F,,H,Autocuration,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,
633,Homo sapiens,51,CHEMBL615981,,1,BAO_0000219,F,9606.0,D,Expert,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,,,
634,Homo sapiens,51,CHEMBL615982,,1,BAO_0000019,F,9606.0,D,Expert,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,,
635,Homo sapiens,51,CHEMBL615983,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,,
636,Homo sapiens,51,CHEMBL615984,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,,
637,Homo sapiens,51,CHEMBL615985,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,,
638,,51,CHEMBL615986,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,
639,,51,CHEMBL615987,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,
640,,51,CHEMBL615988,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,
641,,51,CHEMBL615989,,1,BAO_0000219,F,,H,Expert,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,
642,,51,CHEMBL615990,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,
643,,51,CHEMBL615991,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,,
644,,51,CHEMBL615992,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,
645,,51,CHEMBL615993,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,
646,,51,CHEMBL615994,,1,BAO_0000219,F,,H,Expert,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,
647,,51,CHEMBL615995,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,,
648,,51,CHEMBL615996,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,
649,,51,CHEMBL615997,,1,BAO_0000219,F,,H,Autocuration,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,
650,,51,CHEMBL615998,,1,BAO_0000019,F,,H,Autocuration,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
651,,51,CHEMBL615999,,1,BAO_0000019,F,,H,Autocuration,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
652,,51,CHEMBL616000,,1,BAO_0000019,F,,H,Autocuration,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,
653,,51,CHEMBL616001,,1,BAO_0000219,F,,H,Autocuration,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
654,Homo sapiens,51,CHEMBL616002,,1,BAO_0000019,F,9606.0,D,Expert,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,,
655,,51,CHEMBL616003,,1,BAO_0000019,F,,H,Expert,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,
656,Homo sapiens,51,CHEMBL616004,,1,BAO_0000019,F,9606.0,D,Expert,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,,
657,Homo sapiens,51,CHEMBL616005,,1,BAO_0000019,F,9606.0,D,Expert,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,,
658,,51,CHEMBL616006,,1,BAO_0000019,F,,H,Autocuration,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,
659,,51,CHEMBL616007,,1,BAO_0000019,F,,H,Expert,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,
660,,51,CHEMBL616008,,1,BAO_0000019,F,,H,Autocuration,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,
661,,51,CHEMBL616009,,1,BAO_0000019,F,,H,Autocuration,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,
662,,51,CHEMBL616010,,1,BAO_0000019,F,,H,Expert,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,
663,Homo sapiens,51,CHEMBL616011,,1,BAO_0000019,F,9606.0,D,Expert,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,,
664,Homo sapiens,51,CHEMBL615740,,1,BAO_0000019,F,9606.0,D,Expert,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,,
665,,51,CHEMBL615741,,1,BAO_0000019,F,,H,Autocuration,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,
666,,51,CHEMBL615742,,1,BAO_0000019,F,,H,Expert,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,
667,,51,CHEMBL615743,,1,BAO_0000019,F,,H,Autocuration,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,
668,,51,CHEMBL615744,,1,BAO_0000219,F,,H,Autocuration,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,,
669,,51,CHEMBL615745,,1,BAO_0000219,F,,H,Expert,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,,
670,,51,CHEMBL615746,,1,BAO_0000357,B,,H,Autocuration,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,
671,,51,CHEMBL615747,,1,BAO_0000357,B,,H,Autocuration,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,
672,,51,CHEMBL615748,,1,BAO_0000019,F,,H,Autocuration,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
673,,51,CHEMBL615749,,1,BAO_0000019,F,,H,Autocuration,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,
674,,51,CHEMBL615750,,1,BAO_0000019,F,,H,Autocuration,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,
675,Homo sapiens,51,CHEMBL616259,,1,BAO_0000019,F,9606.0,D,Expert,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,,
676,,51,CHEMBL616260,,1,BAO_0000019,F,,H,Autocuration,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
677,Homo sapiens,51,CHEMBL616261,,1,BAO_0000019,F,9606.0,D,Expert,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,,
678,Homo sapiens,51,CHEMBL616262,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,,
679,Homo sapiens,51,CHEMBL616263,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,,
680,Homo sapiens,51,CHEMBL616264,,1,BAO_0000019,F,9606.0,D,Expert,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,,
681,Homo sapiens,51,CHEMBL616265,,1,BAO_0000019,F,9606.0,D,Expert,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,,
682,Homo sapiens,51,CHEMBL616266,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,,
683,Homo sapiens,51,CHEMBL616267,,1,BAO_0000019,F,9606.0,D,Expert,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,,
684,Homo sapiens,51,CHEMBL616268,,1,BAO_0000019,F,9606.0,D,Expert,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,,
685,Homo sapiens,51,CHEMBL616269,,1,BAO_0000357,B,9606.0,D,Expert,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,,,,
686,,51,CHEMBL884528,,1,BAO_0000219,B,,H,Autocuration,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
687,,105,CHEMBL616270,,1,BAO_0000219,B,,D,Expert,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,,
688,,51,CHEMBL616271,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,,
689,,51,CHEMBL616272,,1,BAO_0000219,F,,H,Autocuration,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,
690,,51,CHEMBL616273,,1,BAO_0000357,B,,H,Expert,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,
691,Homo sapiens,51,CHEMBL616274,,1,BAO_0000357,B,9606.0,D,Expert,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,
692,,51,CHEMBL616275,,1,BAO_0000219,B,,H,Autocuration,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,,
693,,51,CHEMBL616276,,1,BAO_0000219,B,,H,Autocuration,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
694,Rattus norvegicus,22226,CHEMBL616277,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,,,
695,Rattus norvegicus,22226,CHEMBL616278,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,In vivo,,,
696,Rattus norvegicus,22226,CHEMBL616279,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,In vivo,,,
697,Rattus norvegicus,22226,CHEMBL616280,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,,,
698,Rattus norvegicus,22226,CHEMBL616281,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,In vivo,,,
699,Rattus norvegicus,22226,CHEMBL616282,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,In vivo,,,
700,Rattus norvegicus,22226,CHEMBL616283,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,In vivo,,,
701,Rattus norvegicus,22226,CHEMBL616284,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,In vivo,,,
702,Rattus norvegicus,22226,CHEMBL616285,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,In vivo,,,
703,Rattus norvegicus,22226,CHEMBL616286,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,In vivo,,,
704,Rattus norvegicus,22226,CHEMBL616287,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,In vivo,,,
705,Rattus norvegicus,22226,CHEMBL616288,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,In vivo,,,
706,Rattus norvegicus,22226,CHEMBL616289,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,In vivo,,,
707,Rattus norvegicus,22226,CHEMBL615610,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,In vivo,,,
708,Rattus norvegicus,22226,CHEMBL615611,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,In vivo,,,
709,Rattus norvegicus,22226,CHEMBL615612,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,In vivo,,,
710,Rattus norvegicus,22226,CHEMBL615613,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,In vivo,,,
711,Rattus norvegicus,22226,CHEMBL615614,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,In vivo,,,
712,Rattus norvegicus,22226,CHEMBL615615,,1,BAO_0000218,F,10116.0,U,Autocuration,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,In vivo,,,
713,,105093,CHEMBL615616,,1,BAO_0000019,B,,H,Autocuration,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,
714,,11923,CHEMBL615617,,1,BAO_0000249,B,,H,Autocuration,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,,Hypothalamus
715,,10577,CHEMBL615618,,1,BAO_0000019,B,,H,Autocuration,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,
716,,10577,CHEMBL615619,,1,BAO_0000019,B,,H,Autocuration,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,
717,,10577,CHEMBL615620,,1,BAO_0000019,B,,H,Expert,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,
718,,55,CHEMBL615621,,1,BAO_0000357,B,,H,Autocuration,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,
719,,55,CHEMBL615622,,1,BAO_0000357,B,,H,Autocuration,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,
720,,12166,CHEMBL615623,,1,BAO_0000019,F,,H,Autocuration,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,
721,,12166,CHEMBL615624,,1,BAO_0000019,F,,H,Autocuration,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,
722,,12166,CHEMBL615625,,1,BAO_0000019,F,,H,Autocuration,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,
723,,12166,CHEMBL767045,,1,BAO_0000019,F,,H,Autocuration,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,
724,Cavia porcellus,55,CHEMBL615626,,1,BAO_0000019,F,10141.0,H,Autocuration,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,,
725,Cavia porcellus,55,CHEMBL615627,,1,BAO_0000019,F,10141.0,H,Autocuration,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,,
726,Cavia porcellus,55,CHEMBL615628,,1,BAO_0000019,B,10141.0,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,,
727,Cavia porcellus,55,CHEMBL615629,,1,BAO_0000357,B,10141.0,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,,
728,Homo sapiens,55,CHEMBL615630,,1,BAO_0000357,B,9606.0,D,Expert,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,,
729,,55,CHEMBL615631,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,
730,,17087,CHEMBL615632,,1,BAO_0000218,F,,H,Autocuration,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,
731,,17087,CHEMBL615633,,1,BAO_0000357,B,,H,Autocuration,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,
732,,17087,CHEMBL615634,,1,BAO_0000218,F,,H,Autocuration,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,
733,Sus scrofa,55,CHEMBL615635,,1,BAO_0000019,B,9823.0,H,Expert,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,,
734,,12166,CHEMBL615636,,1,BAO_0000357,B,,H,Expert,11006,In vitro inhibition of rat 5-Lipoxygenase,,,,
735,Rattus norvegicus,12166,CHEMBL615637,,1,BAO_0000357,B,10116.0,D,Expert,11481,Inhibitory activity against 5-Lipoxygenase,,,,
736,,12166,CHEMBL615638,,1,BAO_0000219,B,,H,Expert,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,,
737,,12166,CHEMBL615639,,1,BAO_0000219,B,,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,
738,,12166,CHEMBL615640,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,,
739,,12166,CHEMBL615796,,1,BAO_0000019,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,
740,,12166,CHEMBL615845,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,
741,,12166,CHEMBL615846,,1,BAO_0000357,B,,H,Autocuration,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,
742,,12166,CHEMBL615847,,1,BAO_0000219,B,,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,
743,,12166,CHEMBL615848,,1,BAO_0000357,B,,H,Autocuration,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,
744,Rattus norvegicus,22226,CHEMBL615849,,1,BAO_0000019,B,10116.0,U,Autocuration,11481,Ratio of IC50 against 5-LO and COX,,,,
745,,12166,CHEMBL615850,,1,BAO_0000357,B,,H,Autocuration,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,
746,,12166,CHEMBL615851,,1,BAO_0000357,B,,H,Autocuration,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,
747,,12166,CHEMBL615852,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,
748,,12166,CHEMBL615853,,1,BAO_0000019,F,,H,Autocuration,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,
749,,120,CHEMBL884527,,1,BAO_0000357,B,,H,Autocuration,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,,Prostate gland
750,Columba livia,22226,CHEMBL872871,,1,BAO_0000019,B,8932.0,U,Autocuration,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,,
751,Columba livia,22226,CHEMBL615854,,1,BAO_0000019,B,8932.0,U,Autocuration,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,,
752,Columba livia,22226,CHEMBL767046,,1,BAO_0000019,B,8932.0,U,Autocuration,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,,
753,,10732,CHEMBL615855,,1,BAO_0000357,B,,H,Autocuration,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,
754,Rattus norvegicus,12198,CHEMBL615856,,1,BAO_0000019,F,10116.0,D,Expert,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,,
755,Rattus norvegicus,12198,CHEMBL615857,,1,BAO_0000019,F,10116.0,D,Expert,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,,
756,Rattus norvegicus,12198,CHEMBL615858,,1,BAO_0000019,F,10116.0,D,Expert,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,,
757,,10576,CHEMBL615859,,1,BAO_0000221,B,,H,Expert,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,Hippocampus
758,,51,CHEMBL615860,,1,BAO_0000357,B,,H,Autocuration,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,
759,Oryctolagus cuniculus,22226,CHEMBL615861,,1,BAO_0000019,B,9986.0,U,Autocuration,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,,
760,Oryctolagus cuniculus,22226,CHEMBL615862,,1,BAO_0000019,B,9986.0,U,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,,
761,Oryctolagus cuniculus,22226,CHEMBL615863,,1,BAO_0000019,B,9986.0,U,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,,
762,Oryctolagus cuniculus,22226,CHEMBL615864,,1,BAO_0000019,B,9986.0,U,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,,
763,,104744,CHEMBL615865,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,Hippocampus
764,,104744,CHEMBL615866,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,Hippocampus
765,,104744,CHEMBL615867,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,Hippocampus
766,,104744,CHEMBL615868,,1,BAO_0000249,B,,H,Autocuration,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,
767,Rattus norvegicus,104744,CHEMBL615869,,1,BAO_0000249,B,10116.0,D,Autocuration,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,,
768,Rattus norvegicus,104744,CHEMBL615870,,1,BAO_0000019,B,10116.0,D,Autocuration,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,,
769,Rattus norvegicus,104744,CHEMBL615871,,1,BAO_0000019,B,10116.0,D,Autocuration,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,,
770,,104744,CHEMBL615872,,1,BAO_0000224,B,,H,Autocuration,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,
771,,104744,CHEMBL833492,,1,BAO_0000221,B,,H,Autocuration,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,,Hippocampus
772,,104744,CHEMBL615873,,1,BAO_0000221,B,,H,Autocuration,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,,Hippocampus
773,,104744,CHEMBL615479,,1,BAO_0000224,B,,H,Autocuration,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,
774,,104744,CHEMBL615480,,1,BAO_0000019,B,,H,Autocuration,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,
775,Rattus norvegicus,104744,CHEMBL615481,,1,BAO_0000249,B,10116.0,D,Autocuration,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,,
776,,104744,CHEMBL872869,,1,BAO_0000019,B,,H,Autocuration,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
777,,104744,CHEMBL615482,,1,BAO_0000019,B,,H,Autocuration,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
778,,104744,CHEMBL615483,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,Brain
779,,104744,CHEMBL615484,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,Brain
780,,104744,CHEMBL615485,,1,BAO_0000019,B,,H,Autocuration,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,
781,Rattus norvegicus,104744,CHEMBL615486,,1,BAO_0000224,B,10116.0,D,Autocuration,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,,
782,,104744,CHEMBL615487,,1,BAO_0000224,B,,H,Autocuration,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,
783,,104744,CHEMBL615488,,1,BAO_0000224,B,,H,Autocuration,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,
784,,104744,CHEMBL615489,,1,BAO_0000224,B,,H,Autocuration,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,
785,,104744,CHEMBL615389,,1,BAO_0000224,B,,H,Autocuration,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,
786,,104744,CHEMBL615390,,1,BAO_0000019,B,,H,Autocuration,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,
787,,104744,CHEMBL615391,,1,BAO_0000019,B,,H,Autocuration,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,
788,,104744,CHEMBL615392,,1,BAO_0000224,B,,H,Autocuration,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,
789,Rattus norvegicus,22226,CHEMBL615393,,1,BAO_0000019,B,10116.0,U,Autocuration,3070,Affinity for 5-hydroxytryptamine 1 receptor,,,,
790,,104744,CHEMBL615394,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,,Brain
791,,104744,CHEMBL615395,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,Brain
792,,104744,CHEMBL615396,,1,BAO_0000224,B,,H,Autocuration,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,
793,,104744,CHEMBL615397,,1,BAO_0000221,B,,H,Autocuration,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,,Brain
794,,104744,CHEMBL615398,,1,BAO_0000019,B,,H,Autocuration,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,
795,Rattus norvegicus,22226,CHEMBL615399,,1,BAO_0000019,B,10116.0,U,Autocuration,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,,
796,,104744,CHEMBL615400,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,
797,Rattus norvegicus,104744,CHEMBL615401,,1,BAO_0000019,B,10116.0,D,Autocuration,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,,
798,Rattus norvegicus,22226,CHEMBL615402,,1,BAO_0000019,B,10116.0,U,Autocuration,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,,
799,,104744,CHEMBL615403,,1,BAO_0000019,B,,H,Autocuration,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,
800,,104744,CHEMBL615404,,1,BAO_0000221,B,,H,Autocuration,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,,Brain
801,,104744,CHEMBL615781,,1,BAO_0000019,B,,H,Autocuration,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,
802,,104744,CHEMBL615782,,1,BAO_0000220,B,,H,Autocuration,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,,Brain
803,,104744,CHEMBL615783,,1,BAO_0000221,B,,H,Autocuration,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,,Brain
804,,22226,CHEMBL873481,,1,BAO_0000019,B,,U,Autocuration,4639,Compound was tested for binding affinity against 5-HT1 receptor,,,,
805,,22226,CHEMBL615784,,1,BAO_0000019,B,,U,Autocuration,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,
806,,10576,CHEMBL615785,,1,BAO_0000357,B,,H,Expert,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,
807,,10576,CHEMBL615786,,1,BAO_0000249,F,,H,Autocuration,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,
808,,10576,CHEMBL615787,,1,BAO_0000218,F,,H,Autocuration,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,
809,,10576,CHEMBL615788,,1,BAO_0000218,F,,H,Autocuration,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,
810,,10576,CHEMBL767044,,1,BAO_0000019,F,,H,Autocuration,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,
811,,10576,CHEMBL615789,,1,BAO_0000218,F,,H,Autocuration,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,In vivo,,,
812,,10576,CHEMBL615790,,1,BAO_0000218,F,,H,Autocuration,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,In vivo,,,
813,,10576,CHEMBL615813,,1,BAO_0000019,F,,H,Autocuration,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,
814,,10576,CHEMBL615814,,1,BAO_0000219,F,,H,Autocuration,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,
815,,51,CHEMBL615815,,1,BAO_0000219,F,,H,Expert,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,
816,,10576,CHEMBL615816,,1,BAO_0000219,F,,H,Autocuration,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,
817,,10576,CHEMBL615817,,1,BAO_0000249,B,,H,Expert,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,
818,,10576,CHEMBL615818,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,,Hippocampus
819,,10576,CHEMBL615819,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,,Hippocampus
820,,10576,CHEMBL615820,,1,BAO_0000249,B,,H,Expert,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,
821,Rattus norvegicus,10576,CHEMBL615821,,1,BAO_0000221,B,10116.0,D,Expert,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,,Hippocampus
822,Rattus norvegicus,10576,CHEMBL615822,,1,BAO_0000221,B,10116.0,D,Expert,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,,Hippocampus
823,,10576,CHEMBL615823,,1,BAO_0000221,B,,H,Expert,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
824,Rattus norvegicus,10576,CHEMBL615824,,1,BAO_0000221,B,10116.0,D,Expert,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,,Hippocampus
825,Rattus norvegicus,10576,CHEMBL615825,,1,BAO_0000221,B,10116.0,D,Expert,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,,Hippocampus
826,,10576,CHEMBL615826,,1,BAO_0000357,B,,H,Expert,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,
827,,10576,CHEMBL615827,,1,BAO_0000249,B,,H,Expert,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,
828,,10576,CHEMBL615828,,1,BAO_0000249,B,,H,Expert,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
829,,10576,CHEMBL615829,,1,BAO_0000221,B,,H,Expert,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
830,,10576,CHEMBL615830,,1,BAO_0000221,B,,H,Autocuration,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,,Hippocampus
831,,10576,CHEMBL615831,,1,BAO_0000221,B,,H,Expert,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,,Hippocampus
832,,10576,CHEMBL615832,,1,BAO_0000357,B,,H,Autocuration,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,
833,,10576,CHEMBL615833,,1,BAO_0000019,B,,H,Autocuration,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,
834,,10576,CHEMBL615834,,1,BAO_0000221,B,,H,Autocuration,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,,Hippocampus
835,,10576,CHEMBL615835,,1,BAO_0000249,B,,H,Intermediate,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,
836,,10576,CHEMBL615836,,1,BAO_0000249,B,,H,Autocuration,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,,Hippocampus
837,Rattus norvegicus,10576,CHEMBL615837,,1,BAO_0000019,B,10116.0,D,Expert,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,,
838,Rattus norvegicus,10576,CHEMBL615838,,1,BAO_0000019,B,10116.0,D,Expert,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,,
839,,10576,CHEMBL615839,,1,BAO_0000249,B,,H,Expert,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,
840,,10576,CHEMBL884525,,1,BAO_0000019,B,,H,Autocuration,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,
841,,10576,CHEMBL615840,,1,BAO_0000249,B,,H,Autocuration,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,
842,,10576,CHEMBL615405,,1,BAO_0000221,B,,H,Expert,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
843,,10576,CHEMBL615406,,1,BAO_0000019,B,,H,Expert,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,
844,,10576,CHEMBL615900,,1,BAO_0000221,B,,H,Expert,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,Hippocampus
845,,10576,CHEMBL615901,,1,BAO_0000221,B,,H,Expert,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,,Hippocampus
846,,10576,CHEMBL615902,,1,BAO_0000357,B,,H,Expert,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,
847,,10576,CHEMBL615903,,1,BAO_0000221,B,,H,Autocuration,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,Hippocampus
848,,10576,CHEMBL615904,,1,BAO_0000357,B,,H,Autocuration,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,
849,,10576,CHEMBL615905,,1,BAO_0000357,B,,H,Expert,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,
850,,10576,CHEMBL615906,,1,BAO_0000019,B,,H,Autocuration,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,
851,,10576,CHEMBL615907,,1,BAO_0000019,F,,H,Autocuration,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,
852,,10576,CHEMBL615908,,1,BAO_0000019,B,,H,Expert,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,
853,,10576,CHEMBL615909,,1,BAO_0000221,B,,H,Autocuration,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,,Hippocampus
854,,10576,CHEMBL615910,,1,BAO_0000019,B,,H,Autocuration,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,
855,,10576,CHEMBL615911,,1,BAO_0000019,B,,H,Autocuration,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,
856,,10576,CHEMBL615912,,1,BAO_0000019,B,,H,Autocuration,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,
857,,10576,CHEMBL615913,,1,BAO_0000019,B,,H,Expert,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,
858,,10576,CHEMBL615914,,1,BAO_0000357,B,,H,Expert,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,
859,,10576,CHEMBL615915,,1,BAO_0000221,B,,H,Autocuration,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,Hippocampus
860,,10576,CHEMBL615916,,1,BAO_0000357,B,,H,Autocuration,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,
861,,10576,CHEMBL615917,,1,BAO_0000357,B,,H,Expert,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,
862,,10576,CHEMBL615918,,1,BAO_0000357,B,,H,Expert,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,
863,,10576,CHEMBL615919,,1,BAO_0000249,B,,H,Expert,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,,Hippocampus
864,Rattus norvegicus,10576,CHEMBL615920,,1,BAO_0000221,B,10116.0,D,Expert,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,Hippocampus
865,,10576,CHEMBL615921,,1,BAO_0000357,B,,H,Autocuration,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,
866,,10576,CHEMBL615922,,1,BAO_0000357,B,,H,Expert,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,
867,Rattus norvegicus,10576,CHEMBL881290,,1,BAO_0000249,F,10116.0,D,Expert,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,,
868,,10576,CHEMBL615923,,1,BAO_0000221,B,,H,Autocuration,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,,Hippocampus
869,,10576,CHEMBL615924,,1,BAO_0000221,F,,H,Autocuration,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
870,,10576,CHEMBL615925,,1,BAO_0000221,F,,H,Autocuration,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
871,Rattus norvegicus,10576,CHEMBL615926,,1,BAO_0000357,B,10116.0,D,Expert,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,,
872,Rattus norvegicus,10576,CHEMBL615927,,1,BAO_0000019,B,10116.0,D,Expert,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,,
873,,10576,CHEMBL615928,,1,BAO_0000221,B,,H,Autocuration,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus
874,Rattus norvegicus,10576,CHEMBL615929,,1,BAO_0000357,B,10116.0,D,Expert,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,,
875,,10576,CHEMBL615930,,1,BAO_0000221,B,,H,Autocuration,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,,Hippocampus
876,,51,CHEMBL615931,,1,BAO_0000219,B,,H,Autocuration,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,
877,,51,CHEMBL615932,,1,BAO_0000219,F,,H,Autocuration,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,
878,,51,CHEMBL615933,,1,BAO_0000219,F,,H,Autocuration,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,
879,,51,CHEMBL615934,,1,BAO_0000357,B,,H,Autocuration,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,
880,,51,CHEMBL615935,,1,BAO_0000357,B,,H,Autocuration,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,
881,,51,CHEMBL615936,,1,BAO_0000019,F,,H,Autocuration,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,
882,,51,CHEMBL615937,,1,BAO_0000219,B,,H,Autocuration,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,,
883,,51,CHEMBL615938,,1,BAO_0000357,B,,H,Autocuration,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,
884,,51,CHEMBL615797,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,
885,,51,CHEMBL615798,,1,BAO_0000357,B,,H,Autocuration,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
886,,51,CHEMBL872870,,1,BAO_0000357,B,,H,Autocuration,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,
887,,51,CHEMBL615799,,1,BAO_0000357,B,,H,Autocuration,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,
888,,51,CHEMBL615800,,1,BAO_0000357,B,,H,Autocuration,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,
889,,51,CHEMBL615801,,1,BAO_0000219,F,,H,Autocuration,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
890,,51,CHEMBL615802,,1,BAO_0000019,B,,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,
891,,51,CHEMBL615803,,1,BAO_0000357,B,,H,Autocuration,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,
892,,51,CHEMBL835002,,1,BAO_0000019,F,,H,Expert,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,
893,,51,CHEMBL615804,,1,BAO_0000019,F,,H,Autocuration,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,
894,,51,CHEMBL615805,,1,BAO_0000219,B,,H,Expert,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,,
895,,51,CHEMBL615806,,1,BAO_0000219,B,,H,Autocuration,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,,
896,Homo sapiens,51,CHEMBL615807,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,,
897,,51,CHEMBL615808,,1,BAO_0000357,B,,H,Autocuration,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,
898,Homo sapiens,51,CHEMBL615809,,1,BAO_0000357,B,9606.0,D,Expert,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
899,,51,CHEMBL615810,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,,
900,,51,CHEMBL615811,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
901,,51,CHEMBL615812,,1,BAO_0000219,B,,H,Autocuration,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,,
902,,51,CHEMBL615751,,1,BAO_0000219,B,,H,Autocuration,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
903,,51,CHEMBL615752,,1,BAO_0000357,B,,H,Autocuration,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,
904,,51,CHEMBL615753,,1,BAO_0000219,B,,H,Expert,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,,
905,,51,CHEMBL615754,,1,BAO_0000219,B,,H,Autocuration,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,,
906,,51,CHEMBL615755,,1,BAO_0000357,B,,H,Autocuration,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,
907,Homo sapiens,51,CHEMBL615756,,1,BAO_0000219,B,9606.0,D,Expert,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,
908,,51,CHEMBL615757,,1,BAO_0000019,B,,H,Autocuration,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,
909,,51,CHEMBL615758,,1,BAO_0000357,B,,H,Autocuration,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,
910,,51,CHEMBL615759,,1,BAO_0000357,B,,H,Expert,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,
911,,51,CHEMBL615760,,1,BAO_0000357,B,,H,Autocuration,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,
912,,51,CHEMBL615761,,1,BAO_0000219,B,,H,Expert,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,,
913,,51,CHEMBL872104,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,
914,,51,CHEMBL615762,,1,BAO_0000357,B,,H,Autocuration,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
915,,51,CHEMBL615763,,1,BAO_0000357,B,,H,Autocuration,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
916,,51,CHEMBL615764,,1,BAO_0000357,B,,H,Autocuration,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,
917,,51,CHEMBL615765,,1,BAO_0000219,B,,H,Autocuration,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,,
918,,51,CHEMBL615766,,1,BAO_0000019,B,,H,Autocuration,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,
919,,51,CHEMBL615767,,1,BAO_0000357,B,,H,Autocuration,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,
920,,51,CHEMBL615768,,1,BAO_0000357,B,,H,Expert,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
921,,51,CHEMBL615769,,1,BAO_0000357,B,,H,Autocuration,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
922,,51,CHEMBL615770,,1,BAO_0000357,B,,H,Expert,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,
923,,51,CHEMBL615771,,1,BAO_0000357,B,,H,Autocuration,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
924,,51,CHEMBL615772,,1,BAO_0000357,B,,H,Expert,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,
925,,51,CHEMBL615773,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
926,,51,CHEMBL615774,,1,BAO_0000357,B,,H,Expert,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,
927,,51,CHEMBL615775,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
928,,51,CHEMBL615776,,1,BAO_0000357,B,,H,Autocuration,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,
929,,51,CHEMBL615777,,1,BAO_0000357,B,,H,Expert,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
930,,51,CHEMBL615778,,1,BAO_0000219,B,,H,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,
931,Homo sapiens,51,CHEMBL615779,,1,BAO_0000357,B,9606.0,D,Expert,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,
932,,51,CHEMBL615780,,1,BAO_0000357,B,,H,Autocuration,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,
933,,51,CHEMBL616298,,1,BAO_0000357,B,,H,Autocuration,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,
934,,51,CHEMBL616299,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,
935,,51,CHEMBL616300,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,,
936,,51,CHEMBL616301,,1,BAO_0000219,F,,H,Expert,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,,
937,,51,CHEMBL616302,,1,BAO_0000019,B,,H,Autocuration,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,
938,,51,CHEMBL616117,,1,BAO_0000019,B,,H,Autocuration,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,
939,,51,CHEMBL616118,,1,BAO_0000019,B,,H,Autocuration,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,
940,,51,CHEMBL616119,,1,BAO_0000019,B,,H,Autocuration,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,
941,Homo sapiens,51,CHEMBL616120,,1,BAO_0000219,B,9606.0,D,Expert,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,,,
942,,51,CHEMBL616121,,1,BAO_0000357,B,,H,Autocuration,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,
943,,51,CHEMBL616122,,1,BAO_0000357,B,,H,Autocuration,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,
944,,51,CHEMBL616123,,1,BAO_0000357,B,,H,Autocuration,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,
945,Homo sapiens,51,CHEMBL616124,,1,BAO_0000357,B,9606.0,D,Expert,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,,
946,,51,CHEMBL616125,,1,BAO_0000357,B,,H,Expert,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,
947,Rattus norvegicus,51,CHEMBL616126,,1,BAO_0000357,B,10116.0,H,Expert,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,,
948,,51,CHEMBL616127,,1,BAO_0000219,B,,H,Autocuration,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,,
949,,51,CHEMBL616128,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,
950,,51,CHEMBL616129,,1,BAO_0000357,B,,H,Autocuration,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,
951,,51,CHEMBL616130,,1,BAO_0000357,B,,H,Expert,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,
952,,51,CHEMBL616131,,1,BAO_0000357,B,,H,Autocuration,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,
953,,51,CHEMBL616132,,1,BAO_0000219,B,,H,Autocuration,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,,
954,Homo sapiens,51,CHEMBL616133,,1,BAO_0000219,B,9606.0,D,Expert,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,,,
955,,51,CHEMBL616134,,1,BAO_0000357,B,,H,Autocuration,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
956,,51,CHEMBL616135,,1,BAO_0000357,B,,H,Autocuration,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,
957,Homo sapiens,51,CHEMBL616136,,1,BAO_0000357,B,9606.0,D,Expert,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,,
958,,51,CHEMBL616137,,1,BAO_0000019,B,,H,Autocuration,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,
959,,51,CHEMBL872105,,1,BAO_0000019,B,,H,Autocuration,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,
960,,51,CHEMBL616138,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,
961,Homo sapiens,51,CHEMBL616139,,1,BAO_0000357,B,9606.0,D,Expert,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,
962,,51,CHEMBL616140,,1,BAO_0000019,F,,H,Autocuration,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,
963,,51,CHEMBL616141,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,
964,,51,CHEMBL616142,,1,BAO_0000357,B,,H,Autocuration,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,
965,,51,CHEMBL616143,,1,BAO_0000357,B,,H,Autocuration,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,
966,,51,CHEMBL616144,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,
967,,51,CHEMBL616145,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,,
968,,51,CHEMBL616012,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,
969,,51,CHEMBL616013,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,
970,,51,CHEMBL616014,,1,BAO_0000019,F,,H,Autocuration,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,
971,,51,CHEMBL616015,,1,BAO_0000019,F,,H,Autocuration,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,
972,,51,CHEMBL616016,,1,BAO_0000019,F,,H,Autocuration,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,
973,,51,CHEMBL616017,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,In vivo,,,
974,,51,CHEMBL616018,,1,BAO_0000019,B,,H,Autocuration,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,
975,,51,CHEMBL616019,,1,BAO_0000019,F,,H,Autocuration,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,
976,,51,CHEMBL616020,,1,BAO_0000019,F,,H,Autocuration,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,
977,,51,CHEMBL858018,,1,BAO_0000357,B,,H,Autocuration,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,
978,,51,CHEMBL616021,,1,BAO_0000219,F,,H,Autocuration,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
979,,51,CHEMBL616022,,1,BAO_0000019,F,,H,Expert,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,
980,,51,CHEMBL616023,,1,BAO_0000019,F,,H,Autocuration,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,
981,,51,CHEMBL616024,,1,BAO_0000019,F,,H,Autocuration,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,
982,,51,CHEMBL616025,,1,BAO_0000019,F,,H,Autocuration,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,
983,,51,CHEMBL616026,,1,BAO_0000219,F,,H,Autocuration,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,
984,,51,CHEMBL616027,,1,BAO_0000019,F,,H,Autocuration,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,
985,Homo sapiens,51,CHEMBL616028,,1,BAO_0000019,F,9606.0,D,Expert,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,,
986,Homo sapiens,51,CHEMBL616029,,1,BAO_0000019,F,9606.0,D,Expert,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,,
987,,51,CHEMBL616030,,1,BAO_0000219,B,,H,Expert,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,,
988,,51,CHEMBL616031,,1,BAO_0000019,B,,H,Expert,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,
989,Homo sapiens,51,CHEMBL616032,,1,BAO_0000019,F,9606.0,D,Expert,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,,
990,Homo sapiens,51,CHEMBL616033,,1,BAO_0000019,F,9606.0,D,Expert,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,,
991,,51,CHEMBL616034,,1,BAO_0000019,F,,H,Autocuration,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
992,,51,CHEMBL616035,,1,BAO_0000019,F,,H,Autocuration,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
993,,51,CHEMBL616036,,1,BAO_0000019,F,,H,Autocuration,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,
994,,51,CHEMBL616037,,1,BAO_0000019,F,,H,Autocuration,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
995,,51,CHEMBL616038,,1,BAO_0000019,F,,H,Autocuration,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
996,,51,CHEMBL616039,,1,BAO_0000019,F,,H,Autocuration,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,
997,,51,CHEMBL616040,,1,BAO_0000019,F,,H,Autocuration,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,
998,Homo sapiens,51,CHEMBL616041,,1,BAO_0000219,F,9606.0,D,Expert,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,,
999,Homo sapiens,51,CHEMBL616042,,1,BAO_0000219,F,9606.0,D,Expert,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,,
1000,Homo sapiens,51,CHEMBL616043,,1,BAO_0000219,F,9606.0,D,Expert,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,,,
1001,,51,CHEMBL616044,,1,BAO_0000019,F,,H,Autocuration,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,
1002,,51,CHEMBL616045,,1,BAO_0000019,F,,H,Autocuration,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,
1003,,51,CHEMBL616046,,1,BAO_0000219,F,,H,Autocuration,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,
1004,,51,CHEMBL616047,,1,BAO_0000219,F,,H,Autocuration,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,
1005,,51,CHEMBL616048,,1,BAO_0000219,F,,H,Autocuration,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,
1006,Homo sapiens,51,CHEMBL616049,,1,BAO_0000219,F,9606.0,D,Expert,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,,,
1007,,51,CHEMBL616050,,1,BAO_0000219,F,,H,Autocuration,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,
1008,,51,CHEMBL616051,,1,BAO_0000219,F,,H,Expert,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,
1009,,51,CHEMBL616212,,1,BAO_0000219,F,,H,Autocuration,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,
1010,,51,CHEMBL616213,,1,BAO_0000019,F,,H,Autocuration,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,
1011,,51,CHEMBL616214,,1,BAO_0000219,B,,H,Expert,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,In vitro,,,
1012,,51,CHEMBL616215,,1,BAO_0000219,B,,H,Expert,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,In vitro,,,
1013,,51,CHEMBL616216,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
1014,,51,CHEMBL616217,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
1015,,51,CHEMBL616218,,1,BAO_0000357,B,,H,Autocuration,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,
1016,,51,CHEMBL616219,,1,BAO_0000357,B,,H,Autocuration,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,
1017,,51,CHEMBL616220,,1,BAO_0000357,B,,H,Autocuration,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,
1018,Homo sapiens,51,CHEMBL833493,,1,BAO_0000357,B,9606.0,D,Expert,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,,
1019,,51,CHEMBL616221,,1,BAO_0000357,B,,H,Autocuration,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,
1020,Homo sapiens,51,CHEMBL616222,,1,BAO_0000219,B,9606.0,D,Expert,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,,
1021,,51,CHEMBL616223,,1,BAO_0000019,F,,H,Autocuration,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,
1022,,51,CHEMBL616224,,1,BAO_0000019,F,,H,Autocuration,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,
1023,,51,CHEMBL616225,,1,BAO_0000019,B,,H,Expert,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,
1024,Homo sapiens,51,CHEMBL616226,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,,,
1025,,51,CHEMBL616227,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,,
1026,,51,CHEMBL616228,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,,
1027,,51,CHEMBL616229,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,
1028,,51,CHEMBL616230,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,,
1029,,51,CHEMBL616231,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,,
1030,,51,CHEMBL616232,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,
1031,,51,CHEMBL616233,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,
1032,,51,CHEMBL857973,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,,
1033,,51,CHEMBL616234,,1,BAO_0000219,B,,H,Autocuration,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,
1034,,51,CHEMBL616235,,1,BAO_0000357,B,,H,Autocuration,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,
1035,,51,CHEMBL616236,,1,BAO_0000219,B,,H,Expert,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,
1036,,51,CHEMBL616237,,1,BAO_0000019,B,,H,Expert,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,
1037,,51,CHEMBL616238,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,,
1038,,51,CHEMBL616239,,1,BAO_0000219,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,,
1039,,51,CHEMBL616240,,1,BAO_0000219,B,,H,Autocuration,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,
1040,Homo sapiens,51,CHEMBL616241,,1,BAO_0000219,B,9606.0,D,Expert,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,,,
1041,,51,CHEMBL616242,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,,
1042,,51,CHEMBL616243,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,,
1043,,51,CHEMBL616244,,1,BAO_0000357,B,,D,Expert,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,
1044,Homo sapiens,51,CHEMBL616245,,1,BAO_0000357,B,9606.0,D,Autocuration,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,
1045,,106,CHEMBL616246,,1,BAO_0000357,B,,H,Autocuration,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,
1046,,105,CHEMBL616247,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-HT1D receptor,,,,
1047,,105,CHEMBL616248,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1048,,107,CHEMBL616249,,1,BAO_0000357,B,,H,Autocuration,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,
1049,Homo sapiens,10576,CHEMBL616250,,1,BAO_0000357,B,9606.0,H,Autocuration,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,
1050,,51,CHEMBL616251,,1,BAO_0000357,B,,H,Autocuration,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,
1051,,11863,CHEMBL616252,,1,BAO_0000218,F,,H,Autocuration,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,In vivo,,,
1052,,11863,CHEMBL616253,,1,BAO_0000218,F,,H,Autocuration,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,In vivo,,,
1053,,11863,CHEMBL616254,,1,BAO_0000218,F,,H,Autocuration,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,In vivo,,,
1054,Mus musculus,11863,CHEMBL616255,,1,BAO_0000218,F,10090.0,D,Expert,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,,
1055,Mus musculus,11863,CHEMBL832872,,1,BAO_0000218,F,10090.0,D,Expert,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,,
1056,Mus musculus,11863,CHEMBL616256,,1,BAO_0000218,F,10090.0,D,Expert,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,,
1057,Mus musculus,11863,CHEMBL616257,,1,BAO_0000218,F,10090.0,D,Expert,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,,
1058,Mus musculus,11863,CHEMBL616258,,1,BAO_0000218,F,10090.0,D,Expert,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,,
1059,Mus musculus,11863,CHEMBL616384,,1,BAO_0000218,F,10090.0,D,Expert,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,,
1060,,11863,CHEMBL616385,,1,BAO_0000221,B,,H,Autocuration,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,,Hippocampus
1061,,11863,CHEMBL616386,,1,BAO_0000357,B,,H,Expert,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,
1062,Mus musculus,11863,CHEMBL616387,,1,BAO_0000221,B,10090.0,D,Expert,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,,Hippocampus
1063,,11863,CHEMBL616388,,1,BAO_0000221,B,,H,Autocuration,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,Hippocampus
1064,Mus musculus,11863,CHEMBL616389,,1,BAO_0000221,B,10090.0,D,Expert,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,,Hippocampus
1065,,11863,CHEMBL616390,,1,BAO_0000221,B,,H,Autocuration,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,Hippocampus
1066,,11863,CHEMBL616391,,1,BAO_0000357,B,,H,Autocuration,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,
1067,Mus musculus,11863,CHEMBL616392,,1,BAO_0000221,B,10090.0,D,Expert,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,,Hippocampus
1068,Sus scrofa,51,CHEMBL616393,,1,BAO_0000357,B,9823.0,H,Autocuration,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,,
1069,Sus scrofa,51,CHEMBL616394,,1,BAO_0000357,B,9823.0,H,Autocuration,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,,
1070,Sus scrofa,51,CHEMBL616395,,1,BAO_0000019,B,9823.0,H,Autocuration,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,,
1071,Sus scrofa,51,CHEMBL616396,,1,BAO_0000357,B,9823.0,H,Autocuration,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,,
1072,Sus scrofa,51,CHEMBL872907,,1,BAO_0000019,B,9823.0,H,Autocuration,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,,
1073,Sus scrofa,51,CHEMBL616397,,1,BAO_0000019,B,9823.0,H,Autocuration,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,,
1074,Sus scrofa,51,CHEMBL616398,,1,BAO_0000019,B,9823.0,H,Autocuration,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,,
1075,Sus scrofa,51,CHEMBL616399,,1,BAO_0000357,B,9823.0,H,Expert,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,,
1076,Sus scrofa,51,CHEMBL857065,,1,BAO_0000357,B,9823.0,H,Autocuration,12861,Binding activity radioligand.,,,,
1077,Sus scrofa,51,CHEMBL616400,,1,BAO_0000019,B,9823.0,H,Expert,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,,
1078,Sus scrofa,51,CHEMBL616401,,1,BAO_0000019,B,9823.0,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,,
1079,,10624,CHEMBL616402,,1,BAO_0000019,B,,H,Expert,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,
1080,Sus scrofa,51,CHEMBL616403,,1,BAO_0000019,B,9823.0,H,Expert,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,,
1081,Sus scrofa,51,CHEMBL616404,,1,BAO_0000221,B,9823.0,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,,Hippocampus
1082,Sus scrofa,51,CHEMBL616405,,1,BAO_0000249,B,9823.0,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,,
1083,Sus scrofa,51,CHEMBL616406,,1,BAO_0000019,B,9823.0,H,Autocuration,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,,
1084,Sus scrofa,51,CHEMBL616407,,1,BAO_0000019,F,9823.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,,
1085,Oryctolagus cuniculus,51,CHEMBL616408,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,,
1086,Rattus norvegicus,10576,CHEMBL616409,,1,BAO_0000249,B,10116.0,D,Expert,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,,
1087,Rattus norvegicus,10576,CHEMBL616410,,1,BAO_0000221,B,10116.0,D,Expert,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,,Hippocampus
1088,,10576,CHEMBL616411,,1,BAO_0000357,B,,H,Autocuration,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,
1089,Rattus norvegicus,10576,CHEMBL616412,,1,BAO_0000249,F,10116.0,D,Expert,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,,
1090,Rattus norvegicus,10576,CHEMBL616413,,1,BAO_0000249,F,10116.0,D,Expert,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,,Hippocampus
1091,,10576,CHEMBL616414,,1,BAO_0000221,B,,H,Autocuration,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus
1092,Rattus norvegicus,10576,CHEMBL616415,,1,BAO_0000221,B,10116.0,D,Expert,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,,Hippocampus
1093,,10576,CHEMBL616416,,1,BAO_0000019,B,,H,Autocuration,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,
1094,,10576,CHEMBL616417,,1,BAO_0000357,B,,H,Expert,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,
1095,,10576,CHEMBL616418,,1,BAO_0000357,B,,H,Autocuration,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,
1096,,10576,CHEMBL616419,,1,BAO_0000219,B,,H,Autocuration,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,
1097,,10576,CHEMBL616420,,1,BAO_0000357,B,,H,Autocuration,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,
1098,,10576,CHEMBL616421,,1,BAO_0000249,B,,H,Autocuration,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,
1099,,10576,CHEMBL616422,,1,BAO_0000249,B,,H,Autocuration,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,
1100,,10576,CHEMBL616423,,1,BAO_0000249,B,,H,Expert,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,
1101,Rattus norvegicus,10576,CHEMBL616424,,1,BAO_0000357,B,10116.0,D,Expert,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,,
1102,,10576,CHEMBL616425,,1,BAO_0000357,B,,H,Expert,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,
1103,,10576,CHEMBL616426,,1,BAO_0000357,B,,H,Expert,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,
1104,,10576,CHEMBL616427,,1,BAO_0000221,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,,Hippocampus
1105,,10576,CHEMBL616428,,1,BAO_0000221,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,,Hippocampus
1106,,10576,CHEMBL616290,,1,BAO_0000221,B,,H,Autocuration,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1107,Rattus norvegicus,10576,CHEMBL616052,,1,BAO_0000357,B,10116.0,D,Expert,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,,
1108,,10576,CHEMBL616053,,1,BAO_0000357,B,,H,Autocuration,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,
1109,,10576,CHEMBL616054,,1,BAO_0000249,B,,H,Autocuration,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,
1110,,10576,CHEMBL616055,,1,BAO_0000357,B,,H,Autocuration,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1111,,10576,CHEMBL616056,,1,BAO_0000357,B,,H,Autocuration,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,
1112,,10576,CHEMBL616057,,1,BAO_0000019,B,,H,Expert,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,
1113,Rattus norvegicus,10576,CHEMBL616058,,1,BAO_0000221,B,10116.0,D,Expert,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,Brain
1114,,10576,CHEMBL616059,,1,BAO_0000221,B,,H,Autocuration,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,Brain
1115,,10576,CHEMBL616060,,1,BAO_0000249,B,,H,Autocuration,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,
1116,Rattus norvegicus,10576,CHEMBL616061,,1,BAO_0000221,B,10116.0,D,Expert,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,,Hippocampus
1117,,10576,CHEMBL616062,,1,BAO_0000221,B,,H,Expert,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,,Hippocampus
1118,,10576,CHEMBL616063,,1,BAO_0000249,B,,H,Autocuration,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,
1119,,10576,CHEMBL616064,,1,BAO_0000249,B,,H,Autocuration,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,Striatum
1120,Rattus norvegicus,10576,CHEMBL616065,,1,BAO_0000249,B,10116.0,D,Expert,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,,
1121,Rattus norvegicus,10576,CHEMBL616066,,1,BAO_0000249,B,10116.0,D,Expert,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,,
1122,,10576,CHEMBL616067,,1,BAO_0000221,B,,H,Autocuration,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1123,,10576,CHEMBL616068,,1,BAO_0000221,B,,H,Autocuration,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,,Hippocampus
1124,,10576,CHEMBL616069,,1,BAO_0000221,B,,H,Intermediate,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1125,,10576,CHEMBL616070,,1,BAO_0000249,B,,H,Expert,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,
1126,,10576,CHEMBL616071,,1,BAO_0000221,B,,H,Autocuration,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1127,,10576,CHEMBL616072,,1,BAO_0000221,B,,H,Expert,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,Hippocampus
1128,,10576,CHEMBL616073,,1,BAO_0000221,B,,H,Autocuration,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,,Hippocampus
1129,,10576,CHEMBL616074,,1,BAO_0000221,B,,H,Autocuration,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,,Hippocampus
1130,,10576,CHEMBL616075,,1,BAO_0000019,B,,H,Expert,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,
1131,,10576,CHEMBL616076,,1,BAO_0000357,B,,H,Autocuration,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,
1132,Rattus norvegicus,10576,CHEMBL616077,,1,BAO_0000019,B,10116.0,D,Expert,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,,
1133,Rattus norvegicus,10576,CHEMBL616078,,1,BAO_0000019,B,10116.0,D,Expert,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,,
1134,Rattus norvegicus,10576,CHEMBL616079,,1,BAO_0000019,B,10116.0,D,Expert,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,,
1135,Rattus norvegicus,10576,CHEMBL616080,,1,BAO_0000219,B,10116.0,D,Expert,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,,
1136,,10576,CHEMBL616081,,1,BAO_0000357,B,,H,Autocuration,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1137,Rattus norvegicus,10576,CHEMBL616082,,1,BAO_0000221,B,10116.0,D,Expert,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,,Hippocampus
1138,,10576,CHEMBL616083,,1,BAO_0000221,B,,H,Autocuration,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,,Hippocampus
1139,,10576,CHEMBL616084,,1,BAO_0000019,B,,H,Autocuration,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,
1140,,10576,CHEMBL616085,,1,BAO_0000019,B,,H,Expert,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,
1141,,10576,CHEMBL616086,,1,BAO_0000019,B,,H,Autocuration,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,
1142,,10576,CHEMBL616087,,1,BAO_0000221,B,,H,Autocuration,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,,Hippocampus
1143,,10576,CHEMBL616088,,1,BAO_0000357,B,,H,Expert,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,
1144,,10576,CHEMBL616089,,1,BAO_0000019,B,,H,Autocuration,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,
1145,Rattus norvegicus,10576,CHEMBL616090,,1,BAO_0000357,B,10116.0,D,Expert,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,,
1146,,10576,CHEMBL616091,,1,BAO_0000357,B,,H,Autocuration,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,
1147,,10576,CHEMBL616092,,1,BAO_0000249,B,,H,Autocuration,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,Striatum
1148,,10576,CHEMBL616093,,1,BAO_0000357,B,,H,Autocuration,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,
1149,,10576,CHEMBL616094,,1,BAO_0000218,B,,H,Autocuration,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),In vivo,,,
1150,,10576,CHEMBL616095,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,,Brain
1151,Rattus norvegicus,10576,CHEMBL616096,,1,BAO_0000357,B,10116.0,D,Expert,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,
1152,,10576,CHEMBL616097,,1,BAO_0000249,B,,H,Expert,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,
1153,Rattus norvegicus,10576,CHEMBL616098,,1,BAO_0000249,B,10116.0,D,Expert,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,,
1154,,10576,CHEMBL616099,,1,BAO_0000221,B,,H,Autocuration,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1155,,10576,CHEMBL616100,,1,BAO_0000221,B,,H,Autocuration,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1156,,10576,CHEMBL616101,,1,BAO_0000357,B,,H,Expert,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,
1157,,10576,CHEMBL616102,,1,BAO_0000249,B,,H,Expert,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,
1158,,10576,CHEMBL616103,,1,BAO_0000357,B,,H,Autocuration,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,
1159,,10576,CHEMBL616104,,1,BAO_0000019,B,,H,Expert,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,
1160,,10576,CHEMBL616105,,1,BAO_0000019,B,,H,Expert,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,
1161,Rattus norvegicus,10576,CHEMBL616106,,1,BAO_0000019,B,10116.0,D,Expert,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,,
1162,,10576,CHEMBL616107,,1,BAO_0000019,B,,H,Autocuration,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,
1163,,10576,CHEMBL616108,,1,BAO_0000357,B,,H,Expert,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,
1164,,10576,CHEMBL616109,,1,BAO_0000221,B,,H,Expert,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,Hippocampus
1165,,10576,CHEMBL616110,,1,BAO_0000357,B,,H,Autocuration,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,
1166,,10576,CHEMBL616111,,1,BAO_0000219,B,,H,Expert,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,,
1167,,10576,CHEMBL616112,,1,BAO_0000019,B,,H,Expert,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,
1168,,10576,CHEMBL616113,,1,BAO_0000221,B,,H,Autocuration,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,,Hippocampus
1169,,10576,CHEMBL616114,,1,BAO_0000019,B,,H,Autocuration,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,
1170,,10576,CHEMBL616115,,1,BAO_0000019,B,,H,Autocuration,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,
1171,,10576,CHEMBL616116,,1,BAO_0000357,B,,H,Autocuration,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,
1172,,10576,CHEMBL615844,,1,BAO_0000221,B,,H,Expert,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,,Brain
1173,,10576,CHEMBL615939,,1,BAO_0000221,B,,H,Expert,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1174,,10576,CHEMBL615940,,1,BAO_0000019,B,,H,Expert,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,
1175,,10576,CHEMBL615941,,1,BAO_0000221,B,,H,Expert,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,,Hippocampus
1176,,10576,CHEMBL615942,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,,Hippocampus
1177,,10576,CHEMBL615943,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,Hippocampus
1178,,10576,CHEMBL615944,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,,Hippocampus
1179,,10576,CHEMBL615945,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,,Hippocampus
1180,,10576,CHEMBL615946,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,,Hippocampus
1181,,10576,CHEMBL615947,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,,Hippocampus
1182,,10576,CHEMBL615948,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,,Hippocampus
1183,,10576,CHEMBL615949,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,,Hippocampus
1184,,10576,CHEMBL615950,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,,Hippocampus
1185,,10576,CHEMBL615951,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,,Hippocampus
1186,,10576,CHEMBL615952,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,,Hippocampus
1187,,10576,CHEMBL615953,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,,Hippocampus
1188,,10576,CHEMBL615954,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,,Hippocampus
1189,Rattus norvegicus,10576,CHEMBL615955,,1,BAO_0000221,B,10116.0,D,Expert,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,Hippocampus
1190,,10576,CHEMBL615956,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,,Hippocampus
1191,,10576,CHEMBL615957,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,,Hippocampus
1192,,10576,CHEMBL615958,,1,BAO_0000019,B,,H,Expert,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,
1193,,10576,CHEMBL615959,,1,BAO_0000019,B,,H,Expert,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,
1194,,10576,CHEMBL615960,,1,BAO_0000019,B,,H,Autocuration,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,
1195,,10576,CHEMBL615961,,1,BAO_0000019,B,,H,Autocuration,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,
1196,,10576,CHEMBL615962,,1,BAO_0000221,B,,H,Expert,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,Brain
1197,,10576,CHEMBL615963,,1,BAO_0000019,B,,H,Expert,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,
1198,,10576,CHEMBL615964,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,
1199,,10576,CHEMBL615965,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,
1200,,10576,CHEMBL615966,,1,BAO_0000219,B,,H,Expert,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,,
1201,,10576,CHEMBL615967,,1,BAO_0000249,B,,H,Expert,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,
1202,,10576,CHEMBL615968,,1,BAO_0000019,B,,H,Expert,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,
1203,,10576,CHEMBL615969,,1,BAO_0000218,B,,H,Autocuration,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,
1204,,10576,CHEMBL615970,,1,BAO_0000218,B,,H,Autocuration,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,
1205,Rattus norvegicus,10576,CHEMBL615971,,1,BAO_0000357,B,10116.0,D,Expert,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,,
1206,,10576,CHEMBL615972,,1,BAO_0000249,B,,H,Expert,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,
1207,,10576,CHEMBL615973,,1,BAO_0000249,B,,H,Autocuration,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,
1208,,10576,CHEMBL615974,,1,BAO_0000249,B,,H,Autocuration,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,
1209,Homo sapiens,51,CHEMBL615975,,1,BAO_0000219,B,9606.0,D,Expert,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,
1210,,10576,CHEMBL615976,,1,BAO_0000249,B,,H,Expert,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,
1211,Rattus norvegicus,10576,CHEMBL872106,,1,BAO_0000221,B,10116.0,D,Expert,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,Hippocampus
1212,,10576,CHEMBL615977,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
1213,,10576,CHEMBL615978,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,
1214,,10576,CHEMBL616166,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,
1215,,10576,CHEMBL616167,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,
1216,,10576,CHEMBL616168,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,
1217,,10576,CHEMBL616169,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,
1218,,10576,CHEMBL616170,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,
1219,,10576,CHEMBL616171,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,
1220,,10576,CHEMBL616172,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,
1221,,10576,CHEMBL616173,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,
1222,,10576,CHEMBL616174,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,
1223,,10576,CHEMBL616175,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,
1224,,10576,CHEMBL616176,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,
1225,,10576,CHEMBL616177,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,
1226,,10576,CHEMBL616178,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,
1227,,10576,CHEMBL616179,,1,BAO_0000019,B,,H,Autocuration,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,
1228,,10576,CHEMBL616180,,1,BAO_0000357,B,,H,Autocuration,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,
1229,,10576,CHEMBL616181,,1,BAO_0000357,B,,H,Autocuration,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,
1230,,10576,CHEMBL616182,,1,BAO_0000019,B,,H,Autocuration,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,
1231,,10576,CHEMBL616183,,1,BAO_0000221,B,,H,Autocuration,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1232,,10576,CHEMBL615874,,1,BAO_0000019,B,,H,Expert,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,
1233,Rattus norvegicus,10576,CHEMBL615875,,1,BAO_0000219,B,10116.0,D,Expert,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,,,
1234,,10576,CHEMBL615876,,1,BAO_0000019,B,,H,Autocuration,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,
1235,,10576,CHEMBL615877,,1,BAO_0000019,B,,H,Autocuration,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,
1236,,10576,CHEMBL615878,,1,BAO_0000357,B,,H,Autocuration,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,
1237,,10576,CHEMBL615879,,1,BAO_0000357,B,,H,Expert,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,
1238,,10576,CHEMBL615880,,1,BAO_0000357,B,,H,Expert,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,
1239,,10576,CHEMBL615881,,1,BAO_0000019,B,,H,Autocuration,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,
1240,Rattus norvegicus,10576,CHEMBL615882,,1,BAO_0000019,B,10116.0,D,Expert,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,
1241,,10576,CHEMBL615883,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,In vivo,,,
1242,,10576,CHEMBL615884,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),In vivo,,,
1243,,10576,CHEMBL615885,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),In vivo,,,
1244,,10576,CHEMBL615886,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),In vivo,,,
1245,,10576,CHEMBL615887,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),In vivo,,,
1246,,10576,CHEMBL615888,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),In vivo,,,
1247,,10576,CHEMBL615889,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),In vivo,,,
1248,,10576,CHEMBL615890,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),In vivo,,,
1249,,10576,CHEMBL615891,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),In vivo,,,
1250,,10576,CHEMBL615892,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),In vivo,,,
1251,,10576,CHEMBL615893,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),In vivo,,,
1252,,10576,CHEMBL615894,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),In vivo,,,
1253,,10576,CHEMBL615895,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),In vivo,,,
1254,,10576,CHEMBL615896,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),In vivo,,,
1255,,10576,CHEMBL615897,,1,BAO_0000218,F,,H,Autocuration,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,In vivo,,,
1256,Rattus norvegicus,10576,CHEMBL615898,,1,BAO_0000249,F,10116.0,D,Expert,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,,
1257,,10576,CHEMBL615899,,1,BAO_0000019,B,,H,Autocuration,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,
1258,,10576,CHEMBL616291,,1,BAO_0000019,B,,H,Autocuration,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,
1259,,10576,CHEMBL616292,,1,BAO_0000357,B,,H,Autocuration,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,
1260,,10576,CHEMBL616293,,1,BAO_0000249,F,,H,Autocuration,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,
1261,,10576,CHEMBL616294,,1,BAO_0000221,B,,H,Expert,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1262,,10576,CHEMBL616295,,1,BAO_0000249,B,,H,Autocuration,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,,Hippocampus
1263,,10576,CHEMBL616296,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,,Brain
1264,,10576,CHEMBL616297,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,
1265,,10576,CHEMBL616605,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,
1266,,10576,CHEMBL616606,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,
1267,,10576,CHEMBL616607,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,
1268,,10576,CHEMBL616608,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,
1269,,10576,CHEMBL616609,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,
1270,Rattus norvegicus,10576,CHEMBL616610,,1,BAO_0000019,F,10116.0,D,Expert,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,,
1271,,10576,CHEMBL616611,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,
1272,,10576,CHEMBL616612,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,
1273,,10576,CHEMBL616613,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,
1274,,10576,CHEMBL616614,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,
1275,,10576,CHEMBL616615,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,
1276,,10576,CHEMBL616616,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,
1277,,10576,CHEMBL616617,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,
1278,,10576,CHEMBL616618,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,
1279,,10576,CHEMBL616619,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,
1280,,10576,CHEMBL616620,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,
1281,,10576,CHEMBL616621,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,
1282,,10576,CHEMBL616622,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,
1283,,10576,CHEMBL616146,,1,BAO_0000019,F,,H,Expert,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,
1284,,10576,CHEMBL832873,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,
1285,,10576,CHEMBL616147,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,
1286,,10576,CHEMBL872872,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,
1287,,10576,CHEMBL616148,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,
1288,,10576,CHEMBL616149,,1,BAO_0000221,B,,H,Autocuration,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,,Hippocampus
1289,,10576,CHEMBL616150,,1,BAO_0000221,B,,H,Expert,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,,Hippocampus
1290,Rattus norvegicus,10576,CHEMBL616151,,1,BAO_0000249,B,10116.0,D,Expert,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,,
1291,,10576,CHEMBL872873,,1,BAO_0000221,B,,H,Expert,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,,Hippocampus
1292,,10576,CHEMBL616670,,1,BAO_0000221,B,,H,Autocuration,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,,Hippocampus
1293,,10576,CHEMBL616671,,1,BAO_0000221,B,,H,Autocuration,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,,Hippocampus
1294,Rattus norvegicus,10576,CHEMBL884861,,1,BAO_0000249,F,10116.0,D,Expert,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,,
1295,,10576,CHEMBL616672,,1,BAO_0000357,B,,H,Autocuration,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,
1296,,10576,CHEMBL616673,,1,BAO_0000019,B,,H,Autocuration,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,
1297,,10576,CHEMBL616674,,1,BAO_0000019,F,,H,Expert,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,
1298,,10576,CHEMBL616675,,1,BAO_0000357,B,,H,Autocuration,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,
1299,,10576,CHEMBL616676,,1,BAO_0000221,B,,H,Autocuration,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,,Hippocampus
1300,,10576,CHEMBL616677,,1,BAO_0000221,B,,H,Autocuration,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus
1301,,10576,CHEMBL616678,,1,BAO_0000221,B,,H,Autocuration,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus
1302,Rattus norvegicus,10576,CHEMBL616679,,1,BAO_0000357,B,10116.0,D,Expert,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,
1303,,10576,CHEMBL616680,,1,BAO_0000221,B,,H,Expert,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,,Hippocampus
1304,,10576,CHEMBL616681,,1,BAO_0000221,B,,H,Autocuration,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1305,,10576,CHEMBL616682,,1,BAO_0000221,B,,H,Autocuration,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1306,,10576,CHEMBL616683,,1,BAO_0000221,B,,H,Autocuration,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1307,,10576,CHEMBL616684,,1,BAO_0000221,B,,H,Autocuration,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1308,,10576,CHEMBL616685,,1,BAO_0000221,B,,H,Autocuration,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,,Hippocampus
1309,,10576,CHEMBL616686,,1,BAO_0000221,B,,H,Autocuration,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,,Brain
1310,,10576,CHEMBL616687,,1,BAO_0000357,B,,H,Autocuration,9919,Affinity for 5-hydroxytryptamine 1A receptor site,,,,
1311,,10576,CHEMBL616688,,1,BAO_0000357,B,,H,Autocuration,9919,Affinity for 5-hydroxytryptamine 1A receptor site,,,,
1312,,10576,CHEMBL616689,,1,BAO_0000221,B,,H,Autocuration,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,,Hippocampus
1313,,10576,CHEMBL616690,,1,BAO_0000357,B,,H,Autocuration,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,
1314,,10576,CHEMBL616691,,1,BAO_0000357,B,,H,Expert,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,
1315,Rattus norvegicus,10576,CHEMBL616692,,1,BAO_0000221,B,10116.0,D,Expert,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,,Hippocampus
1316,,10576,CHEMBL616693,,1,BAO_0000249,B,,H,Expert,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,
1317,Rattus norvegicus,10576,CHEMBL616694,,1,BAO_0000019,B,10116.0,D,Expert,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,
1318,,10576,CHEMBL616695,,1,BAO_0000221,B,,H,Autocuration,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,,Hippocampus
1319,,10576,CHEMBL616696,,1,BAO_0000357,B,,H,Autocuration,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,
1320,,10576,CHEMBL616697,,1,BAO_0000357,B,,H,Autocuration,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,
1321,,10576,CHEMBL616698,,1,BAO_0000357,B,,H,Autocuration,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,
1322,Rattus norvegicus,10576,CHEMBL616949,,1,BAO_0000019,B,10116.0,D,Expert,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,,
1323,,10576,CHEMBL616950,,1,BAO_0000221,B,,H,Autocuration,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,,Hippocampus
1324,,10576,CHEMBL832875,,1,BAO_0000357,B,,H,Autocuration,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,
1325,,10576,CHEMBL616951,,1,BAO_0000221,B,,H,Expert,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,Brain
1326,,10576,CHEMBL616952,,1,BAO_0000221,B,,H,Expert,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,Brain
1327,,10576,CHEMBL616953,,1,BAO_0000357,B,,H,Expert,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,
1328,,10576,CHEMBL616954,,1,BAO_0000357,B,,H,Autocuration,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,
1329,,106,CHEMBL616955,,1,BAO_0000357,B,,H,Autocuration,14875,GTPgammaS radioligand binding assay,,,,
1330,,106,CHEMBL616956,,1,BAO_0000357,B,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,
1331,,106,CHEMBL616957,,1,BAO_0000019,F,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,
1332,,106,CHEMBL616958,,1,BAO_0000019,F,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,
1333,,106,CHEMBL616959,,1,BAO_0000357,B,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,
1334,,106,CHEMBL616960,,1,BAO_0000357,B,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,
1335,,106,CHEMBL616961,,1,BAO_0000019,F,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,
1336,,106,CHEMBL616962,,1,BAO_0000219,B,,H,Expert,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,,
1337,,106,CHEMBL616963,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,,
1338,Homo sapiens,106,CHEMBL616524,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,,
1339,,106,CHEMBL616525,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,
1340,,106,CHEMBL872908,,1,BAO_0000019,B,,H,Autocuration,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,
1341,,106,CHEMBL616526,,1,BAO_0000019,B,,H,Autocuration,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,
1342,Homo sapiens,106,CHEMBL616527,,1,BAO_0000357,B,9606.0,D,Expert,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,,
1343,,106,CHEMBL616528,,1,BAO_0000219,B,,H,Expert,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,
1344,,106,CHEMBL616529,,1,BAO_0000357,B,,H,Autocuration,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,
1345,,106,CHEMBL616530,,1,BAO_0000357,B,,H,Autocuration,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,
1346,,106,CHEMBL616531,,1,BAO_0000357,B,,H,Expert,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,
1347,,106,CHEMBL616532,,1,BAO_0000357,B,,H,Autocuration,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,
1348,,106,CHEMBL616533,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,
1349,,106,CHEMBL616534,,1,BAO_0000357,B,,H,Expert,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,
1350,,106,CHEMBL616535,,1,BAO_0000357,B,,H,Expert,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,
1351,,106,CHEMBL616536,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,
1352,,106,CHEMBL616537,,1,BAO_0000357,B,,H,Autocuration,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,
1353,,106,CHEMBL616538,,1,BAO_0000219,F,,H,Expert,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,,
1354,,106,CHEMBL616539,,1,BAO_0000019,F,,H,Expert,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,
1355,,106,CHEMBL616540,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,
1356,,106,CHEMBL616429,,1,BAO_0000357,B,,H,Autocuration,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,
1357,,106,CHEMBL616430,,1,BAO_0000357,B,,H,Expert,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,
1358,Homo sapiens,106,CHEMBL616431,,1,BAO_0000219,B,9606.0,D,Expert,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,,
1359,Homo sapiens,106,CHEMBL616432,,1,BAO_0000357,B,9606.0,D,Expert,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,
1360,Homo sapiens,106,CHEMBL616433,,1,BAO_0000357,B,9606.0,D,Expert,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,,
1361,Homo sapiens,106,CHEMBL616434,,1,BAO_0000357,B,9606.0,D,Expert,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,,
1362,,106,CHEMBL616435,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,,
1363,,106,CHEMBL616436,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,
1364,,106,CHEMBL616437,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,
1365,,106,CHEMBL616438,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,,
1366,,106,CHEMBL616439,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,
1367,Homo sapiens,106,CHEMBL616440,,1,BAO_0000357,B,9606.0,D,Expert,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,,
1368,,106,CHEMBL616441,,1,BAO_0000219,B,,H,Autocuration,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,,
1369,,106,CHEMBL616442,,1,BAO_0000357,B,,H,Expert,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,
1370,,106,CHEMBL616443,,1,BAO_0000357,B,,H,Autocuration,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,
1371,,106,CHEMBL616444,,1,BAO_0000219,B,,H,Expert,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,,
1372,Homo sapiens,106,CHEMBL616445,,1,BAO_0000357,B,9606.0,D,Expert,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,,,,
1373,Homo sapiens,106,CHEMBL616446,,1,BAO_0000357,B,9606.0,D,Expert,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,,,,
1374,Homo sapiens,106,CHEMBL616447,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,
1375,,106,CHEMBL616448,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,
1376,,106,CHEMBL616449,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,,
1377,,106,CHEMBL616450,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,,
1378,,106,CHEMBL857974,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,,
1379,,106,CHEMBL616451,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,
1380,,106,CHEMBL616452,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,
1381,,106,CHEMBL616453,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,
1382,,106,CHEMBL616454,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,,
1383,Homo sapiens,106,CHEMBL616455,,1,BAO_0000357,B,9606.0,D,Expert,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,,
1384,,106,CHEMBL616456,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,
1385,,106,CHEMBL616457,,1,BAO_0000357,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,
1386,,106,CHEMBL616458,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,
1387,,106,CHEMBL616459,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,,
1388,,106,CHEMBL616460,,1,BAO_0000019,F,,H,Expert,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,
1389,,106,CHEMBL616461,,1,BAO_0000019,F,,H,Expert,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,
1390,,106,CHEMBL616462,,1,BAO_0000219,F,,H,Autocuration,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,
1391,,106,CHEMBL616463,,1,BAO_0000219,F,,H,Autocuration,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,
1392,,105,CHEMBL616464,,1,BAO_0000019,F,,H,Autocuration,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,
1393,,105,CHEMBL616465,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,,
1394,,17105,CHEMBL832874,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1395,Oryctolagus cuniculus,106,CHEMBL616184,,1,BAO_0000019,F,9986.0,H,Autocuration,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,,
1396,Oryctolagus cuniculus,106,CHEMBL616185,,1,BAO_0000019,B,9986.0,H,Autocuration,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,,
1397,Oryctolagus cuniculus,106,CHEMBL616186,,1,BAO_0000019,B,9986.0,H,Intermediate,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,,
1398,Oryctolagus cuniculus,106,CHEMBL616187,,1,BAO_0000019,B,9986.0,H,Autocuration,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,,
1399,,10577,CHEMBL616188,,1,BAO_0000357,B,,H,Expert,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,
1400,,10577,CHEMBL873475,,1,BAO_0000357,B,,D,Intermediate,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,
1401,Rattus norvegicus,10577,CHEMBL616189,,1,BAO_0000019,B,10116.0,D,Expert,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,,Striatum
1402,,10577,CHEMBL616190,,1,BAO_0000357,B,,H,Expert,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,
1403,,10576,CHEMBL616191,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,
1404,,10576,CHEMBL616192,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,
1405,,10576,CHEMBL616193,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,
1406,,10576,CHEMBL616194,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,
1407,,10576,CHEMBL616195,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,
1408,,10576,CHEMBL616196,,1,BAO_0000357,B,,H,Autocuration,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,
1409,,10576,CHEMBL616197,,1,BAO_0000249,B,,H,Autocuration,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,,Hippocampus
1410,,10576,CHEMBL616198,,1,BAO_0000019,B,,H,Intermediate,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,
1411,,10576,CHEMBL616199,,1,BAO_0000221,B,,H,Autocuration,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,Hippocampus
1412,,10576,CHEMBL616200,,1,BAO_0000221,B,,H,Expert,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,,Hippocampus
1413,,10576,CHEMBL616201,,1,BAO_0000221,B,,H,Expert,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1414,,10576,CHEMBL616202,,1,BAO_0000221,B,,H,Expert,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,Hippocampus
1415,,10576,CHEMBL616203,,1,BAO_0000221,B,,H,Expert,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,Hippocampus
1416,,10576,CHEMBL616204,,1,BAO_0000221,B,,H,Expert,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,,Hippocampus
1417,,10576,CHEMBL616205,,1,BAO_0000221,B,,H,Expert,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,,Hippocampus
1418,,10576,CHEMBL616206,,1,BAO_0000221,B,,H,Expert,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,,Hippocampus
1419,,10576,CHEMBL616207,,1,BAO_0000249,B,,H,Expert,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,
1420,,10576,CHEMBL616208,,1,BAO_0000249,B,,H,Autocuration,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,
1421,,10576,CHEMBL616209,,1,BAO_0000249,B,,H,Autocuration,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,
1422,,10576,CHEMBL616210,,1,BAO_0000357,B,,H,Expert,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,
1423,,10576,CHEMBL616211,,1,BAO_0000221,B,,H,Expert,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,,Hippocampus
1424,,10576,CHEMBL616504,,1,BAO_0000221,B,,H,Autocuration,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,,Hippocampus
1425,Rattus norvegicus,10576,CHEMBL616505,,1,BAO_0000221,B,10116.0,D,Expert,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1426,,10576,CHEMBL616506,,1,BAO_0000019,F,,H,Autocuration,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,
1427,,10576,CHEMBL872107,,1,BAO_0000221,B,,H,Autocuration,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus
1428,Rattus norvegicus,10576,CHEMBL616507,,1,BAO_0000221,B,10116.0,D,Expert,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,,Hippocampus
1429,,10576,CHEMBL616303,,1,BAO_0000249,B,,H,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,
1430,,10576,CHEMBL616304,,1,BAO_0000221,B,,H,Autocuration,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,,Hippocampus
1431,,10576,CHEMBL616305,,1,BAO_0000221,B,,H,Expert,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,Hippocampus
1432,,10576,CHEMBL616306,,1,BAO_0000221,F,,H,Intermediate,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1433,,10576,CHEMBL616307,,1,BAO_0000357,B,,H,Autocuration,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,
1434,Rattus norvegicus,10576,CHEMBL881829,,1,BAO_0000221,B,10116.0,D,Expert,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,,Hippocampus
1435,,10576,CHEMBL616308,,1,BAO_0000357,B,,H,Expert,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,
1436,,10576,CHEMBL616309,,1,BAO_0000019,B,,H,Autocuration,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,
1437,,10576,CHEMBL616310,,1,BAO_0000019,B,,H,Expert,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,
1438,,10576,CHEMBL616311,,1,BAO_0000219,B,,H,Autocuration,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,,
1439,,10576,CHEMBL616312,,1,BAO_0000357,B,,H,Expert,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,
1440,,10576,CHEMBL616313,,1,BAO_0000357,B,,H,Autocuration,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,
1441,Rattus norvegicus,10576,CHEMBL616314,,1,BAO_0000221,B,10116.0,D,Expert,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus
1442,,10576,CHEMBL616315,,1,BAO_0000221,B,,H,Autocuration,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1443,,10576,CHEMBL616567,,1,BAO_0000221,B,,H,Autocuration,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,,Hippocampus
1444,,10576,CHEMBL616568,,1,BAO_0000221,B,,H,Autocuration,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,,Hippocampus
1445,,10576,CHEMBL616569,,1,BAO_0000019,B,,H,Intermediate,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,
1446,,10576,CHEMBL616570,,1,BAO_0000357,B,,H,Expert,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,
1447,,10576,CHEMBL616571,,1,BAO_0000357,B,,H,Autocuration,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,
1448,,10576,CHEMBL616572,,1,BAO_0000221,B,,H,Autocuration,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,,Hippocampus
1449,,10576,CHEMBL616573,,1,BAO_0000249,B,,H,Expert,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,
1450,Rattus norvegicus,10576,CHEMBL616574,,1,BAO_0000357,B,10116.0,D,Expert,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,,
1451,,10576,CHEMBL616575,,1,BAO_0000221,B,,H,Expert,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,,Hippocampus
1452,,10576,CHEMBL872108,,1,BAO_0000221,B,,H,Autocuration,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,,Hippocampus
1453,,10576,CHEMBL616576,,1,BAO_0000357,B,,H,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,
1454,,10576,CHEMBL616577,,1,BAO_0000249,B,,H,Autocuration,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,
1455,,10576,CHEMBL616578,,1,BAO_0000249,B,,H,Autocuration,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,
1456,,10576,CHEMBL616579,,1,BAO_0000357,B,,H,Expert,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,
1457,Rattus norvegicus,10576,CHEMBL616580,,1,BAO_0000019,B,10116.0,D,Expert,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,,
1458,,10576,CHEMBL616581,,1,BAO_0000019,B,,H,Autocuration,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,
1459,,10576,CHEMBL616582,,1,BAO_0000221,B,,H,Autocuration,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1460,,10576,CHEMBL616583,,1,BAO_0000221,B,,H,Expert,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus
1461,Rattus norvegicus,10576,CHEMBL616584,,1,BAO_0000221,B,10116.0,D,Expert,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,,Hippocampus
1462,,10576,CHEMBL616585,,1,BAO_0000357,B,,H,Expert,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1463,Rattus norvegicus,10576,CHEMBL616586,,1,BAO_0000221,B,10116.0,D,Expert,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,,Hippocampus
1464,,10576,CHEMBL616587,,1,BAO_0000221,B,,H,Autocuration,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,,Hippocampus
1465,,10576,CHEMBL616588,,1,BAO_0000221,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,,Hippocampus
1466,,10576,CHEMBL616589,,1,BAO_0000221,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,Hippocampus
1467,,10576,CHEMBL616590,,1,BAO_0000221,B,,H,Expert,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus
1468,,10576,CHEMBL616591,,1,BAO_0000219,B,,H,Expert,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,,
1469,,10576,CHEMBL616592,,1,BAO_0000357,B,,H,Expert,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,
1470,,10576,CHEMBL616593,,1,BAO_0000357,B,,H,Autocuration,10058,The inhibition activity of 5-HT1A at 1 uM,,,,
1471,,10576,CHEMBL616594,,1,BAO_0000219,B,,H,Expert,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,,
1472,,10576,CHEMBL616595,,1,BAO_0000249,B,,H,Expert,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,
1473,,10576,CHEMBL616596,,1,BAO_0000357,B,,H,Autocuration,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,
1474,,10576,CHEMBL616597,,1,BAO_0000221,B,,H,Autocuration,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,Hippocampus
1475,,10576,CHEMBL616598,,1,BAO_0000221,B,,H,Expert,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,Hippocampus
1476,Rattus norvegicus,10576,CHEMBL616599,,1,BAO_0000249,F,10116.0,D,Expert,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,,
1477,Rattus norvegicus,10576,CHEMBL616600,,1,BAO_0000249,F,10116.0,D,Expert,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,,Hippocampus
1478,,10576,CHEMBL616601,,1,BAO_0000019,B,,H,Autocuration,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,
1479,,10576,CHEMBL616602,,1,BAO_0000019,B,,H,Autocuration,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,
1480,,10576,CHEMBL616603,,1,BAO_0000019,B,,H,Autocuration,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,
1481,,10576,CHEMBL616604,,1,BAO_0000019,B,,H,Autocuration,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,
1482,,10576,CHEMBL616316,,1,BAO_0000249,B,,H,Autocuration,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,
1483,,10576,CHEMBL616317,,1,BAO_0000249,B,,H,Autocuration,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,
1484,Rattus norvegicus,10576,CHEMBL616318,,1,BAO_0000019,B,10116.0,D,Expert,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,,
1485,,10576,CHEMBL616319,,1,BAO_0000221,B,,H,Autocuration,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,,Hippocampus
1486,,10576,CHEMBL616320,,1,BAO_0000221,B,,H,Autocuration,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,,Hippocampus
1487,Rattus norvegicus,10576,CHEMBL616321,,1,BAO_0000221,B,10116.0,D,Expert,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,,Hippocampus
1488,,10576,CHEMBL616322,,1,BAO_0000019,F,,H,Autocuration,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,
1489,,10576,CHEMBL616323,,1,BAO_0000019,F,,H,Autocuration,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,
1490,,10576,CHEMBL616324,,1,BAO_0000357,B,,H,Autocuration,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,
1491,,10576,CHEMBL616325,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,Hippocampus
1492,,10576,CHEMBL616326,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,Hippocampus
1493,,10576,CHEMBL616327,,1,BAO_0000221,B,,H,Autocuration,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,,Hippocampus
1494,,10576,CHEMBL616328,,1,BAO_0000357,B,,H,Autocuration,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,
1495,,10576,CHEMBL858110,,1,BAO_0000249,B,,H,Autocuration,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,
1496,,10576,CHEMBL616329,,1,BAO_0000249,F,,H,Autocuration,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,
1497,,10576,CHEMBL616330,,1,BAO_0000249,B,,H,Autocuration,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,
1498,,10576,CHEMBL616331,,1,BAO_0000249,F,,H,Autocuration,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,
1499,,10576,CHEMBL616332,,1,BAO_0000249,F,,H,Autocuration,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,
1500,,10576,CHEMBL857063,,1,BAO_0000249,B,,H,Autocuration,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain
1501,,10576,CHEMBL616333,,1,BAO_0000019,B,,H,Autocuration,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,
1502,,10576,CHEMBL616334,,1,BAO_0000019,F,,H,Expert,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,
1503,,10576,CHEMBL616335,,1,BAO_0000221,B,,H,Autocuration,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,Hippocampus
1504,,10576,CHEMBL616336,,1,BAO_0000019,B,,H,Autocuration,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,
1505,,10576,CHEMBL616337,,1,BAO_0000249,B,,H,Expert,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,
1506,,10576,CHEMBL616338,,1,BAO_0000019,B,,H,Autocuration,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,
1507,,10576,CHEMBL616339,,1,BAO_0000221,B,,H,Autocuration,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,,Hippocampus
1508,,10576,CHEMBL616340,,1,BAO_0000221,B,,H,Autocuration,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,,Hippocampus
1509,,10576,CHEMBL616341,,1,BAO_0000357,B,,H,Autocuration,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,
1510,Rattus norvegicus,10576,CHEMBL616342,,1,BAO_0000357,B,10116.0,D,Expert,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,
1511,Rattus norvegicus,10576,CHEMBL616343,,1,BAO_0000019,B,10116.0,D,Expert,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,,
1512,,10576,CHEMBL616344,,1,BAO_0000019,B,,H,Expert,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,
1513,,10576,CHEMBL616345,,1,BAO_0000357,B,,H,Expert,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,
1514,,10576,CHEMBL616346,,1,BAO_0000019,B,,H,Expert,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,
1515,,10576,CHEMBL616347,,1,BAO_0000221,B,,H,Autocuration,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,Hippocampus
1516,,10576,CHEMBL616348,,1,BAO_0000019,B,,H,Expert,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,
1517,,10576,CHEMBL616349,,1,BAO_0000357,B,,H,Expert,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,
1518,Rattus norvegicus,10576,CHEMBL616152,,1,BAO_0000249,B,10116.0,D,Expert,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,,
1519,,10576,CHEMBL616153,,1,BAO_0000249,B,,H,Autocuration,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,
1520,,10576,CHEMBL616154,,1,BAO_0000019,B,,H,Expert,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,
1521,,10576,CHEMBL616155,,1,BAO_0000019,B,,H,Autocuration,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,
1522,Rattus norvegicus,10576,CHEMBL616156,,1,BAO_0000221,B,10116.0,D,Expert,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,,Hippocampus
1523,Rattus norvegicus,10576,CHEMBL616157,,1,BAO_0000221,B,10116.0,D,Expert,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,,Hippocampus
1524,,10576,CHEMBL616158,,1,BAO_0000221,B,,H,Autocuration,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,,Hippocampus
1525,,10576,CHEMBL616159,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,
1526,,10576,CHEMBL616160,,1,BAO_0000357,B,,H,Expert,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,
1527,,10576,CHEMBL616161,,1,BAO_0000019,B,,H,Autocuration,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,
1528,,10576,CHEMBL616162,,1,BAO_0000019,F,,H,Autocuration,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,
1529,Rattus norvegicus,12687,CHEMBL616163,,1,BAO_0000357,B,10116.0,D,Expert,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,,
1530,,10626,CHEMBL616164,,1,BAO_0000249,B,,H,Expert,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,
1531,,10576,CHEMBL616165,,1,BAO_0000221,B,,H,Autocuration,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,,Brain
1532,Rattus norvegicus,51,CHEMBL616355,,1,BAO_0000019,B,10116.0,H,Autocuration,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,,
1533,,10576,CHEMBL616356,,1,BAO_0000019,F,,H,Autocuration,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,
1534,,10576,CHEMBL616357,,1,BAO_0000221,B,,H,Autocuration,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,Brain
1535,,10576,CHEMBL616358,,1,BAO_0000019,B,,H,Autocuration,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,
1536,,51,CHEMBL616359,,1,BAO_0000357,B,,H,Autocuration,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1537,,51,CHEMBL616360,,1,BAO_0000357,B,,H,Expert,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,
1538,,51,CHEMBL616361,,1,BAO_0000357,B,,H,Expert,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1539,,51,CHEMBL616362,,1,BAO_0000357,B,,H,Autocuration,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,
1540,,51,CHEMBL616363,,1,BAO_0000249,B,,H,Autocuration,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,
1541,,51,CHEMBL616364,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,
1542,,51,CHEMBL616365,,1,BAO_0000357,B,,H,Autocuration,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,
1543,,51,CHEMBL616366,,1,BAO_0000357,B,,H,Expert,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,
1544,,51,CHEMBL872906,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,
1545,,51,CHEMBL616367,,1,BAO_0000357,B,,H,Autocuration,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,
1546,,51,CHEMBL616368,,1,BAO_0000357,B,,H,Autocuration,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1547,,51,CHEMBL616369,,1,BAO_0000357,B,,H,Autocuration,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,
1548,Homo sapiens,51,CHEMBL616370,,1,BAO_0000357,B,9606.0,D,Expert,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,,
1549,Homo sapiens,51,CHEMBL616371,,1,BAO_0000357,B,9606.0,D,Expert,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,,
1550,,51,CHEMBL616372,,1,BAO_0000219,B,,H,Autocuration,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
1551,,51,CHEMBL616373,,1,BAO_0000219,B,,H,Expert,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,
1552,,51,CHEMBL616374,,1,BAO_0000218,B,,H,Autocuration,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,In vivo,,,
1553,,51,CHEMBL616375,,1,BAO_0000221,B,,H,Autocuration,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus
1554,,51,CHEMBL616376,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,
1555,,51,CHEMBL857064,,1,BAO_0000357,B,,H,Expert,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,
1556,,51,CHEMBL616377,,1,BAO_0000357,B,,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,
1557,,51,CHEMBL616378,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,
1558,,51,CHEMBL616379,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,
1559,,11863,CHEMBL616380,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,
1560,,11863,CHEMBL616381,,1,BAO_0000357,B,,H,Autocuration,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,
1561,,11863,CHEMBL616382,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,
1562,,11863,CHEMBL616383,,1,BAO_0000357,B,,H,Autocuration,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,
1563,Mus musculus,11863,CHEMBL616350,,1,BAO_0000219,B,10090.0,D,Expert,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,,,
1564,,11863,CHEMBL616351,,1,BAO_0000357,B,,H,Autocuration,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,
1565,,11863,CHEMBL616352,,1,BAO_0000357,B,,H,Autocuration,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,
1566,,11863,CHEMBL616353,,1,BAO_0000357,B,,H,Autocuration,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1567,,11863,CHEMBL616354,,1,BAO_0000357,B,,H,Autocuration,13033,Binding affinity against serotonergic 5-HT1a receptor,,,,
1568,,11863,CHEMBL616508,,1,BAO_0000357,B,,H,Autocuration,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,
1569,Mus musculus,11863,CHEMBL616559,,1,BAO_0000357,B,10090.0,D,Expert,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,
1570,,11863,CHEMBL616560,,1,BAO_0000357,B,,H,Autocuration,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,
1571,,11863,CHEMBL616561,,1,BAO_0000357,B,,H,Autocuration,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,
1572,,11863,CHEMBL616562,,1,BAO_0000219,B,,H,Autocuration,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
1573,,11863,CHEMBL616563,,1,BAO_0000219,B,,H,Autocuration,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,
1574,,11863,CHEMBL616564,,1,BAO_0000357,B,,H,Autocuration,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,
1575,,11863,CHEMBL616565,,1,BAO_0000357,B,,H,Autocuration,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,
1576,,11863,CHEMBL616566,,1,BAO_0000218,B,,H,Autocuration,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,
1577,,11863,CHEMBL616989,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,
1578,,11863,CHEMBL857975,,1,BAO_0000357,B,,H,Autocuration,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,
1579,Mus musculus,11863,CHEMBL616990,,1,BAO_0000357,B,10090.0,D,Expert,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1580,,11863,CHEMBL616991,,1,BAO_0000357,B,,H,Autocuration,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,
1581,,11863,CHEMBL616992,,1,BAO_0000357,B,,H,Autocuration,12146,Tested against 5-hydroxytryptamine 1A receptor,,,,
1582,,11863,CHEMBL616993,,1,BAO_0000357,B,,H,Autocuration,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,
1583,Oryctolagus cuniculus,106,CHEMBL616994,,1,BAO_0000019,B,9986.0,H,Expert,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,,
1584,Oryctolagus cuniculus,106,CHEMBL616995,,1,BAO_0000019,B,9986.0,H,Autocuration,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,,
1585,Gorilla gorilla,105571,CHEMBL616996,,1,BAO_0000219,B,9593.0,D,Intermediate,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,,
1586,Cavia porcellus,106,CHEMBL616997,,1,BAO_0000218,F,10141.0,H,Autocuration,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,,,
1587,Cavia porcellus,106,CHEMBL616998,,1,BAO_0000218,F,10141.0,H,Autocuration,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,In vivo,,,
1588,Cavia porcellus,106,CHEMBL616999,,1,BAO_0000019,F,10141.0,H,Autocuration,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,,
1589,Cavia porcellus,106,CHEMBL617000,,1,BAO_0000019,F,10141.0,H,Autocuration,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,,
1590,Cavia porcellus,106,CHEMBL617001,,1,BAO_0000019,F,10141.0,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,,
1591,Cavia porcellus,106,CHEMBL858111,,1,BAO_0000019,F,10141.0,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,,
1592,,106,CHEMBL617002,,1,BAO_0000019,F,,H,Autocuration,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,
1593,,106,CHEMBL617003,,1,BAO_0000019,F,,H,Autocuration,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,
1594,,106,CHEMBL617004,,1,BAO_0000019,F,,H,Autocuration,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,
1595,Homo sapiens,106,CHEMBL617005,,1,BAO_0000019,F,9606.0,D,Expert,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,,
1596,Homo sapiens,106,CHEMBL616623,,1,BAO_0000219,F,9606.0,D,Expert,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,,,
1597,,106,CHEMBL616624,,1,BAO_0000219,F,,H,Autocuration,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,,
1598,,106,CHEMBL883243,,1,BAO_0000357,B,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,
1599,,106,CHEMBL616625,,1,BAO_0000019,F,,H,Autocuration,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,
1600,,106,CHEMBL616626,,1,BAO_0000219,F,,H,Expert,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,,
1601,,106,CHEMBL616627,,1,BAO_0000219,F,,H,Autocuration,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,,
1602,,106,CHEMBL616628,,1,BAO_0000219,F,,H,Autocuration,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,,
1603,,106,CHEMBL616629,,1,BAO_0000219,F,,H,Autocuration,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,,
1604,,106,CHEMBL616630,,1,BAO_0000219,F,,H,Autocuration,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,,
1605,,106,CHEMBL616631,,1,BAO_0000019,F,,H,Expert,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,
1606,,106,CHEMBL616632,,1,BAO_0000019,F,,H,Autocuration,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,
1607,Homo sapiens,106,CHEMBL616633,,1,BAO_0000357,B,9606.0,D,Expert,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,,
1608,,106,CHEMBL616634,,1,BAO_0000219,B,,H,Expert,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,,
1609,,106,CHEMBL616635,,1,BAO_0000357,B,,H,Autocuration,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,
1610,Homo sapiens,106,CHEMBL885358,,1,BAO_0000357,B,9606.0,D,Expert,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1611,Homo sapiens,106,CHEMBL616636,,1,BAO_0000219,B,9606.0,D,Expert,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,
1612,,106,CHEMBL616637,,1,BAO_0000219,B,,H,Expert,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,,
1613,,106,CHEMBL616638,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,
1614,,106,CHEMBL616639,,1,BAO_0000219,B,,H,Expert,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,
1615,,106,CHEMBL616640,,1,BAO_0000219,B,,H,Expert,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,
1616,,106,CHEMBL616641,,1,BAO_0000219,B,,H,Expert,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,
1617,,106,CHEMBL616642,,1,BAO_0000219,B,,H,Expert,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,,
1618,,106,CHEMBL616643,,1,BAO_0000219,B,,H,Expert,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,
1619,,106,CHEMBL616644,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,
1620,,106,CHEMBL616645,,1,BAO_0000357,B,,H,Autocuration,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,
1621,Oryctolagus cuniculus,105,CHEMBL616646,,1,BAO_0000019,F,9986.0,H,Autocuration,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,,
1622,Oryctolagus cuniculus,105,CHEMBL616647,,1,BAO_0000019,F,9986.0,H,Expert,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,,
1623,,105,CHEMBL616509,,1,BAO_0000357,B,,H,Autocuration,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,
1624,,105,CHEMBL616510,,1,BAO_0000357,B,,H,Autocuration,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,
1625,,105,CHEMBL616511,,1,BAO_0000357,B,,H,Autocuration,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,
1626,Bos taurus,105,CHEMBL616512,,1,BAO_0000357,B,9913.0,H,Expert,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,,
1627,Bos taurus,105,CHEMBL616513,,1,BAO_0000357,B,9913.0,H,Autocuration,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,,
1628,Bos taurus,105,CHEMBL616514,,1,BAO_0000019,B,9913.0,H,Autocuration,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,,Striatum
1629,Bos taurus,105,CHEMBL616515,,1,BAO_0000357,B,9913.0,H,Expert,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,,
1630,Bos taurus,105,CHEMBL616516,,1,BAO_0000019,B,9913.0,H,Autocuration,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,,
1631,Bos taurus,105,CHEMBL616517,,1,BAO_0000357,B,9913.0,H,Autocuration,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,,
1632,Bos taurus,105,CHEMBL616518,,1,BAO_0000357,B,9913.0,H,Autocuration,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,,
1633,Bos taurus,105,CHEMBL616519,,1,BAO_0000357,B,9913.0,H,Autocuration,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,,
1634,Bos taurus,105,CHEMBL616520,,1,BAO_0000357,B,9913.0,H,Autocuration,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,,
1635,Bos taurus,105,CHEMBL616521,,1,BAO_0000357,B,9913.0,H,Autocuration,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,,
1636,Bos taurus,105,CHEMBL616522,,1,BAO_0000357,B,9913.0,H,Autocuration,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,,
1637,Bos taurus,105,CHEMBL884531,,1,BAO_0000357,B,9913.0,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,,
1638,Bos taurus,105,CHEMBL616523,,1,BAO_0000357,B,9913.0,H,Autocuration,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,,
1639,Bos taurus,105,CHEMBL616731,,1,BAO_0000019,B,9913.0,H,Autocuration,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,,Striatum
1640,Bos taurus,105,CHEMBL616732,,1,BAO_0000019,B,9913.0,H,Autocuration,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,,
1641,Bos taurus,105,CHEMBL616733,,1,BAO_0000357,B,9913.0,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,,
1642,Bos taurus,105,CHEMBL616734,,1,BAO_0000357,B,9913.0,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,,
1643,Bos taurus,105,CHEMBL616735,,1,BAO_0000249,B,9913.0,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,,
1644,Bos taurus,105,CHEMBL616736,,1,BAO_0000249,B,9913.0,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,,
1645,Bos taurus,105,CHEMBL616737,,1,BAO_0000019,F,9913.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,
1646,Bos taurus,105,CHEMBL616738,,1,BAO_0000019,B,9913.0,H,Autocuration,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,,
1647,Bos taurus,105,CHEMBL616739,,1,BAO_0000019,F,9913.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,
1648,Bos taurus,105,CHEMBL616740,,1,BAO_0000019,F,9913.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,
1649,Bos taurus,105,CHEMBL616741,,1,BAO_0000019,F,9913.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,
1650,Gorilla gorilla,105,CHEMBL616742,,1,BAO_0000219,B,9593.0,H,Autocuration,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,,,
1651,Cavia porcellus,105570,CHEMBL616743,,1,BAO_0000019,B,10141.0,D,Intermediate,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,,
1652,Cavia porcellus,105570,CHEMBL616744,,1,BAO_0000019,B,10141.0,D,Intermediate,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,,
1653,Cavia porcellus,105570,CHEMBL616745,,1,BAO_0000019,F,10141.0,D,Intermediate,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,,
1654,Cavia porcellus,105570,CHEMBL616746,,1,BAO_0000019,F,10141.0,D,Intermediate,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,
1655,Cavia porcellus,105570,CHEMBL616747,,1,BAO_0000019,F,10141.0,D,Intermediate,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,,
1656,Cavia porcellus,105570,CHEMBL616748,,1,BAO_0000019,F,10141.0,D,Intermediate,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,,
1657,Cavia porcellus,105570,CHEMBL616648,,1,BAO_0000019,F,10141.0,D,Intermediate,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,,
1658,Cavia porcellus,105570,CHEMBL616649,,1,BAO_0000357,B,10141.0,D,Intermediate,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1659,Cavia porcellus,105570,CHEMBL616650,,1,BAO_0000357,B,10141.0,D,Intermediate,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,,
1660,Cavia porcellus,105570,CHEMBL616651,,1,BAO_0000218,F,10141.0,D,Intermediate,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,
1661,Cavia porcellus,105570,CHEMBL616652,,1,BAO_0000218,F,10141.0,D,Intermediate,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,
1662,Cavia porcellus,105570,CHEMBL616653,,1,BAO_0000218,F,10141.0,D,Intermediate,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,
1663,Cavia porcellus,105570,CHEMBL616654,,1,BAO_0000218,F,10141.0,D,Intermediate,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,,
1664,Cavia porcellus,105570,CHEMBL616655,,1,BAO_0000019,B,10141.0,D,Intermediate,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,,
1665,Cavia porcellus,105570,CHEMBL616656,,1,BAO_0000357,B,10141.0,D,Intermediate,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,,
1666,Cavia porcellus,105,CHEMBL616657,,1,BAO_0000019,B,10141.0,H,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,,
1667,Cavia porcellus,105570,CHEMBL616658,,1,BAO_0000357,B,10141.0,D,Intermediate,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,,Striatum
1668,Cavia porcellus,105570,CHEMBL616659,,1,BAO_0000357,B,10141.0,D,Intermediate,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,,
1669,,51,CHEMBL616660,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1670,,106,CHEMBL616661,,1,BAO_0000357,B,,H,Autocuration,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,
1671,,105,CHEMBL616662,,1,BAO_0000019,F,,H,Expert,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,
1672,,105,CHEMBL616663,,1,BAO_0000019,F,,H,Autocuration,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,
1673,,105,CHEMBL616664,,1,BAO_0000019,F,,H,Autocuration,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,
1674,Homo sapiens,105,CHEMBL881820,,1,BAO_0000219,F,9606.0,D,Expert,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,,,
1675,,105,CHEMBL616665,,1,BAO_0000219,F,,H,Autocuration,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,,
1676,,105,CHEMBL616666,,1,BAO_0000219,B,,H,Expert,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,
1677,,105,CHEMBL616667,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,,
1678,,105,CHEMBL616668,,1,BAO_0000219,F,,H,Expert,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,
1679,Homo sapiens,105,CHEMBL616669,,1,BAO_0000219,F,9606.0,D,Expert,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,
1680,,105,CHEMBL617040,,1,BAO_0000219,F,,H,Expert,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,,
1681,,105,CHEMBL617041,,1,BAO_0000219,F,,H,Autocuration,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,,
1682,,105,CHEMBL617042,,1,BAO_0000219,F,,H,Expert,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,,
1683,,105,CHEMBL617043,,1,BAO_0000219,F,,H,Expert,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,,
1684,,105,CHEMBL617044,,1,BAO_0000019,F,,H,Autocuration,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,
1685,,105,CHEMBL617045,,1,BAO_0000219,F,,H,Expert,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,
1686,Homo sapiens,105,CHEMBL617046,,1,BAO_0000219,F,9606.0,D,Expert,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,,
1687,Homo sapiens,105,CHEMBL617047,,1,BAO_0000219,F,9606.0,D,Expert,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,,,
1688,,105,CHEMBL617048,,1,BAO_0000019,F,,H,Expert,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,
1689,,105,CHEMBL616897,,1,BAO_0000019,F,,H,Autocuration,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,
1690,Homo sapiens,105,CHEMBL616898,,1,BAO_0000019,F,9606.0,D,Expert,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,,
1691,Homo sapiens,105,CHEMBL858201,,1,BAO_0000219,F,9606.0,D,Expert,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,,,
1692,,105,CHEMBL616899,,1,BAO_0000019,F,,H,Autocuration,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,
1693,,105,CHEMBL616900,,1,BAO_0000219,B,,H,Autocuration,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),In vitro,,,
1694,,105,CHEMBL616901,,1,BAO_0000219,B,,H,Expert,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,,
1695,,105,CHEMBL616902,,1,BAO_0000357,B,,H,Autocuration,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,
1696,Homo sapiens,105,CHEMBL616903,,1,BAO_0000219,B,9606.0,D,Expert,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,
1697,,105,CHEMBL616904,,1,BAO_0000219,B,,H,Expert,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,,
1698,,105,CHEMBL616905,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,
1699,,105,CHEMBL616906,,1,BAO_0000219,B,,H,Expert,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,
1700,,105,CHEMBL616907,,1,BAO_0000219,B,,H,Expert,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,
1701,,105,CHEMBL616908,,1,BAO_0000219,B,,H,Expert,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,
1702,Homo sapiens,105,CHEMBL616909,,1,BAO_0000219,B,9606.0,D,Expert,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,
1703,Homo sapiens,105,CHEMBL616910,,1,BAO_0000219,B,9606.0,D,Expert,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,
1704,,105,CHEMBL616911,,1,BAO_0000219,B,,H,Expert,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,
1705,,105,CHEMBL616912,,1,BAO_0000219,B,,H,Expert,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,
1706,,105,CHEMBL616913,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,
1707,Homo sapiens,105,CHEMBL616914,,1,BAO_0000219,B,9606.0,D,Expert,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,,,
1708,,105,CHEMBL616915,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,
1709,,105,CHEMBL616916,,1,BAO_0000019,B,,H,Autocuration,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,
1710,Homo sapiens,105,CHEMBL616917,,1,BAO_0000357,B,9606.0,D,Expert,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,,
1711,,105,CHEMBL616918,,1,BAO_0000357,B,,H,Autocuration,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,
1712,,105,CHEMBL616919,,1,BAO_0000219,B,,H,Expert,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,
1713,,105,CHEMBL616920,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,
1714,,105,CHEMBL872914,,1,BAO_0000357,B,,H,Autocuration,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,
1715,,105,CHEMBL616921,,1,BAO_0000357,B,,H,Autocuration,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,
1716,,105,CHEMBL616922,,1,BAO_0000357,B,,H,Expert,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,
1717,,105,CHEMBL616923,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,
1718,,105,CHEMBL616924,,1,BAO_0000357,B,,H,Expert,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,
1719,,105,CHEMBL875909,,1,BAO_0000357,B,,H,Expert,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,
1720,,105,CHEMBL616925,,1,BAO_0000357,B,,H,Autocuration,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,
1721,,105,CHEMBL616926,,1,BAO_0000357,B,,H,Autocuration,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,
1722,,105,CHEMBL616927,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,
1723,,105,CHEMBL616928,,1,BAO_0000219,F,,H,Expert,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,,
1724,Homo sapiens,105,CHEMBL616929,,1,BAO_0000219,B,9606.0,D,Expert,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),In vitro,,,
1725,Homo sapiens,105,CHEMBL616930,,1,BAO_0000357,B,9606.0,D,Expert,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,,
1726,,105,CHEMBL616931,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,
1727,,105,CHEMBL616932,,1,BAO_0000357,B,,H,Autocuration,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,
1728,,105,CHEMBL616933,,1,BAO_0000357,B,,H,Expert,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,
1729,Homo sapiens,105,CHEMBL616934,,1,BAO_0000219,B,9606.0,D,Expert,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,,
1730,Homo sapiens,105,CHEMBL616935,,1,BAO_0000357,B,9606.0,D,Expert,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,,
1731,,105,CHEMBL616936,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,
1732,Homo sapiens,105,CHEMBL616937,,1,BAO_0000357,B,9606.0,D,Expert,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,,
1733,Homo sapiens,105,CHEMBL616938,,1,BAO_0000357,B,9606.0,D,Expert,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,,
1734,,105,CHEMBL616939,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,
1735,,105,CHEMBL616940,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,
1736,Homo sapiens,105,CHEMBL616941,,1,BAO_0000357,B,9606.0,D,Expert,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,,
1737,,105,CHEMBL616942,,1,BAO_0000219,B,,H,Autocuration,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,,
1738,,105,CHEMBL616943,,1,BAO_0000219,B,,H,Autocuration,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,,
1739,,104802,CHEMBL616944,,1,BAO_0000219,B,,H,Autocuration,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,,
1740,,105,CHEMBL616945,,1,BAO_0000019,F,,H,Autocuration,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,
1741,,105,CHEMBL616946,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
1742,,105,CHEMBL616947,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
1743,,105,CHEMBL616948,,1,BAO_0000219,B,,H,Expert,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,,
1744,,105,CHEMBL616851,,1,BAO_0000357,B,,H,Autocuration,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,
1745,,105,CHEMBL616852,,1,BAO_0000357,B,,H,Autocuration,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,
1746,,105,CHEMBL616853,,1,BAO_0000357,B,,H,Autocuration,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,
1747,Homo sapiens,105,CHEMBL616854,,1,BAO_0000357,B,9606.0,D,Expert,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,,,,
1748,Homo sapiens,105,CHEMBL616855,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,
1749,,105,CHEMBL616856,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,,
1750,,105,CHEMBL616857,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
1751,,105,CHEMBL616858,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,
1752,,105,CHEMBL616859,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,,
1753,,105,CHEMBL616860,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,,
1754,,105,CHEMBL616861,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,
1755,,105,CHEMBL616541,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,
1756,,105,CHEMBL616542,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,,
1757,,105,CHEMBL616543,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,,
1758,Homo sapiens,105,CHEMBL616544,,1,BAO_0000357,B,9606.0,D,Expert,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,,
1759,,105,CHEMBL616545,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,,
1760,,105,CHEMBL616546,,1,BAO_0000357,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,
1761,,105,CHEMBL616547,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,,
1762,,105,CHEMBL616548,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,,
1763,,105,CHEMBL616549,,1,BAO_0000019,F,,H,Expert,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,
1764,,105,CHEMBL616550,,1,BAO_0000019,F,,H,Expert,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,
1765,,108,CHEMBL857066,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-HT2C receptor,,,,
1766,,108,CHEMBL616551,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1767,,10577,CHEMBL616552,,1,BAO_0000357,B,,H,Autocuration,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,
1768,,10577,CHEMBL832876,,1,BAO_0000019,F,,H,Autocuration,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,
1769,,10577,CHEMBL616553,,1,BAO_0000019,B,,H,Expert,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,
1770,,10577,CHEMBL616554,,1,BAO_0000357,B,,H,Autocuration,9098,Binding affinity towards 5-HT1B was determined,,,,
1771,,10577,CHEMBL616555,,1,BAO_0000019,B,,H,Expert,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,
1772,,10577,CHEMBL616556,,1,BAO_0000019,B,,H,Expert,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,
1773,,10577,CHEMBL616557,,1,BAO_0000019,B,,H,Autocuration,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,
1774,,10577,CHEMBL616558,,1,BAO_0000019,B,,H,Expert,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,
1775,Rattus norvegicus,10577,CHEMBL616749,,1,BAO_0000019,B,10116.0,D,Expert,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,,
1776,,10577,CHEMBL616750,,1,BAO_0000357,B,,H,Autocuration,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,
1777,,10577,CHEMBL616751,,1,BAO_0000357,B,,H,Autocuration,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,
1778,,10577,CHEMBL616752,,1,BAO_0000249,B,,H,Autocuration,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,
1779,,10577,CHEMBL616753,,1,BAO_0000019,B,,H,Autocuration,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,,Striatum
1780,Rattus norvegicus,10577,CHEMBL616754,,1,BAO_0000357,B,10116.0,D,Expert,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,,
1781,,10577,CHEMBL616755,,1,BAO_0000019,B,,H,Autocuration,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,
1782,,10577,CHEMBL616756,,1,BAO_0000019,B,,H,Autocuration,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,,Striatum
1783,,10577,CHEMBL616757,,1,BAO_0000019,B,,H,Autocuration,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,,Striatum
1784,,10577,CHEMBL616758,,1,BAO_0000357,B,,H,Autocuration,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,,Striatum
1785,,10577,CHEMBL616759,,1,BAO_0000249,B,,H,Autocuration,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,
1786,,10577,CHEMBL616760,,1,BAO_0000357,B,,H,Autocuration,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,
1787,,10577,CHEMBL616761,,1,BAO_0000019,B,,H,Autocuration,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,,Striatum
1788,,10577,CHEMBL616762,,1,BAO_0000019,B,,H,Autocuration,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,,Striatum
1789,,10577,CHEMBL616763,,1,BAO_0000019,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,
1790,,10577,CHEMBL872909,,1,BAO_0000357,B,,H,Expert,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,
1791,,10577,CHEMBL616764,,1,BAO_0000357,B,,H,Autocuration,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,
1792,Rattus norvegicus,10577,CHEMBL616765,,1,BAO_0000357,B,10116.0,D,Expert,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,,
1793,,10577,CHEMBL616766,,1,BAO_0000357,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,,Striatum
1794,,10577,CHEMBL616767,,1,BAO_0000357,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,,Striatum
1795,,10577,CHEMBL616768,,1,BAO_0000357,B,,H,Autocuration,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,
1796,,10577,CHEMBL616769,,1,BAO_0000357,B,,H,Autocuration,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,
1797,,10577,CHEMBL616770,,1,BAO_0000019,B,,H,Autocuration,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,
1798,,10577,CHEMBL616771,,1,BAO_0000019,B,,H,Autocuration,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,
1799,,10577,CHEMBL616772,,1,BAO_0000019,B,,H,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,,Striatum
1800,,10577,CHEMBL616773,,1,BAO_0000019,B,,H,Expert,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,
1801,,10577,CHEMBL616774,,1,BAO_0000019,B,,H,Autocuration,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,
1802,,10577,CHEMBL616775,,1,BAO_0000357,B,,H,Autocuration,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,
1803,,10577,CHEMBL616776,,1,BAO_0000249,B,,H,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,
1804,,10577,CHEMBL616777,,1,BAO_0000357,B,,H,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,
1805,,10577,CHEMBL616778,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,
1806,Rattus norvegicus,10577,CHEMBL616779,,1,BAO_0000249,B,10116.0,D,Expert,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,,
1807,Rattus norvegicus,10577,CHEMBL616780,,1,BAO_0000357,B,10116.0,D,Expert,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,
1808,,10577,CHEMBL616781,,1,BAO_0000019,B,,H,Autocuration,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,
1809,,10577,CHEMBL616782,,1,BAO_0000357,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,
1810,,10577,CHEMBL616783,,1,BAO_0000357,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,
1811,,10577,CHEMBL616784,,1,BAO_0000019,B,,H,Expert,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,,Striatum
1812,,10577,CHEMBL616785,,1,BAO_0000357,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,
1813,,10577,CHEMBL857067,,1,BAO_0000249,B,,H,Autocuration,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain
1814,,10577,CHEMBL616786,,1,BAO_0000019,B,,H,Autocuration,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,
1815,,10577,CHEMBL616787,,1,BAO_0000249,B,,H,Autocuration,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain
1816,,10577,CHEMBL616788,,1,BAO_0000357,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,
1817,,10577,CHEMBL616789,,1,BAO_0000357,B,,H,Autocuration,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,
1818,Rattus norvegicus,10577,CHEMBL616790,,1,BAO_0000019,B,10116.0,D,Expert,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,,
1819,,10577,CHEMBL616791,,1,BAO_0000357,B,,H,Expert,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,
1820,,10577,CHEMBL616792,,1,BAO_0000019,B,,H,Autocuration,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,
1821,Rattus norvegicus,10577,CHEMBL616793,,1,BAO_0000249,B,10116.0,D,Expert,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,,
1822,,10577,CHEMBL616794,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,
1823,,10577,CHEMBL616795,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,
1824,,104686,CHEMBL616796,,1,BAO_0000019,B,,H,Autocuration,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,
1825,,106,CHEMBL616797,,1,BAO_0000357,B,,H,Autocuration,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1826,,106,CHEMBL616798,,1,BAO_0000249,B,,H,Autocuration,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,
1827,,106,CHEMBL616799,,1,BAO_0000357,B,,H,Autocuration,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,
1828,,106,CHEMBL616800,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,
1829,,106,CHEMBL616801,,1,BAO_0000357,B,,H,Autocuration,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,
1830,,106,CHEMBL616802,,1,BAO_0000357,B,,H,Autocuration,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,
1831,,106,CHEMBL616803,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,
1832,,106,CHEMBL857068,,1,BAO_0000357,B,,H,Expert,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,
1833,,106,CHEMBL616804,,1,BAO_0000357,B,,H,Autocuration,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,
1834,,106,CHEMBL616805,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,
1835,,106,CHEMBL616806,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,
1836,,106,CHEMBL616807,,1,BAO_0000357,B,,H,Autocuration,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,
1837,,106,CHEMBL616808,,1,BAO_0000357,B,,H,Autocuration,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,
1838,,106,CHEMBL616809,,1,BAO_0000357,B,,H,Autocuration,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,
1839,,106,CHEMBL616810,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,
1840,,104802,CHEMBL616811,,1,BAO_0000224,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,
1841,Bos taurus,108,CHEMBL616812,,1,BAO_0000357,B,9913.0,H,Autocuration,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,,
1842,Sus scrofa,108,CHEMBL616813,,1,BAO_0000357,B,9823.0,H,Autocuration,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,,
1843,Sus scrofa,108,CHEMBL616814,,1,BAO_0000357,B,9823.0,H,Autocuration,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,,
1844,Sus scrofa,108,CHEMBL616815,,1,BAO_0000357,B,9823.0,H,Autocuration,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,,
1845,Sus scrofa,108,CHEMBL616816,,1,BAO_0000357,B,9823.0,H,Autocuration,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,,
1846,Sus scrofa,108,CHEMBL616817,,1,BAO_0000357,B,9823.0,H,Autocuration,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,,
1847,Sus scrofa,108,CHEMBL616818,,1,BAO_0000357,B,9823.0,H,Autocuration,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,,
1848,Sus scrofa,108,CHEMBL616819,,1,BAO_0000357,B,9823.0,H,Expert,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,,
1849,Sus scrofa,108,CHEMBL616820,,1,BAO_0000357,B,9823.0,H,Expert,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,,
1850,Sus scrofa,108,CHEMBL616821,,1,BAO_0000019,B,9823.0,H,Expert,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,,
1851,Sus scrofa,108,CHEMBL616822,,1,BAO_0000357,B,9823.0,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,,
1852,Oryctolagus cuniculus,108,CHEMBL616823,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,,
1853,Rattus norvegicus,12689,CHEMBL616824,,1,BAO_0000357,B,10116.0,D,Autocuration,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,,
1854,Rattus norvegicus,12689,CHEMBL616825,,1,BAO_0000357,B,10116.0,D,Autocuration,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,,
1855,Rattus norvegicus,12689,CHEMBL616826,,1,BAO_0000357,B,10116.0,D,Autocuration,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,,
1856,Rattus norvegicus,12689,CHEMBL616827,,1,BAO_0000019,B,10116.0,D,Expert,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,,
1857,Rattus norvegicus,12689,CHEMBL616828,,1,BAO_0000357,B,10116.0,D,Autocuration,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,,
1858,Rattus norvegicus,12689,CHEMBL616829,,1,BAO_0000357,B,10116.0,D,Autocuration,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,,
1859,Rattus norvegicus,12689,CHEMBL616830,,1,BAO_0000019,B,10116.0,D,Autocuration,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,,
1860,Rattus norvegicus,12689,CHEMBL616831,,1,BAO_0000357,B,10116.0,D,Expert,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,
1861,Rattus norvegicus,12689,CHEMBL616832,,1,BAO_0000019,B,10116.0,D,Autocuration,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,
1862,Rattus norvegicus,12689,CHEMBL616833,,1,BAO_0000019,B,10116.0,D,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,
1863,Rattus norvegicus,12689,CHEMBL616834,,1,BAO_0000019,B,10116.0,D,Expert,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,
1864,Rattus norvegicus,12689,CHEMBL829595,,1,BAO_0000019,B,10116.0,D,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,
1865,Rattus norvegicus,12689,CHEMBL616835,,1,BAO_0000357,B,10116.0,D,Autocuration,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,,
1866,Rattus norvegicus,12689,CHEMBL872910,,1,BAO_0000249,B,10116.0,D,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,,
1867,,12689,CHEMBL616836,,1,BAO_0000357,B,,H,Expert,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,
1868,Rattus norvegicus,12689,CHEMBL616837,,1,BAO_0000357,B,10116.0,D,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,,
1869,Rattus norvegicus,12689,CHEMBL616466,,1,BAO_0000019,B,10116.0,D,Autocuration,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,,
1870,Rattus norvegicus,12689,CHEMBL616467,,1,BAO_0000219,B,10116.0,D,Autocuration,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,,,
1871,,108,CHEMBL616468,,1,BAO_0000357,B,,H,Autocuration,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,
1872,,108,CHEMBL616469,,1,BAO_0000357,B,,H,Autocuration,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,
1873,,108,CHEMBL616470,,1,BAO_0000357,B,,H,Autocuration,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,
1874,,12689,CHEMBL616471,,1,BAO_0000357,B,,H,Autocuration,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,
1875,,12689,CHEMBL616472,,1,BAO_0000357,B,,H,Autocuration,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,
1876,,12689,CHEMBL616473,,1,BAO_0000357,B,,H,Autocuration,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,
1877,,12689,CHEMBL616474,,1,BAO_0000357,B,,H,Autocuration,13033,Binding affinity against serotonergic 5-HT1c receptor,,,,
1878,,12689,CHEMBL616475,,1,BAO_0000357,B,,H,Autocuration,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,
1879,,12689,CHEMBL616476,,1,BAO_0000357,B,,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,
1880,Oryctolagus cuniculus,105,CHEMBL616477,,1,BAO_0000019,B,9986.0,H,Autocuration,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,,
1881,,104686,CHEMBL616478,,1,BAO_0000224,B,,H,Autocuration,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,
1882,,104686,CHEMBL616479,,1,BAO_0000224,B,,H,Autocuration,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,
1883,,104686,CHEMBL616480,,1,BAO_0000019,B,,H,Autocuration,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,
1884,Rattus norvegicus,104686,CHEMBL616481,,1,BAO_0000019,B,10116.0,D,Autocuration,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,,
1885,Rattus norvegicus,104686,CHEMBL616482,,1,BAO_0000249,B,10116.0,D,Autocuration,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,,
1886,Rattus norvegicus,104686,CHEMBL884713,,1,BAO_0000221,B,10116.0,D,Autocuration,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,,Brain
1887,,104686,CHEMBL616483,,1,BAO_0000224,B,,H,Autocuration,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,
1888,,104686,CHEMBL616484,,1,BAO_0000224,B,,H,Autocuration,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,
1889,,104686,CHEMBL616485,,1,BAO_0000019,B,,H,Autocuration,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,
1890,,104686,CHEMBL616486,,1,BAO_0000224,B,,H,Autocuration,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,
1891,,104686,CHEMBL616487,,1,BAO_0000224,B,,H,Autocuration,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,
1892,,104686,CHEMBL616488,,1,BAO_0000224,B,,H,Autocuration,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,
1893,,104686,CHEMBL616489,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1894,,104686,CHEMBL616490,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1895,,104686,CHEMBL616491,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,
1896,,104686,CHEMBL616492,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,
1897,,104686,CHEMBL616493,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1898,,104686,CHEMBL616494,,1,BAO_0000019,B,,H,Autocuration,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,
1899,,104686,CHEMBL616495,,1,BAO_0000019,B,,H,Autocuration,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,
1900,,104686,CHEMBL616496,,1,BAO_0000019,B,,H,Autocuration,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,
1901,,104686,CHEMBL616497,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1902,,104686,CHEMBL616498,,1,BAO_0000019,B,,H,Autocuration,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,
1903,,104686,CHEMBL616499,,1,BAO_0000019,B,,H,Autocuration,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,
1904,,104686,CHEMBL616500,,1,BAO_0000019,B,,H,Autocuration,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,
1905,Rattus norvegicus,104686,CHEMBL616501,,1,BAO_0000221,B,10116.0,D,Autocuration,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,,Brain
1906,,104686,CHEMBL616502,,1,BAO_0000221,B,,H,Autocuration,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,,Brain
1907,,104686,CHEMBL884529,,1,BAO_0000249,B,,H,Autocuration,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,
1908,,104686,CHEMBL616503,,1,BAO_0000249,B,,H,Autocuration,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,
1909,,104686,CHEMBL616964,,1,BAO_0000224,B,,H,Autocuration,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,
1910,,104686,CHEMBL616965,,1,BAO_0000249,B,,H,Autocuration,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,
1911,,104686,CHEMBL616966,,1,BAO_0000224,B,,H,Autocuration,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,
1912,,104686,CHEMBL616967,,1,BAO_0000224,B,,H,Autocuration,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,
1913,Rattus norvegicus,104686,CHEMBL616968,,1,BAO_0000224,B,10116.0,D,Autocuration,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,,
1914,,104686,CHEMBL616969,,1,BAO_0000224,B,,H,Autocuration,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,
1915,,104686,CHEMBL884530,,1,BAO_0000019,B,,H,Autocuration,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,
1916,,104686,CHEMBL616970,,1,BAO_0000224,B,,H,Autocuration,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,
1917,,104686,CHEMBL616971,,1,BAO_0000224,B,,H,Autocuration,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,
1918,,104686,CHEMBL616972,,1,BAO_0000224,B,,H,Autocuration,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,
1919,,104686,CHEMBL616973,,1,BAO_0000224,B,,H,Autocuration,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,
1920,,104686,CHEMBL616974,,1,BAO_0000224,B,,H,Autocuration,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,
1921,,104686,CHEMBL616975,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,
1922,,104686,CHEMBL616976,,1,BAO_0000019,B,,H,Autocuration,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,
1923,,104686,CHEMBL616977,,1,BAO_0000224,B,,H,Autocuration,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,
1924,,104686,CHEMBL616978,,1,BAO_0000224,B,,H,Autocuration,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,
1925,,104686,CHEMBL616979,,1,BAO_0000224,B,,H,Autocuration,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,
1926,,104686,CHEMBL616980,,1,BAO_0000224,B,,H,Autocuration,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,
1927,,104686,CHEMBL616981,,1,BAO_0000249,B,,H,Autocuration,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,
1928,,104686,CHEMBL616982,,1,BAO_0000249,B,,H,Autocuration,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,
1929,,104686,CHEMBL616983,,1,BAO_0000224,B,,H,Autocuration,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,
1930,,104686,CHEMBL616984,,1,BAO_0000019,B,,H,Autocuration,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,
1931,Rattus norvegicus,104686,CHEMBL616985,,1,BAO_0000224,B,10116.0,D,Autocuration,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,
1932,,104686,CHEMBL616986,,1,BAO_0000224,B,,H,Autocuration,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,
1933,,104686,CHEMBL616987,,1,BAO_0000224,B,,H,Autocuration,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,
1934,,104686,CHEMBL616988,,1,BAO_0000019,B,,H,Autocuration,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,
1935,,104686,CHEMBL617243,,1,BAO_0000019,B,,H,Autocuration,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,
1936,,104686,CHEMBL617244,,1,BAO_0000019,B,,H,Autocuration,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,
1937,Rattus norvegicus,104686,CHEMBL617245,,1,BAO_0000219,B,10116.0,D,Autocuration,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,,
1938,,104686,CHEMBL617246,,1,BAO_0000249,B,,H,Autocuration,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,
1939,,104686,CHEMBL617546,,1,BAO_0000224,B,,H,Autocuration,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,
1940,,104686,CHEMBL617547,,1,BAO_0000249,B,,H,Autocuration,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,
1941,,104686,CHEMBL617548,,1,BAO_0000219,B,,H,Autocuration,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,
1942,,104686,CHEMBL617549,,1,BAO_0000224,B,,H,Autocuration,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
1943,,104686,CHEMBL617550,,1,BAO_0000224,B,,H,Autocuration,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,
1944,,104686,CHEMBL617551,,1,BAO_0000224,B,,H,Autocuration,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,
1945,,104686,CHEMBL617552,,1,BAO_0000249,B,,H,Autocuration,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,
1946,,104686,CHEMBL617553,,1,BAO_0000249,B,,H,Autocuration,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,
1947,,104686,CHEMBL617554,,1,BAO_0000019,F,,H,Autocuration,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,,Thoracic aorta
1948,,104686,CHEMBL617555,,1,BAO_0000019,B,,H,Autocuration,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,
1949,,104686,CHEMBL617556,,1,BAO_0000224,B,,H,Autocuration,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,
1950,,10624,CHEMBL617557,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,
1951,,10624,CHEMBL617558,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,
1952,,17106,CHEMBL617559,,1,BAO_0000357,B,,H,Expert,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,
1953,,17106,CHEMBL617560,,1,BAO_0000357,B,,D,Expert,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,
1954,,17106,CHEMBL617561,,1,BAO_0000249,B,,H,Autocuration,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,
1955,,17106,CHEMBL617562,,1,BAO_0000249,B,,H,Autocuration,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,
1956,,17106,CHEMBL617563,,1,BAO_0000357,B,,H,Autocuration,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,,Striatum
1957,,17106,CHEMBL617564,,1,BAO_0000019,F,,H,Autocuration,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,
1958,,17106,CHEMBL617565,,1,BAO_0000019,B,,H,Expert,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,
1959,,17106,CHEMBL856076,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
1960,,17106,CHEMBL617566,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,
1961,,17106,CHEMBL875911,,1,BAO_0000019,B,,H,Expert,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
1962,,17106,CHEMBL617567,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,
1963,,17106,CHEMBL617568,,1,BAO_0000249,B,,H,Autocuration,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,
1964,,17106,CHEMBL617569,,1,BAO_0000019,B,,H,Expert,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,
1965,,17106,CHEMBL617570,,1,BAO_0000249,B,,H,Expert,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,
1966,,17106,CHEMBL617571,,1,BAO_0000357,B,,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,
1967,Sus scrofa,105,CHEMBL617572,,1,BAO_0000357,B,9823.0,H,Autocuration,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,,
1968,Oryctolagus cuniculus,105,CHEMBL617573,,1,BAO_0000357,B,9986.0,H,Expert,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,,,,
1969,Oryctolagus cuniculus,105,CHEMBL617574,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,,
1970,Oryctolagus cuniculus,105,CHEMBL617575,,1,BAO_0000357,B,9986.0,H,Expert,13047,The compound was tested for binding affinity against 5-HT1D receptor,,,,
1971,,10578,CHEMBL617576,,1,BAO_0000357,B,,H,Autocuration,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,
1972,,10578,CHEMBL617577,,1,BAO_0000019,F,,H,Autocuration,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,
1973,,10578,CHEMBL617578,,1,BAO_0000019,F,,H,Autocuration,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,
1974,,10578,CHEMBL617579,,1,BAO_0000357,B,,H,Autocuration,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,
1975,,10578,CHEMBL617580,,1,BAO_0000019,B,,H,Expert,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,
1976,,10578,CHEMBL617581,,1,BAO_0000249,B,,H,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,
1977,,10578,CHEMBL617582,,1,BAO_0000357,B,,H,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,
1978,,10578,CHEMBL617583,,1,BAO_0000019,B,,H,Expert,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,
1979,,105,CHEMBL617584,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,
1980,,105,CHEMBL617585,,1,BAO_0000357,B,,H,Autocuration,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1981,,105,CHEMBL875912,,1,BAO_0000357,B,,H,Autocuration,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,
1982,,105,CHEMBL617586,,1,BAO_0000357,B,,H,Autocuration,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,
1983,,105,CHEMBL617587,,1,BAO_0000357,B,,H,Autocuration,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,
1984,,105,CHEMBL617588,,1,BAO_0000357,B,,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,
1985,,105,CHEMBL857980,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,
1986,,105,CHEMBL617589,,1,BAO_0000357,B,,H,Autocuration,12146,Tested against 5-hydroxytryptamine 1D receptor,,,,
1987,,105,CHEMBL617590,,1,BAO_0000357,B,,H,Autocuration,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,
1988,,105,CHEMBL617591,,1,BAO_0000219,B,,H,Autocuration,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,
1989,Homo sapiens,105,CHEMBL617592,,1,BAO_0000357,B,9606.0,D,Expert,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,,
1990,,105,CHEMBL617593,,1,BAO_0000357,B,,H,Autocuration,15250,,,,,
1991,,106,CHEMBL617594,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,
1992,,105,CHEMBL617595,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,
1993,,105,CHEMBL617596,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,,
1994,,105,CHEMBL617597,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,
1995,,105,CHEMBL617598,,1,BAO_0000019,B,,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,
1996,,105,CHEMBL872916,,1,BAO_0000357,B,,H,Autocuration,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,
1997,,105,CHEMBL617599,,1,BAO_0000357,B,,H,Expert,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,
1998,,105,CHEMBL617091,,1,BAO_0000357,B,,H,Autocuration,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,
1999,,105,CHEMBL617092,,1,BAO_0000219,B,,H,Expert,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,,
2000,,105,CHEMBL617093,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,
2001,,105,CHEMBL617094,,1,BAO_0000019,F,,H,Autocuration,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,
2002,,105,CHEMBL617095,,1,BAO_0000019,F,,H,Autocuration,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,
2003,,105,CHEMBL617096,,1,BAO_0000019,F,,H,Autocuration,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,
2004,,105,CHEMBL617097,,1,BAO_0000019,F,,H,Autocuration,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,
2005,,105,CHEMBL617098,,1,BAO_0000019,F,,H,Autocuration,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,
2006,,105,CHEMBL617301,,1,BAO_0000357,B,,H,Autocuration,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,
2007,,105,CHEMBL617302,,1,BAO_0000357,B,,H,Autocuration,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,
2008,,105,CHEMBL617303,,1,BAO_0000357,B,,H,Autocuration,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,
2009,,105,CHEMBL617304,,1,BAO_0000357,B,,H,Expert,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,
2010,,105,CHEMBL617305,,1,BAO_0000219,B,,H,Expert,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,,
2011,Homo sapiens,105,CHEMBL617306,,1,BAO_0000219,B,9606.0,D,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,,
2012,,17106,CHEMBL617307,,1,BAO_0000357,B,,H,Autocuration,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,
2013,Oryctolagus cuniculus,105,CHEMBL617308,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,,
2014,,105,CHEMBL617309,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,
2015,,105,CHEMBL617310,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,
2016,,105,CHEMBL617311,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,
2017,,105,CHEMBL617312,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,
2018,,105,CHEMBL617313,,1,BAO_0000357,B,,H,Autocuration,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,
2019,,105,CHEMBL617314,,1,BAO_0000357,B,,H,Expert,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,
2020,,106,CHEMBL617315,,1,BAO_0000019,F,,H,Autocuration,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,
2021,,106,CHEMBL617316,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,,
2022,,106,CHEMBL617317,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,
2023,,106,CHEMBL617318,,1,BAO_0000219,B,,H,Autocuration,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,
2024,,106,CHEMBL617319,,1,BAO_0000019,B,,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,
2025,,106,CHEMBL617320,,1,BAO_0000357,B,,D,Expert,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,
2026,,106,CHEMBL617321,,1,BAO_0000357,B,,D,Expert,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,
2027,,106,CHEMBL617322,,1,BAO_0000357,B,,D,Expert,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,
2028,,106,CHEMBL616862,,1,BAO_0000357,B,,H,Autocuration,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,
2029,,106,CHEMBL616863,,1,BAO_0000357,B,,H,Autocuration,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,
2030,,106,CHEMBL616864,,1,BAO_0000219,B,,H,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,,
2031,,106,CHEMBL616865,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,,
2032,,106,CHEMBL616866,,1,BAO_0000219,B,,H,Autocuration,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,,
2033,,106,CHEMBL616867,,1,BAO_0000019,F,,H,Autocuration,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,
2034,,106,CHEMBL616868,,1,BAO_0000219,B,,H,Expert,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,,
2035,,105,CHEMBL616869,,1,BAO_0000357,B,,H,Expert,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,
2036,,106,CHEMBL616870,,1,BAO_0000219,B,,H,Expert,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,
2037,,105,CHEMBL616871,,1,BAO_0000219,F,,H,Autocuration,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,,
2038,,105,CHEMBL616872,,1,BAO_0000219,F,,H,Autocuration,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,,
2039,,105,CHEMBL616873,,1,BAO_0000219,F,,H,Autocuration,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,,
2040,,105,CHEMBL616838,,1,BAO_0000219,F,,H,Autocuration,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,,
2041,,105,CHEMBL616839,,1,BAO_0000357,B,,H,Autocuration,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,
2042,Oryctolagus cuniculus,106,CHEMBL616840,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,,
2043,,105,CHEMBL616841,,1,BAO_0000357,B,,H,Autocuration,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,
2044,,105,CHEMBL616842,,1,BAO_0000357,B,,H,Autocuration,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,
2045,,105,CHEMBL857976,,1,BAO_0000357,B,,H,Expert,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,
2046,,10618,CHEMBL616843,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,,
2047,Homo sapiens,10618,CHEMBL616844,,1,BAO_0000357,B,9606.0,D,Expert,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,,
2048,,10618,CHEMBL616845,,1,BAO_0000357,B,,H,Autocuration,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,
2049,Homo sapiens,10618,CHEMBL616846,,1,BAO_0000357,B,9606.0,D,Expert,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,,
2050,,10618,CHEMBL616847,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,
2051,,10618,CHEMBL616848,,1,BAO_0000019,B,,H,Autocuration,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,
2052,,10618,CHEMBL616849,,1,BAO_0000357,B,,H,Autocuration,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,
2053,,10618,CHEMBL872911,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,
2054,,10618,CHEMBL616850,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,
2055,Homo sapiens,10618,CHEMBL616699,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,,,
2056,,10618,CHEMBL616700,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,
2057,,10618,CHEMBL616701,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
2058,,10618,CHEMBL616702,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,,
2059,,10618,CHEMBL616703,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,
2060,,10618,CHEMBL616704,,1,BAO_0000357,B,,H,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,
2061,,10618,CHEMBL616705,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,,
2062,,10618,CHEMBL616706,,1,BAO_0000357,B,,H,Autocuration,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,
2063,,10618,CHEMBL616707,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,,
2064,,10618,CHEMBL616708,,1,BAO_0000357,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,
2065,,10618,CHEMBL616709,,1,BAO_0000357,B,,H,Autocuration,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,
2066,,10618,CHEMBL616710,,1,BAO_0000219,B,,H,Autocuration,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,,
2067,,10618,CHEMBL616711,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,,
2068,,10618,CHEMBL616712,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,,
2069,,10618,CHEMBL616713,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,
2070,,10618,CHEMBL616714,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,
2071,,10618,CHEMBL616715,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,
2072,,10618,CHEMBL616716,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,
2073,,279,CHEMBL616717,,1,BAO_0000019,F,,H,Autocuration,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,
2074,,279,CHEMBL616718,,1,BAO_0000019,F,,H,Expert,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,
2075,,279,CHEMBL875905,,1,BAO_0000019,F,,H,Autocuration,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,
2076,,279,CHEMBL616719,,1,BAO_0000019,F,,H,Autocuration,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,
2077,,279,CHEMBL616720,,1,BAO_0000019,F,,H,Expert,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,
2078,,279,CHEMBL616721,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,
2079,,279,CHEMBL616722,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,,
2080,,279,CHEMBL616723,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,
2081,,279,CHEMBL616724,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,,
2082,,279,CHEMBL616725,,1,BAO_0000357,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,
2083,,279,CHEMBL616726,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,
2084,,279,CHEMBL616727,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,
2085,,279,CHEMBL616728,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,
2086,,279,CHEMBL616729,,1,BAO_0000357,B,,H,Autocuration,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,
2087,,279,CHEMBL616730,,1,BAO_0000019,B,,H,Expert,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,
2088,,279,CHEMBL617125,,1,BAO_0000357,B,,H,Autocuration,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,
2089,,279,CHEMBL857977,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,
2090,,279,CHEMBL617126,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,
2091,,279,CHEMBL617127,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,,
2092,,279,CHEMBL617128,,1,BAO_0000357,B,,H,Autocuration,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,
2093,,279,CHEMBL617129,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,,
2094,,279,CHEMBL617130,,1,BAO_0000357,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,
2095,,279,CHEMBL617131,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,,
2096,,279,CHEMBL617132,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,
2097,,279,CHEMBL617133,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,
2098,,279,CHEMBL617134,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,
2099,,279,CHEMBL617135,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,
2100,,279,CHEMBL617136,,1,BAO_0000357,B,,H,Autocuration,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,
2101,,104686,CHEMBL617137,,1,BAO_0000019,B,,H,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,
2102,,104686,CHEMBL617138,,1,BAO_0000019,B,,H,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,
2103,,104686,CHEMBL617139,,1,BAO_0000019,B,,H,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,
2104,,12687,CHEMBL617140,,1,BAO_0000019,B,,H,Autocuration,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,
2105,,104686,CHEMBL617141,,1,BAO_0000218,F,,H,Autocuration,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",In vivo,,,
2106,,104686,CHEMBL858112,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2107,,17005,CHEMBL617142,,1,BAO_0000019,B,,H,Intermediate,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,
2108,Bos taurus,22226,CHEMBL617143,,1,BAO_0000019,B,9913.0,U,Autocuration,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,,
2109,Bos taurus,22226,CHEMBL617144,,1,BAO_0000019,B,9913.0,U,Autocuration,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,,
2110,Bos taurus,22226,CHEMBL617145,,1,BAO_0000019,B,9913.0,U,Autocuration,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,,
2111,,22226,CHEMBL617146,,1,BAO_0000019,B,,U,Autocuration,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,
2112,Cavia porcellus,104784,CHEMBL617147,,1,BAO_0000019,B,10141.0,H,Autocuration,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,,
2113,Cavia porcellus,104784,CHEMBL617148,,1,BAO_0000019,B,10141.0,H,Autocuration,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,,
2114,Cavia porcellus,104784,CHEMBL617149,,1,BAO_0000019,B,10141.0,H,Autocuration,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,,
2115,,104784,CHEMBL617150,,1,BAO_0000224,B,,H,Autocuration,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,
2116,,104784,CHEMBL617151,,1,BAO_0000224,B,,H,Autocuration,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,
2117,,104784,CHEMBL617201,,1,BAO_0000224,B,,H,Autocuration,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,
2118,,10209,CHEMBL617202,,1,BAO_0000357,B,,H,Autocuration,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,
2119,,104826,CHEMBL617203,,1,BAO_0000218,B,,H,Autocuration,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,
2120,,104826,CHEMBL617204,,1,BAO_0000019,B,,H,Autocuration,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,
2121,,104826,CHEMBL617205,,1,BAO_0000224,B,,H,Autocuration,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,
2122,Mus musculus,104826,CHEMBL617206,,1,BAO_0000019,B,10090.0,D,Autocuration,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,,
2123,,104826,CHEMBL617207,,1,BAO_0000218,B,,H,Autocuration,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,In vivo,,,
2124,Mus musculus,104826,CHEMBL617208,,1,BAO_0000019,B,10090.0,D,Autocuration,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,,
2125,,104826,CHEMBL617209,,1,BAO_0000224,B,,H,Autocuration,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2126,,104826,CHEMBL617210,,1,BAO_0000224,B,,H,Autocuration,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,
2127,,104826,CHEMBL617211,,1,BAO_0000224,B,,H,Autocuration,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,
2128,Mus musculus,104826,CHEMBL617212,,1,BAO_0000019,B,10090.0,D,Autocuration,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,
2129,Sus scrofa,104784,CHEMBL617213,,1,BAO_0000224,B,9823.0,H,Autocuration,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,,
2130,Sus scrofa,104784,CHEMBL617214,,1,BAO_0000224,B,9823.0,H,Autocuration,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,,
2131,,22226,CHEMBL617215,,1,BAO_0000221,B,,U,Autocuration,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,
2132,,22226,CHEMBL617216,,1,BAO_0000221,B,,U,Autocuration,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,
2133,Sus scrofa,17005,CHEMBL617217,,1,BAO_0000357,B,9823.0,H,Autocuration,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,,
2134,,104686,CHEMBL617218,,1,BAO_0000019,B,,H,Autocuration,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,
2135,,104686,CHEMBL872913,,1,BAO_0000019,B,,H,Autocuration,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,
2136,,104826,CHEMBL617219,,1,BAO_0000019,B,,H,Autocuration,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,
2137,,104686,CHEMBL873482,,1,BAO_0000224,B,,H,Autocuration,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,
2138,Rattus norvegicus,104686,CHEMBL617220,,1,BAO_0000019,B,10116.0,D,Autocuration,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,,
2139,,104686,CHEMBL617221,,1,BAO_0000019,B,,H,Autocuration,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,
2140,,104686,CHEMBL617222,,1,BAO_0000019,B,,H,Autocuration,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,
2141,,104686,CHEMBL875906,,1,BAO_0000019,F,,H,Autocuration,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,
2142,,104686,CHEMBL617223,,1,BAO_0000019,B,,H,Autocuration,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,
2143,,104686,CHEMBL617224,,1,BAO_0000224,B,,H,Autocuration,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,
2144,Rattus norvegicus,104686,CHEMBL617225,,1,BAO_0000224,B,10116.0,D,Autocuration,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,
2145,,104686,CHEMBL617226,,1,BAO_0000224,B,,H,Autocuration,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,
2146,,104686,CHEMBL617227,,1,BAO_0000224,B,,H,Autocuration,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,
2147,,104686,CHEMBL617228,,1,BAO_0000224,B,,H,Autocuration,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,
2148,,104686,CHEMBL617229,,1,BAO_0000224,B,,H,Autocuration,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,
2149,,104686,CHEMBL617230,,1,BAO_0000224,B,,H,Autocuration,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,
2150,,104686,CHEMBL617231,,1,BAO_0000224,B,,H,Autocuration,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,
2151,,104686,CHEMBL617232,,1,BAO_0000224,B,,H,Autocuration,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,
2152,,104686,CHEMBL617233,,1,BAO_0000224,B,,H,Autocuration,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,
2153,,104686,CHEMBL617234,,1,BAO_0000224,B,,H,Autocuration,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,
2154,,104686,CHEMBL617235,,1,BAO_0000019,F,,H,Autocuration,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,
2155,,104686,CHEMBL617236,,1,BAO_0000019,F,,H,Autocuration,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,
2156,,104686,CHEMBL617237,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,,Hippocampus
2157,,104686,CHEMBL617238,,1,BAO_0000221,B,,H,Autocuration,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,,Hippocampus
2158,Rattus norvegicus,104686,CHEMBL617239,,1,BAO_0000221,B,10116.0,D,Autocuration,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,,Brain
2159,,104686,CHEMBL617240,,1,BAO_0000019,B,,H,Autocuration,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,
2160,,104686,CHEMBL617241,,1,BAO_0000249,B,,H,Autocuration,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,
2161,,104686,CHEMBL875907,,1,BAO_0000249,B,,H,Autocuration,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,
2162,,104686,CHEMBL617242,,1,BAO_0000019,B,,H,Autocuration,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,
2163,,104686,CHEMBL617152,,1,BAO_0000019,F,,H,Autocuration,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,
2164,Rattus norvegicus,104686,CHEMBL617153,,1,BAO_0000221,B,10116.0,D,Autocuration,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,,Brain
2165,Rattus norvegicus,104686,CHEMBL617154,,1,BAO_0000249,B,10116.0,D,Autocuration,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,,
2166,,104686,CHEMBL617155,,1,BAO_0000221,B,,H,Autocuration,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,,Brain
2167,,104686,CHEMBL617156,,1,BAO_0000019,F,,H,Autocuration,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,
2168,,104686,CHEMBL617157,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,
2169,,104686,CHEMBL617158,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2170,,104686,CHEMBL617159,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,
2171,,104686,CHEMBL617160,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,
2172,,104686,CHEMBL858113,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2173,,104686,CHEMBL617247,,1,BAO_0000220,B,,H,Autocuration,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,,Brain
2174,,104686,CHEMBL617248,,1,BAO_0000019,B,,H,Autocuration,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,
2175,,104686,CHEMBL617249,,1,BAO_0000249,B,,H,Autocuration,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain
2176,,104686,CHEMBL617250,,1,BAO_0000019,B,,H,Autocuration,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,
2177,,104686,CHEMBL617251,,1,BAO_0000019,B,,H,Autocuration,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,
2178,Rattus norvegicus,104686,CHEMBL617252,,1,BAO_0000019,B,10116.0,D,Autocuration,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,,
2179,,104686,CHEMBL617006,,1,BAO_0000019,B,,H,Autocuration,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,
2180,,104686,CHEMBL617007,,1,BAO_0000019,B,,H,Autocuration,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,
2181,,104686,CHEMBL617008,,1,BAO_0000019,F,,H,Autocuration,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,
2182,,104686,CHEMBL617009,,1,BAO_0000019,B,,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,
2183,Rattus norvegicus,104686,CHEMBL617010,,1,BAO_0000224,B,10116.0,D,Autocuration,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,,
2184,Rattus norvegicus,104686,CHEMBL857978,,1,BAO_0000019,B,10116.0,D,Autocuration,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,,
2185,Rattus norvegicus,104686,CHEMBL617011,,1,BAO_0000019,B,10116.0,D,Autocuration,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,,
2186,Rattus norvegicus,104686,CHEMBL617012,,1,BAO_0000019,B,10116.0,D,Autocuration,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,,
2187,,104686,CHEMBL617013,,1,BAO_0000224,B,,H,Autocuration,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,
2188,,104686,CHEMBL617014,,1,BAO_0000249,B,,H,Autocuration,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,
2189,,104686,CHEMBL617015,,1,BAO_0000019,B,,H,Autocuration,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,
2190,,104686,CHEMBL617016,,1,BAO_0000019,B,,H,Autocuration,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,
2191,,104686,CHEMBL617017,,1,BAO_0000224,B,,H,Autocuration,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,
2192,,104686,CHEMBL617018,,1,BAO_0000221,B,,H,Autocuration,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,,Brain
2193,,104686,CHEMBL617019,,1,BAO_0000019,F,,H,Autocuration,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,
2194,,105075,CHEMBL617020,,1,BAO_0000019,B,,H,Autocuration,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2195,,105075,CHEMBL617021,,1,BAO_0000019,B,,H,Autocuration,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2196,,105075,CHEMBL617022,,1,BAO_0000019,B,,H,Autocuration,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2197,,105075,CHEMBL617023,,1,BAO_0000019,B,,H,Autocuration,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2198,,105075,CHEMBL617024,,1,BAO_0000019,B,,H,Autocuration,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2199,,105075,CHEMBL617025,,1,BAO_0000019,B,,H,Autocuration,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,
2200,,105075,CHEMBL617026,,1,BAO_0000224,B,,H,Autocuration,9523,Hill coefficient of compound was determined,,,,
2201,,22226,CHEMBL617027,,1,BAO_0000019,B,,U,Autocuration,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,
2202,Rattus norvegicus,104686,CHEMBL617028,,1,BAO_0000019,B,10116.0,D,Autocuration,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,,
2203,,12687,CHEMBL617029,,1,BAO_0000019,B,,H,Expert,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,
2204,,12687,CHEMBL875908,,1,BAO_0000019,B,,H,Expert,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,
2205,,12687,CHEMBL617030,,1,BAO_0000357,B,,H,Autocuration,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,
2206,,12687,CHEMBL617031,,1,BAO_0000019,B,,H,Autocuration,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,
2207,,12687,CHEMBL617032,,1,BAO_0000019,B,,H,Autocuration,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,
2208,Rattus norvegicus,104686,CHEMBL617033,,1,BAO_0000224,B,10116.0,D,Autocuration,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,,
2209,,104686,CHEMBL617034,,1,BAO_0000224,B,,H,Autocuration,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,
2210,,104686,CHEMBL617035,,1,BAO_0000224,B,,H,Autocuration,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,
2211,,104686,CHEMBL617036,,1,BAO_0000019,B,,H,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,
2212,,104784,CHEMBL617037,,1,BAO_0000224,B,,H,Autocuration,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,
2213,,22226,CHEMBL617038,,1,BAO_0000219,B,,U,Autocuration,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,
2214,,104784,CHEMBL617039,,1,BAO_0000219,B,,H,Autocuration,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,
2215,,104784,CHEMBL617161,,1,BAO_0000224,B,,H,Autocuration,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,
2216,,104784,CHEMBL617162,,1,BAO_0000224,B,,H,Autocuration,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,
2217,,104784,CHEMBL617163,,1,BAO_0000224,B,,H,Autocuration,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,
2218,,104784,CHEMBL617164,,1,BAO_0000224,B,,H,Autocuration,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2219,,104784,CHEMBL617165,,1,BAO_0000249,B,,H,Autocuration,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,
2220,,104784,CHEMBL617166,,1,BAO_0000224,B,,H,Autocuration,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,
2221,,104784,CHEMBL617167,,1,BAO_0000224,B,,H,Autocuration,17066,Binding affinity towards 5-HT2 receptor,,,,
2222,,104784,CHEMBL872912,,1,BAO_0000224,B,,H,Autocuration,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2223,,104784,CHEMBL617168,,1,BAO_0000224,B,,H,Autocuration,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,
2224,,104686,CHEMBL617169,,1,BAO_0000224,B,,H,Autocuration,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,
2225,,104784,CHEMBL617170,,1,BAO_0000224,B,,H,Autocuration,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2226,,104784,CHEMBL617171,,1,BAO_0000224,B,,H,Autocuration,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,
2227,,104784,CHEMBL617172,,1,BAO_0000224,B,,H,Autocuration,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,
2228,,104784,CHEMBL617173,,1,BAO_0000224,B,,H,Autocuration,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2229,,22226,CHEMBL617174,,1,BAO_0000019,B,,U,Autocuration,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2230,,104784,CHEMBL617175,,1,BAO_0000224,B,,H,Autocuration,1263,5-hydroxytryptamine 2 receptor binding affinity,,,,
2231,,17005,CHEMBL617176,,1,BAO_0000357,B,,H,Autocuration,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,
2232,,17005,CHEMBL617177,,1,BAO_0000357,B,,H,Autocuration,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,
2233,,104784,CHEMBL617178,,1,BAO_0000224,B,,H,Autocuration,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,
2234,,104784,CHEMBL617179,,1,BAO_0000224,B,,H,Autocuration,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,
2235,,104784,CHEMBL617180,,1,BAO_0000224,B,,H,Autocuration,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,
2236,,17005,CHEMBL617181,,1,BAO_0000357,B,,H,Autocuration,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,
2237,,17005,CHEMBL617182,,1,BAO_0000357,B,,H,Autocuration,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,
2238,,17005,CHEMBL617183,,1,BAO_0000357,B,,H,Autocuration,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,
2239,,17005,CHEMBL617184,,1,BAO_0000357,B,,H,Autocuration,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,
2240,,17005,CHEMBL617185,,1,BAO_0000357,B,,H,Autocuration,13033,Binding affinity against serotonergic 5-HT2 receptor,,,,
2241,,17005,CHEMBL617186,,1,BAO_0000357,B,,H,Autocuration,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,
2242,,17005,CHEMBL617187,,1,BAO_0000357,B,,H,Autocuration,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,
2243,,17005,CHEMBL617188,,1,BAO_0000357,B,,H,Autocuration,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,
2244,,17005,CHEMBL617189,,1,BAO_0000218,B,,H,Autocuration,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,
2245,Homo sapiens,104784,CHEMBL617190,,1,BAO_0000224,B,9606.0,D,Autocuration,13378,Inhibitory activity against cloned human 5-HT2 receptor,,,,
2246,Homo sapiens,104784,CHEMBL617191,,1,BAO_0000219,B,9606.0,D,Autocuration,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,,,
2247,Homo sapiens,104784,CHEMBL617192,,1,BAO_0000219,B,9606.0,D,Autocuration,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,,,
2248,Homo sapiens,104784,CHEMBL617193,,1,BAO_0000219,B,9606.0,D,Autocuration,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,,,
2249,Homo sapiens,104784,CHEMBL617194,,1,BAO_0000219,B,9606.0,D,Autocuration,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,,,
2250,,104784,CHEMBL617195,,1,BAO_0000224,B,,H,Autocuration,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2251,,104784,CHEMBL881830,,1,BAO_0000224,B,,H,Autocuration,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,
2252,,17005,CHEMBL617196,,1,BAO_0000357,B,,H,Autocuration,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2253,,104686,CHEMBL617197,,1,BAO_0000224,B,,H,Autocuration,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,
2254,,17005,CHEMBL617198,,1,BAO_0000357,B,,H,Expert,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,
2255,,17005,CHEMBL873476,,1,BAO_0000357,B,,H,Expert,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2256,,17005,CHEMBL617199,,1,BAO_0000019,B,,H,Expert,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,
2257,Cavia porcellus,107,CHEMBL617200,,1,BAO_0000357,B,10141.0,H,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,,
2258,,51,CHEMBL617484,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2259,,107,CHEMBL617485,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2260,,51,CHEMBL617486,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2261,,107,CHEMBL858022,,1,BAO_0000357,B,,H,Autocuration,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,
2262,,107,CHEMBL617049,,1,BAO_0000219,B,,H,Autocuration,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,
2263,Homo sapiens,107,CHEMBL617050,,1,BAO_0000219,F,9606.0,D,Expert,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,,,
2264,,107,CHEMBL617051,,1,BAO_0000219,F,,H,Autocuration,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,
2265,,107,CHEMBL617052,,1,BAO_0000219,F,,H,Autocuration,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,
2266,,107,CHEMBL617053,,1,BAO_0000219,F,,H,Autocuration,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,
2267,,107,CHEMBL617054,,1,BAO_0000219,B,,H,Autocuration,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,,
2268,,107,CHEMBL617055,,1,BAO_0000219,B,,H,Autocuration,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,,
2269,,107,CHEMBL882924,,1,BAO_0000357,B,,H,Autocuration,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,
2270,Homo sapiens,107,CHEMBL617056,,1,BAO_0000357,B,9606.0,D,Expert,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,,,,
2271,,107,CHEMBL617057,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2272,,107,CHEMBL617058,,1,BAO_0000219,B,,H,Expert,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,
2273,,107,CHEMBL617059,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,
2274,,107,CHEMBL617060,,1,BAO_0000219,B,,H,Autocuration,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,,
2275,,107,CHEMBL617061,,1,BAO_0000219,B,,H,Expert,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,,
2276,,107,CHEMBL617062,,1,BAO_0000219,B,,H,Expert,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,,
2277,,107,CHEMBL617063,,1,BAO_0000219,B,,H,Expert,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2278,,107,CHEMBL617064,,1,BAO_0000019,F,,H,Autocuration,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,
2279,,107,CHEMBL617065,,1,BAO_0000019,F,,H,Autocuration,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2280,,107,CHEMBL617066,,1,BAO_0000219,B,,H,Autocuration,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,
2281,,107,CHEMBL617067,,1,BAO_0000219,B,,H,Autocuration,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,,
2282,,107,CHEMBL617068,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,
2283,,107,CHEMBL617069,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,
2284,,107,CHEMBL617070,,1,BAO_0000019,F,,H,Autocuration,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2285,,107,CHEMBL617071,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,
2286,,107,CHEMBL872915,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2287,,107,CHEMBL617072,,1,BAO_0000357,B,,H,Autocuration,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,
2288,,107,CHEMBL617073,,1,BAO_0000357,B,,H,Autocuration,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,
2289,,107,CHEMBL617074,,1,BAO_0000357,B,,H,Autocuration,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,
2290,,107,CHEMBL617075,,1,BAO_0000219,B,,H,Expert,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2291,,107,CHEMBL617076,,1,BAO_0000357,B,,H,Autocuration,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,
2292,Homo sapiens,107,CHEMBL617077,,1,BAO_0000019,B,9606.0,D,Expert,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,,
2293,,107,CHEMBL617078,,1,BAO_0000357,B,,H,Expert,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,
2294,Homo sapiens,107,CHEMBL617079,,1,BAO_0000357,B,9606.0,D,Expert,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,,
2295,,107,CHEMBL617080,,1,BAO_0000357,B,,H,Autocuration,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,
2296,,107,CHEMBL617081,,1,BAO_0000219,B,,H,Expert,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,,
2297,,107,CHEMBL617082,,1,BAO_0000219,B,,H,Expert,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,
2298,,107,CHEMBL617083,,1,BAO_0000357,B,,H,Autocuration,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,
2299,,107,CHEMBL617084,,1,BAO_0000357,B,,H,Autocuration,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,
2300,Homo sapiens,107,CHEMBL617085,,1,BAO_0000357,B,9606.0,D,Expert,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,,
2301,,107,CHEMBL617086,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2302,,107,CHEMBL617087,,1,BAO_0000219,B,,H,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,
2303,,107,CHEMBL617088,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,
2304,,107,CHEMBL617089,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,
2305,,107,CHEMBL617090,,1,BAO_0000019,B,,H,Expert,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,
2306,,107,CHEMBL617513,,1,BAO_0000357,B,,H,Autocuration,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,
2307,,107,CHEMBL617514,,1,BAO_0000219,B,,H,Autocuration,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,,
2308,,107,CHEMBL617515,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,
2309,,107,CHEMBL617516,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2310,Homo sapiens,107,CHEMBL617517,,1,BAO_0000357,B,9606.0,D,Expert,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,
2311,Homo sapiens,107,CHEMBL617518,,1,BAO_0000219,B,9606.0,D,Expert,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,,,
2312,,107,CHEMBL617519,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2313,Homo sapiens,107,CHEMBL617520,,1,BAO_0000357,B,9606.0,D,Expert,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,,
2314,,107,CHEMBL617521,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,
2315,Homo sapiens,107,CHEMBL617522,,1,BAO_0000357,B,9606.0,D,Expert,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,,
2316,,107,CHEMBL617523,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,
2317,,107,CHEMBL617524,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2318,,104686,CHEMBL617525,,1,BAO_0000019,B,,H,Autocuration,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,
2319,Rattus norvegicus,104686,CHEMBL617526,,1,BAO_0000019,B,10116.0,D,Autocuration,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,,
2320,,104686,CHEMBL617527,,1,BAO_0000224,B,,H,Autocuration,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,
2321,,104686,CHEMBL617528,,1,BAO_0000019,B,,H,Autocuration,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,
2322,,104686,CHEMBL617529,,1,BAO_0000019,B,,H,Autocuration,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,
2323,,104686,CHEMBL617530,,1,BAO_0000224,B,,H,Autocuration,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,
2324,,104686,CHEMBL617531,,1,BAO_0000019,B,,H,Autocuration,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,
2325,,104686,CHEMBL617532,,1,BAO_0000019,B,,H,Autocuration,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,
2326,,104686,CHEMBL617533,,1,BAO_0000019,B,,H,Autocuration,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,
2327,,104686,CHEMBL617534,,1,BAO_0000019,B,,H,Autocuration,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,
2328,,104686,CHEMBL617535,,1,BAO_0000224,B,,H,Autocuration,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,
2329,,104686,CHEMBL617536,,1,BAO_0000224,B,,H,Autocuration,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,
2330,,104686,CHEMBL617537,,1,BAO_0000224,B,,H,Autocuration,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,
2331,,104686,CHEMBL617538,,1,BAO_0000224,B,,H,Autocuration,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,
2332,,104686,CHEMBL617539,,1,BAO_0000219,B,,H,Autocuration,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,In vitro,,,
2333,Rattus norvegicus,104686,CHEMBL617540,,1,BAO_0000224,B,10116.0,D,Autocuration,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2334,Rattus norvegicus,104686,CHEMBL617541,,1,BAO_0000224,B,10116.0,D,Autocuration,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,,
2335,,104686,CHEMBL617542,,1,BAO_0000224,B,,H,Autocuration,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,
2336,,104686,CHEMBL617543,,1,BAO_0000224,B,,H,Autocuration,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,
2337,Rattus norvegicus,104686,CHEMBL617544,,1,BAO_0000219,B,10116.0,D,Autocuration,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,,
2338,Rattus norvegicus,104686,CHEMBL617545,,1,BAO_0000219,B,10116.0,D,Autocuration,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,,,
2339,Rattus norvegicus,104686,CHEMBL617413,,1,BAO_0000019,B,10116.0,D,Autocuration,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,,
2340,,104686,CHEMBL617414,,1,BAO_0000019,B,,H,Autocuration,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,
2341,Rattus norvegicus,104686,CHEMBL617415,,1,BAO_0000019,B,10116.0,D,Autocuration,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,,
2342,,104686,CHEMBL617416,,1,BAO_0000224,B,,H,Autocuration,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2343,,104686,CHEMBL617417,,1,BAO_0000224,B,,H,Autocuration,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,
2344,,104686,CHEMBL617418,,1,BAO_0000019,B,,H,Autocuration,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,
2345,,104686,CHEMBL617419,,1,BAO_0000019,B,,H,Autocuration,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,
2346,,104686,CHEMBL617420,,1,BAO_0000224,B,,H,Autocuration,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,
2347,Rattus norvegicus,104686,CHEMBL617421,,1,BAO_0000224,B,10116.0,D,Autocuration,3070,Affinity for 5-hydroxytryptamine 2 receptor,,,,
2348,,104686,CHEMBL617422,,1,BAO_0000224,B,,H,Autocuration,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,
2349,,104686,CHEMBL617423,,1,BAO_0000019,B,,H,Autocuration,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,
2350,,104686,CHEMBL617424,,1,BAO_0000019,B,,H,Autocuration,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,
2351,,104686,CHEMBL617425,,1,BAO_0000019,B,,H,Autocuration,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,
2352,,104686,CHEMBL617426,,1,BAO_0000224,B,,H,Autocuration,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,
2353,,104686,CHEMBL617427,,1,BAO_0000218,B,,H,Autocuration,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),In vivo,,,
2354,,104686,CHEMBL617428,,1,BAO_0000221,B,,H,Autocuration,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,,Brain
2355,,104686,CHEMBL617429,,1,BAO_0000224,B,,H,Autocuration,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,
2356,,104686,CHEMBL617430,,1,BAO_0000019,B,,H,Autocuration,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,
2357,,104686,CHEMBL617431,,1,BAO_0000019,B,,H,Autocuration,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,
2358,,104686,CHEMBL617432,,1,BAO_0000019,B,,H,Autocuration,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,,Frontal cortex
2359,,104686,CHEMBL617433,,1,BAO_0000224,B,,H,Autocuration,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,
2360,,104686,CHEMBL617434,,1,BAO_0000224,B,,H,Autocuration,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,
2361,Rattus norvegicus,104686,CHEMBL617435,,1,BAO_0000224,B,10116.0,D,Autocuration,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,,
2362,,104686,CHEMBL617436,,1,BAO_0000019,B,,H,Autocuration,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,
2363,Rattus norvegicus,104686,CHEMBL617437,,1,BAO_0000019,B,10116.0,D,Autocuration,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,,Striatum
2364,,104686,CHEMBL617438,,1,BAO_0000019,B,,H,Autocuration,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,
2365,,104686,CHEMBL617439,,1,BAO_0000019,B,,H,Autocuration,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,
2366,,104686,CHEMBL617440,,1,BAO_0000224,B,,H,Autocuration,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,
2367,,104686,CHEMBL617441,,1,BAO_0000224,B,,H,Autocuration,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,
2368,Rattus norvegicus,104686,CHEMBL872918,,1,BAO_0000019,B,10116.0,D,Autocuration,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,,
2369,Rattus norvegicus,104686,CHEMBL617442,,1,BAO_0000019,B,10116.0,D,Autocuration,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,,
2370,,104686,CHEMBL617443,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,
2371,,104686,CHEMBL617444,,1,BAO_0000019,B,,H,Autocuration,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,
2372,,104686,CHEMBL617445,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,
2373,,104686,CHEMBL617446,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,
2374,,104686,CHEMBL617447,,1,BAO_0000249,B,,H,Autocuration,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,
2375,,104686,CHEMBL617448,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,
2376,,104686,CHEMBL617449,,1,BAO_0000019,B,,H,Autocuration,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,
2377,,104686,CHEMBL617450,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,
2378,,104686,CHEMBL617451,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,
2379,,104686,CHEMBL617452,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,
2380,,104686,CHEMBL617453,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,
2381,,104686,CHEMBL617660,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,
2382,,104686,CHEMBL617661,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,
2383,,104686,CHEMBL617662,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,
2384,,104686,CHEMBL872919,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,
2385,,104686,CHEMBL617663,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,
2386,,104686,CHEMBL617664,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,
2387,,104686,CHEMBL617665,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,
2388,,104686,CHEMBL617666,,1,BAO_0000019,B,,H,Autocuration,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,
2389,,104686,CHEMBL617667,,1,BAO_0000019,B,,H,Autocuration,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,
2390,,104686,CHEMBL617668,,1,BAO_0000249,B,,H,Autocuration,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,
2391,,104686,CHEMBL617669,,1,BAO_0000249,B,,H,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,
2392,,104686,CHEMBL617670,,1,BAO_0000224,B,,H,Autocuration,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,
2393,Rattus norvegicus,104686,CHEMBL617671,,1,BAO_0000224,B,10116.0,D,Autocuration,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,,
2394,,104686,CHEMBL617672,,1,BAO_0000224,B,,H,Autocuration,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2395,,104686,CHEMBL617673,,1,BAO_0000019,B,,H,Autocuration,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,
2396,,104686,CHEMBL617674,,1,BAO_0000224,B,,H,Autocuration,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,
2397,,104686,CHEMBL617675,,1,BAO_0000019,B,,H,Autocuration,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,
2398,,104686,CHEMBL617676,,1,BAO_0000019,B,,H,Autocuration,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,
2399,,104686,CHEMBL617677,,1,BAO_0000019,B,,H,Autocuration,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,
2400,,104686,CHEMBL617678,,1,BAO_0000019,B,,D,Autocuration,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,
2401,,104686,CHEMBL617679,,1,BAO_0000224,B,,H,Autocuration,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,
2402,,104686,CHEMBL617680,,1,BAO_0000224,B,,H,Autocuration,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,
2403,,104686,CHEMBL617681,,1,BAO_0000019,B,,H,Autocuration,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,
2404,,104686,CHEMBL617682,,1,BAO_0000221,B,,H,Autocuration,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,,Brain
2405,,104686,CHEMBL617683,,1,BAO_0000224,B,,H,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,
2406,,104686,CHEMBL617684,,1,BAO_0000224,B,,H,Autocuration,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,
2407,Rattus norvegicus,104686,CHEMBL617685,,1,BAO_0000224,B,10116.0,D,Autocuration,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,
2408,,104686,CHEMBL617686,,1,BAO_0000019,B,,H,Autocuration,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,
2409,,104686,CHEMBL617687,,1,BAO_0000224,B,,H,Autocuration,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,
2410,,104686,CHEMBL617688,,1,BAO_0000224,B,,H,Autocuration,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,
2411,,104686,CHEMBL617689,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2412,,104686,CHEMBL617690,,1,BAO_0000019,F,,H,Autocuration,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,
2413,,104686,CHEMBL617691,,1,BAO_0000218,F,,H,Autocuration,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,
2414,,104686,CHEMBL617692,,1,BAO_0000218,F,,H,Autocuration,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,
2415,,104686,CHEMBL617693,,1,BAO_0000218,F,,H,Autocuration,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",In vivo,,,
2416,,104686,CHEMBL617694,,1,BAO_0000218,F,,H,Autocuration,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",In vivo,,,
2417,,12687,CHEMBL857985,,1,BAO_0000221,B,,H,Expert,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,,Brain
2418,Rattus norvegicus,12687,CHEMBL617695,,1,BAO_0000019,B,10116.0,D,Expert,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,,
2419,,12687,CHEMBL617696,,1,BAO_0000019,B,,H,Autocuration,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,
2420,,12687,CHEMBL617697,,1,BAO_0000357,B,,H,Autocuration,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,
2421,Rattus norvegicus,12687,CHEMBL617257,,1,BAO_0000019,B,10116.0,D,Expert,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,,
2422,Rattus norvegicus,12687,CHEMBL617258,,1,BAO_0000357,B,10116.0,D,Expert,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,
2423,,12687,CHEMBL617259,,1,BAO_0000019,B,,H,Expert,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,
2424,,12687,CHEMBL617260,,1,BAO_0000357,B,,H,Autocuration,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,
2425,Rattus norvegicus,12687,CHEMBL617261,,1,BAO_0000357,B,10116.0,D,Expert,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,,
2426,,12687,CHEMBL617262,,1,BAO_0000019,B,,H,Autocuration,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,
2427,,12687,CHEMBL617263,,1,BAO_0000019,B,,H,Expert,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,
2428,,12687,CHEMBL617264,,1,BAO_0000019,B,,H,Autocuration,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,
2429,Rattus norvegicus,12687,CHEMBL617265,,1,BAO_0000019,B,10116.0,D,Expert,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,,
2430,,12687,CHEMBL617266,,1,BAO_0000249,B,,H,Autocuration,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,
2431,,12687,CHEMBL617267,,1,BAO_0000019,B,,H,Autocuration,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,
2432,,12687,CHEMBL617268,,1,BAO_0000019,B,,H,Expert,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,
2433,,12687,CHEMBL617269,,1,BAO_0000219,B,,H,Autocuration,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,
2434,,12687,CHEMBL617323,,1,BAO_0000357,B,,H,Expert,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,
2435,,12687,CHEMBL617324,,1,BAO_0000357,B,,H,Autocuration,15577,Serotonergic activity of the compound.,,,,
2436,,12687,CHEMBL617325,,1,BAO_0000249,B,,H,Autocuration,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,
2437,Rattus norvegicus,12687,CHEMBL617326,,1,BAO_0000019,B,10116.0,D,Expert,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,,
2438,,12687,CHEMBL617327,,1,BAO_0000249,B,,H,Expert,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,
2439,Rattus norvegicus,12687,CHEMBL617328,,1,BAO_0000019,F,10116.0,D,Expert,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,
2440,Rattus norvegicus,12687,CHEMBL617329,,1,BAO_0000019,F,10116.0,D,Expert,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,
2441,Rattus norvegicus,12687,CHEMBL617330,,1,BAO_0000019,F,10116.0,D,Expert,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,
2442,,12687,CHEMBL617331,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2443,,12687,CHEMBL617332,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,
2444,,107,CHEMBL617333,,1,BAO_0000357,B,,H,Expert,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2445,,107,CHEMBL617334,,1,BAO_0000357,B,,H,Autocuration,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,
2446,,107,CHEMBL617335,,1,BAO_0000357,B,,H,Autocuration,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,
2447,,107,CHEMBL617336,,1,BAO_0000357,B,,H,Autocuration,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,
2448,,107,CHEMBL617337,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,
2449,Homo sapiens,107,CHEMBL617338,,1,BAO_0000357,B,9606.0,D,Expert,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,,
2450,,107,CHEMBL617339,,1,BAO_0000357,B,,H,Autocuration,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,
2451,,107,CHEMBL617340,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2452,,107,CHEMBL617341,,1,BAO_0000357,B,,H,Autocuration,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,
2453,,107,CHEMBL617342,,1,BAO_0000357,B,,H,Expert,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,
2454,,107,CHEMBL617343,,1,BAO_0000357,B,,H,Expert,5163,Affinity for 5-hydroxytryptamine 2A receptor,,,,
2455,,107,CHEMBL617344,,1,BAO_0000219,B,,H,Expert,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,,
2456,,107,CHEMBL617345,,1,BAO_0000357,B,,H,Expert,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,
2457,,107,CHEMBL617346,,1,BAO_0000357,B,,H,Expert,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,
2458,,107,CHEMBL617347,,1,BAO_0000357,B,,H,Autocuration,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,
2459,,107,CHEMBL617348,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,
2460,,107,CHEMBL617349,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,
2461,,107,CHEMBL617350,,1,BAO_0000019,F,,H,Autocuration,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,
2462,,107,CHEMBL872339,,1,BAO_0000357,B,,H,Expert,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,
2463,,107,CHEMBL617351,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,
2464,,107,CHEMBL617352,,1,BAO_0000357,B,,H,Expert,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,
2465,,107,CHEMBL617353,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2466,,107,CHEMBL617354,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,
2467,,107,CHEMBL617355,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,
2468,Mus musculus,107,CHEMBL617356,,1,BAO_0000219,B,10090.0,H,Expert,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,,,
2469,,107,CHEMBL617357,,1,BAO_0000357,B,,H,Autocuration,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,
2470,,107,CHEMBL617358,,1,BAO_0000357,B,,H,Autocuration,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,
2471,,107,CHEMBL617359,,1,BAO_0000357,B,,H,Expert,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,
2472,,107,CHEMBL617360,,1,BAO_0000357,B,,H,Autocuration,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,
2473,,107,CHEMBL875913,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,
2474,,107,CHEMBL617361,,1,BAO_0000357,B,,H,Autocuration,3269,Affinity against 5-hydroxytryptamine 2A receptor,,,,
2475,Homo sapiens,107,CHEMBL617362,,1,BAO_0000357,B,9606.0,D,Expert,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,,
2476,,107,CHEMBL617363,,1,BAO_0000357,B,,H,Autocuration,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,
2477,,107,CHEMBL617364,,1,BAO_0000357,B,,H,Autocuration,12146,Tested against 5-hydroxytryptamine 2A receptor,,,,
2478,,105075,CHEMBL617365,,1,BAO_0000224,B,,H,Autocuration,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,
2479,,105075,CHEMBL617366,,1,BAO_0000224,B,,H,Autocuration,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,
2480,,105075,CHEMBL617367,,1,BAO_0000224,B,,H,Autocuration,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,
2481,,105075,CHEMBL617368,,1,BAO_0000224,B,,H,Autocuration,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,
2482,,107,CHEMBL617369,,1,BAO_0000357,B,,H,Autocuration,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,
2483,Homo sapiens,227,CHEMBL617370,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,,,
2484,Homo sapiens,227,CHEMBL617371,,1,BAO_0000219,F,9606.0,D,Expert,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,,,
2485,,227,CHEMBL617372,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,
2486,Homo sapiens,227,CHEMBL617373,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,,
2487,,227,CHEMBL617374,,1,BAO_0000019,F,,H,Autocuration,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,
2488,,227,CHEMBL617375,,1,BAO_0000019,F,,H,Autocuration,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,
2489,,227,CHEMBL617376,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,
2490,,227,CHEMBL617377,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,
2491,,227,CHEMBL617378,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,
2492,,227,CHEMBL617379,,1,BAO_0000019,F,,H,Autocuration,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,
2493,,227,CHEMBL617380,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,
2494,,227,CHEMBL617381,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,
2495,,227,CHEMBL617382,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,
2496,,107,CHEMBL617383,,1,BAO_0000357,B,,H,Autocuration,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,
2497,,107,CHEMBL617384,,1,BAO_0000357,B,,H,Expert,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,
2498,,107,CHEMBL617385,,1,BAO_0000357,B,,H,Expert,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,
2499,,107,CHEMBL617386,,1,BAO_0000019,B,,H,Autocuration,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,
2500,,107,CHEMBL617387,,1,BAO_0000019,B,,H,Autocuration,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,
2501,,107,CHEMBL617388,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2502,,107,CHEMBL617389,,1,BAO_0000219,F,,H,Autocuration,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,
2503,Homo sapiens,107,CHEMBL617390,,1,BAO_0000219,F,9606.0,D,Expert,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,
2504,,104817,CHEMBL617391,,1,BAO_0000224,B,,H,Autocuration,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,
2505,,107,CHEMBL617392,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
2506,,107,CHEMBL617393,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,
2507,,107,CHEMBL617394,,1,BAO_0000219,B,,H,Autocuration,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,
2508,,107,CHEMBL617395,,1,BAO_0000219,B,,H,Expert,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,
2509,,107,CHEMBL617396,,1,BAO_0000219,B,,H,Expert,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,,
2510,,107,CHEMBL617397,,1,BAO_0000219,B,,H,Autocuration,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,,
2511,,107,CHEMBL617398,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-HT2A receptor,,,,
2512,,107,CHEMBL617399,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,
2513,,107,CHEMBL617400,,1,BAO_0000219,B,,H,Autocuration,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,
2514,,107,CHEMBL617401,,1,BAO_0000219,B,,H,Autocuration,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,
2515,Homo sapiens,107,CHEMBL617402,,1,BAO_0000219,B,9606.0,D,Expert,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,,,
2516,Homo sapiens,107,CHEMBL617403,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,,
2517,,107,CHEMBL617404,,1,BAO_0000357,B,,H,Expert,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,
2518,Homo sapiens,107,CHEMBL857981,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,,
2519,Homo sapiens,107,CHEMBL617405,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,,
2520,Homo sapiens,107,CHEMBL617253,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,,,
2521,,107,CHEMBL617254,,1,BAO_0000357,B,,H,Expert,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,
2522,,107,CHEMBL617255,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2523,,107,CHEMBL617256,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2524,,107,CHEMBL616874,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2525,Homo sapiens,107,CHEMBL616875,,1,BAO_0000219,B,9606.0,D,Expert,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,,,
2526,,107,CHEMBL616876,,1,BAO_0000219,B,,H,Expert,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,,
2527,,107,CHEMBL616877,,1,BAO_0000219,B,,H,Expert,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,,
2528,Homo sapiens,107,CHEMBL616878,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,,,
2529,,107,CHEMBL616879,,1,BAO_0000219,B,,H,Expert,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,,
2530,,107,CHEMBL616880,,1,BAO_0000219,B,,H,Expert,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,,
2531,Homo sapiens,107,CHEMBL616881,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,,,
2532,,107,CHEMBL616882,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,
2533,,107,CHEMBL616883,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2534,,107,CHEMBL616884,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2535,,107,CHEMBL616885,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,,
2536,,107,CHEMBL616886,,1,BAO_0000219,B,,H,Autocuration,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,,
2537,,107,CHEMBL616887,,1,BAO_0000219,B,,H,Expert,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,,
2538,Homo sapiens,107,CHEMBL616888,,1,BAO_0000357,B,9606.0,D,Expert,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,,
2539,,107,CHEMBL616889,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,,
2540,,107,CHEMBL616890,,1,BAO_0000219,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,
2541,Homo sapiens,107,CHEMBL616891,,1,BAO_0000219,B,9606.0,D,Expert,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,
2542,,107,CHEMBL616892,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,,
2543,,107,CHEMBL616893,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,,
2544,,10620,CHEMBL616894,,1,BAO_0000219,F,,H,Autocuration,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,,
2545,,107,CHEMBL616895,,1,BAO_0000219,B,,H,Expert,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,,
2546,,10620,CHEMBL616896,,1,BAO_0000019,F,,H,Autocuration,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,
2547,,10621,CHEMBL617099,,1,BAO_0000357,B,,H,Autocuration,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,
2548,,10621,CHEMBL617100,,1,BAO_0000357,B,,H,Autocuration,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,
2549,Oryctolagus cuniculus,107,CHEMBL884532,,1,BAO_0000357,B,9986.0,H,Autocuration,16312,Binding affinity against rabbit aorta 5-HT2A receptor,,,,
2550,Oryctolagus cuniculus,107,CHEMBL617101,,1,BAO_0000357,B,9986.0,H,Expert,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,,
2551,Oryctolagus cuniculus,107,CHEMBL617102,,1,BAO_0000357,B,9986.0,H,Expert,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,,
2552,Oryctolagus cuniculus,107,CHEMBL617103,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,,
2553,Oryctolagus cuniculus,107,CHEMBL617104,,1,BAO_0000357,B,9986.0,H,Expert,13047,The compound was tested for binding affinity against 5-HT2A receptor,,,,
2554,,10576,CHEMBL857979,,1,BAO_0000219,B,,H,Autocuration,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,,
2555,,12687,CHEMBL857502,,1,BAO_0000019,B,,H,Autocuration,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,
2556,,12687,CHEMBL617105,,1,BAO_0000019,B,,H,Autocuration,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,
2557,,12687,CHEMBL858021,,1,BAO_0000019,B,,H,Autocuration,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,,Stomach
2558,Rattus norvegicus,12687,CHEMBL875910,,1,BAO_0000019,B,10116.0,D,Expert,13463,Binding affinity for 5-HT 2A in rat stomach fundus,,,,Stomach
2559,,12687,CHEMBL617106,,1,BAO_0000019,B,,H,Autocuration,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,
2560,,12687,CHEMBL617107,,1,BAO_0000219,B,,H,Expert,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,,
2561,,12687,CHEMBL617108,,1,BAO_0000019,F,,H,Autocuration,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,
2562,,12687,CHEMBL617109,,1,BAO_0000019,F,,H,Autocuration,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,
2563,,12687,CHEMBL617110,,1,BAO_0000357,B,,H,Autocuration,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,
2564,,12687,CHEMBL617111,,1,BAO_0000357,B,,H,Autocuration,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,
2565,Rattus norvegicus,12687,CHEMBL617112,,1,BAO_0000019,F,10116.0,D,Expert,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,,
2566,,12687,CHEMBL617113,,1,BAO_0000357,B,,H,Autocuration,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,
2567,,12687,CHEMBL617114,,1,BAO_0000357,B,,H,Autocuration,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,
2568,,12687,CHEMBL617115,,1,BAO_0000357,B,,H,Autocuration,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,
2569,,12687,CHEMBL617116,,1,BAO_0000219,F,,H,Autocuration,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,
2570,,12687,CHEMBL617117,,1,BAO_0000019,F,,H,Autocuration,15363,Efficacy at 5-hydroxytryptamine 2A receptor,,,,
2571,,12687,CHEMBL617118,,1,BAO_0000357,B,,H,Autocuration,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,
2572,Rattus norvegicus,12687,CHEMBL617119,,1,BAO_0000357,B,10116.0,D,Expert,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,
2573,Rattus norvegicus,12687,CHEMBL617120,,1,BAO_0000357,B,10116.0,D,Expert,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,,
2574,Rattus norvegicus,12687,CHEMBL617121,,1,BAO_0000219,F,10116.0,D,Expert,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,
2575,,12687,CHEMBL617122,,1,BAO_0000219,F,,H,Autocuration,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,
2576,,12687,CHEMBL617123,,1,BAO_0000019,B,,H,Autocuration,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,
2577,,12687,CHEMBL617124,,1,BAO_0000019,B,,H,Expert,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,
2578,,12687,CHEMBL617600,,1,BAO_0000249,B,,H,Expert,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,
2579,,12687,CHEMBL617601,,1,BAO_0000357,B,,H,Expert,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,
2580,,12687,CHEMBL882923,,1,BAO_0000019,B,,H,Expert,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,
2581,,12687,CHEMBL617602,,1,BAO_0000357,B,,H,Autocuration,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2582,,12687,CHEMBL617603,,1,BAO_0000019,B,,H,Autocuration,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,
2583,,12687,CHEMBL617604,,1,BAO_0000357,B,,H,Autocuration,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,
2584,,12687,CHEMBL617605,,1,BAO_0000019,B,,H,Expert,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,
2585,,12687,CHEMBL617606,,1,BAO_0000019,B,,H,Expert,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,
2586,Rattus norvegicus,12687,CHEMBL617607,,1,BAO_0000019,B,10116.0,D,Expert,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,,
2587,,12687,CHEMBL617455,,1,BAO_0000249,B,,H,Autocuration,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2588,Rattus norvegicus,12687,CHEMBL617456,,1,BAO_0000019,B,10116.0,D,Expert,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,,
2589,,12687,CHEMBL617457,,1,BAO_0000357,B,,H,Expert,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,
2590,Rattus norvegicus,12687,CHEMBL617458,,1,BAO_0000357,B,10116.0,D,Expert,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,,
2591,Rattus norvegicus,12687,CHEMBL617459,,1,BAO_0000019,B,10116.0,D,Expert,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,,
2592,,12687,CHEMBL617460,,1,BAO_0000357,B,,H,Expert,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,
2593,,12687,CHEMBL617461,,1,BAO_0000357,B,,H,Expert,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,
2594,Rattus norvegicus,12687,CHEMBL617462,,1,BAO_0000019,B,10116.0,D,Expert,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,,
2595,,12687,CHEMBL617463,,1,BAO_0000357,B,,H,Autocuration,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,
2596,,12687,CHEMBL617464,,1,BAO_0000019,B,,H,Autocuration,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,
2597,,12687,CHEMBL617465,,1,BAO_0000019,B,,H,Autocuration,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,
2598,,12687,CHEMBL617466,,1,BAO_0000019,B,,H,Expert,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,
2599,,12687,CHEMBL617467,,1,BAO_0000019,B,,H,Autocuration,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,
2600,,12687,CHEMBL617468,,1,BAO_0000019,B,,H,Expert,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,
2601,,12687,CHEMBL617469,,1,BAO_0000019,B,,H,Autocuration,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,
2602,,12687,CHEMBL617470,,1,BAO_0000019,B,,H,Autocuration,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,
2603,,12687,CHEMBL617471,,1,BAO_0000019,B,,H,Autocuration,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,
2604,,12687,CHEMBL617472,,1,BAO_0000219,B,,H,Expert,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,,
2605,,12687,CHEMBL617473,,1,BAO_0000357,B,,H,Expert,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,
2606,Rattus norvegicus,12687,CHEMBL617474,,1,BAO_0000019,B,10116.0,D,Expert,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,,
2607,Rattus norvegicus,12687,CHEMBL617475,,1,BAO_0000019,B,10116.0,D,Expert,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,,
2608,,12687,CHEMBL617476,,1,BAO_0000221,B,,H,Autocuration,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,,Brain
2609,,12687,CHEMBL617477,,1,BAO_0000357,B,,H,Expert,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,
2610,,12687,CHEMBL617478,,1,BAO_0000219,B,,H,Expert,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,,
2611,,12687,CHEMBL617479,,1,BAO_0000221,F,,H,Autocuration,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,
2612,,12687,CHEMBL617480,,1,BAO_0000357,B,,H,Autocuration,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,
2613,,12687,CHEMBL617481,,1,BAO_0000357,B,,H,Expert,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,
2614,,12687,CHEMBL617482,,1,BAO_0000019,B,,H,Expert,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,
2615,,12687,CHEMBL617483,,1,BAO_0000019,B,,H,Autocuration,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,
2616,,12687,CHEMBL621528,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2617,Rattus norvegicus,12687,CHEMBL621529,,1,BAO_0000219,B,10116.0,D,Expert,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,,,
2618,,12687,CHEMBL621530,,1,BAO_0000357,B,,H,Expert,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2619,,12687,CHEMBL621531,,1,BAO_0000357,B,,H,Expert,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2620,Rattus norvegicus,12687,CHEMBL621532,,1,BAO_0000019,B,10116.0,D,Expert,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,,
2621,,12687,CHEMBL621533,,1,BAO_0000357,B,,H,Expert,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2622,,12687,CHEMBL621534,,1,BAO_0000219,B,,H,Expert,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,
2623,,12687,CHEMBL621535,,1,BAO_0000019,B,,H,Autocuration,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,
2624,,12687,CHEMBL621536,,1,BAO_0000357,B,,H,Autocuration,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,
2625,,12687,CHEMBL621537,,1,BAO_0000357,B,,H,Autocuration,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,
2626,Rattus norvegicus,12687,CHEMBL621538,,1,BAO_0000357,B,10116.0,D,Expert,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,,,,
2627,,12687,CHEMBL621539,,1,BAO_0000019,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,
2628,,12687,CHEMBL621540,,1,BAO_0000019,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,
2629,,12687,CHEMBL621541,,1,BAO_0000019,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,
2630,,12687,CHEMBL621542,,1,BAO_0000019,B,,H,Autocuration,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,
2631,,12687,CHEMBL621543,,1,BAO_0000357,B,,H,Expert,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,
2632,,12687,CHEMBL621544,,1,BAO_0000357,B,,H,Expert,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,
2633,Rattus norvegicus,12687,CHEMBL621545,,1,BAO_0000357,B,10116.0,D,Expert,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,,
2634,,12687,CHEMBL621546,,1,BAO_0000357,B,,H,Autocuration,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2635,,12687,CHEMBL621547,,1,BAO_0000357,B,,H,Autocuration,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,
2636,,12687,CHEMBL618692,,1,BAO_0000219,B,,H,Expert,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,,
2637,,12687,CHEMBL618693,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,
2638,,12687,CHEMBL872922,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,
2639,,12687,CHEMBL618694,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,
2640,Rattus norvegicus,12687,CHEMBL618695,,1,BAO_0000357,B,10116.0,D,Expert,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,,
2641,,12687,CHEMBL618696,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,
2642,,12687,CHEMBL618697,,1,BAO_0000357,B,,H,Expert,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,
2643,,12687,CHEMBL618892,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,
2644,,12687,CHEMBL618893,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,
2645,,12687,CHEMBL618894,,1,BAO_0000357,B,,H,Autocuration,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,
2646,,12687,CHEMBL618895,,1,BAO_0000219,B,,H,Expert,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,,
2647,Rattus norvegicus,12687,CHEMBL618896,,1,BAO_0000357,B,10116.0,D,Expert,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,,
2648,,12687,CHEMBL618897,,1,BAO_0000019,B,,H,Autocuration,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,,Caudate-putamen
2649,,12687,CHEMBL618898,,1,BAO_0000357,B,,H,Autocuration,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,
2650,,12687,CHEMBL618899,,1,BAO_0000357,B,,H,Autocuration,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,
2651,,12687,CHEMBL618900,,1,BAO_0000357,B,,H,Autocuration,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,
2652,,12687,CHEMBL618901,,1,BAO_0000019,B,,H,Autocuration,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,
2653,,12687,CHEMBL618902,,1,BAO_0000357,B,,H,Autocuration,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,
2654,Rattus norvegicus,12687,CHEMBL618903,,1,BAO_0000221,B,10116.0,D,Expert,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,,Hippocampus
2655,,12687,CHEMBL618904,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,
2656,,12687,CHEMBL618905,,1,BAO_0000357,B,,H,Autocuration,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,
2657,,12687,CHEMBL618906,,1,BAO_0000357,B,,H,Autocuration,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,
2658,,12687,CHEMBL618907,,1,BAO_0000219,B,,H,Expert,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,,
2659,,12687,CHEMBL618908,,1,BAO_0000019,B,,H,Autocuration,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,
2660,,12687,CHEMBL617909,,1,BAO_0000357,B,,H,Autocuration,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,
2661,,12687,CHEMBL617910,,1,BAO_0000019,B,,H,Expert,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,
2662,,12687,CHEMBL617911,,1,BAO_0000221,B,,H,Autocuration,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,,Brain
2663,,12687,CHEMBL872923,,1,BAO_0000249,B,,H,Autocuration,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2664,,12687,CHEMBL617912,,1,BAO_0000249,B,,H,Autocuration,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2665,Rattus norvegicus,12687,CHEMBL617913,,1,BAO_0000019,B,10116.0,D,Expert,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,,
2666,,12687,CHEMBL617914,,1,BAO_0000249,B,,H,Expert,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2667,,12687,CHEMBL617915,,1,BAO_0000249,B,,H,Autocuration,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2668,,12687,CHEMBL617916,,1,BAO_0000249,B,,H,Autocuration,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,
2669,Rattus norvegicus,12687,CHEMBL617917,,1,BAO_0000019,B,10116.0,D,Expert,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,,
2670,,12687,CHEMBL617918,,1,BAO_0000019,B,,H,Expert,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,
2671,,12687,CHEMBL617919,,1,BAO_0000019,B,,H,Autocuration,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,
2672,Rattus norvegicus,12687,CHEMBL617920,,1,BAO_0000019,B,10116.0,D,Expert,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,,
2673,Rattus norvegicus,12687,CHEMBL617921,,1,BAO_0000019,B,10116.0,D,Expert,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,,
2674,Rattus norvegicus,105102,CHEMBL617922,,1,BAO_0000224,B,10116.0,D,Expert,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,,
2675,,12687,CHEMBL617923,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,
2676,,12687,CHEMBL617924,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,
2677,,12687,CHEMBL617925,,1,BAO_0000357,B,,H,Autocuration,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,
2678,Rattus norvegicus,12687,CHEMBL617926,,1,BAO_0000357,B,10116.0,D,Expert,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,,
2679,,12687,CHEMBL617927,,1,BAO_0000357,B,,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,
2680,,12687,CHEMBL617928,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,
2681,Rattus norvegicus,12687,CHEMBL617929,,1,BAO_0000019,B,10116.0,D,Expert,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,
2682,,12687,CHEMBL617930,,1,BAO_0000019,B,,H,Expert,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,
2683,,12687,CHEMBL617931,,1,BAO_0000019,B,,H,Autocuration,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,
2684,,12687,CHEMBL617932,,1,BAO_0000019,B,,H,Autocuration,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,
2685,,12687,CHEMBL617933,,1,BAO_0000219,B,,H,Autocuration,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,,
2686,,12687,CHEMBL617934,,1,BAO_0000019,B,,H,Autocuration,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,
2687,,12687,CHEMBL617935,,1,BAO_0000019,B,,H,Autocuration,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,
2688,,12687,CHEMBL617936,,1,BAO_0000357,B,,H,Autocuration,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,
2689,,12687,CHEMBL617937,,1,BAO_0000019,B,,H,Autocuration,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,
2690,,12687,CHEMBL617938,,1,BAO_0000019,B,,H,Autocuration,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,
2691,,12687,CHEMBL617939,,1,BAO_0000218,B,,H,Autocuration,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,
2692,,12687,CHEMBL617940,,1,BAO_0000218,B,,H,Autocuration,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,
2693,,12687,CHEMBL617941,,1,BAO_0000218,B,,H,Autocuration,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,
2694,,12687,CHEMBL617942,,1,BAO_0000357,B,,H,Expert,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,
2695,,12687,CHEMBL617943,,1,BAO_0000357,B,,H,Expert,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,
2696,,105093,CHEMBL617944,,1,BAO_0000224,B,,H,Expert,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,
2697,,105093,CHEMBL617945,,1,BAO_0000224,B,,H,Expert,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,
2698,,105075,CHEMBL617946,,1,BAO_0000224,B,,H,Expert,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,
2699,,12687,CHEMBL617947,,1,BAO_0000357,B,,H,Autocuration,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,
2700,,12687,CHEMBL617948,,1,BAO_0000357,B,,H,Expert,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,
2701,,12687,CHEMBL858116,,1,BAO_0000019,F,,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,
2702,,12687,CHEMBL617949,,1,BAO_0000019,F,,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,
2703,,12687,CHEMBL617950,,1,BAO_0000019,F,,H,Autocuration,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,
2704,,12687,CHEMBL617951,,1,BAO_0000019,F,,H,Expert,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,,Thoracic aorta
2705,,12687,CHEMBL617952,,1,BAO_0000019,F,,H,Expert,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,,Thoracic aorta
2706,,12687,CHEMBL617953,,1,BAO_0000019,F,,H,Autocuration,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,,Thoracic aorta
2707,,12687,CHEMBL617954,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
2708,,12687,CHEMBL617955,,1,BAO_0000019,B,,H,Expert,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,
2709,,12687,CHEMBL857071,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,
2710,,12687,CHEMBL617270,,1,BAO_0000019,B,,H,Expert,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,
2711,,12687,CHEMBL617271,,1,BAO_0000219,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,,
2712,,12687,CHEMBL617272,,1,BAO_0000219,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,,
2713,,12687,CHEMBL617273,,1,BAO_0000019,B,,H,Autocuration,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,
2714,Rattus norvegicus,12687,CHEMBL617274,,1,BAO_0000019,F,10116.0,D,Expert,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,,
2715,,108,CHEMBL617275,,1,BAO_0000357,B,,H,Autocuration,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,
2716,,108,CHEMBL617276,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2717,,108,CHEMBL617277,,1,BAO_0000357,B,,H,Autocuration,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,
2718,,108,CHEMBL617278,,1,BAO_0000019,B,,H,Expert,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,
2719,,108,CHEMBL617279,,1,BAO_0000019,B,,H,Expert,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,
2720,,108,CHEMBL617280,,1,BAO_0000019,B,,H,Expert,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,
2721,,108,CHEMBL617281,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,
2722,,108,CHEMBL617282,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,
2723,,108,CHEMBL617283,,1,BAO_0000019,B,,H,Expert,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,
2724,,108,CHEMBL617284,,1,BAO_0000019,B,,H,Expert,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,
2725,,108,CHEMBL617285,,1,BAO_0000219,B,,H,Autocuration,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,,
2726,,108,CHEMBL617286,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,
2727,Homo sapiens,108,CHEMBL617287,,1,BAO_0000357,B,9606.0,D,Expert,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,,
2728,,108,CHEMBL617288,,1,BAO_0000357,B,,H,Expert,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,
2729,,108,CHEMBL617289,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,
2730,,108,CHEMBL872917,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2731,,108,CHEMBL617290,,1,BAO_0000357,B,,H,Autocuration,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,
2732,,108,CHEMBL617291,,1,BAO_0000219,B,,H,Autocuration,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,
2733,,108,CHEMBL617292,,1,BAO_0000219,B,,H,Autocuration,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,,
2734,,108,CHEMBL617293,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,
2735,Homo sapiens,108,CHEMBL617294,,1,BAO_0000219,F,9606.0,D,Expert,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,
2736,,108,CHEMBL617295,,1,BAO_0000019,B,,H,Expert,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,
2737,,108,CHEMBL617296,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
2738,,108,CHEMBL617297,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,
2739,,108,CHEMBL617298,,1,BAO_0000219,B,,H,Expert,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,,
2740,,108,CHEMBL617299,,1,BAO_0000219,B,,H,Expert,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,,
2741,,108,CHEMBL617300,,1,BAO_0000219,B,,H,Autocuration,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,,
2742,,108,CHEMBL617454,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-HT2C receptor,,,,
2743,,108,CHEMBL617505,,1,BAO_0000219,B,,H,Autocuration,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,
2744,Homo sapiens,108,CHEMBL617506,,1,BAO_0000219,B,9606.0,D,Expert,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,,,
2745,Homo sapiens,108,CHEMBL617507,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,,
2746,,108,CHEMBL617508,,1,BAO_0000357,B,,H,Expert,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,
2747,Homo sapiens,108,CHEMBL857982,,1,BAO_0000219,B,9606.0,D,Expert,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,,,
2748,Homo sapiens,108,CHEMBL617509,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,,,
2749,Homo sapiens,108,CHEMBL617510,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,,,
2750,,108,CHEMBL617511,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,
2751,,108,CHEMBL617512,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,,
2752,,108,CHEMBL617749,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,,
2753,,108,CHEMBL617750,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
2754,,108,CHEMBL617751,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
2755,,108,CHEMBL617752,,1,BAO_0000219,B,,H,Expert,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,,
2756,,108,CHEMBL617753,,1,BAO_0000219,B,,H,Autocuration,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,,
2757,,108,CHEMBL617754,,1,BAO_0000219,B,,H,Expert,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,,
2758,Homo sapiens,108,CHEMBL617755,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,,,
2759,,108,CHEMBL617756,,1,BAO_0000219,B,,H,Autocuration,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,,
2760,,108,CHEMBL617757,,1,BAO_0000219,B,,H,Expert,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,,
2761,,108,CHEMBL617758,,1,BAO_0000219,B,,H,Expert,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,,
2762,,108,CHEMBL617759,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,
2763,,108,CHEMBL617760,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,,
2764,,108,CHEMBL617761,,1,BAO_0000219,B,,H,Expert,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,,
2765,Homo sapiens,108,CHEMBL617762,,1,BAO_0000357,B,9606.0,D,Expert,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2766,,108,CHEMBL617763,,1,BAO_0000357,B,,H,Autocuration,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,
2767,,108,CHEMBL857983,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,,
2768,,108,CHEMBL617764,,1,BAO_0000219,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,,
2769,,108,CHEMBL617765,,1,BAO_0000219,B,,H,Autocuration,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,,
2770,,108,CHEMBL617766,,1,BAO_0000019,F,,H,Autocuration,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,
2771,,108,CHEMBL617767,,1,BAO_0000221,F,,H,Autocuration,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,,Hippocampus
2772,,108,CHEMBL617768,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,,
2773,,108,CHEMBL617769,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,,
2774,,11864,CHEMBL858023,,1,BAO_0000357,B,,H,Autocuration,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,
2775,,11864,CHEMBL617770,,1,BAO_0000019,B,,H,Autocuration,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,,Stomach
2776,,11864,CHEMBL617771,,1,BAO_0000019,B,,H,Autocuration,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,,Stomach
2777,,11864,CHEMBL617772,,1,BAO_0000219,F,,H,Autocuration,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,,
2778,,11864,CHEMBL617773,,1,BAO_0000219,B,,H,Autocuration,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,
2779,,11864,CHEMBL617850,,1,BAO_0000219,B,,H,Autocuration,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,,
2780,,11864,CHEMBL617851,,1,BAO_0000219,B,,H,Autocuration,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,
2781,,11864,CHEMBL617852,,1,BAO_0000019,F,,H,Autocuration,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,
2782,Mus musculus,12689,CHEMBL858024,,1,BAO_0000019,B,10090.0,H,Autocuration,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,,Stomach
2783,Rattus norvegicus,12689,CHEMBL617853,,1,BAO_0000019,B,10116.0,D,Expert,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,,Stomach
2784,,108,CHEMBL617854,,1,BAO_0000357,B,,H,Expert,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,
2785,Sus scrofa,108,CHEMBL873477,,1,BAO_0000357,B,9823.0,H,Expert,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,
2786,,108,CHEMBL617855,,1,BAO_0000357,B,,H,Expert,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2787,,108,CHEMBL617856,,1,BAO_0000019,B,,H,Expert,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,
2788,,108,CHEMBL617857,,1,BAO_0000019,B,,H,Autocuration,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,
2789,,108,CHEMBL617858,,1,BAO_0000249,B,,H,Autocuration,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,
2790,,108,CHEMBL617859,,1,BAO_0000357,B,,H,Autocuration,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,
2791,,108,CHEMBL617860,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2792,,108,CHEMBL617861,,1,BAO_0000357,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
2793,,108,CHEMBL617862,,1,BAO_0000019,B,,H,Expert,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,
2794,,108,CHEMBL617863,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,
2795,,108,CHEMBL617864,,1,BAO_0000249,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,
2796,,108,CHEMBL617649,,1,BAO_0000249,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,
2797,Sus scrofa,108,CHEMBL617650,,1,BAO_0000019,F,9823.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,,
2798,Sus scrofa,108,CHEMBL617651,,1,BAO_0000019,F,9823.0,H,Expert,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,,
2799,Sus scrofa,108,CHEMBL617652,,1,BAO_0000357,B,9823.0,H,Autocuration,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,,
2800,Sus scrofa,108,CHEMBL857072,,1,BAO_0000019,B,9823.0,H,Autocuration,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,,
2801,Sus scrofa,108,CHEMBL617653,,1,BAO_0000357,B,9823.0,H,Autocuration,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,,
2802,,12687,CHEMBL617654,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,
2803,,12689,CHEMBL617655,,1,BAO_0000019,F,,H,Autocuration,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,
2804,,12689,CHEMBL617656,,1,BAO_0000357,B,,H,Expert,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,
2805,,12689,CHEMBL617657,,1,BAO_0000357,B,,H,Autocuration,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,
2806,,12689,CHEMBL617658,,1,BAO_0000357,B,,H,Autocuration,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,
2807,Rattus norvegicus,12689,CHEMBL617659,,1,BAO_0000357,B,10116.0,D,Expert,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,,
2808,Rattus norvegicus,12689,CHEMBL617838,,1,BAO_0000357,B,10116.0,D,Expert,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,,
2809,Rattus norvegicus,12689,CHEMBL617839,,1,BAO_0000249,B,10116.0,D,Expert,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,,
2810,,12689,CHEMBL617840,,1,BAO_0000357,B,,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,
2811,,12689,CHEMBL617841,,1,BAO_0000019,B,,H,Autocuration,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,
2812,,12689,CHEMBL875915,,1,BAO_0000019,B,,H,Autocuration,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,
2813,,12689,CHEMBL617842,,1,BAO_0000219,B,,H,Expert,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,In vitro,,,
2814,,12689,CHEMBL617843,,1,BAO_0000219,B,,H,Expert,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,,
2815,,12689,CHEMBL617844,,1,BAO_0000357,B,,H,Expert,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,
2816,,12689,CHEMBL617845,,1,BAO_0000357,B,,H,Expert,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,
2817,,12689,CHEMBL617846,,1,BAO_0000219,B,,H,Expert,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,,
2818,,12689,CHEMBL617847,,1,BAO_0000357,B,,H,Autocuration,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,
2819,,12689,CHEMBL617848,,1,BAO_0000357,B,,H,Expert,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2820,,12689,CHEMBL617849,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,
2821,,12689,CHEMBL621507,,1,BAO_0000357,B,,H,Expert,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2822,,12689,CHEMBL621508,,1,BAO_0000357,B,,H,Expert,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,
2823,,12689,CHEMBL621509,,1,BAO_0000019,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,
2824,,12689,CHEMBL621510,,1,BAO_0000019,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,
2825,,12689,CHEMBL621511,,1,BAO_0000019,B,,H,Autocuration,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,
2826,,12689,CHEMBL621512,,1,BAO_0000219,B,,H,Expert,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,,
2827,,12689,CHEMBL621513,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,
2828,,12689,CHEMBL621514,,1,BAO_0000357,B,,H,Expert,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,
2829,,12689,CHEMBL621515,,1,BAO_0000219,B,,H,Expert,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,In vitro,,,
2830,,12689,CHEMBL621516,,1,BAO_0000219,B,,H,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,
2831,,12689,CHEMBL621517,,1,BAO_0000019,B,,H,Autocuration,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,,Caudate-putamen
2832,,12689,CHEMBL621518,,1,BAO_0000357,B,,H,Autocuration,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,
2833,,12689,CHEMBL621519,,1,BAO_0000019,B,,H,Autocuration,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,
2834,,12689,CHEMBL621520,,1,BAO_0000357,B,,H,Autocuration,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,
2835,,12689,CHEMBL621521,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,
2836,,12689,CHEMBL621522,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,
2837,,12689,CHEMBL621523,,1,BAO_0000219,B,,H,Expert,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,
2838,,12689,CHEMBL621524,,1,BAO_0000357,B,,H,Autocuration,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,
2839,Rattus norvegicus,12689,CHEMBL621525,,1,BAO_0000357,B,10116.0,D,Expert,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,,
2840,,12689,CHEMBL872921,,1,BAO_0000357,B,,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,
2841,,12689,CHEMBL621526,,1,BAO_0000357,B,,H,Autocuration,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,
2842,,12689,CHEMBL621527,,1,BAO_0000219,B,,H,Expert,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,
2843,Rattus norvegicus,12689,CHEMBL617865,,1,BAO_0000019,B,10116.0,D,Expert,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,,
2844,,12689,CHEMBL617866,,1,BAO_0000357,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2845,,12689,CHEMBL617867,,1,BAO_0000019,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,
2846,,12689,CHEMBL617487,,1,BAO_0000357,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,
2847,,12689,CHEMBL617488,,1,BAO_0000357,B,,H,Expert,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,
2848,,12689,CHEMBL617489,,1,BAO_0000357,B,,H,Autocuration,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,
2849,,12689,CHEMBL617490,,1,BAO_0000019,B,,H,Autocuration,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,
2850,,12689,CHEMBL617491,,1,BAO_0000019,B,,H,Autocuration,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,
2851,,12689,CHEMBL617492,,1,BAO_0000019,B,,H,Autocuration,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,
2852,,12689,CHEMBL617493,,1,BAO_0000019,B,,H,Autocuration,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,
2853,,12689,CHEMBL617494,,1,BAO_0000357,B,,H,Autocuration,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,
2854,Rattus norvegicus,12689,CHEMBL617495,,1,BAO_0000019,B,10116.0,D,Expert,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,,
2855,,12689,CHEMBL617496,,1,BAO_0000357,B,,H,Autocuration,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,
2856,,12689,CHEMBL617497,,1,BAO_0000219,B,,H,Autocuration,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,,
2857,,12689,CHEMBL617498,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2858,,12689,CHEMBL617499,,1,BAO_0000357,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,
2859,,12689,CHEMBL617500,,1,BAO_0000019,F,,H,Autocuration,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,
2860,,108,CHEMBL617501,,1,BAO_0000357,B,,H,Autocuration,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,
2861,,108,CHEMBL617502,,1,BAO_0000357,B,,H,Expert,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,
2862,,227,CHEMBL617503,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,
2863,,227,CHEMBL617504,,1,BAO_0000357,B,,H,Autocuration,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,
2864,,227,CHEMBL617406,,1,BAO_0000357,B,,H,Autocuration,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,
2865,Homo sapiens,227,CHEMBL617407,,1,BAO_0000019,B,9606.0,D,Expert,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,,
2866,,227,CHEMBL617408,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,
2867,,227,CHEMBL617409,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,
2868,,227,CHEMBL617410,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,
2869,,227,CHEMBL617411,,1,BAO_0000357,B,,H,Autocuration,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,
2870,,227,CHEMBL617412,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,
2871,Homo sapiens,227,CHEMBL617774,,1,BAO_0000357,B,9606.0,D,Expert,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,,
2872,Homo sapiens,227,CHEMBL617775,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,,
2873,Homo sapiens,227,CHEMBL617776,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,,,
2874,Homo sapiens,227,CHEMBL617777,,1,BAO_0000219,F,9606.0,D,Expert,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,
2875,Homo sapiens,227,CHEMBL617778,,1,BAO_0000219,F,9606.0,D,Expert,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,
2876,,227,CHEMBL617779,,1,BAO_0000219,B,,H,Autocuration,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,
2877,,227,CHEMBL617780,,1,BAO_0000219,B,,H,Expert,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,,
2878,,227,CHEMBL617781,,1,BAO_0000219,B,,H,Autocuration,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,,
2879,Homo sapiens,227,CHEMBL617782,,1,BAO_0000219,B,9606.0,D,Expert,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,,,
2880,Homo sapiens,227,CHEMBL617783,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,,,
2881,,227,CHEMBL617784,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,
2882,,227,CHEMBL617785,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,,
2883,,227,CHEMBL857984,,1,BAO_0000219,B,,H,Expert,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,,
2884,,227,CHEMBL617786,,1,BAO_0000219,B,,H,Expert,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,,
2885,,227,CHEMBL617787,,1,BAO_0000219,B,,H,Expert,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,,
2886,Homo sapiens,227,CHEMBL617788,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,,,
2887,Homo sapiens,227,CHEMBL617789,,1,BAO_0000219,B,9606.0,D,Expert,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,,,
2888,,227,CHEMBL617790,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,,
2889,,227,CHEMBL617791,,1,BAO_0000219,B,,H,Expert,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,,
2890,,227,CHEMBL617608,,1,BAO_0000357,B,,H,Expert,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,
2891,,227,CHEMBL617609,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,,
2892,,227,CHEMBL617610,,1,BAO_0000219,B,,H,Autocuration,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,
2893,,227,CHEMBL617611,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,,
2894,,227,CHEMBL617612,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,
2895,,227,CHEMBL617613,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,
2896,Oryctolagus cuniculus,227,CHEMBL617614,,1,BAO_0000019,B,9986.0,H,Autocuration,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,,
2897,,12688,CHEMBL617615,,1,BAO_0000019,B,,H,Expert,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,,Stomach
2898,,12688,CHEMBL858114,,1,BAO_0000357,B,,H,Expert,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,,Stomach
2899,,12688,CHEMBL617616,,1,BAO_0000357,B,,H,Autocuration,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,,Stomach
2900,Rattus norvegicus,12688,CHEMBL617617,,1,BAO_0000019,F,10116.0,D,Expert,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,,Stomach
2901,Rattus norvegicus,12688,CHEMBL875914,,1,BAO_0000019,F,10116.0,D,Expert,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,,,,
2902,,12688,CHEMBL617618,,1,BAO_0000019,F,,H,Autocuration,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,,Stomach
2903,Rattus norvegicus,12688,CHEMBL617619,,1,BAO_0000357,B,10116.0,D,Expert,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,,Stomach
2904,,12688,CHEMBL617620,,1,BAO_0000019,F,,H,Autocuration,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,
2905,,12688,CHEMBL617621,,1,BAO_0000019,F,,H,Autocuration,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,
2906,,12688,CHEMBL617622,,1,BAO_0000019,F,,H,Autocuration,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,
2907,Rattus norvegicus,12688,CHEMBL617623,,1,BAO_0000357,B,10116.0,D,Expert,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,,Stomach
2908,Rattus norvegicus,12688,CHEMBL617624,,1,BAO_0000357,B,10116.0,D,Expert,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,,Stomach
2909,Rattus norvegicus,12688,CHEMBL617625,,1,BAO_0000357,B,10116.0,D,Expert,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,,Stomach
2910,Rattus norvegicus,12688,CHEMBL617626,,1,BAO_0000357,B,10116.0,D,Expert,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,,Stomach
2911,,12688,CHEMBL617627,,1,BAO_0000019,F,,H,Autocuration,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,Stomach
2912,,12688,CHEMBL617628,,1,BAO_0000019,F,,H,Expert,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,Stomach
2913,,12688,CHEMBL617629,,1,BAO_0000019,F,,H,Autocuration,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,,Stomach
2914,,12688,CHEMBL858115,,1,BAO_0000019,F,,H,Autocuration,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,,Stomach
2915,Rattus norvegicus,12688,CHEMBL617630,,1,BAO_0000019,F,10116.0,D,Expert,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,,Stomach
2916,,12688,CHEMBL617631,,1,BAO_0000019,F,,H,Autocuration,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,,Thoracic aorta
2917,,12688,CHEMBL617632,,1,BAO_0000357,B,,H,Autocuration,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,
2918,,12688,CHEMBL617633,,1,BAO_0000357,B,,H,Expert,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,
2919,,12688,CHEMBL617634,,1,BAO_0000357,B,,H,Autocuration,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,
2920,,12688,CHEMBL617635,,1,BAO_0000357,B,,H,Autocuration,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,
2922,Rattus norvegicus,12688,CHEMBL617637,,1,BAO_0000019,F,10116.0,D,Autocuration,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,Stomach
2923,,227,CHEMBL617638,,1,BAO_0000357,B,,H,Autocuration,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,
2924,,227,CHEMBL617639,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,
2925,,227,CHEMBL617640,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,
2926,,227,CHEMBL617641,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity to 5-HT 2B receptor,,,,
2927,,227,CHEMBL617642,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,
2928,,227,CHEMBL617643,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,
2929,,227,CHEMBL617644,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,
2930,,227,CHEMBL617645,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,
2931,,108,CHEMBL617646,,1,BAO_0000357,B,,H,Expert,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,
2932,Bos taurus,108,CHEMBL617647,,1,BAO_0000357,B,9913.0,H,Autocuration,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,,
2933,Bos taurus,108,CHEMBL617648,,1,BAO_0000357,B,9913.0,H,Autocuration,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,,
2934,Bos taurus,108,CHEMBL617875,,1,BAO_0000357,B,9913.0,H,Autocuration,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,,
2935,Bos taurus,108,CHEMBL617876,,1,BAO_0000357,B,9913.0,H,Autocuration,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,,
2936,Bos taurus,108,CHEMBL617877,,1,BAO_0000357,B,9913.0,H,Expert,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,,
2937,Bos taurus,108,CHEMBL617878,,1,BAO_0000357,B,9913.0,H,Expert,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,
2938,Bos taurus,108,CHEMBL617879,,1,BAO_0000357,B,9913.0,H,Autocuration,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,,
2939,Cavia porcellus,108,CHEMBL617880,,1,BAO_0000019,B,10141.0,H,Autocuration,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,,
2940,Cavia porcellus,20033,CHEMBL617881,,1,BAO_0000357,B,10141.0,D,Intermediate,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,,Striatum
2941,,51,CHEMBL857073,,1,BAO_0000357,B,,H,Autocuration,5254,Binding affinity against 5-HT1A receptor,,,,
2942,,108,CHEMBL617882,,1,BAO_0000219,F,,H,Expert,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,,
2943,Homo sapiens,108,CHEMBL617883,,1,BAO_0000219,F,9606.0,D,Expert,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,,,
2944,,108,CHEMBL617884,,1,BAO_0000219,F,,H,Autocuration,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,
2945,,108,CHEMBL617885,,1,BAO_0000219,B,,H,Autocuration,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,,
2946,,108,CHEMBL617886,,1,BAO_0000219,B,,H,Autocuration,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,,
2947,Homo sapiens,108,CHEMBL617887,,1,BAO_0000357,B,9606.0,D,Expert,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,,,,
2948,,108,CHEMBL617888,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,
2949,,108,CHEMBL617889,,1,BAO_0000019,B,,H,Autocuration,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,
2950,,108,CHEMBL617890,,1,BAO_0000357,B,,H,Autocuration,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,
2951,,108,CHEMBL617891,,1,BAO_0000357,B,,H,Autocuration,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,
2952,,108,CHEMBL617892,,1,BAO_0000357,B,,H,Autocuration,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,
2953,,108,CHEMBL617893,,1,BAO_0000219,B,,H,Expert,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,,
2954,,108,CHEMBL617894,,1,BAO_0000219,B,,H,Expert,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,,
2955,,108,CHEMBL617895,,1,BAO_0000219,B,,H,Expert,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,
2956,,108,CHEMBL617896,,1,BAO_0000219,B,,H,Autocuration,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,,
2957,Homo sapiens,108,CHEMBL617897,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,,
2958,,108,CHEMBL617898,,1,BAO_0000019,F,,H,Autocuration,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,
2959,,108,CHEMBL617899,,1,BAO_0000019,F,,H,Autocuration,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,
2960,Rattus norvegicus,108,CHEMBL617900,,1,BAO_0000219,B,10116.0,H,Expert,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,,,
2961,,108,CHEMBL617901,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,
2962,,108,CHEMBL617902,,1,BAO_0000019,F,,H,Autocuration,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,
2963,,108,CHEMBL617903,,1,BAO_0000019,F,,H,Autocuration,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
2964,,108,CHEMBL617904,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,
2965,,108,CHEMBL617905,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,
2966,,108,CHEMBL617906,,1,BAO_0000357,B,,H,Autocuration,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,
2967,,108,CHEMBL617907,,1,BAO_0000357,B,,H,Autocuration,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,
2968,,108,CHEMBL617908,,1,BAO_0000357,B,,H,Autocuration,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,
2969,,108,CHEMBL620617,,1,BAO_0000219,B,,H,Expert,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,
2970,Homo sapiens,108,CHEMBL620618,,1,BAO_0000019,B,9606.0,D,Expert,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,,
2971,,108,CHEMBL620619,,1,BAO_0000357,B,,H,Expert,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,
2972,Homo sapiens,108,CHEMBL620620,,1,BAO_0000357,B,9606.0,D,Expert,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,,
2973,,108,CHEMBL620621,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,
2974,Rattus norvegicus,104698,CHEMBL872920,,1,BAO_0000249,B,10116.0,D,Autocuration,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,,
2975,,104698,CHEMBL620622,,1,BAO_0000223,B,,H,Autocuration,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,
2976,Rattus norvegicus,104698,CHEMBL620623,,1,BAO_0000019,B,10116.0,D,Autocuration,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,,
2977,,104698,CHEMBL620624,,1,BAO_0000019,B,,H,Autocuration,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,
2978,,104698,CHEMBL620625,,1,BAO_0000019,B,,H,Autocuration,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,
2979,,104698,CHEMBL620626,,1,BAO_0000219,B,,H,Autocuration,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,
2980,,104698,CHEMBL621307,,1,BAO_0000019,B,,H,Autocuration,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,
2981,,104698,CHEMBL621308,,1,BAO_0000019,B,,H,Autocuration,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,
2982,,104698,CHEMBL621309,,1,BAO_0000223,B,,H,Autocuration,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,
2983,,104698,CHEMBL621310,,1,BAO_0000223,B,,H,Autocuration,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,
2984,,104698,CHEMBL621311,,1,BAO_0000223,B,,H,Autocuration,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,
2985,,104698,CHEMBL621502,,1,BAO_0000249,B,,H,Autocuration,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,
2986,,104698,CHEMBL621503,,1,BAO_0000249,B,,H,Autocuration,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,
2987,,104698,CHEMBL621504,,1,BAO_0000249,B,,H,Autocuration,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,
2988,,104698,CHEMBL621505,,1,BAO_0000223,B,,H,Autocuration,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,
2989,,104698,CHEMBL621506,,1,BAO_0000019,B,,H,Autocuration,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,
2990,,104698,CHEMBL619781,,1,BAO_0000223,B,,H,Autocuration,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,
2991,,104698,CHEMBL619782,,1,BAO_0000223,B,,H,Autocuration,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,
2992,,104698,CHEMBL619783,,1,BAO_0000019,B,,H,Autocuration,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,
2993,Rattus norvegicus,104698,CHEMBL619784,,1,BAO_0000019,B,10116.0,D,Autocuration,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,,
2994,,104698,CHEMBL619785,,1,BAO_0000249,B,,H,Autocuration,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,
2995,,104698,CHEMBL619786,,1,BAO_0000223,B,,H,Autocuration,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,
2996,,104698,CHEMBL619787,,1,BAO_0000019,B,,H,Autocuration,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,
2997,,104698,CHEMBL872925,,1,BAO_0000019,B,,H,Autocuration,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,
2998,,104698,CHEMBL619788,,1,BAO_0000019,B,,H,Autocuration,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,
2999,,104698,CHEMBL619789,,1,BAO_0000249,B,,H,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,
3000,,104698,CHEMBL619790,,1,BAO_0000249,B,,H,Autocuration,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,
3001,,104698,CHEMBL619791,,1,BAO_0000019,B,,H,Autocuration,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,
3002,,104698,CHEMBL619792,,1,BAO_0000019,B,,H,Autocuration,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,
3003,,104698,CHEMBL619793,,1,BAO_0000249,B,,H,Autocuration,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,
3004,Rattus norvegicus,104698,CHEMBL619794,,1,BAO_0000223,B,10116.0,D,Autocuration,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,
3005,,104698,CHEMBL619795,,1,BAO_0000221,B,,H,Autocuration,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,,Brain
3006,,104698,CHEMBL619796,,1,BAO_0000019,B,,H,Autocuration,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,
3007,,104698,CHEMBL620448,,1,BAO_0000223,B,,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,
3008,,104698,CHEMBL620449,,1,BAO_0000223,B,,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,
3009,,104698,CHEMBL620450,,1,BAO_0000223,B,,H,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,
3010,,104698,CHEMBL620451,,1,BAO_0000223,B,,H,Autocuration,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,
3011,,104698,CHEMBL620631,,1,BAO_0000223,B,,H,Autocuration,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,
3012,,104698,CHEMBL620632,,1,BAO_0000019,B,,H,Autocuration,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,
3013,,104698,CHEMBL620633,,1,BAO_0000019,B,,H,Autocuration,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,
3014,,104698,CHEMBL620634,,1,BAO_0000223,B,,H,Autocuration,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,
3015,,104698,CHEMBL620635,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,
3016,,104698,CHEMBL620636,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3017,,104698,CHEMBL620637,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3018,,104698,CHEMBL620638,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3019,,104698,CHEMBL620639,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,
3020,,104698,CHEMBL620640,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3021,,104698,CHEMBL620641,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3022,,104698,CHEMBL620642,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,In vivo,,,
3023,,104698,CHEMBL620643,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3024,,104698,CHEMBL620644,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,
3025,,104698,CHEMBL620645,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3026,,104698,CHEMBL620646,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3027,,104698,CHEMBL620647,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3028,,104698,CHEMBL620648,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,In vivo,,,
3029,,104698,CHEMBL620649,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,In vivo,,,
3030,,104698,CHEMBL620650,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3031,,104698,CHEMBL620651,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3032,,104698,CHEMBL872875,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,In vivo,,,
3033,,104698,CHEMBL620652,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,In vivo,,,
3034,,104698,CHEMBL620653,,1,BAO_0000019,F,,H,Autocuration,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,
3035,,104698,CHEMBL857076,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,
3036,Rattus norvegicus,104698,CHEMBL620654,,1,BAO_0000019,B,10116.0,D,Autocuration,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,,
3037,,104698,CHEMBL620655,,1,BAO_0000223,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
3038,,104698,CHEMBL620656,,1,BAO_0000249,B,,H,Autocuration,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,
3039,,104698,CHEMBL620657,,1,BAO_0000249,B,,H,Autocuration,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,
3040,,108,CHEMBL620658,,1,BAO_0000357,B,,H,Autocuration,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,
3041,,108,CHEMBL620659,,1,BAO_0000357,B,,H,Autocuration,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,
3042,,108,CHEMBL620660,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,
3043,,108,CHEMBL620661,,1,BAO_0000357,B,,H,Autocuration,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,
3044,,108,CHEMBL620662,,1,BAO_0000357,B,,H,Autocuration,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,
3045,,108,CHEMBL620663,,1,BAO_0000357,B,,H,Expert,5163,Affinity for 5-hydroxytryptamine 2C receptor,,,,
3046,,108,CHEMBL620664,,1,BAO_0000357,B,,H,Autocuration,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,
3047,,108,CHEMBL620665,,1,BAO_0000357,B,,H,Expert,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,
3048,,108,CHEMBL620666,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,
3049,,108,CHEMBL620667,,1,BAO_0000357,B,,H,Autocuration,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,
3050,,108,CHEMBL620668,,1,BAO_0000357,B,,H,Expert,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,
3051,,108,CHEMBL620669,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,
3052,,108,CHEMBL620670,,1,BAO_0000357,B,,H,Expert,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,
3053,,108,CHEMBL620671,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,
3054,,108,CHEMBL620672,,1,BAO_0000357,B,,H,Autocuration,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,
3055,,108,CHEMBL620673,,1,BAO_0000357,B,,H,Autocuration,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,
3056,,108,CHEMBL620674,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,
3057,,108,CHEMBL620675,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,
3058,,108,CHEMBL620676,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,
3059,,108,CHEMBL621382,,1,BAO_0000357,B,,H,Autocuration,3269,Affinity against 5-hydroxytryptamine 2C receptor,,,,
3060,Homo sapiens,108,CHEMBL621383,,1,BAO_0000357,B,9606.0,D,Expert,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,
3061,,108,CHEMBL621384,,1,BAO_0000357,B,,H,Autocuration,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,
3062,Bos taurus,144,CHEMBL621385,,1,BAO_0000357,B,9913.0,H,Autocuration,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,,
3063,Bos taurus,144,CHEMBL617989,,1,BAO_0000357,B,9913.0,H,Autocuration,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,,
3064,Cavia porcellus,104714,CHEMBL617990,,1,BAO_0000019,F,10141.0,H,Expert,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,,
3065,Cavia porcellus,104714,CHEMBL875085,,1,BAO_0000221,B,10141.0,H,Autocuration,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,,Ileum
3066,Cavia porcellus,104714,CHEMBL617991,,1,BAO_0000019,F,10141.0,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,,
3067,Cavia porcellus,104714,CHEMBL617992,,1,BAO_0000019,F,10141.0,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,,
3068,Cavia porcellus,104714,CHEMBL617993,,1,BAO_0000221,B,10141.0,H,Autocuration,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,,Ileum
3069,Cavia porcellus,104714,CHEMBL617994,,1,BAO_0000221,B,10141.0,H,Autocuration,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,,Ileum
3070,Cavia porcellus,104714,CHEMBL617995,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,,
3071,Cavia porcellus,104714,CHEMBL617996,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,,
3072,Cavia porcellus,104714,CHEMBL617997,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,,
3073,Cavia porcellus,104714,CHEMBL617998,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,,
3074,Cavia porcellus,104714,CHEMBL617999,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,,
3075,Cavia porcellus,104714,CHEMBL618000,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,,
3076,Cavia porcellus,104714,CHEMBL617815,,1,BAO_0000221,F,10141.0,H,Autocuration,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,,Ileum
3077,Cavia porcellus,104714,CHEMBL617816,,1,BAO_0000221,F,10141.0,H,Autocuration,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,,Ileum
3078,Cavia porcellus,104714,CHEMBL617817,,1,BAO_0000221,F,10141.0,H,Autocuration,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,,Ileum
3079,Cavia porcellus,104714,CHEMBL617818,,1,BAO_0000221,B,10141.0,H,Autocuration,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,,Ileum
3080,Cavia porcellus,104714,CHEMBL617819,,1,BAO_0000221,B,10141.0,H,Autocuration,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,,Ileum
3081,Cavia porcellus,104714,CHEMBL617820,,1,BAO_0000223,B,10141.0,H,Autocuration,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,,
3082,Cavia porcellus,104714,CHEMBL617821,,1,BAO_0000221,B,10141.0,H,Autocuration,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,,Ileum
3083,Cavia porcellus,104714,CHEMBL617822,,1,BAO_0000221,F,10141.0,H,Autocuration,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,,Ileum
3084,Cavia porcellus,104714,CHEMBL617823,,1,BAO_0000221,F,10141.0,H,Autocuration,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,,Ileum
3085,Cavia porcellus,104714,CHEMBL617824,,1,BAO_0000221,F,10141.0,H,Autocuration,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,,Ileum
3086,Cavia porcellus,104714,CHEMBL617825,,1,BAO_0000221,F,10141.0,H,Autocuration,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,,Ileum
3087,Cavia porcellus,104714,CHEMBL617826,,1,BAO_0000221,F,10141.0,H,Autocuration,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,,Ileum
3088,Cavia porcellus,104714,CHEMBL617827,,1,BAO_0000221,B,10141.0,H,Autocuration,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,,Ileum
3089,Cavia porcellus,104714,CHEMBL617828,,1,BAO_0000221,F,10141.0,H,Autocuration,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,,Ileum
3090,Cavia porcellus,104714,CHEMBL617829,,1,BAO_0000221,B,10141.0,H,Autocuration,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,,Ileum
3091,Cavia porcellus,104714,CHEMBL617830,,1,BAO_0000221,B,10141.0,H,Autocuration,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,,Ileum
3092,Cavia porcellus,104714,CHEMBL617831,,1,BAO_0000221,B,10141.0,H,Autocuration,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,,Ileum
3093,Cavia porcellus,104714,CHEMBL617832,,1,BAO_0000221,B,10141.0,H,Autocuration,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,,Ileum
3094,Cavia porcellus,22226,CHEMBL617833,,1,BAO_0000019,B,10141.0,U,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,,
3095,,51,CHEMBL617834,,1,BAO_0000357,B,,H,Autocuration,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,
3096,Homo sapiens,104714,CHEMBL617835,,1,BAO_0000223,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,,
3097,,104714,CHEMBL617836,,1,BAO_0000223,B,,H,Autocuration,6013,Binding affinity towards 5-HT3 receptor,,,,
3098,,104714,CHEMBL617837,,1,BAO_0000223,B,,H,Autocuration,12861,Binding activity radioligand.,,,,
3099,,104714,CHEMBL620392,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,
3100,,104714,CHEMBL620393,,1,BAO_0000223,B,,H,Autocuration,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,
3101,,104714,CHEMBL620394,,1,BAO_0000223,B,,H,Autocuration,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,
3102,,104714,CHEMBL620395,,1,BAO_0000223,B,,H,Autocuration,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,
3103,,22226,CHEMBL620396,,1,BAO_0000019,B,,U,Autocuration,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,
3104,,105030,CHEMBL620582,,1,BAO_0000219,B,,H,Expert,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,,
3105,,105030,CHEMBL620583,,1,BAO_0000218,B,,H,Autocuration,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",In vivo,,,
3106,,105030,CHEMBL620584,,1,BAO_0000019,B,,H,Autocuration,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,
3107,,105030,CHEMBL620585,,1,BAO_0000224,B,,H,Autocuration,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,
3108,,105030,CHEMBL620586,,1,BAO_0000224,B,,H,Autocuration,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,
3109,,105030,CHEMBL620587,,1,BAO_0000019,B,,H,Autocuration,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,
3110,,105030,CHEMBL620588,,1,BAO_0000019,B,,H,Autocuration,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,
3111,,105030,CHEMBL620589,,1,BAO_0000218,F,,H,Autocuration,12918,5-hydroxytryptamine 3 receptor agonism in mouse,,,,
3112,,105030,CHEMBL620590,,1,BAO_0000219,B,,H,Autocuration,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,
3113,,105030,CHEMBL617956,,1,BAO_0000019,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,
3114,,105030,CHEMBL617957,,1,BAO_0000019,B,,H,Autocuration,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,
3115,,105030,CHEMBL617958,,1,BAO_0000224,B,,H,Autocuration,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,
3116,,105030,CHEMBL617959,,1,BAO_0000219,B,,H,Autocuration,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,
3117,,105030,CHEMBL617960,,1,BAO_0000219,B,,H,Autocuration,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,
3118,,105030,CHEMBL617961,,1,BAO_0000224,B,,H,Autocuration,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,
3119,,105030,CHEMBL617962,,1,BAO_0000219,B,,H,Autocuration,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,In vitro,,,
3120,,105030,CHEMBL617963,,1,BAO_0000219,B,,H,Autocuration,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,,
3121,,11765,CHEMBL617964,,1,BAO_0000019,B,,H,Autocuration,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,
3122,,11765,CHEMBL617965,,1,BAO_0000219,B,,H,Autocuration,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,
3123,Mus musculus,10630,CHEMBL617966,,1,BAO_0000357,B,10090.0,D,Autocuration,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,,
3124,,17106,CHEMBL857074,,1,BAO_0000019,B,,H,Autocuration,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,
3125,Sus scrofa,144,CHEMBL617967,,1,BAO_0000357,B,9823.0,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,,
3126,Sus scrofa,144,CHEMBL617968,,1,BAO_0000357,B,9823.0,H,Autocuration,12861,Binding activity radioligand.,,,,
3127,Oryctolagus cuniculus,104714,CHEMBL617969,,1,BAO_0000223,B,9986.0,H,Autocuration,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,,
3128,Oryctolagus cuniculus,104714,CHEMBL617970,,1,BAO_0000223,B,9986.0,H,Autocuration,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,
3129,Oryctolagus cuniculus,104714,CHEMBL617971,,1,BAO_0000223,B,9986.0,H,Autocuration,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,,
3130,Oryctolagus cuniculus,104714,CHEMBL617972,,1,BAO_0000019,B,9986.0,H,Autocuration,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,
3131,Oryctolagus cuniculus,104714,CHEMBL617973,,1,BAO_0000019,F,9986.0,H,Autocuration,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,,
3132,Oryctolagus cuniculus,104714,CHEMBL617974,,1,BAO_0000019,F,9986.0,H,Autocuration,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,,
3133,Oryctolagus cuniculus,104714,CHEMBL617975,,1,BAO_0000221,F,9986.0,H,Autocuration,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,,Ileum
3134,Oryctolagus cuniculus,104714,CHEMBL617976,,1,BAO_0000019,F,9986.0,H,Autocuration,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,,
3135,Oryctolagus cuniculus,104714,CHEMBL617977,,1,BAO_0000019,F,9986.0,H,Autocuration,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,,
3136,Oryctolagus cuniculus,104714,CHEMBL617978,,1,BAO_0000019,F,9986.0,H,Autocuration,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,,
3137,Oryctolagus cuniculus,104714,CHEMBL617979,,1,BAO_0000019,F,9986.0,H,Autocuration,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,,
3138,Oryctolagus cuniculus,104714,CHEMBL617980,,1,BAO_0000219,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,,,
3139,Rattus norvegicus,104698,CHEMBL617981,,1,BAO_0000019,B,10116.0,D,Autocuration,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,,
3140,,12020,CHEMBL617982,,1,BAO_0000019,B,,H,Autocuration,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,
3141,,12020,CHEMBL617983,,1,BAO_0000357,B,,H,Autocuration,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,
3142,Rattus norvegicus,104698,CHEMBL617984,,1,BAO_0000019,B,10116.0,D,Autocuration,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,,
3143,,104698,CHEMBL617985,,1,BAO_0000019,B,,H,Autocuration,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,
3144,,104698,CHEMBL617986,,1,BAO_0000218,F,,H,Autocuration,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",In vivo,,,Heart
3145,,104698,CHEMBL617987,,1,BAO_0000019,F,,H,Autocuration,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,Heart
3146,,104698,CHEMBL617988,,1,BAO_0000019,F,,H,Autocuration,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,,Heart
3147,,104698,CHEMBL617792,,1,BAO_0000019,F,,H,Autocuration,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,,Heart
3148,,104698,CHEMBL617793,,1,BAO_0000019,F,,H,Autocuration,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,Heart
3149,,104698,CHEMBL617794,,1,BAO_0000019,F,,H,Autocuration,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,
3150,,104698,CHEMBL617795,,1,BAO_0000019,F,,H,Autocuration,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,
3151,,104698,CHEMBL617796,,1,BAO_0000019,F,,H,Autocuration,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,
3152,,104698,CHEMBL617797,,1,BAO_0000019,F,,H,Autocuration,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,
3153,Rattus norvegicus,104698,CHEMBL617798,,1,BAO_0000218,F,10116.0,D,Autocuration,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),In vivo,,,
3154,,104698,CHEMBL617799,,1,BAO_0000218,F,,H,Autocuration,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),In vivo,,,
3155,Rattus norvegicus,104698,CHEMBL617800,,1,BAO_0000218,F,10116.0,D,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3156,Rattus norvegicus,104698,CHEMBL617801,,1,BAO_0000019,F,10116.0,D,Autocuration,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,,
3157,Rattus norvegicus,104698,CHEMBL617802,,1,BAO_0000218,F,10116.0,D,Autocuration,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,In vivo,,,
3158,Rattus norvegicus,104698,CHEMBL617803,,1,BAO_0000019,F,10116.0,D,Autocuration,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,,
3159,,104698,CHEMBL617804,,1,BAO_0000019,B,,H,Autocuration,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,
3160,Rattus norvegicus,104698,CHEMBL617805,,1,BAO_0000019,B,10116.0,D,Autocuration,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,,
3161,,104698,CHEMBL617806,,1,BAO_0000223,B,,H,Autocuration,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,
3162,,104698,CHEMBL617807,,1,BAO_0000019,B,,H,Autocuration,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,
3163,,104698,CHEMBL617808,,1,BAO_0000019,B,,H,Autocuration,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,
3164,,104698,CHEMBL617809,,1,BAO_0000249,B,,H,Autocuration,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,
3165,,104698,CHEMBL617810,,1,BAO_0000019,B,,H,Autocuration,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,
3166,,104698,CHEMBL617811,,1,BAO_0000249,B,,H,Autocuration,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,,Brain
3167,,104698,CHEMBL617812,,1,BAO_0000221,B,,H,Autocuration,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,,Brain
3168,,104698,CHEMBL617813,,1,BAO_0000249,B,,H,Autocuration,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,
3169,,104698,CHEMBL617814,,1,BAO_0000249,B,,H,Autocuration,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,
3170,,104698,CHEMBL617698,,1,BAO_0000019,B,,H,Autocuration,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,
3171,Rattus norvegicus,104698,CHEMBL617699,,1,BAO_0000019,B,10116.0,D,Autocuration,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,,
3172,Rattus norvegicus,104698,CHEMBL617700,,1,BAO_0000019,B,10116.0,D,Autocuration,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,,
3173,Rattus norvegicus,104698,CHEMBL617701,,1,BAO_0000223,B,10116.0,D,Autocuration,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,,
3174,,104698,CHEMBL617702,,1,BAO_0000019,B,,H,Autocuration,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,
3175,,104698,CHEMBL617703,,1,BAO_0000249,B,,H,Autocuration,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,
3176,Rattus norvegicus,104698,CHEMBL617704,,1,BAO_0000019,B,10116.0,D,Autocuration,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,,
3177,,104698,CHEMBL617705,,1,BAO_0000223,B,,H,Autocuration,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,
3178,Rattus norvegicus,104698,CHEMBL617706,,1,BAO_0000223,B,10116.0,D,Autocuration,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,,
3179,,104698,CHEMBL617707,,1,BAO_0000219,B,,H,Autocuration,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,,
3180,,104698,CHEMBL617708,,1,BAO_0000219,B,,H,Autocuration,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,,
3181,,104698,CHEMBL617709,,1,BAO_0000019,B,,H,Autocuration,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,
3182,,104698,CHEMBL617710,,1,BAO_0000019,B,,H,Autocuration,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,
3183,,104698,CHEMBL882925,,1,BAO_0000019,B,,H,Autocuration,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,
3184,,104698,CHEMBL617711,,1,BAO_0000019,B,,H,Autocuration,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,
3185,,104698,CHEMBL617712,,1,BAO_0000019,F,,H,Autocuration,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,
3186,Rattus norvegicus,104698,CHEMBL617713,,1,BAO_0000019,F,10116.0,D,Autocuration,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,,
3187,,104698,CHEMBL617714,,1,BAO_0000019,F,,H,Autocuration,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,
3188,,104698,CHEMBL617715,,1,BAO_0000218,F,,H,Autocuration,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,
3189,,104698,CHEMBL617716,,1,BAO_0000218,F,,H,Autocuration,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,In vivo,,,
3190,,104698,CHEMBL617717,,1,BAO_0000218,F,,H,Autocuration,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,
3191,,104698,CHEMBL617718,,1,BAO_0000218,F,,H,Autocuration,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3192,,104698,CHEMBL617719,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3193,,104698,CHEMBL617720,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),In vivo,,,
3194,Rattus norvegicus,104698,CHEMBL617721,,1,BAO_0000218,F,10116.0,D,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3195,,104698,CHEMBL617722,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3196,,104698,CHEMBL617723,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,In vivo,,,
3197,,104698,CHEMBL617724,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3198,,104698,CHEMBL617725,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3199,,104698,CHEMBL617726,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3200,,104698,CHEMBL617727,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3201,,104698,CHEMBL617728,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3202,,104698,CHEMBL617729,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3203,,104698,CHEMBL617730,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,In vivo,,,
3204,,104698,CHEMBL617731,,1,BAO_0000218,F,,H,Autocuration,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3205,,104698,CHEMBL617732,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3206,,104698,CHEMBL617733,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3207,,104698,CHEMBL617734,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3208,,104698,CHEMBL872874,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,In vivo,,,
3209,,104698,CHEMBL617735,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,In vivo,,,
3210,,104698,CHEMBL617736,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,In vivo,,,
3211,,104698,CHEMBL617737,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,In vivo,,,
3212,,104698,CHEMBL617738,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,In vivo,,,
3213,,104698,CHEMBL617739,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3214,,104698,CHEMBL617740,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3215,,104698,CHEMBL617741,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3216,,104698,CHEMBL617742,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3217,,104698,CHEMBL617743,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3218,,104698,CHEMBL617744,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3219,,104698,CHEMBL617745,,1,BAO_0000218,F,,H,Autocuration,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,In vivo,,,
3220,,104698,CHEMBL617746,,1,BAO_0000218,F,,H,Autocuration,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,
3221,,104698,CHEMBL617747,,1,BAO_0000218,F,,H,Autocuration,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,
3222,,104698,CHEMBL617748,,1,BAO_0000218,F,,H,Autocuration,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,In vivo,,,
3223,,104698,CHEMBL618909,,1,BAO_0000218,F,,H,Autocuration,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,In vivo,,,
3224,,104698,CHEMBL618910,,1,BAO_0000218,F,,H,Autocuration,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,In vivo,,,
3225,,104698,CHEMBL618911,,1,BAO_0000218,F,,H,Autocuration,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,In vivo,,,
3226,,104698,CHEMBL618912,,1,BAO_0000218,F,,H,Autocuration,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,In vivo,,,
3227,,104698,CHEMBL618913,,1,BAO_0000218,F,,H,Autocuration,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),In vivo,,,
3228,,104698,CHEMBL618914,,1,BAO_0000019,F,,H,Autocuration,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,
3229,,104698,CHEMBL618915,,1,BAO_0000019,F,,H,Autocuration,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,
3230,Rattus norvegicus,104698,CHEMBL618916,,1,BAO_0000223,B,10116.0,D,Autocuration,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,,
3231,,104698,CHEMBL618917,,1,BAO_0000019,F,,H,Autocuration,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,
3232,,104698,CHEMBL618918,,1,BAO_0000221,B,,D,Intermediate,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,,Hippocampus
3233,Rattus norvegicus,104698,CHEMBL618919,,1,BAO_0000019,B,10116.0,D,Autocuration,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,,
3234,Rattus norvegicus,104698,CHEMBL618920,,1,BAO_0000019,B,10116.0,D,Autocuration,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,,
3235,,104698,CHEMBL618921,,1,BAO_0000223,B,,H,Autocuration,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,
3236,,104698,CHEMBL618922,,1,BAO_0000019,B,,H,Autocuration,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,
3237,,104698,CHEMBL618923,,1,BAO_0000019,B,,H,Autocuration,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,
3238,,104698,CHEMBL618924,,1,BAO_0000019,B,,H,Autocuration,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,
3239,,104698,CHEMBL618925,,1,BAO_0000019,B,,H,Autocuration,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,
3240,,104698,CHEMBL618926,,1,BAO_0000019,B,,H,Autocuration,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,
3241,Cavia porcellus,20033,CHEMBL618927,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,,Ileum
3242,Cavia porcellus,20033,CHEMBL618928,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,,Ileum
3243,Cavia porcellus,20033,CHEMBL618929,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,,Ileum
3244,Cavia porcellus,20033,CHEMBL618930,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,,Ileum
3245,Cavia porcellus,20033,CHEMBL618931,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,,Ileum
3246,Cavia porcellus,20033,CHEMBL619594,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,,Ileum
3247,Cavia porcellus,20033,CHEMBL619595,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,,Ileum
3248,Cavia porcellus,20033,CHEMBL619596,,1,BAO_0000221,F,10141.0,D,Intermediate,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,,Ileum
3249,Cavia porcellus,20033,CHEMBL619755,,1,BAO_0000221,F,10141.0,D,Intermediate,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,,Ileum
3250,Cavia porcellus,20033,CHEMBL619756,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,,Ileum
3251,Cavia porcellus,20033,CHEMBL619757,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,,Ileum
3252,Cavia porcellus,20033,CHEMBL619758,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,,Ileum
3253,Cavia porcellus,20033,CHEMBL619759,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,,Ileum
3254,Cavia porcellus,20033,CHEMBL619760,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,,Ileum
3255,Cavia porcellus,20033,CHEMBL619761,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,,Ileum
3256,Cavia porcellus,20033,CHEMBL619762,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,,Ileum
3257,Cavia porcellus,20033,CHEMBL619763,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,,Ileum
3258,Cavia porcellus,20033,CHEMBL617868,,1,BAO_0000221,F,10141.0,D,Intermediate,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,,Ileum
3259,Cavia porcellus,20033,CHEMBL617869,,1,BAO_0000357,B,10141.0,D,Intermediate,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,,
3260,Cavia porcellus,20033,CHEMBL882926,,1,BAO_0000249,B,10141.0,D,Intermediate,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,,Striatum
3261,Cavia porcellus,20033,CHEMBL617870,,1,BAO_0000249,B,10141.0,D,Intermediate,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,,Striatum
3262,Cavia porcellus,20033,CHEMBL617871,,1,BAO_0000357,B,10141.0,D,Intermediate,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,,Striatum
3263,Cavia porcellus,20033,CHEMBL617872,,1,BAO_0000357,B,10141.0,D,Intermediate,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,,Striatum
3264,Cavia porcellus,20033,CHEMBL617873,,1,BAO_0000357,B,10141.0,D,Intermediate,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,,Striatum
3265,Cavia porcellus,20033,CHEMBL617874,,1,BAO_0000357,B,10141.0,D,Intermediate,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,,Striatum
3266,Cavia porcellus,20033,CHEMBL619067,,1,BAO_0000221,F,10141.0,D,Intermediate,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,,Ileum
3267,Cavia porcellus,20033,CHEMBL619068,,1,BAO_0000221,F,10141.0,D,Intermediate,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,,Ileum
3268,Cavia porcellus,20033,CHEMBL619069,,1,BAO_0000221,F,10141.0,D,Intermediate,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,,Ileum
3269,Cavia porcellus,20033,CHEMBL619070,,1,BAO_0000357,B,10141.0,D,Intermediate,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,,
3270,Cavia porcellus,20033,CHEMBL619071,,1,BAO_0000357,B,10141.0,D,Intermediate,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,,
3271,Cavia porcellus,20033,CHEMBL619072,,1,BAO_0000019,F,10141.0,D,Intermediate,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,,
3272,Cavia porcellus,20033,CHEMBL619073,,1,BAO_0000019,F,10141.0,D,Intermediate,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,,
3273,Cavia porcellus,20033,CHEMBL619074,,1,BAO_0000019,F,10141.0,D,Intermediate,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,,
3274,Cavia porcellus,20033,CHEMBL619075,,1,BAO_0000357,B,10141.0,D,Intermediate,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,,
3275,Cavia porcellus,20033,CHEMBL619076,,1,BAO_0000357,B,10141.0,D,Intermediate,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,,Striatum
3276,Cavia porcellus,20033,CHEMBL619077,,1,BAO_0000357,B,10141.0,D,Intermediate,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,,Striatum
3277,Cavia porcellus,20033,CHEMBL619078,,1,BAO_0000249,B,10141.0,D,Intermediate,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,,Striatum
3278,Cavia porcellus,20033,CHEMBL619079,,1,BAO_0000249,B,10141.0,D,Intermediate,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,,Striatum
3279,Cavia porcellus,20033,CHEMBL619080,,1,BAO_0000221,B,10141.0,D,Intermediate,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,,Ileum
3280,Cavia porcellus,20033,CHEMBL619081,,1,BAO_0000357,B,10141.0,D,Expert,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,,
3281,Cavia porcellus,20033,CHEMBL619082,,1,BAO_0000357,B,10141.0,D,Intermediate,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,,
3282,Cavia porcellus,20033,CHEMBL619083,,1,BAO_0000357,B,10141.0,D,Intermediate,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,,
3283,Cavia porcellus,20033,CHEMBL619084,,1,BAO_0000357,B,10141.0,D,Intermediate,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,,
3284,Cavia porcellus,20033,CHEMBL859397,,1,BAO_0000221,F,10141.0,D,Intermediate,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,,Ileum
3285,Cavia porcellus,20033,CHEMBL619085,,1,BAO_0000221,F,10141.0,D,Intermediate,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,,Ileum
3286,Cavia porcellus,20033,CHEMBL619086,,1,BAO_0000221,F,10141.0,D,Intermediate,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,,Ileum
3287,Cavia porcellus,20033,CHEMBL619087,,1,BAO_0000221,F,10141.0,D,Intermediate,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,,Ileum
3288,Cavia porcellus,20033,CHEMBL619088,,1,BAO_0000221,F,10141.0,D,Intermediate,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,,Ileum
3289,Cavia porcellus,20033,CHEMBL619089,,1,BAO_0000357,B,10141.0,D,Intermediate,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,,
3290,Cavia porcellus,168,CHEMBL619090,,1,BAO_0000357,B,10141.0,H,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,,
3291,Cavia porcellus,20033,CHEMBL619091,,1,BAO_0000019,F,10141.0,D,Intermediate,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,,
3292,Cavia porcellus,20033,CHEMBL619092,,1,BAO_0000357,B,10141.0,D,Intermediate,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,,
3293,Cavia porcellus,20033,CHEMBL619093,,1,BAO_0000019,B,10141.0,D,Intermediate,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,,
3294,Cavia porcellus,168,CHEMBL619094,,1,BAO_0000219,B,10141.0,H,Autocuration,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,,,
3295,Cavia porcellus,20033,CHEMBL619095,,1,BAO_0000019,B,10141.0,D,Intermediate,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,,
3296,Cavia porcellus,20033,CHEMBL857988,,1,BAO_0000357,B,10141.0,D,Intermediate,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,,
3297,Cavia porcellus,20033,CHEMBL619096,,1,BAO_0000357,B,10141.0,D,Intermediate,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,,
3298,Cavia porcellus,20033,CHEMBL619097,,1,BAO_0000357,B,10141.0,D,Intermediate,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,,Striatum
3299,Cavia porcellus,20033,CHEMBL619098,,1,BAO_0000221,B,10141.0,D,Intermediate,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,,Hippocampus
3300,Cavia porcellus,20033,CHEMBL619751,,1,BAO_0000357,B,10141.0,D,Intermediate,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,,
3301,Cavia porcellus,20033,CHEMBL619752,,1,BAO_0000357,B,10141.0,D,Intermediate,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,,
3302,Cavia porcellus,20033,CHEMBL875096,,1,BAO_0000221,F,10141.0,D,Intermediate,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,,Ileum
3303,,108,CHEMBL619004,,1,BAO_0000357,B,,H,Autocuration,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,
3304,,168,CHEMBL619005,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,
3305,,168,CHEMBL619006,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,
3306,,168,CHEMBL619007,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,,
3307,,168,CHEMBL619008,,1,BAO_0000357,B,,H,Autocuration,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,
3308,,168,CHEMBL619009,,1,BAO_0000357,B,,H,Autocuration,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,
3309,,168,CHEMBL619010,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,,
3310,,10622,CHEMBL619011,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,
3311,,10622,CHEMBL619012,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,
3312,,10622,CHEMBL619013,,1,BAO_0000219,B,,H,Autocuration,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,
3313,,10622,CHEMBL619014,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,
3314,,11249,CHEMBL857503,,1,BAO_0000019,F,,H,Autocuration,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,,Cardiac atrium
3315,,11249,CHEMBL619015,,1,BAO_0000019,F,,H,Autocuration,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,,Cardiac atrium
3316,,11249,CHEMBL619016,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,
3317,,11249,CHEMBL619017,,1,BAO_0000221,B,,H,Autocuration,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,,Hippocampus
3318,Sus scrofa,168,CHEMBL619018,,1,BAO_0000221,B,9823.0,H,Autocuration,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,,Hippocampus
3319,Oryctolagus cuniculus,168,CHEMBL619019,,1,BAO_0000019,B,9986.0,H,Autocuration,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,,
3320,Rattus norvegicus,10623,CHEMBL619020,,1,BAO_0000357,B,10116.0,D,Expert,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,,
3321,,10623,CHEMBL619021,,1,BAO_0000019,F,,H,Autocuration,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,
3322,,10623,CHEMBL619022,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,
3323,,10623,CHEMBL619023,,1,BAO_0000357,B,,H,Autocuration,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,
3324,,10623,CHEMBL619024,,1,BAO_0000019,F,,H,Autocuration,670,lntrinsic activity relative to 5-HT receptor,,,,
3325,,10623,CHEMBL619025,,1,BAO_0000019,F,,H,Autocuration,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,
3326,,10623,CHEMBL619026,,1,BAO_0000019,F,,H,Expert,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,
3327,,10623,CHEMBL619027,,1,BAO_0000019,F,,H,Autocuration,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,
3328,,10623,CHEMBL619028,,1,BAO_0000019,F,,H,Autocuration,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,
3329,,10623,CHEMBL619029,,1,BAO_0000019,F,,H,Autocuration,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,
3330,,10623,CHEMBL619030,,1,BAO_0000019,F,,H,Autocuration,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,
3331,,10623,CHEMBL619031,,1,BAO_0000357,B,,H,Expert,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,
3332,,10623,CHEMBL619032,,1,BAO_0000019,F,,H,Autocuration,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,
3333,Rattus norvegicus,10623,CHEMBL619033,,1,BAO_0000357,B,10116.0,D,Expert,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,,
3334,,10623,CHEMBL619034,,1,BAO_0000357,B,,H,Autocuration,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,
3335,,10623,CHEMBL619035,,1,BAO_0000357,B,,H,Autocuration,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,
3336,,10623,CHEMBL619036,,1,BAO_0000357,B,,H,Autocuration,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,
3337,Rattus norvegicus,10623,CHEMBL619037,,1,BAO_0000019,B,10116.0,D,Expert,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,,
3338,,10623,CHEMBL619038,,1,BAO_0000249,B,,H,Autocuration,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,,Striatum
3339,,10623,CHEMBL619039,,1,BAO_0000249,B,,H,Autocuration,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,
3340,,10623,CHEMBL619040,,1,BAO_0000249,B,,H,Expert,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,
3341,Rattus norvegicus,10623,CHEMBL619041,,1,BAO_0000019,B,10116.0,D,Expert,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,,Striatum
3342,,10623,CHEMBL619042,,1,BAO_0000019,B,,H,Autocuration,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,,Striatum
3343,,10623,CHEMBL619043,,1,BAO_0000249,B,,H,Expert,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,,Striatum
3344,,10623,CHEMBL619044,,1,BAO_0000019,B,,H,Expert,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,,Striatum
3345,,10623,CHEMBL619045,,1,BAO_0000249,B,,H,Expert,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,,Striatum
3346,,10623,CHEMBL619046,,1,BAO_0000249,B,,H,Expert,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,Striatum
3347,,10623,CHEMBL619047,,1,BAO_0000249,B,,H,Expert,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,
3348,,10623,CHEMBL619048,,1,BAO_0000221,F,,H,Autocuration,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,,Brain
3349,,10623,CHEMBL859398,,1,BAO_0000019,F,,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,
3350,,10623,CHEMBL619049,,1,BAO_0000019,F,,H,Autocuration,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,
3351,,10623,CHEMBL857886,,1,BAO_0000019,F,,H,Autocuration,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,
3352,,10623,CHEMBL619050,,1,BAO_0000019,F,,H,Autocuration,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,
3353,,10623,CHEMBL620591,,1,BAO_0000019,F,,H,Autocuration,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,
3354,Rattus norvegicus,10623,CHEMBL620592,,1,BAO_0000357,B,10116.0,D,Expert,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,,
3355,,10623,CHEMBL620593,,1,BAO_0000249,B,,H,Expert,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,Striatum
3356,Rattus norvegicus,10623,CHEMBL620594,,1,BAO_0000019,F,10116.0,D,Expert,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,,
3357,,10623,CHEMBL875079,,1,BAO_0000019,F,,H,Expert,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,
3358,,10623,CHEMBL620595,,1,BAO_0000019,F,,H,Expert,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,
3359,Rattus norvegicus,10623,CHEMBL620596,,1,BAO_0000019,F,10116.0,D,Expert,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,,
3360,,10623,CHEMBL620597,,1,BAO_0000019,F,,H,Autocuration,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,
3361,,10623,CHEMBL620598,,1,BAO_0000019,F,,H,Expert,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,
3362,,10623,CHEMBL620599,,1,BAO_0000218,F,,H,Expert,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,
3363,,10623,CHEMBL620600,,1,BAO_0000019,F,,H,Autocuration,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,
3364,Rattus norvegicus,168,CHEMBL620601,,1,BAO_0000019,F,10116.0,H,Autocuration,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,,
3365,,168,CHEMBL620602,,1,BAO_0000019,F,,H,Autocuration,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,
3366,,168,CHEMBL620603,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,
3367,,168,CHEMBL620604,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,
3368,,168,CHEMBL620605,,1,BAO_0000357,B,,H,Autocuration,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,
3369,,168,CHEMBL620606,,1,BAO_0000357,B,,H,Autocuration,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,
3370,,168,CHEMBL620607,,1,BAO_0000019,F,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,
3371,,168,CHEMBL620608,,1,BAO_0000357,B,,H,Autocuration,16117,In vitro binding affinity towards 5-HT4 receptor was determined,,,,
3372,,168,CHEMBL620609,,1,BAO_0000019,F,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,
3373,,168,CHEMBL620610,,1,BAO_0000019,F,,H,Autocuration,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,
3374,,168,CHEMBL620611,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,
3375,,168,CHEMBL620612,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,
3376,,168,CHEMBL620613,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,
3377,,168,CHEMBL620614,,1,BAO_0000357,B,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,
3378,,168,CHEMBL620615,,1,BAO_0000357,B,,H,Expert,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,
3379,,104698,CHEMBL857075,,1,BAO_0000249,B,,H,Autocuration,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,
3380,,104698,CHEMBL620616,,1,BAO_0000249,B,,H,Autocuration,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,
3381,,104698,CHEMBL619411,,1,BAO_0000249,B,,H,Autocuration,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,
3382,,104698,CHEMBL619412,,1,BAO_0000019,B,,H,Autocuration,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,
3383,Rattus norvegicus,104698,CHEMBL619413,,1,BAO_0000019,B,10116.0,D,Autocuration,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,,
3384,,104698,CHEMBL619414,,1,BAO_0000221,B,,H,Autocuration,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,,Hippocampus
3385,,104698,CHEMBL619415,,1,BAO_0000019,B,,H,Autocuration,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,
3386,,104698,CHEMBL619416,,1,BAO_0000019,B,,H,Autocuration,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,
3387,,104698,CHEMBL619417,,1,BAO_0000019,F,,H,Autocuration,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,
3388,Rattus norvegicus,104698,CHEMBL619418,,1,BAO_0000223,B,10116.0,D,Autocuration,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,,
3389,Rattus norvegicus,104698,CHEMBL619419,,1,BAO_0000223,B,10116.0,D,Autocuration,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,,
3390,,104698,CHEMBL619420,,1,BAO_0000019,B,,H,Autocuration,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,
3391,,104698,CHEMBL619421,,1,BAO_0000249,B,,H,Autocuration,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,
3392,Rattus norvegicus,104698,CHEMBL619422,,1,BAO_0000019,B,10116.0,D,Autocuration,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,,
3393,,104698,CHEMBL619423,,1,BAO_0000019,B,,H,Autocuration,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,
3394,,104698,CHEMBL875080,,1,BAO_0000019,B,,H,Autocuration,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,
3395,,104698,CHEMBL619424,,1,BAO_0000019,B,,H,Autocuration,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,
3396,,104698,CHEMBL619425,,1,BAO_0000249,B,,H,Autocuration,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,
3397,,104698,CHEMBL619426,,1,BAO_0000223,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,
3398,,104698,CHEMBL619427,,1,BAO_0000223,B,,H,Autocuration,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,
3399,Rattus norvegicus,104698,CHEMBL619645,,1,BAO_0000223,B,10116.0,D,Autocuration,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,,
3400,,10576,CHEMBL619646,,1,BAO_0000249,B,,D,Expert,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,
3401,,12020,CHEMBL619647,,1,BAO_0000221,F,,H,Autocuration,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,,Brain
3402,,12020,CHEMBL619648,,1,BAO_0000019,F,,H,Autocuration,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,
3403,,12020,CHEMBL619165,,1,BAO_0000019,F,,H,Autocuration,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,
3404,,12020,CHEMBL620719,,1,BAO_0000218,F,,H,Autocuration,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,In vivo,,,
3405,,12020,CHEMBL872924,,1,BAO_0000019,B,,H,Autocuration,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,
3406,,12020,CHEMBL620720,,1,BAO_0000357,B,,H,Autocuration,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3407,,12020,CHEMBL620721,,1,BAO_0000019,B,,H,Autocuration,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,
3408,,12020,CHEMBL620722,,1,BAO_0000019,B,,H,Autocuration,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,
3409,,104698,CHEMBL620723,,1,BAO_0000019,B,,H,Autocuration,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,
3410,,12020,CHEMBL620724,,1,BAO_0000019,B,,H,Autocuration,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,
3411,,104698,CHEMBL620725,,1,BAO_0000249,B,,H,Autocuration,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,
3412,Rattus norvegicus,12020,CHEMBL620726,,1,BAO_0000019,F,10116.0,D,Autocuration,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,,
3413,,144,CHEMBL620727,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3414,,104714,CHEMBL620728,,1,BAO_0000223,B,,H,Autocuration,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,
3415,,22226,CHEMBL620729,,1,BAO_0000019,B,,U,Autocuration,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,
3416,,104714,CHEMBL858288,,1,BAO_0000019,F,,H,Autocuration,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,
3417,,104714,CHEMBL620730,,1,BAO_0000223,B,,H,Autocuration,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3418,,104714,CHEMBL620731,,1,BAO_0000223,B,,H,Autocuration,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3419,Cavia porcellus,104714,CHEMBL620732,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,,
3420,Cavia porcellus,104714,CHEMBL618042,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,,
3421,Cavia porcellus,104714,CHEMBL618043,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,,
3422,,104714,CHEMBL618044,,1,BAO_0000223,B,,H,Autocuration,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,
3423,,104714,CHEMBL618045,,1,BAO_0000019,F,,H,Autocuration,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,
3424,,104714,CHEMBL618046,,1,BAO_0000223,B,,H,Autocuration,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,
3425,,104714,CHEMBL618047,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,
3426,,104714,CHEMBL875084,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,
3427,,104714,CHEMBL618048,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,
3428,,104714,CHEMBL618049,,1,BAO_0000223,B,,H,Autocuration,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,
3429,,104714,CHEMBL619764,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,
3430,,104714,CHEMBL619765,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,
3431,,104714,CHEMBL619766,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,
3432,,104714,CHEMBL619767,,1,BAO_0000223,B,,H,Autocuration,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,
3433,,104714,CHEMBL619768,,1,BAO_0000223,B,,H,Autocuration,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,
3434,,104714,CHEMBL619769,,1,BAO_0000019,F,,H,Autocuration,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,
3435,,104714,CHEMBL619770,,1,BAO_0000223,B,,H,Autocuration,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,
3436,,104714,CHEMBL619771,,1,BAO_0000223,B,,H,Autocuration,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3437,,104714,CHEMBL619772,,1,BAO_0000219,B,,H,Autocuration,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,
3438,,104714,CHEMBL619773,,1,BAO_0000223,B,,H,Autocuration,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,
3439,,104714,CHEMBL619774,,1,BAO_0000219,B,,H,Autocuration,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,,
3440,,104714,CHEMBL875083,,1,BAO_0000019,B,,H,Autocuration,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,
3441,,104714,CHEMBL620718,,1,BAO_0000219,B,,H,Autocuration,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,,
3442,,104714,CHEMBL618127,,1,BAO_0000223,B,,H,Autocuration,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,
3443,,104714,CHEMBL618128,,1,BAO_0000223,B,,H,Autocuration,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,
3444,,104714,CHEMBL618129,,1,BAO_0000219,B,,H,Autocuration,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,In vitro,,,
3445,,104714,CHEMBL618130,,1,BAO_0000223,B,,H,Autocuration,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,
3446,,104714,CHEMBL618131,,1,BAO_0000019,F,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,
3447,Cavia porcellus,104714,CHEMBL618132,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,,
3448,Cavia porcellus,104714,CHEMBL618133,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,,
3449,Cavia porcellus,104714,CHEMBL618134,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,,
3450,Cavia porcellus,104714,CHEMBL618135,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,,
3451,,104714,CHEMBL618136,,1,BAO_0000223,B,,H,Autocuration,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,
3452,,104714,CHEMBL618137,,1,BAO_0000223,B,,H,Autocuration,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3453,,104714,CHEMBL618138,,1,BAO_0000223,B,,H,Autocuration,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,
3454,,104714,CHEMBL618139,,1,BAO_0000223,B,,H,Autocuration,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,
3455,,104714,CHEMBL618140,,1,BAO_0000223,B,,H,Autocuration,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,
3456,,104714,CHEMBL618141,,1,BAO_0000223,B,,H,Autocuration,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,
3457,,108,CHEMBL873478,,1,BAO_0000357,B,,H,Expert,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,
3458,,104698,CHEMBL618142,,1,BAO_0000223,B,,H,Autocuration,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3459,,144,CHEMBL618143,,1,BAO_0000357,B,,H,Autocuration,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,
3460,,144,CHEMBL618144,,1,BAO_0000357,B,,H,Autocuration,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,
3461,,144,CHEMBL618145,,1,BAO_0000357,B,,H,Autocuration,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,
3462,,104714,CHEMBL618146,,1,BAO_0000223,B,,H,Autocuration,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,
3463,,104714,CHEMBL618147,,1,BAO_0000223,B,,H,Autocuration,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,
3464,,104714,CHEMBL618148,,1,BAO_0000223,B,,H,Autocuration,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,
3465,,144,CHEMBL618149,,1,BAO_0000019,B,,H,Autocuration,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,
3466,,144,CHEMBL872927,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3467,,144,CHEMBL618150,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,
3468,,144,CHEMBL618151,,1,BAO_0000357,B,,H,Autocuration,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,
3469,,144,CHEMBL875094,,1,BAO_0000357,B,,H,Autocuration,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,
3470,,144,CHEMBL618152,,1,BAO_0000019,B,,H,Autocuration,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,
3471,,144,CHEMBL618153,,1,BAO_0000357,B,,H,Autocuration,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,
3472,,144,CHEMBL618888,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,
3473,,144,CHEMBL618889,,1,BAO_0000019,F,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,
3474,,144,CHEMBL618890,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,
3475,,144,CHEMBL618891,,1,BAO_0000019,B,,H,Autocuration,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,
3476,,144,CHEMBL619054,,1,BAO_0000019,B,,H,Autocuration,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,
3477,,104714,CHEMBL619055,,1,BAO_0000223,B,,H,Autocuration,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,
3478,,144,CHEMBL619056,,1,BAO_0000357,B,,H,Autocuration,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,
3479,,144,CHEMBL619057,,1,BAO_0000019,F,,H,Autocuration,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,
3480,,144,CHEMBL619058,,1,BAO_0000357,B,,H,Autocuration,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,
3481,Rattus norvegicus,12020,CHEMBL619059,,1,BAO_0000219,F,10116.0,D,Expert,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,,
3482,Rattus norvegicus,12020,CHEMBL619060,,1,BAO_0000219,F,10116.0,D,Expert,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,,
3483,Rattus norvegicus,12020,CHEMBL875095,,1,BAO_0000219,F,10116.0,D,Expert,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,,
3484,Cavia porcellus,20033,CHEMBL619061,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,,Ileum
3485,Cavia porcellus,20033,CHEMBL619062,,1,BAO_0000221,F,10141.0,D,Intermediate,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,,Ileum
3486,Cavia porcellus,20033,CHEMBL619063,,1,BAO_0000019,F,10141.0,D,Intermediate,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,,
3487,Cavia porcellus,20033,CHEMBL619064,,1,BAO_0000221,B,10141.0,D,Intermediate,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,,Ileum
3488,Cavia porcellus,20033,CHEMBL619065,,1,BAO_0000357,B,10141.0,D,Intermediate,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,,
3489,Cavia porcellus,20033,CHEMBL619066,,1,BAO_0000221,B,10141.0,D,Intermediate,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,,Ileum
3490,,10209,CHEMBL619775,,1,BAO_0000221,B,,H,Autocuration,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,Ileum
3491,,10209,CHEMBL619776,,1,BAO_0000357,B,,H,Autocuration,3269,Affinity against 5-hydroxytryptamine 7 receptor,,,,
3492,Cavia porcellus,104841,CHEMBL619777,,1,BAO_0000224,B,10141.0,H,Autocuration,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,,
3493,Cavia porcellus,104841,CHEMBL619778,,1,BAO_0000224,B,10141.0,H,Autocuration,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,,
3494,Cavia porcellus,104841,CHEMBL619779,,1,BAO_0000221,B,10141.0,H,Autocuration,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,,Ileum
3495,Cavia porcellus,104841,CHEMBL619780,,1,BAO_0000224,B,10141.0,H,Autocuration,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,,
3496,Cavia porcellus,104841,CHEMBL619166,,1,BAO_0000224,B,10141.0,H,Autocuration,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,,
3497,Cavia porcellus,104841,CHEMBL619167,,1,BAO_0000019,F,10141.0,H,Autocuration,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,,
3498,Cavia porcellus,104841,CHEMBL619168,,1,BAO_0000019,F,10141.0,H,Autocuration,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,,
3499,Homo sapiens,168,CHEMBL619169,,1,BAO_0000219,B,9606.0,D,Expert,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,,Cardiac atrium
3500,Homo sapiens,168,CHEMBL619170,,1,BAO_0000219,B,9606.0,D,Expert,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,,Cardiac atrium
3501,Homo sapiens,104841,CHEMBL619171,,1,BAO_0000019,F,9606.0,D,Autocuration,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,,
3502,Homo sapiens,168,CHEMBL619172,,1,BAO_0000219,F,9606.0,D,Expert,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,,Cardiac atrium
3503,Mus musculus,22226,CHEMBL619173,,1,BAO_0000019,B,10090.0,U,Autocuration,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,,
3504,Mus musculus,22226,CHEMBL619174,,1,BAO_0000019,B,10090.0,U,Autocuration,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,,
3505,,104705,CHEMBL619175,,1,BAO_0000019,B,,H,Autocuration,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,
3506,,104705,CHEMBL619176,,1,BAO_0000224,B,,H,Autocuration,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,
3507,,104705,CHEMBL619177,,1,BAO_0000019,B,,H,Autocuration,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,
3508,,104705,CHEMBL619178,,1,BAO_0000224,B,,H,Autocuration,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,
3509,,104705,CHEMBL619179,,1,BAO_0000224,B,,H,Autocuration,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,
3510,,104705,CHEMBL619180,,1,BAO_0000019,F,,H,Autocuration,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,,Stomach
3511,,104705,CHEMBL619181,,1,BAO_0000019,F,,H,Autocuration,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,,Stomach
3512,,104705,CHEMBL619182,,1,BAO_0000019,F,,H,Autocuration,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,
3513,,104705,CHEMBL619183,,1,BAO_0000224,B,,H,Autocuration,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,
3514,,104705,CHEMBL619184,,1,BAO_0000224,B,,H,Autocuration,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,
3515,,10576,CHEMBL619185,,1,BAO_0000221,B,,H,Autocuration,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,Hippocampus
3516,,12198,CHEMBL619186,,1,BAO_0000357,B,,H,Expert,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,
3517,,104705,CHEMBL619187,,1,BAO_0000019,B,,H,Autocuration,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,
3518,Rattus norvegicus,104705,CHEMBL619188,,1,BAO_0000019,B,10116.0,D,Autocuration,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,,
3519,Rattus norvegicus,104705,CHEMBL619189,,1,BAO_0000224,B,10116.0,D,Autocuration,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,,
3520,Rattus norvegicus,12198,CHEMBL619190,,1,BAO_0000019,F,10116.0,D,Expert,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,,Brain
3521,Rattus norvegicus,12198,CHEMBL619191,,1,BAO_0000221,F,10116.0,D,Expert,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,,Cerebellum
3522,Rattus norvegicus,104705,CHEMBL619192,,1,BAO_0000019,B,10116.0,D,Autocuration,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,,
3523,Rattus norvegicus,104705,CHEMBL619193,,1,BAO_0000224,B,10116.0,D,Autocuration,6347,Percent binding affinity against 5-hydroxytryptamine receptor,,,,
3524,,22226,CHEMBL619194,,1,BAO_0000019,B,,U,Autocuration,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,
3525,Rattus norvegicus,104705,CHEMBL619195,,1,BAO_0000224,B,10116.0,D,Autocuration,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,,
3526,Rattus norvegicus,104705,CHEMBL619196,,1,BAO_0000224,B,10116.0,D,Autocuration,1579,Affinity against 5-hydroxytryptamine receptor was determined,,,,
3527,Rattus norvegicus,104705,CHEMBL619197,,1,BAO_0000019,B,10116.0,D,Autocuration,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,,Stomach
3528,Homo sapiens,121,CHEMBL619198,,1,BAO_0000219,B,9606.0,D,Expert,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,,,
3529,Homo sapiens,121,CHEMBL875081,,1,BAO_0000219,B,9606.0,D,Expert,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,In vitro,,,
3530,,18065,CHEMBL884712,,1,BAO_0000357,B,,H,Autocuration,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,
3531,,121,CHEMBL884710,,1,BAO_0000357,B,,H,Expert,15796,Inhibition of 5-hydroxytryptamine reuptake,,,,
3532,,18065,CHEMBL619199,,1,BAO_0000019,F,,H,Autocuration,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,
3533,,18065,CHEMBL619200,,1,BAO_0000019,F,,H,Autocuration,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,
3534,,18065,CHEMBL619201,,1,BAO_0000019,F,,H,Autocuration,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,
3535,,18065,CHEMBL619202,,1,BAO_0000019,F,,H,Autocuration,12409,Tested for 5-hydroxytryptamine receptor uptake,,,,
3536,Homo sapiens,51,CHEMBL619203,,1,BAO_0000219,B,9606.0,D,Expert,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,,,
3537,Homo sapiens,51,CHEMBL619204,,1,BAO_0000019,F,9606.0,D,Expert,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,,
3538,Homo sapiens,10576,CHEMBL619205,,1,BAO_0000249,B,9606.0,H,Autocuration,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,,
3539,,10576,CHEMBL619206,,1,BAO_0000357,B,,H,Autocuration,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,
3540,,10576,CHEMBL619207,,1,BAO_0000249,B,,H,Expert,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,
3541,,10825,CHEMBL619208,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,,Striatum
3542,,10825,CHEMBL619209,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,,Striatum
3543,,10825,CHEMBL619210,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,,Striatum
3544,,10825,CHEMBL619211,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,Striatum
3545,,10825,CHEMBL619212,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,,Striatum
3546,,10825,CHEMBL620681,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,,Striatum
3547,,10825,CHEMBL620682,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,,Striatum
3548,,10825,CHEMBL620683,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,,Striatum
3549,,10825,CHEMBL620684,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,,Striatum
3550,,10825,CHEMBL620685,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,Striatum
3551,,10825,CHEMBL620686,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,,Striatum
3552,,10825,CHEMBL620687,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,,Limbic system
3553,,10825,CHEMBL620688,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,Limbic system
3554,,10825,CHEMBL620689,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,,Limbic system
3555,,10825,CHEMBL620690,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,,Limbic system
3556,,10825,CHEMBL620691,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,,Limbic system
3557,,10825,CHEMBL620692,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,,Limbic system
3558,,10825,CHEMBL620693,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,,Limbic system
3559,,168,CHEMBL620694,,1,BAO_0000357,B,,H,Expert,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,
3560,,168,CHEMBL857986,,1,BAO_0000019,F,,H,Autocuration,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,
3561,,168,CHEMBL620695,,1,BAO_0000357,B,,H,Autocuration,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,
3562,,168,CHEMBL620696,,1,BAO_0000357,B,,H,Expert,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,
3563,,168,CHEMBL620697,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,
3564,,168,CHEMBL620698,,1,BAO_0000357,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,
3565,,168,CHEMBL620699,,1,BAO_0000357,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,
3566,,168,CHEMBL620700,,1,BAO_0000357,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,
3567,,168,CHEMBL620701,,1,BAO_0000219,B,,H,Autocuration,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,,
3568,,168,CHEMBL875082,,1,BAO_0000219,B,,H,Autocuration,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,,
3569,,168,CHEMBL620702,,1,BAO_0000219,B,,H,Autocuration,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,,
3570,,168,CHEMBL620703,,1,BAO_0000219,B,,H,Autocuration,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,,
3571,,168,CHEMBL620704,,1,BAO_0000219,B,,H,Autocuration,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,
3572,,168,CHEMBL620705,,1,BAO_0000219,B,,H,Expert,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,
3573,,168,CHEMBL620706,,1,BAO_0000219,B,,H,Expert,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,,
3574,,168,CHEMBL620707,,1,BAO_0000219,B,,H,Expert,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,,
3575,,10624,CHEMBL620708,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,
3576,,105,CHEMBL620709,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,
3577,Homo sapiens,10624,CHEMBL620710,,1,BAO_0000357,B,9606.0,D,Expert,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,,,,
3578,,10624,CHEMBL620711,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,,
3579,Homo sapiens,10624,CHEMBL620712,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,,
3580,Homo sapiens,10624,CHEMBL620713,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,
3581,Homo sapiens,10624,CHEMBL620714,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,,
3582,Homo sapiens,10624,CHEMBL620715,,1,BAO_0000357,B,9606.0,D,Expert,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,,
3583,,10624,CHEMBL620716,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-HT5A receptor,,,,
3584,,10624,CHEMBL620717,,1,BAO_0000357,B,,H,Expert,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,
3585,,10624,CHEMBL618072,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,
3586,,10624,CHEMBL857987,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,
3587,,10624,CHEMBL618073,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
3588,,10624,CHEMBL618074,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,
3589,,10624,CHEMBL618075,,1,BAO_0000219,B,,H,Autocuration,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,,
3590,Mus musculus,10625,CHEMBL618076,,1,BAO_0000357,B,10090.0,D,Expert,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,,
3591,Mus musculus,10625,CHEMBL618077,,1,BAO_0000357,B,10090.0,D,Expert,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,,
3592,Mus musculus,10625,CHEMBL618078,,1,BAO_0000357,B,10090.0,D,Expert,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,,
3593,Mus musculus,10625,CHEMBL881821,,1,BAO_0000357,B,10090.0,D,Expert,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,,
3594,Mus musculus,10625,CHEMBL618079,,1,BAO_0000357,B,10090.0,D,Expert,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,,
3595,,10625,CHEMBL618080,,1,BAO_0000357,B,,H,Expert,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,
3596,,10576,CHEMBL618081,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,
3597,,10626,CHEMBL618082,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,
3598,,10624,CHEMBL618083,,1,BAO_0000357,B,,H,Expert,4820,Binding affinity towards 5-HT5a receptor,,,,
3599,Homo sapiens,10624,CHEMBL618084,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,,
3600,,10624,CHEMBL618085,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,
3601,,10624,CHEMBL618086,,1,BAO_0000357,B,,H,Expert,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,
3602,,10624,CHEMBL875092,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,
3603,,10624,CHEMBL618087,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,
3604,,10624,CHEMBL872926,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,
3605,Cavia porcellus,104714,CHEMBL618088,,1,BAO_0000019,F,10141.0,H,Autocuration,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,,
3606,,104714,CHEMBL618089,,1,BAO_0000223,B,,H,Autocuration,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,
3607,Homo sapiens,10627,CHEMBL618090,,1,BAO_0000357,B,9606.0,D,Expert,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,,,,
3608,Homo sapiens,10627,CHEMBL618091,,1,BAO_0000357,B,9606.0,D,Expert,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,,
3609,,10627,CHEMBL618092,,1,BAO_0000357,B,,H,Autocuration,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,
3610,Homo sapiens,10627,CHEMBL618093,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,,
3611,,10627,CHEMBL618094,,1,BAO_0000219,B,,H,Expert,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,,
3612,Homo sapiens,10627,CHEMBL618095,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,,
3613,Homo sapiens,10627,CHEMBL875093,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3614,Homo sapiens,10627,CHEMBL618096,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,,
3615,Homo sapiens,10627,CHEMBL618118,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,,
3616,Homo sapiens,10627,CHEMBL618119,,1,BAO_0000357,B,9606.0,D,Expert,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,,,,
3617,,10627,CHEMBL618120,,1,BAO_0000357,B,,H,Expert,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3618,,10627,CHEMBL618121,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3619,,10627,CHEMBL618122,,1,BAO_0000219,B,,H,Expert,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,,
3620,,10627,CHEMBL618123,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,
3621,,10627,CHEMBL618124,,1,BAO_0000219,B,,H,Expert,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,,
3622,,10627,CHEMBL618125,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3623,Homo sapiens,10627,CHEMBL618126,,1,BAO_0000219,B,9606.0,D,Expert,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,
3624,,10627,CHEMBL618236,,1,BAO_0000019,B,,H,Expert,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,
3625,,10627,CHEMBL618237,,1,BAO_0000019,B,,H,Expert,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,
3626,,10627,CHEMBL618238,,1,BAO_0000219,B,,H,Expert,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,,
3627,Homo sapiens,10627,CHEMBL618239,,1,BAO_0000357,B,9606.0,D,Expert,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,,
3628,,10627,CHEMBL618240,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,
3629,,10627,CHEMBL618241,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,
3630,,10627,CHEMBL859399,,1,BAO_0000219,B,,H,Autocuration,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,
3631,,10627,CHEMBL618242,,1,BAO_0000019,F,,H,Autocuration,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,
3632,,10627,CHEMBL857991,,1,BAO_0000357,B,,H,Autocuration,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,
3633,,10627,CHEMBL619951,,1,BAO_0000357,B,,H,Expert,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,
3634,Homo sapiens,10627,CHEMBL619952,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,,,
3635,Homo sapiens,10627,CHEMBL619953,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,,,
3636,,10627,CHEMBL619954,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,,
3637,,10627,CHEMBL619955,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,
3638,,10627,CHEMBL619956,,1,BAO_0000219,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,
3639,,10627,CHEMBL619957,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,
3640,,10627,CHEMBL619958,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,
3641,,10627,CHEMBL620627,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,,
3642,,10627,CHEMBL620628,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,
3643,,10627,CHEMBL620629,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,,
3644,,10627,CHEMBL620630,,1,BAO_0000357,B,,H,Autocuration,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3645,,10627,CHEMBL620782,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,,
3646,,10627,CHEMBL620783,,1,BAO_0000357,B,,H,Autocuration,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,
3647,,10627,CHEMBL620784,,1,BAO_0000357,B,,H,Expert,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,
3648,,10627,CHEMBL620785,,1,BAO_0000219,B,,H,Expert,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,,
3649,,10627,CHEMBL857992,,1,BAO_0000357,B,,H,Autocuration,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,
3650,,10627,CHEMBL620786,,1,BAO_0000219,B,,H,Autocuration,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,
3651,,10627,CHEMBL620787,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,,
3652,,10627,CHEMBL620788,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,,
3653,,10627,CHEMBL620789,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,,
3654,,10627,CHEMBL620790,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,,
3655,,10628,CHEMBL620791,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,,
3656,,10628,CHEMBL620792,,1,BAO_0000019,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,
3657,,10628,CHEMBL620793,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,
3658,,10628,CHEMBL620794,,1,BAO_0000357,B,,H,Autocuration,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,
3659,Homo sapiens,10627,CHEMBL620795,,1,BAO_0000219,B,9606.0,D,Autocuration,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,,,
3660,,10627,CHEMBL620796,,1,BAO_0000357,B,,H,Expert,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3661,,10627,CHEMBL620797,,1,BAO_0000357,B,,H,Autocuration,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,
3662,Homo sapiens,10627,CHEMBL620798,,1,BAO_0000019,F,9606.0,D,Expert,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,
3663,,10627,CHEMBL620799,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,
3664,,10627,CHEMBL620800,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,
3665,,10627,CHEMBL620801,,1,BAO_0000357,B,,H,Autocuration,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,
3666,,10627,CHEMBL875100,,1,BAO_0000357,B,,H,Autocuration,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,
3667,,10627,CHEMBL620802,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,
3668,,10627,CHEMBL620803,,1,BAO_0000019,F,,H,Expert,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,
3669,,10627,CHEMBL620804,,1,BAO_0000019,F,,H,Expert,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,
3670,,10627,CHEMBL620805,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,
3671,,10627,CHEMBL620806,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,
3672,,10627,CHEMBL620807,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,
3673,,10627,CHEMBL620808,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,
3674,,10627,CHEMBL620809,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,
3675,,10627,CHEMBL620810,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,
3676,Homo sapiens,10627,CHEMBL620811,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,,
3677,,10627,CHEMBL620812,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,
3678,,10627,CHEMBL620813,,1,BAO_0000357,B,,H,Autocuration,3269,Affinity against 5-hydroxytryptamine 6 receptor,,,,
3679,,10627,CHEMBL620814,,1,BAO_0000357,B,,H,Autocuration,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,
3680,Homo sapiens,10209,CHEMBL620815,,1,BAO_0000357,B,9606.0,D,Expert,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,,,,
3681,,10209,CHEMBL620816,,1,BAO_0000219,B,,H,Autocuration,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,,
3682,,10209,CHEMBL620817,,1,BAO_0000357,B,,H,Autocuration,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,
3683,,10209,CHEMBL620818,,1,BAO_0000357,B,,H,Autocuration,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,
3684,,10209,CHEMBL620819,,1,BAO_0000219,B,,H,Expert,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,,
3685,Homo sapiens,10209,CHEMBL620820,,1,BAO_0000357,B,9606.0,D,Expert,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,,
3686,,10209,CHEMBL620821,,1,BAO_0000219,B,,H,Autocuration,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,,
3687,Homo sapiens,10209,CHEMBL620822,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,
3688,Homo sapiens,10209,CHEMBL620823,,1,BAO_0000357,B,9606.0,D,Expert,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,,
3689,Homo sapiens,10209,CHEMBL620824,,1,BAO_0000357,B,9606.0,D,Expert,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,,,,
3690,,10209,CHEMBL620825,,1,BAO_0000219,B,,H,Expert,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,,
3691,,10209,CHEMBL872930,,1,BAO_0000357,B,,H,Autocuration,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,
3692,,10209,CHEMBL620826,,1,BAO_0000357,B,,H,Autocuration,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,
3693,,10209,CHEMBL620827,,1,BAO_0000357,B,,H,Autocuration,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,
3694,,10209,CHEMBL620828,,1,BAO_0000357,B,,H,Autocuration,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,
3695,,10209,CHEMBL620829,,1,BAO_0000357,B,,H,Autocuration,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,
3696,,10209,CHEMBL620830,,1,BAO_0000219,B,,H,Expert,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,,
3697,,10209,CHEMBL620831,,1,BAO_0000019,B,,H,Expert,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,
3698,,10209,CHEMBL620832,,1,BAO_0000019,B,,H,Expert,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,
3699,Homo sapiens,10209,CHEMBL621548,,1,BAO_0000357,B,9606.0,D,Expert,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,,
3700,,10209,CHEMBL621549,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,
3701,,10209,CHEMBL621550,,1,BAO_0000357,B,,H,Autocuration,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,
3702,,10209,CHEMBL621551,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,,
3703,,10209,CHEMBL621552,,1,BAO_0000019,B,,H,Autocuration,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,
3704,,10209,CHEMBL857077,,1,BAO_0000357,B,,H,Autocuration,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,
3705,,10209,CHEMBL618158,,1,BAO_0000357,B,,H,Autocuration,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,
3706,Homo sapiens,10209,CHEMBL618159,,1,BAO_0000219,B,9606.0,D,Expert,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,
3707,,10209,CHEMBL875101,,1,BAO_0000219,B,,H,Autocuration,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,
3708,Homo sapiens,10209,CHEMBL618160,,1,BAO_0000219,B,9606.0,D,Expert,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,,,
3709,,10209,CHEMBL618161,,1,BAO_0000357,B,,H,Expert,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,
3710,,10209,CHEMBL618162,,1,BAO_0000219,B,,H,Expert,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,,
3711,,10209,CHEMBL618163,,1,BAO_0000357,B,,H,Expert,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,
3712,,10209,CHEMBL618164,,1,BAO_0000357,B,,H,Autocuration,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,
3713,,10209,CHEMBL618165,,1,BAO_0000219,B,,H,Expert,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,
3714,,10209,CHEMBL618166,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,,
3715,,10209,CHEMBL857989,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3716,,10209,CHEMBL619888,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3717,,10209,CHEMBL619889,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3718,,10209,CHEMBL619890,,1,BAO_0000219,B,,H,Autocuration,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,,
3719,,10209,CHEMBL619891,,1,BAO_0000219,B,,H,Autocuration,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,,
3720,,10209,CHEMBL619892,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,,
3721,,10209,CHEMBL619893,,1,BAO_0000219,B,,D,Expert,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,,
3722,,10209,CHEMBL619894,,1,BAO_0000219,B,,H,Autocuration,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,,
3723,,10209,CHEMBL619895,,1,BAO_0000219,B,,D,Intermediate,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,,
3724,,10209,CHEMBL619896,,1,BAO_0000357,B,,D,Intermediate,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,
3725,,10209,CHEMBL619897,,1,BAO_0000219,B,,H,Autocuration,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,,
3726,,10209,CHEMBL619898,,1,BAO_0000219,B,,H,Autocuration,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,,
3727,,10209,CHEMBL619899,,1,BAO_0000219,B,,H,Expert,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,,
3728,,10209,CHEMBL619900,,1,BAO_0000219,B,,H,Autocuration,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,,
3729,Homo sapiens,10209,CHEMBL619901,,1,BAO_0000219,B,9606.0,D,Expert,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,,,
3730,,10209,CHEMBL620580,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,,
3731,,10209,CHEMBL620581,,1,BAO_0000219,B,,H,Autocuration,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,,
3732,,10209,CHEMBL620733,,1,BAO_0000219,B,,H,Autocuration,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,,
3733,Homo sapiens,10209,CHEMBL620734,,1,BAO_0000357,B,9606.0,D,Autocuration,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,,
3734,Mus musculus,10022,CHEMBL620735,,1,BAO_0000357,B,10090.0,D,Expert,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,,
3735,Oryctolagus cuniculus,10209,CHEMBL620736,,1,BAO_0000019,B,9986.0,H,Autocuration,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,,
3736,,11923,CHEMBL620737,,1,BAO_0000219,B,,H,Autocuration,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,,
3737,,11923,CHEMBL620738,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,,
3738,,11923,CHEMBL620739,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,,
3739,,11923,CHEMBL620740,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,,
3740,,11923,CHEMBL620741,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,,
3741,,11923,CHEMBL620742,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,,
3742,,11923,CHEMBL620743,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,,
3743,,11923,CHEMBL620744,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,,
3744,,11923,CHEMBL620745,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,,
3745,,11923,CHEMBL620746,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,,
3746,,11923,CHEMBL620747,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,,
3747,,11923,CHEMBL620748,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,,
3748,,11923,CHEMBL620749,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,,
3749,,11923,CHEMBL620750,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,
3750,Rattus norvegicus,11923,CHEMBL620751,,1,BAO_0000357,B,10116.0,D,Expert,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,,
3751,,11923,CHEMBL620752,,1,BAO_0000357,B,,H,Expert,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,
3752,,11923,CHEMBL872929,,1,BAO_0000019,B,,H,Autocuration,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,,
3753,Rattus norvegicus,11923,CHEMBL620753,,1,BAO_0000357,B,10116.0,D,Expert,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,,
3754,Rattus norvegicus,11923,CHEMBL620754,,1,BAO_0000357,B,10116.0,D,Expert,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,,
3755,Rattus norvegicus,11923,CHEMBL620755,,1,BAO_0000219,B,10116.0,D,Expert,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,,,
3756,,11923,CHEMBL620756,,1,BAO_0000357,B,,H,Autocuration,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,
3757,,11923,CHEMBL620757,,1,BAO_0000357,B,,H,Autocuration,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,,
3758,,11923,CHEMBL620758,,1,BAO_0000219,B,,H,Autocuration,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,,,
3759,,11923,CHEMBL620759,,1,BAO_0000219,B,,H,Autocuration,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,,,
3760,,11923,CHEMBL620760,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,,,
3761,,11923,CHEMBL620761,,1,BAO_0000219,B,,H,Autocuration,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,,,
3762,,11923,CHEMBL620762,,1,BAO_0000221,F,,H,Autocuration,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,Ileum
3763,,11923,CHEMBL620763,,1,BAO_0000221,F,,H,Autocuration,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,Ileum
3764,,11923,CHEMBL620764,,1,BAO_0000221,F,,H,Autocuration,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,,Ileum
3765,Rattus norvegicus,11923,CHEMBL857990,,1,BAO_0000249,B,10116.0,D,Expert,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,,
3766,,11923,CHEMBL620765,,1,BAO_0000357,B,,H,Autocuration,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,,
3767,,11923,CHEMBL620766,,1,BAO_0000357,B,,H,Expert,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,,
3768,,11923,CHEMBL620767,,1,BAO_0000019,B,,H,Expert,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,,Hypothalamus
3769,,11923,CHEMBL620768,,1,BAO_0000357,B,,H,Autocuration,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,,
3770,,11923,CHEMBL619051,,1,BAO_0000249,B,,H,Expert,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,,Hypothalamus
3771,,11923,CHEMBL619052,,1,BAO_0000357,B,,H,Expert,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,
3772,Rattus norvegicus,11923,CHEMBL619053,,1,BAO_0000219,F,10116.0,D,Expert,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,,,
3773,Rattus norvegicus,11923,CHEMBL619703,,1,BAO_0000219,F,10116.0,D,Expert,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,,,
3774,Rattus norvegicus,11923,CHEMBL619704,,1,BAO_0000219,F,10116.0,D,Autocuration,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,,,
3775,,10209,CHEMBL619851,,1,BAO_0000357,B,,H,Expert,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,
3776,,10209,CHEMBL619852,,1,BAO_0000357,B,,H,Autocuration,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,,
3777,,10209,CHEMBL619853,,1,BAO_0000357,B,,H,Autocuration,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,,
3778,Homo sapiens,10209,CHEMBL619854,,1,BAO_0000357,B,9606.0,D,Expert,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,
3779,,10209,CHEMBL619855,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,,
3780,,10209,CHEMBL619856,,1,BAO_0000357,B,,H,Autocuration,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,,
3781,,10209,CHEMBL619857,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,
3782,,10209,CHEMBL619858,,1,BAO_0000019,F,,H,Expert,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,,
3783,,10209,CHEMBL619859,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,,
3784,,10209,CHEMBL619860,,1,BAO_0000357,B,,H,Autocuration,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,
3785,,10209,CHEMBL619861,,1,BAO_0000357,B,,H,Autocuration,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,,
3786,,10209,CHEMBL619862,,1,BAO_0000357,B,,H,Expert,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,,
3787,,10209,CHEMBL619863,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,,
3788,,10209,CHEMBL619864,,1,BAO_0000357,B,,H,Autocuration,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,,
3789,,10209,CHEMBL872928,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,,,,
3790,,10209,CHEMBL619865,,1,BAO_0000357,B,,H,Autocuration,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,,
3791,,10209,CHEMBL619866,,1,BAO_0000357,B,,H,Expert,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,,
3792,,10209,CHEMBL619867,,1,BAO_0000357,B,,H,Autocuration,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,,
3793,,10209,CHEMBL619868,,1,BAO_0000221,B,,H,Autocuration,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,,Ileum
3794,,55,CHEMBL619869,,1,BAO_0000019,F,,H,Autocuration,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,,
3795,Homo sapiens,55,CHEMBL619870,,1,BAO_0000019,F,9606.0,D,Expert,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,,
3796,,55,CHEMBL619871,,1,BAO_0000357,B,,H,Autocuration,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,,
3797,,55,CHEMBL619872,,1,BAO_0000357,B,,H,Autocuration,409,In vitro inhibition of human recombinant lipoxygenase enzyme,,,,
3798,,55,CHEMBL619873,,1,BAO_0000357,B,,H,Autocuration,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,,
3799,,55,CHEMBL619874,,1,BAO_0000357,B,,H,Expert,11090,Inhibition of 5-lipoxygenase in human whole blood.,,,,Blood
3800,,55,CHEMBL619875,,1,BAO_0000357,B,,H,Expert,11090,Inhibition of 5-lipoxygenase in human whole blood.,,,,Blood
3801,,55,CHEMBL619876,,1,BAO_0000357,B,,H,Autocuration,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,,
3802,,55,CHEMBL619877,,1,BAO_0000357,B,,H,Autocuration,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,,
3803,,55,CHEMBL619878,,1,BAO_0000219,F,,H,Expert,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,,
3804,,55,CHEMBL619879,,1,BAO_0000019,F,,H,Autocuration,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,,Blood
3805,,55,CHEMBL619880,,1,BAO_0000357,B,,H,Autocuration,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,,
3806,,55,CHEMBL619881,,1,BAO_0000357,B,,H,Autocuration,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,,
3807,,55,CHEMBL619882,,1,BAO_0000357,B,,H,Expert,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,,
3808,,55,CHEMBL619883,,1,BAO_0000357,B,,H,Autocuration,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,,
3809,Homo sapiens,55,CHEMBL619884,,1,BAO_0000357,B,9606.0,D,Expert,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,,Blood
3810,,55,CHEMBL619885,,1,BAO_0000357,B,,H,Autocuration,12703,In vitro potency against human 5-Lipoxygenase,,,,
3811,Homo sapiens,55,CHEMBL619886,,1,BAO_0000019,F,9606.0,D,Expert,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,,
3812,,55,CHEMBL619887,,1,BAO_0000019,F,,H,Autocuration,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,,Blood
3813,,55,CHEMBL875097,,1,BAO_0000019,F,,H,Autocuration,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,
3814,,55,CHEMBL618001,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,,
3815,,55,CHEMBL618002,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,,
3816,,55,CHEMBL618003,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,,
3817,,55,CHEMBL618004,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,,
3818,,55,CHEMBL618005,,1,BAO_0000219,B,,H,Autocuration,12365,Inhibition of human 5-lipoxygenase in human cells,,,,
3819,,55,CHEMBL618006,,1,BAO_0000357,B,,H,Expert,10603,Inhibition of human neutrophil 5-lipoxygenase,,,,
3820,,55,CHEMBL875086,,1,BAO_0000019,B,,H,Autocuration,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,,
3821,,55,CHEMBL618007,,1,BAO_0000357,B,,H,Expert,12281,Inhibition of 5-lipoxygenase from human whole blood,,,,Blood
3822,,55,CHEMBL618008,,1,BAO_0000357,B,,H,Autocuration,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,
3823,,55,CHEMBL618009,,1,BAO_0000219,B,,H,Autocuration,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,,
3824,,55,CHEMBL618010,,1,BAO_0000357,B,,H,Expert,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,,
3825,,55,CHEMBL618011,,1,BAO_0000357,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,
3826,,55,CHEMBL618012,,1,BAO_0000357,B,,H,Expert,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,,
3827,,55,CHEMBL882927,,1,BAO_0000357,B,,H,Autocuration,12780,Tested against 5-lipoxygenase,,,,
3828,,55,CHEMBL618013,,1,BAO_0000357,B,,H,Autocuration,12780,Tested for activity against 5-Lipoxygenase (5-LO),,,,
3829,,55,CHEMBL618014,,1,BAO_0000357,B,,H,Autocuration,12780,Tested for activity against 5-lipoxygenase,,,,
3830,,55,CHEMBL618015,,1,BAO_0000357,B,,H,Autocuration,11966,Tested for inhibition of 5-HPETE production by human 5-LO,,,,
3831,,55,CHEMBL618016,,1,BAO_0000019,F,,H,Autocuration,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,
3832,,55,CHEMBL618017,,1,BAO_0000357,B,,H,Expert,13165,Inhibition of Human 5-lipoxygenase,,,,
3833,,55,CHEMBL618018,,1,BAO_0000019,B,,H,Autocuration,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,,
3834,,55,CHEMBL875087,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,
3835,,55,CHEMBL618019,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,,
3836,,55,CHEMBL618020,,1,BAO_0000019,B,,H,Autocuration,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,,
3837,,55,CHEMBL618021,,1,BAO_0000019,B,,H,Autocuration,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,,
3838,,55,CHEMBL618022,,1,BAO_0000357,B,,H,Autocuration,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,,Blood
3839,,55,CHEMBL618023,,1,BAO_0000357,B,,H,Autocuration,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,,
3840,,55,CHEMBL618024,,1,BAO_0000357,B,,H,Autocuration,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,
3841,,55,CHEMBL873950,,1,BAO_0000019,B,,H,Expert,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,,
3842,,55,CHEMBL618025,,1,BAO_0000357,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,
3843,,55,CHEMBL618026,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,,
3844,,55,CHEMBL618027,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,,
3845,,55,CHEMBL618028,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,,
3846,,55,CHEMBL618029,,1,BAO_0000219,B,,H,Autocuration,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,,
3847,,55,CHEMBL618030,,1,BAO_0000357,B,,H,Expert,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,,
3848,,55,CHEMBL618031,,1,BAO_0000357,B,,H,Expert,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,,
3849,,55,CHEMBL618032,,1,BAO_0000357,B,,H,Autocuration,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,,
3850,,55,CHEMBL618033,,1,BAO_0000357,B,,H,Autocuration,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,
3851,,55,CHEMBL618034,,1,BAO_0000357,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,,
3852,,55,CHEMBL875088,,1,BAO_0000357,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,
3853,,55,CHEMBL618035,,1,BAO_0000019,B,,H,Autocuration,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,,
3854,,55,CHEMBL618036,,1,BAO_0000019,B,,H,Autocuration,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,,
3855,,55,CHEMBL618037,,1,BAO_0000357,B,,H,Expert,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,,
3856,,55,CHEMBL618038,,1,BAO_0000357,B,,H,Expert,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,
3857,,55,CHEMBL618761,,1,BAO_0000019,F,,H,Autocuration,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,
3858,,55,CHEMBL618762,,1,BAO_0000357,B,,H,Expert,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,,
3859,,55,CHEMBL618763,,1,BAO_0000357,B,,H,Expert,10603,Inhibition of lipoxygenase at the concentration of 1 uM,,,,
3860,,55,CHEMBL618764,,1,BAO_0000357,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,,
3861,Homo sapiens,55,CHEMBL618765,,1,BAO_0000357,B,9606.0,D,Expert,14580,Inhibition of 5-Lipoxygenase (5-LOX),,,,
3862,,17087,CHEMBL618766,,1,BAO_0000357,B,,H,Expert,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,
3863,,17087,CHEMBL618767,,1,BAO_0000357,B,,H,Expert,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,
3864,,17087,CHEMBL619380,,1,BAO_0000357,B,,H,Autocuration,6339,Inhibitory activity against lipoxygenase-2 in mice,,,,
3865,,17087,CHEMBL619381,,1,BAO_0000357,B,,H,Expert,6339,Inhibitory activity against murine lipoxygenase-2.,,,,
3866,Mus musculus,17087,CHEMBL619382,,1,BAO_0000357,B,10090.0,D,Expert,12281,Inhibition of 5-lipoxygenase from mouse macrophage,,,,
3867,,17087,CHEMBL619383,,1,BAO_0000357,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,,
3868,Sus scrofa,55,CHEMBL619384,,1,BAO_0000019,B,9823.0,H,Autocuration,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,,
3869,Sus scrofa,55,CHEMBL619385,,1,BAO_0000019,B,9823.0,H,Autocuration,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,,
3870,Oryctolagus cuniculus,55,CHEMBL882928,,1,BAO_0000019,B,9986.0,H,Autocuration,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,,
3871,Rattus norvegicus,12166,CHEMBL619386,,1,BAO_0000019,B,10116.0,D,Expert,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,,
3872,,12166,CHEMBL619387,,1,BAO_0000019,B,,H,Autocuration,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,,
3873,,12166,CHEMBL619388,,1,BAO_0000019,B,,H,Autocuration,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,
3874,,12166,CHEMBL619389,,1,BAO_0000019,B,,H,Autocuration,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,,
3875,,12166,CHEMBL619390,,1,BAO_0000019,B,,H,Expert,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,,
3876,,12166,CHEMBL619391,,1,BAO_0000019,B,,H,Expert,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,,
3877,,12166,CHEMBL619392,,1,BAO_0000019,B,,H,Autocuration,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,,
3878,,12166,CHEMBL619393,,1,BAO_0000019,B,,H,Autocuration,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,,
3879,,12166,CHEMBL619394,,1,BAO_0000019,B,,H,Autocuration,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,,
3880,,12166,CHEMBL619395,,1,BAO_0000219,B,,H,Autocuration,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,
3881,,12166,CHEMBL619396,,1,BAO_0000219,B,,H,Autocuration,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,,,
3882,,12166,CHEMBL619397,,1,BAO_0000357,B,,H,Autocuration,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,,
3883,,12166,CHEMBL619398,,1,BAO_0000357,B,,H,Autocuration,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,,
3884,,12166,CHEMBL619399,,1,BAO_0000357,B,,H,Autocuration,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,,
3885,,12166,CHEMBL619400,,1,BAO_0000357,B,,H,Autocuration,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,
3886,,12166,CHEMBL619401,,1,BAO_0000019,B,,H,Autocuration,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,
3887,,12166,CHEMBL619402,,1,BAO_0000019,B,,H,Autocuration,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,,
3888,Rattus norvegicus,12166,CHEMBL619403,,1,BAO_0000219,B,10116.0,D,Expert,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,,,
3889,,12166,CHEMBL619404,,1,BAO_0000357,B,,H,Autocuration,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,
3890,,12166,CHEMBL619405,,1,BAO_0000357,B,,H,Autocuration,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,,
3891,,12166,CHEMBL619406,,1,BAO_0000219,B,,H,Expert,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,,,
3892,Rattus norvegicus,12166,CHEMBL619407,,1,BAO_0000219,B,10116.0,D,Expert,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,,,
3893,,12166,CHEMBL619408,,1,BAO_0000357,B,,H,Autocuration,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,,
3894,,12166,CHEMBL619409,,1,BAO_0000219,B,,H,Autocuration,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,,,
3895,,12166,CHEMBL619410,,1,BAO_0000219,B,,H,Expert,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,,,
3896,,12166,CHEMBL619753,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,
3897,,12166,CHEMBL619754,,1,BAO_0000219,B,,H,Autocuration,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,,,
3898,,12166,CHEMBL619903,,1,BAO_0000357,B,,H,Expert,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,,
3899,,12166,CHEMBL619904,,1,BAO_0000357,B,,H,Expert,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,,
3900,,12166,CHEMBL619905,,1,BAO_0000357,B,,H,Expert,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,,
3901,,12166,CHEMBL619906,,1,BAO_0000019,B,,H,Autocuration,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,,
3902,,12166,CHEMBL619907,,1,BAO_0000019,B,,H,Autocuration,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,,
3903,,12166,CHEMBL619908,,1,BAO_0000019,B,,H,Autocuration,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,,
3904,,12166,CHEMBL619909,,1,BAO_0000019,B,,H,Autocuration,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,,
3905,,12166,CHEMBL619910,,1,BAO_0000219,F,,H,Expert,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,,,
3906,,12166,CHEMBL882929,,1,BAO_0000219,B,,H,Expert,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,,,
3907,,12166,CHEMBL619911,,1,BAO_0000219,B,,H,Expert,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,,,
3908,,12166,CHEMBL619912,,1,BAO_0000019,B,,H,Autocuration,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,,
3909,Rattus norvegicus,12166,CHEMBL619913,,1,BAO_0000357,B,10116.0,D,Expert,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,,
3910,,12166,CHEMBL619914,,1,BAO_0000219,B,,H,Expert,9295,In vitro inhibitory activity against RBL-1 5-LO,,,,
3911,,12166,CHEMBL619915,,1,BAO_0000219,B,,H,Autocuration,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,,,
3912,,12166,CHEMBL619916,,1,BAO_0000219,B,,H,Autocuration,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,,,
3913,,12166,CHEMBL619917,,1,BAO_0000218,B,,H,Autocuration,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,,
3914,,12166,CHEMBL619918,,1,BAO_0000357,B,,H,Autocuration,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,,
3915,,12166,CHEMBL619919,,1,BAO_0000218,B,,H,Autocuration,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,,
3916,,12166,CHEMBL883710,,1,BAO_0000219,B,,H,Autocuration,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,,,
3917,,12166,CHEMBL619920,,1,BAO_0000019,B,,H,Autocuration,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,,Blood
3918,,12166,CHEMBL619921,,1,BAO_0000357,B,,H,Expert,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,,
3919,,12166,CHEMBL619922,,1,BAO_0000019,F,,H,Autocuration,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,,
3920,,12166,CHEMBL619923,,1,BAO_0000219,F,,H,Autocuration,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,,
3921,,12166,CHEMBL619924,,1,BAO_0000219,B,,H,Expert,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,,,
3922,,12166,CHEMBL619925,,1,BAO_0000357,B,,H,Expert,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,,
3923,,12166,CHEMBL619926,,1,BAO_0000219,B,,H,Expert,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,,,
3924,,12166,CHEMBL619927,,1,BAO_0000219,B,,H,Autocuration,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,,,
3925,,12166,CHEMBL619928,,1,BAO_0000219,B,,H,Expert,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,,,
3926,,12166,CHEMBL619929,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase,,,,
3927,,12166,CHEMBL875089,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,,,
3928,,12166,CHEMBL619930,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,,,
3929,,12166,CHEMBL619931,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,,,
3930,,12166,CHEMBL619932,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,,,
3931,,12166,CHEMBL619933,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,,,
3932,,12166,CHEMBL619934,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,,,
3933,,12166,CHEMBL619935,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,,,
3934,,12166,CHEMBL619936,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,,,
3935,,12166,CHEMBL619937,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,,,
3936,,12166,CHEMBL619938,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,,,
3937,,12166,CHEMBL619939,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,,,
3938,,12166,CHEMBL619940,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,,,
3939,,12166,CHEMBL875090,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,,,
3940,,12166,CHEMBL619941,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,,,
3941,,12166,CHEMBL619942,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,,,
3942,,12166,CHEMBL883711,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,,,
3943,,12166,CHEMBL619943,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,,,
3944,,12166,CHEMBL619944,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,,,
3945,,12166,CHEMBL619945,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,,,
3946,,12166,CHEMBL619946,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,,,
3947,,12166,CHEMBL619947,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,,,
3948,,12166,CHEMBL619948,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,,,
3949,,12166,CHEMBL619949,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,,,
3950,,12166,CHEMBL619950,,1,BAO_0000019,B,,H,Expert,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,,
3951,,12166,CHEMBL618050,,1,BAO_0000019,B,,H,Autocuration,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,,
3952,,12166,CHEMBL875091,,1,BAO_0000219,F,,H,Expert,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,,,
3953,,12166,CHEMBL618051,,1,BAO_0000219,F,,H,Expert,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,,,
3954,Rattus norvegicus,12166,CHEMBL618052,,1,BAO_0000219,B,10116.0,D,Expert,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,,,
3955,,12166,CHEMBL618053,,1,BAO_0000019,B,,H,Autocuration,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,,
3956,,12166,CHEMBL618054,,1,BAO_0000019,B,,H,Expert,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,,
3957,Rattus norvegicus,12166,CHEMBL618055,,1,BAO_0000219,B,10116.0,D,Expert,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,,
3958,,12166,CHEMBL618056,,1,BAO_0000219,B,,H,Expert,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,,,
3959,,12166,CHEMBL618057,,1,BAO_0000357,B,,H,Autocuration,137,In vitro inhibitory activity against 5-lipoxygenase was determined,,,,
3960,,12166,CHEMBL618058,,1,BAO_0000219,B,,H,Autocuration,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,,,
3961,,12166,CHEMBL618059,,1,BAO_0000219,B,,H,Expert,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,,,
3962,Rattus norvegicus,12166,CHEMBL618060,,1,BAO_0000019,F,10116.0,D,Expert,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,,
3963,,12166,CHEMBL618061,,1,BAO_0000219,B,,H,Autocuration,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,,,
3964,,12166,CHEMBL618062,,1,BAO_0000019,B,,H,Autocuration,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,,
3965,,12166,CHEMBL618063,,1,BAO_0000219,B,,H,Expert,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,,,
3966,,12166,CHEMBL618064,,1,BAO_0000357,B,,H,Autocuration,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,,
3967,Rattus norvegicus,12166,CHEMBL618065,,1,BAO_0000219,B,10116.0,D,Expert,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,,,
3968,Rattus norvegicus,12166,CHEMBL618066,,1,BAO_0000219,B,10116.0,D,Expert,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,,,
3969,,12166,CHEMBL618067,,1,BAO_0000219,B,,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,
3970,,12166,CHEMBL618068,,1,BAO_0000219,B,,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,
3971,Rattus norvegicus,12166,CHEMBL618069,,1,BAO_0000219,B,10116.0,D,Expert,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,,,
3972,,12166,CHEMBL618070,,1,BAO_0000219,B,,H,Expert,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
3973,,10825,CHEMBL618071,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,,Limbic system
3974,,10825,CHEMBL619247,,1,BAO_0000019,F,,H,Autocuration,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,Limbic system
3975,,10825,CHEMBL619248,,1,BAO_0000019,F,,H,Autocuration,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,,
3976,,10576,CHEMBL619249,,1,BAO_0000221,B,,H,Autocuration,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,Hippocampus
3977,,10576,CHEMBL619250,,1,BAO_0000221,B,,H,Autocuration,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,Hippocampus
3978,,10577,CHEMBL619251,,1,BAO_0000019,B,,H,Autocuration,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,
3979,Canis lupus familiaris,55,CHEMBL619252,,1,BAO_0000019,F,9615.0,H,Autocuration,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,,Blood
3980,,55,CHEMBL619253,,1,BAO_0000019,F,,H,Autocuration,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,,Blood
3981,,12166,CHEMBL619254,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,
3982,,17140,CHEMBL619255,,1,BAO_0000219,B,,H,Expert,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,,
3983,,17140,CHEMBL619256,,1,BAO_0000219,B,,H,Expert,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,,
3984,,17140,CHEMBL875418,,1,BAO_0000219,B,,H,Autocuration,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,,
3985,,17140,CHEMBL619257,,1,BAO_0000219,B,,H,Expert,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,
3986,,17140,CHEMBL619258,,1,BAO_0000219,B,,H,Autocuration,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,
3987,,17140,CHEMBL619259,,1,BAO_0000357,B,,H,Expert,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,,
3988,,17140,CHEMBL619260,,1,BAO_0000357,B,,H,Expert,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,,
3989,Canis lupus familiaris,55,CHEMBL619261,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3990,Canis lupus familiaris,55,CHEMBL619263,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3991,Canis lupus familiaris,55,CHEMBL619264,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3992,Canis lupus familiaris,55,CHEMBL619265,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3993,Canis lupus familiaris,55,CHEMBL619266,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3994,Canis lupus familiaris,55,CHEMBL619902,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3995,Canis lupus familiaris,55,CHEMBL620058,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3996,Canis lupus familiaris,55,CHEMBL620059,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3997,Canis lupus familiaris,55,CHEMBL620060,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3998,Canis lupus familiaris,55,CHEMBL620061,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
3999,Canis lupus familiaris,55,CHEMBL620062,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4000,Canis lupus familiaris,55,CHEMBL620063,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4001,Canis lupus familiaris,55,CHEMBL620064,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4002,Canis lupus familiaris,55,CHEMBL620065,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4003,Canis lupus familiaris,55,CHEMBL620066,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4004,Canis lupus familiaris,55,CHEMBL620067,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4005,Canis lupus familiaris,55,CHEMBL620068,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4006,Canis lupus familiaris,55,CHEMBL620069,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4007,Canis lupus familiaris,55,CHEMBL620070,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4008,Canis lupus familiaris,55,CHEMBL620071,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4009,Canis lupus familiaris,55,CHEMBL620072,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4010,Canis lupus familiaris,55,CHEMBL620036,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4011,Canis lupus familiaris,55,CHEMBL857702,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4012,Canis lupus familiaris,55,CHEMBL620037,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4013,Canis lupus familiaris,55,CHEMBL620038,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4014,Canis lupus familiaris,55,CHEMBL620039,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4015,Canis lupus familiaris,55,CHEMBL620040,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4016,Canis lupus familiaris,55,CHEMBL620041,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4017,Canis lupus familiaris,55,CHEMBL620042,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4018,Canis lupus familiaris,55,CHEMBL620043,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4019,Canis lupus familiaris,55,CHEMBL620044,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4020,Canis lupus familiaris,55,CHEMBL620045,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4021,Canis lupus familiaris,55,CHEMBL620046,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4022,Canis lupus familiaris,55,CHEMBL620047,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4023,Canis lupus familiaris,55,CHEMBL620048,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",In vivo,,,Blood
4024,Canis lupus familiaris,55,CHEMBL857703,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4025,Canis lupus familiaris,55,CHEMBL620049,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",In vivo,,,Blood
4026,Canis lupus familiaris,55,CHEMBL620050,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4027,Canis lupus familiaris,55,CHEMBL620051,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4028,Canis lupus familiaris,55,CHEMBL619213,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4029,Canis lupus familiaris,55,CHEMBL619214,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4030,Canis lupus familiaris,55,CHEMBL619804,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4031,Canis lupus familiaris,55,CHEMBL619805,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4032,Canis lupus familiaris,55,CHEMBL619806,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4033,Canis lupus familiaris,55,CHEMBL619807,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4034,Canis lupus familiaris,55,CHEMBL619808,,1,BAO_0000218,F,9615.0,H,Autocuration,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",In vivo,,,Blood
4035,Canis lupus familiaris,55,CHEMBL619809,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,,
4036,Canis lupus familiaris,55,CHEMBL619810,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,,
4037,Canis lupus familiaris,55,CHEMBL619811,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,,
4038,Canis lupus familiaris,55,CHEMBL620769,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,,
4039,Canis lupus familiaris,55,CHEMBL620770,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,,
4040,Canis lupus familiaris,55,CHEMBL620771,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,,
4041,Canis lupus familiaris,55,CHEMBL620772,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,,
4042,Canis lupus familiaris,55,CHEMBL620773,,1,BAO_0000218,B,9615.0,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,,
4043,Cavia porcellus,55,CHEMBL620774,,1,BAO_0000357,B,10141.0,H,Autocuration,9203,Ability to inhibit 5-lipoxygenase in guinea pig,,,,
4044,Cavia porcellus,55,CHEMBL620775,,1,BAO_0000357,B,10141.0,H,Expert,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,,
4045,Cavia porcellus,55,CHEMBL620776,,1,BAO_0000357,B,10141.0,H,Autocuration,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,,
4046,Cavia porcellus,55,CHEMBL620777,,1,BAO_0000218,B,10141.0,H,Autocuration,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,,Blood
4047,Cavia porcellus,55,CHEMBL620778,,1,BAO_0000357,B,10141.0,H,Autocuration,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,,
4048,Cavia porcellus,55,CHEMBL620779,,1,BAO_0000357,B,10141.0,H,Autocuration,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,,
4049,Cavia porcellus,55,CHEMBL621500,,1,BAO_0000019,B,10141.0,H,Expert,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,,
4050,Cavia porcellus,55,CHEMBL621501,,1,BAO_0000019,B,10141.0,H,Expert,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,,
4051,Cavia porcellus,55,CHEMBL618098,,1,BAO_0000019,B,10141.0,H,Autocuration,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,,
4052,Cavia porcellus,55,CHEMBL618099,,1,BAO_0000019,B,10141.0,H,Autocuration,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,,
4053,Cavia porcellus,55,CHEMBL618100,,1,BAO_0000357,B,10141.0,H,Autocuration,7788,Inhibitory activity against 5-lipoxygenase,,,,
4054,Cavia porcellus,55,CHEMBL618101,,1,BAO_0000357,B,10141.0,H,Autocuration,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,,
4055,Cavia porcellus,55,CHEMBL618102,,1,BAO_0000357,B,10141.0,H,Autocuration,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,,
4056,Cavia porcellus,55,CHEMBL618103,,1,BAO_0000357,B,10141.0,H,Autocuration,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,,
4057,Cavia porcellus,55,CHEMBL618104,,1,BAO_0000357,B,10141.0,H,Autocuration,13243,Inhibitory activity uM,,,,
4058,Cavia porcellus,55,CHEMBL883712,,1,BAO_0000219,B,10141.0,H,Autocuration,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,,
4059,Cavia porcellus,55,CHEMBL618105,,1,BAO_0000357,B,10141.0,H,Autocuration,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,,,,
4060,Cavia porcellus,55,CHEMBL618106,,1,BAO_0000357,B,10141.0,H,Autocuration,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,,
4061,Cavia porcellus,55,CHEMBL618107,,1,BAO_0000357,B,10141.0,H,Autocuration,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,,
4062,Cavia porcellus,55,CHEMBL618108,,1,BAO_0000357,B,10141.0,H,Autocuration,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,,
4063,Cavia porcellus,55,CHEMBL618109,,1,BAO_0000357,B,10141.0,H,Autocuration,13243,Inhibitory activity uM,,,,
4064,Cavia porcellus,55,CHEMBL618110,,1,BAO_0000357,B,10141.0,H,Autocuration,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,,
4065,Cavia porcellus,55,CHEMBL618111,,1,BAO_0000357,B,10141.0,H,Expert,13243,Inhibitory activity uM,,,,
4066,Cavia porcellus,55,CHEMBL618112,,1,BAO_0000019,F,10141.0,H,Autocuration,13243,Inhibitory activity uM,,,,
4067,Cavia porcellus,55,CHEMBL618113,,1,BAO_0000019,B,10141.0,H,Autocuration,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,,
4068,Cavia porcellus,55,CHEMBL618114,,1,BAO_0000357,B,10141.0,H,Autocuration,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,,
4069,Cavia porcellus,55,CHEMBL620871,,1,BAO_0000221,F,10141.0,H,Expert,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,,Ileum
4070,,55,CHEMBL620872,,1,BAO_0000357,B,,H,Autocuration,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,
4071,,55,CHEMBL620873,,1,BAO_0000357,B,,H,Autocuration,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,
4072,,55,CHEMBL620874,,1,BAO_0000357,B,,H,Autocuration,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,,
4073,,55,CHEMBL620875,,1,BAO_0000357,B,,H,Expert,12780,In vitro inhibition of human 5-Lipoxygenase.,,,,
4074,Rattus norvegicus,22226,CHEMBL620876,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,,Liver
4075,Rattus norvegicus,22226,CHEMBL620877,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,,Liver
4076,Rattus norvegicus,22226,CHEMBL857854,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,,Liver
4077,Rattus norvegicus,22226,CHEMBL620878,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,,Liver
4078,Rattus norvegicus,22226,CHEMBL620879,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,,Liver
4079,Rattus norvegicus,22226,CHEMBL620880,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,,Liver
4080,Rattus norvegicus,22226,CHEMBL620881,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,,Liver
4081,Rattus norvegicus,22226,CHEMBL620882,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,,Liver
4082,Rattus norvegicus,22226,CHEMBL620883,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,,Liver
4083,Rattus norvegicus,22226,CHEMBL620884,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,,Liver
4084,Rattus norvegicus,22226,CHEMBL620885,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,,Liver
4085,Rattus norvegicus,22226,CHEMBL620886,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,,Liver
4086,Rattus norvegicus,22226,CHEMBL620887,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,,Liver
4087,Rattus norvegicus,22226,CHEMBL618039,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,,Liver
4088,Rattus norvegicus,22226,CHEMBL618040,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,,Liver
4089,Rattus norvegicus,22226,CHEMBL618041,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,,Liver
4090,Rattus norvegicus,22226,CHEMBL618216,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,,Liver
4091,Rattus norvegicus,22226,CHEMBL618217,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,,Liver
4092,Rattus norvegicus,22226,CHEMBL618218,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,,Liver
4093,Rattus norvegicus,22226,CHEMBL618219,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,,Liver
4094,Rattus norvegicus,22226,CHEMBL618220,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,,Liver
4095,Rattus norvegicus,22226,CHEMBL618221,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,,Liver
4096,Rattus norvegicus,22226,CHEMBL618222,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,,Liver
4097,Rattus norvegicus,22226,CHEMBL618223,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,,Liver
4098,Rattus norvegicus,22226,CHEMBL618224,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,,Liver
4099,Rattus norvegicus,22226,CHEMBL618225,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,,Liver
4100,Rattus norvegicus,22226,CHEMBL618226,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,,Liver
4101,Rattus norvegicus,22226,CHEMBL618227,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,,Liver
4102,Rattus norvegicus,22226,CHEMBL618228,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,,Liver
4103,Rattus norvegicus,22226,CHEMBL618229,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,,Liver
4104,Rattus norvegicus,22226,CHEMBL618230,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,,Liver
4105,Rattus norvegicus,22226,CHEMBL618231,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,,Liver
4106,Rattus norvegicus,22226,CHEMBL618232,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,,Liver
4107,Rattus norvegicus,22226,CHEMBL618233,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,,Liver
4108,Rattus norvegicus,22226,CHEMBL618234,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,,Liver
4109,Rattus norvegicus,22226,CHEMBL618235,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,,Liver
4110,Rattus norvegicus,22226,CHEMBL618115,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,,Liver
4111,Rattus norvegicus,22226,CHEMBL618116,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,,Liver
4112,Rattus norvegicus,22226,CHEMBL618117,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,,Liver
4113,Rattus norvegicus,22226,CHEMBL619968,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,,Liver
4114,Rattus norvegicus,22226,CHEMBL619969,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,,Liver
4115,Rattus norvegicus,22226,CHEMBL619970,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,,Liver
4116,Rattus norvegicus,22226,CHEMBL619971,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,,Liver
4117,Rattus norvegicus,22226,CHEMBL619972,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,,Liver
4118,Rattus norvegicus,22226,CHEMBL619973,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,,Liver
4119,Rattus norvegicus,22226,CHEMBL619974,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,,Liver
4120,Rattus norvegicus,22226,CHEMBL619975,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,,Liver
4121,Rattus norvegicus,22226,CHEMBL619976,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,,
4122,Rattus norvegicus,22226,CHEMBL619977,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,,Liver
4123,Rattus norvegicus,22226,CHEMBL619978,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,,Liver
4124,Rattus norvegicus,22226,CHEMBL619979,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,,Liver
4125,Rattus norvegicus,22226,CHEMBL619980,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,,Liver
4126,Rattus norvegicus,22226,CHEMBL619981,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,,Liver
4127,Homo sapiens,80433,CHEMBL619982,,1,BAO_0000219,F,9606.0,N,Intermediate,10797,In vitro inhibition of 7226/S myeloma cancer cell line,,,,
4128,Homo sapiens,80698,CHEMBL619983,,1,BAO_0000219,F,9606.0,N,Intermediate,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,,,
4129,Homo sapiens,80640,CHEMBL620031,,1,BAO_0000219,F,9606.0,N,Intermediate,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,,
4130,Homo sapiens,80640,CHEMBL620032,,1,BAO_0000219,F,9606.0,N,Intermediate,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,,,
4131,Cricetulus griseus,81264,CHEMBL620033,,1,BAO_0000219,F,10029.0,N,Expert,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,,,
4132,Cricetulus griseus,81264,CHEMBL620034,,1,BAO_0000219,F,10029.0,N,Expert,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,,,
4133,Rattus norvegicus,80635,CHEMBL620035,,1,BAO_0000219,F,10116.0,N,Intermediate,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,,,
4134,Rattus norvegicus,80635,CHEMBL618318,,1,BAO_0000219,F,10116.0,N,Intermediate,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,,,
4135,Rattus norvegicus,80635,CHEMBL618319,,1,BAO_0000219,F,10116.0,N,Intermediate,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,,,
4136,Rattus norvegicus,80635,CHEMBL618320,,1,BAO_0000219,F,10116.0,N,Intermediate,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,,,
4137,Rattus norvegicus,80635,CHEMBL618321,,1,BAO_0000219,F,10116.0,N,Intermediate,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,,,
4138,Rattus norvegicus,80635,CHEMBL883118,,1,BAO_0000219,F,10116.0,N,Intermediate,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,,,
4139,Homo sapiens,80640,CHEMBL883795,,1,BAO_0000219,F,9606.0,N,Intermediate,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,,,,
4140,Homo sapiens,80640,CHEMBL618322,,1,BAO_0000219,F,9606.0,N,Intermediate,12858,Cytotoxic activity against 786-0 Renal cancer cell line,,,,
4141,Homo sapiens,80640,CHEMBL618323,,1,BAO_0000219,F,9606.0,N,Intermediate,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,,,
4142,Homo sapiens,80640,CHEMBL618324,,1,BAO_0000219,F,9606.0,N,Intermediate,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,,,
4143,Homo sapiens,80640,CHEMBL618325,,1,BAO_0000219,F,9606.0,N,Intermediate,5858,In vitro antitumor activity against human renal 786-0 cell line,,,,
4144,Homo sapiens,80640,CHEMBL875416,,1,BAO_0000219,F,9606.0,N,Intermediate,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,,,,
4145,Homo sapiens,80640,CHEMBL618326,,1,BAO_0000219,F,9606.0,N,Intermediate,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,,,
4146,Homo sapiens,80640,CHEMBL618327,,1,BAO_0000219,F,9606.0,N,Intermediate,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,,,
4147,Homo sapiens,80640,CHEMBL619215,,1,BAO_0000219,F,9606.0,N,Intermediate,14696,inhibition of the growth of renal cancer(786-0) cell line,,,,
4148,Homo sapiens,80640,CHEMBL619216,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,,
4149,Homo sapiens,80640,CHEMBL619217,,1,BAO_0000219,F,9606.0,N,Intermediate,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,,,
4150,Homo sapiens,80640,CHEMBL619218,,1,BAO_0000219,F,9606.0,N,Intermediate,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,,,,
4151,Homo sapiens,80640,CHEMBL619219,,1,BAO_0000219,F,9606.0,N,Intermediate,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,,,
4152,Homo sapiens,80640,CHEMBL619220,,1,BAO_0000219,F,9606.0,N,Intermediate,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,,,,
4153,Homo sapiens,80640,CHEMBL619221,,1,BAO_0000219,F,9606.0,N,Intermediate,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,,,
4154,Homo sapiens,80640,CHEMBL619222,,1,BAO_0000219,F,9606.0,N,Intermediate,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,,,,
4155,Homo sapiens,80640,CHEMBL857454,,1,BAO_0000219,F,9606.0,N,Intermediate,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,,,,
4156,,12166,CHEMBL619223,,1,BAO_0000219,B,,H,Autocuration,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,,,
4157,,12166,CHEMBL619224,,1,BAO_0000219,B,,H,Autocuration,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,,,
4158,,12166,CHEMBL619225,,1,BAO_0000019,B,,H,Autocuration,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,
4159,,12166,CHEMBL619226,,1,BAO_0000219,B,,H,Expert,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,
4160,,12166,CHEMBL619227,,1,BAO_0000219,B,,H,Expert,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,,,
4161,,12166,CHEMBL619228,,1,BAO_0000357,B,,H,Autocuration,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,,
4162,,12166,CHEMBL619229,,1,BAO_0000219,B,,H,Autocuration,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,,
4163,,12166,CHEMBL619230,,1,BAO_0000219,B,,H,Autocuration,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,,,
4164,,12166,CHEMBL619231,,1,BAO_0000357,B,,H,Autocuration,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,,
4165,,12166,CHEMBL619232,,1,BAO_0000357,B,,H,Autocuration,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,,
4166,,12166,CHEMBL619233,,1,BAO_0000357,B,,H,Expert,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,,
4167,,12166,CHEMBL619234,,1,BAO_0000357,B,,H,Autocuration,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,,
4168,,12166,CHEMBL619235,,1,BAO_0000357,B,,H,Autocuration,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,,
4169,Rattus norvegicus,12166,CHEMBL619236,,1,BAO_0000019,B,10116.0,D,Expert,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,,
4170,,12166,CHEMBL619237,,1,BAO_0000219,B,,H,Autocuration,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,,,
4171,,12166,CHEMBL619238,,1,BAO_0000357,B,,H,Autocuration,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,,
4172,,12166,CHEMBL619239,,1,BAO_0000357,B,,H,Expert,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,,
4173,,12166,CHEMBL619240,,1,BAO_0000357,B,,H,Autocuration,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,,
4174,,12166,CHEMBL875417,,1,BAO_0000019,B,,H,Autocuration,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,
4175,,12166,CHEMBL619241,,1,BAO_0000219,B,,H,Autocuration,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,,,
4176,,12166,CHEMBL619242,,1,BAO_0000019,F,,H,Expert,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,
4177,,12166,CHEMBL883796,,1,BAO_0000219,B,,H,Autocuration,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,,,
4178,,12166,CHEMBL619243,,1,BAO_0000357,B,,H,Autocuration,414,Tested for its inhibitory activity against 5-lipoxygenase,,,,
4179,,12166,CHEMBL619244,,1,BAO_0000357,B,,H,Autocuration,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,,
4180,,12166,CHEMBL619245,,1,BAO_0000019,B,,H,Expert,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,,
4181,,12166,CHEMBL619246,,1,BAO_0000019,B,,H,Expert,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,
4182,,12166,CHEMBL619984,,1,BAO_0000219,B,,H,Expert,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,
4183,,12166,CHEMBL619985,,1,BAO_0000219,B,,H,Autocuration,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,,,
4184,,12166,CHEMBL619986,,1,BAO_0000219,B,,H,Autocuration,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,
4185,,12166,CHEMBL619987,,1,BAO_0000219,B,,H,Expert,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,,,
4186,,12166,CHEMBL619988,,1,BAO_0000218,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,,
4187,,12166,CHEMBL619989,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,,,
4188,,12166,CHEMBL619990,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,,,
4189,,12166,CHEMBL619991,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,
4190,,12166,CHEMBL619992,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,,
4191,,12166,CHEMBL619993,,1,BAO_0000218,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),In vivo,,,
4192,,12166,CHEMBL619994,,1,BAO_0000219,F,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,,,
4193,,12166,CHEMBL619995,,1,BAO_0000219,F,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,,,
4194,,12166,CHEMBL619996,,1,BAO_0000019,B,,H,Autocuration,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,,
4195,,12166,CHEMBL619997,,1,BAO_0000019,B,,H,Autocuration,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,,
4196,,12166,CHEMBL619998,,1,BAO_0000019,B,,H,Expert,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,,
4197,,12166,CHEMBL619999,,1,BAO_0000019,B,,H,Expert,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,,
4198,,12166,CHEMBL620000,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,,
4199,,12166,CHEMBL620001,,1,BAO_0000219,B,,H,Autocuration,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,,,
4200,Rattus norvegicus,12166,CHEMBL620002,,1,BAO_0000357,B,10116.0,D,Expert,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,,
4201,,12166,CHEMBL620003,,1,BAO_0000219,B,,H,Autocuration,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,,,
4202,,12166,CHEMBL620004,,1,BAO_0000219,F,,H,Expert,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,,,
4203,,12166,CHEMBL874063,,1,BAO_0000357,B,,H,Autocuration,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,,,,
4204,,12166,CHEMBL620005,,1,BAO_0000219,B,,H,Autocuration,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,,,
4205,,12166,CHEMBL620006,,1,BAO_0000219,B,,H,Autocuration,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,,,
4206,,12166,CHEMBL620007,,1,BAO_0000219,B,,H,Autocuration,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,,,
4207,,12166,CHEMBL620008,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,,,
4208,Rattus norvegicus,12166,CHEMBL620009,,1,BAO_0000219,B,10116.0,D,Expert,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,,,
4209,,12166,CHEMBL620010,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,,,
4210,,12166,CHEMBL620011,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,,,
4211,,12166,CHEMBL620677,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,,,
4212,,12166,CHEMBL620678,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,,,
4213,,12166,CHEMBL620679,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,,,
4214,,12166,CHEMBL620680,,1,BAO_0000219,B,,H,Autocuration,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,,,
4215,Rattus norvegicus,12166,CHEMBL620838,,1,BAO_0000357,B,10116.0,D,Expert,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,,,,
4216,,12166,CHEMBL620839,,1,BAO_0000357,B,,H,Autocuration,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,,
4217,,12166,CHEMBL620840,,1,BAO_0000357,B,,H,Expert,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,,
4218,,12166,CHEMBL620841,,1,BAO_0000219,B,,H,Expert,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,,,
4219,,12166,CHEMBL620842,,1,BAO_0000219,B,,H,Autocuration,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,,,
4220,,12166,CHEMBL620843,,1,BAO_0000219,B,,H,Autocuration,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,,,
4221,,12166,CHEMBL620844,,1,BAO_0000219,B,,H,Autocuration,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,,,
4222,,12166,CHEMBL620845,,1,BAO_0000219,B,,H,Autocuration,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,,,
4223,,12166,CHEMBL620846,,1,BAO_0000019,B,,H,Autocuration,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,,
4224,,12166,CHEMBL873951,,1,BAO_0000357,B,,H,Autocuration,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,
4225,,12166,CHEMBL620847,,1,BAO_0000357,B,,H,Autocuration,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,
4226,,12166,CHEMBL620848,,1,BAO_0000219,B,,H,Autocuration,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,
4227,,12166,CHEMBL620849,,1,BAO_0000219,B,,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,
4228,,12166,CHEMBL620850,,1,BAO_0000219,B,,H,Autocuration,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,,,
4229,,12166,CHEMBL620851,,1,BAO_0000219,B,,H,Autocuration,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,,,
4230,,12166,CHEMBL620852,,1,BAO_0000219,B,,H,Autocuration,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,,,
4231,,12166,CHEMBL875098,,1,BAO_0000219,B,,H,Autocuration,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
4232,Rattus norvegicus,12166,CHEMBL620853,,1,BAO_0000219,B,10116.0,D,Expert,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,,,
4233,,12166,CHEMBL620854,,1,BAO_0000019,B,,H,Autocuration,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,,
4234,,12166,CHEMBL620855,,1,BAO_0000219,B,,H,Autocuration,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,,,
4235,,12166,CHEMBL839884,,1,BAO_0000219,B,,H,Expert,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,
4236,,12166,CHEMBL620856,,1,BAO_0000219,B,,H,Autocuration,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
4237,,12166,CHEMBL620857,,1,BAO_0000219,B,,H,Autocuration,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,,,
4238,,12166,CHEMBL620858,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,
4239,,12166,CHEMBL620859,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,
4240,,12166,CHEMBL620860,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,
4241,,12166,CHEMBL620861,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,,
4242,,12166,CHEMBL620862,,1,BAO_0000357,B,,H,Expert,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,,
4243,,12166,CHEMBL620863,,1,BAO_0000357,B,,H,Autocuration,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,,
4244,,12166,CHEMBL620864,,1,BAO_0000019,B,,H,Autocuration,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,
4245,,12166,CHEMBL620865,,1,BAO_0000219,B,,H,Autocuration,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,,,
4246,,12166,CHEMBL620866,,1,BAO_0000219,B,,H,Autocuration,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,,,
4247,,12166,CHEMBL620867,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,,,
4248,,12166,CHEMBL620868,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,
4249,,12166,CHEMBL620869,,1,BAO_0000219,F,,H,Autocuration,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,,,
4250,,12166,CHEMBL873952,,1,BAO_0000019,F,,H,Autocuration,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,,
4251,,12166,CHEMBL875099,,1,BAO_0000357,B,,H,Autocuration,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,,,,
4252,,12166,CHEMBL620870,,1,BAO_0000219,F,,H,Autocuration,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,,,
4253,,12166,CHEMBL618261,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,,
4254,,12166,CHEMBL618262,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,,
4255,,12166,CHEMBL619428,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,,
4256,,12166,CHEMBL619429,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,
4257,,12166,CHEMBL619430,,1,BAO_0000019,B,,H,Autocuration,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,
4258,,12166,CHEMBL620017,,1,BAO_0000219,B,,H,Autocuration,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,,,
4259,,12166,CHEMBL620018,,1,BAO_0000219,B,,H,Autocuration,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,,,
4260,,12166,CHEMBL620019,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,,,
4261,,12166,CHEMBL620020,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,,,
4262,,12166,CHEMBL620021,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,,,
4263,,12166,CHEMBL620022,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,,,
4264,,12166,CHEMBL620023,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,,,
4265,,12166,CHEMBL620024,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,,,
4266,,12166,CHEMBL620025,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,,,
4267,,12166,CHEMBL620026,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,,,
4268,,12166,CHEMBL620027,,1,BAO_0000219,F,,H,Autocuration,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,,,
4269,Rattus norvegicus,12166,CHEMBL620028,,1,BAO_0000019,F,10116.0,D,Expert,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,,
4270,,12166,CHEMBL620029,,1,BAO_0000357,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,,
4271,,12166,CHEMBL620030,,1,BAO_0000357,B,,H,Autocuration,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,,
4272,,12166,CHEMBL875415,,1,BAO_0000219,B,,H,Autocuration,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,,,
4273,,12166,CHEMBL618256,,1,BAO_0000219,B,,H,Autocuration,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,,,
4274,,12166,CHEMBL618257,,1,BAO_0000219,B,,H,Autocuration,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,,,
4275,,12166,CHEMBL618258,,1,BAO_0000219,B,,H,Autocuration,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,,,
4276,,12166,CHEMBL618259,,1,BAO_0000219,B,,H,Autocuration,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,,,
4277,,12166,CHEMBL618260,,1,BAO_0000019,B,,H,Autocuration,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,
4278,,12166,CHEMBL618215,,1,BAO_0000219,B,,H,Autocuration,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,,,
4279,,12166,CHEMBL618390,,1,BAO_0000219,B,,H,Autocuration,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,,,
4280,,12166,CHEMBL618391,,1,BAO_0000219,B,,H,Autocuration,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,,,
4281,,12166,CHEMBL618392,,1,BAO_0000219,B,,H,Autocuration,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,,,
4282,,12166,CHEMBL618393,,1,BAO_0000219,B,,H,Autocuration,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,,,
4283,,12166,CHEMBL618394,,1,BAO_0000219,B,,H,Autocuration,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,,
4284,Homo sapiens,12166,CHEMBL618395,,1,BAO_0000219,B,9606.0,H,Expert,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,,
4285,Rattus norvegicus,12166,CHEMBL618396,,1,BAO_0000219,B,10116.0,D,Expert,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,,,
4286,Rattus norvegicus,12166,CHEMBL858253,,1,BAO_0000219,B,10116.0,D,Expert,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,,,
4287,Rattus norvegicus,12166,CHEMBL618397,,1,BAO_0000019,B,10116.0,D,Autocuration,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,
4288,Glycine max,12054,CHEMBL618398,,1,BAO_0000357,B,3847.0,H,Autocuration,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,,
4289,,22226,CHEMBL618399,,1,BAO_0000019,B,,U,Autocuration,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,,
4290,,55,CHEMBL618400,,1,BAO_0000357,B,,H,Expert,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,,
4291,,55,CHEMBL618401,,1,BAO_0000357,B,,H,Autocuration,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,,
4292,,55,CHEMBL618402,,1,BAO_0000357,B,,H,Autocuration,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,,
4293,,55,CHEMBL876400,,1,BAO_0000219,B,,H,Autocuration,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,,,
4294,,55,CHEMBL618403,,1,BAO_0000357,B,,H,Expert,168,Inhibitory activity against 5-lipoxygenase.,,,,
4295,,55,CHEMBL618404,,1,BAO_0000357,B,,H,Autocuration,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,,
4296,,55,CHEMBL618405,,1,BAO_0000357,B,,H,Autocuration,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,,
4297,,55,CHEMBL618406,,1,BAO_0000357,B,,H,Autocuration,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,,
4298,,55,CHEMBL618407,,1,BAO_0000019,F,,H,Expert,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,,
4299,,55,CHEMBL618408,,1,BAO_0000357,B,,H,Autocuration,4501,Tested for the inhibitory activity against 5-lipoxygenase,,,,
4300,,55,CHEMBL618409,,1,BAO_0000357,B,,H,Autocuration,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,,
4301,,55,CHEMBL618410,,1,BAO_0000357,B,,H,Autocuration,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,,
4302,,55,CHEMBL618411,,1,BAO_0000357,B,,H,Autocuration,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,,
4303,,55,CHEMBL618412,,1,BAO_0000357,B,,H,Autocuration,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,,
4304,,12166,CHEMBL618413,,1,BAO_0000219,B,,H,Autocuration,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,,,
4305,,12166,CHEMBL618414,,1,BAO_0000357,B,,H,Autocuration,11089,,,,,
4306,,10102,CHEMBL618415,,1,BAO_0000357,B,,H,Autocuration,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,,
4307,,10102,CHEMBL618416,,1,BAO_0000019,B,,H,Autocuration,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,,
4308,,10102,CHEMBL876401,,1,BAO_0000357,B,,H,Autocuration,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,,
4309,,10102,CHEMBL618417,,1,BAO_0000357,B,,H,Expert,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,,
4310,,10102,CHEMBL618418,,1,BAO_0000357,B,,H,Autocuration,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,,
4311,,10102,CHEMBL618419,,1,BAO_0000357,B,,H,Autocuration,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,,
4312,,10102,CHEMBL618420,,1,BAO_0000357,B,,H,Autocuration,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,,
4313,,10102,CHEMBL618421,,1,BAO_0000357,B,,H,Autocuration,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,,
4314,,11238,CHEMBL618422,,1,BAO_0000019,B,,H,Autocuration,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,,
4315,,11238,CHEMBL618423,,1,BAO_0000019,B,,H,Autocuration,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,,
4316,,11238,CHEMBL618424,,1,BAO_0000019,B,,H,Autocuration,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,,
4317,,100284,CHEMBL618425,,1,BAO_0000220,B,,S,Intermediate,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,,
4318,Homo sapiens,22226,CHEMBL618426,,1,BAO_0000019,F,9606.0,U,Autocuration,4349,The dark toxicity against 543 human galactophore carcinoma cells,,,,
4319,Homo sapiens,80623,CHEMBL618427,,1,BAO_0000219,F,9606.0,N,Expert,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,,,
4320,Homo sapiens,80008,CHEMBL618428,,1,BAO_0000219,F,9606.0,N,Expert,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,,,
4321,Homo sapiens,80008,CHEMBL618429,,1,BAO_0000219,F,9606.0,N,Intermediate,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,,,
4322,Homo sapiens,80008,CHEMBL618430,,1,BAO_0000219,F,9606.0,N,Intermediate,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,,,
4323,Homo sapiens,80008,CHEMBL618431,,1,BAO_0000219,F,9606.0,N,Expert,17589,Growth inhibition against human 5637 cell lines,,,,
4324,Homo sapiens,80008,CHEMBL883799,,1,BAO_0000219,F,9606.0,N,Expert,16748,Antitumor activity against human bladder carcinoma 5637 cells.,,,,
4325,Homo sapiens,80008,CHEMBL618432,,1,BAO_0000219,F,9606.0,N,Intermediate,16747,Antitumor activity against human bladder carcinoma 5637 cells,,,,
4326,Homo sapiens,80008,CHEMBL618433,,1,BAO_0000219,F,9606.0,N,Intermediate,16747,Antitumor activity against human bladder carcinoma 5637 cells,,,,
4327,Bos taurus,10443,CHEMBL618434,,1,BAO_0000357,B,9913.0,D,Expert,15285,In vitro inhibition of bovine trypsin(Trp).,,,,
4328,Cercopithecidae,240,CHEMBL618435,,1,BAO_0000219,B,9527.0,H,Expert,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,,,
4329,,10577,CHEMBL876402,,1,BAO_0000357,B,,H,Autocuration,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,,
4330,,104698,CHEMBL618436,,1,BAO_0000019,F,,H,Autocuration,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,,
4331,,22226,CHEMBL618437,,1,BAO_0000218,F,,U,Autocuration,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,In vivo,,,
4332,Cavia porcellus,20033,CHEMBL618438,,1,BAO_0000357,B,10141.0,D,Intermediate,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,,
4333,Rattus norvegicus,17045,CHEMBL883800,,1,BAO_0000251,A,10116.0,H,Expert,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,,
4334,Rattus norvegicus,17045,CHEMBL618439,,1,BAO_0000251,A,10116.0,H,Expert,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,,
4335,,22226,CHEMBL618440,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,
4336,,22226,CHEMBL618441,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,
4337,Trypanosoma brucei,11938,CHEMBL618442,,1,BAO_0000019,B,5691.0,H,Expert,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,,
4338,Trypanosoma brucei,11938,CHEMBL618443,,1,BAO_0000019,B,5691.0,H,Autocuration,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,,
4339,Ovis aries,11938,CHEMBL619158,,1,BAO_0000019,B,9940.0,H,Expert,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,,
4340,Ovis aries,11938,CHEMBL620974,,1,BAO_0000019,B,9940.0,H,Autocuration,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,,
4341,,11938,CHEMBL620975,,1,BAO_0000357,B,,H,Autocuration,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,,
4342,Homo sapiens,22226,CHEMBL620976,,1,BAO_0000019,F,9606.0,U,Intermediate,4337,Average inhibitory concentration against 60 human cell lines was reported,,,,
4343,Homo sapiens,22226,CHEMBL620977,,1,BAO_0000019,F,9606.0,U,Expert,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,,
4344,Homo sapiens,80315,CHEMBL620978,,1,BAO_0000219,F,9606.0,N,Intermediate,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,,,
4345,Homo sapiens,80315,CHEMBL620979,,1,BAO_0000219,F,9606.0,N,Intermediate,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,,,
4346,,80315,CHEMBL620980,,1,BAO_0000219,F,,N,Expert,17376,In vitro mean growth inhibitory activity against 60-cell panel,,,,
4347,,80315,CHEMBL620981,,1,BAO_0000219,F,,N,Expert,17376,In vitro mean growth lethal concentration against 60-cell panel,,,,
4348,,80315,CHEMBL620982,,1,BAO_0000219,F,,N,Expert,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,,,
4349,,80315,CHEMBL620983,,1,BAO_0000219,F,,N,Expert,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,,,
4350,,104775,CHEMBL620984,,1,BAO_0000019,F,,H,Autocuration,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,
4351,,104775,CHEMBL620985,,1,BAO_0000019,F,,H,Autocuration,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,
4352,,275,CHEMBL620986,,1,BAO_0000357,B,,H,Expert,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,,
4353,Plasmodium falciparum,50425,CHEMBL620987,,1,BAO_0000218,F,5833.0,N,Expert,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,,
4354,Plasmodium falciparum,50425,CHEMBL620988,,1,BAO_0000218,F,5833.0,N,Expert,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,,
4355,Plasmodium falciparum,50425,CHEMBL620989,,1,BAO_0000218,F,5833.0,N,Expert,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,,
4356,Plasmodium falciparum,50425,CHEMBL620990,,1,BAO_0000218,F,5833.0,N,Expert,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,,
4357,Plasmodium falciparum,50425,CHEMBL620991,,1,BAO_0000218,F,5833.0,N,Intermediate,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,,
4358,Mus musculus,80628,CHEMBL620992,,1,BAO_0000218,F,10090.0,N,Intermediate,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,,
4359,Mus musculus,80628,CHEMBL620993,,1,BAO_0000218,F,10090.0,N,Intermediate,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,,
4360,Mus musculus,80628,CHEMBL620994,,1,BAO_0000218,F,10090.0,N,Intermediate,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,,,
4361,Mus musculus,80628,CHEMBL620995,,1,BAO_0000218,F,10090.0,N,Intermediate,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,,
4362,Mus musculus,80628,CHEMBL620996,,1,BAO_0000218,F,10090.0,N,Intermediate,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,,
4363,Mus musculus,80628,CHEMBL875581,,1,BAO_0000218,F,10090.0,N,Intermediate,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,,,
4364,Mus musculus,22224,CHEMBL620997,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,In vivo,,,
4365,Mus musculus,22224,CHEMBL620998,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,In vivo,,,
4366,Mus musculus,22224,CHEMBL620999,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),In vivo,,,
4367,Mus musculus,22224,CHEMBL621000,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,In vivo,,,
4368,Mus musculus,22224,CHEMBL621001,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,In vivo,,,
4369,Mus musculus,22224,CHEMBL621002,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,In vivo,,,
4370,Mus musculus,22224,CHEMBL621003,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,In vivo,,,
4371,Mus musculus,22224,CHEMBL621004,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",In vivo,,,
4372,Mus musculus,22224,CHEMBL621005,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),In vivo,,,
4373,Mus musculus,22224,CHEMBL621006,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),In vivo,,,
4374,Mus musculus,22224,CHEMBL621007,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,In vivo,,,
4375,Mus musculus,22224,CHEMBL621008,,1,BAO_0000218,F,10090.0,U,Autocuration,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,,
4376,Mus musculus,22224,CHEMBL621009,,1,BAO_0000218,F,10090.0,U,Autocuration,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,,
4377,Mus musculus,22224,CHEMBL857705,,1,BAO_0000218,F,10090.0,U,Autocuration,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,,
4378,Mus musculus,22224,CHEMBL619828,,1,BAO_0000218,F,10090.0,U,Autocuration,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,,
4379,Mus musculus,22224,CHEMBL619829,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,,
4380,Mus musculus,22224,CHEMBL619830,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,,
4381,Mus musculus,22224,CHEMBL619831,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,,
4382,Mus musculus,22224,CHEMBL619832,,1,BAO_0000218,F,10090.0,U,Autocuration,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,,
4383,Mus musculus,22224,CHEMBL619833,,1,BAO_0000218,A,10090.0,U,Autocuration,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,,
4384,Mus musculus,22224,CHEMBL619834,,1,BAO_0000218,A,10090.0,U,Autocuration,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,,
4385,Mus musculus,22224,CHEMBL619835,,1,BAO_0000218,A,10090.0,U,Autocuration,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,,
4386,Mus musculus,22224,CHEMBL619836,,1,BAO_0000218,A,10090.0,U,Autocuration,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,,
4387,Mus musculus,80628,CHEMBL619837,,1,BAO_0000218,F,10090.0,N,Intermediate,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,,,
4388,,22224,CHEMBL619838,,1,BAO_0000218,F,,U,Autocuration,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,In vivo,,,
4389,Mus musculus,50594,CHEMBL619839,,1,BAO_0000218,A,10090.0,N,Intermediate,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,,
4390,Mus musculus,80628,CHEMBL619840,,1,BAO_0000218,F,10090.0,N,Intermediate,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,In vivo,,,
4391,Mus musculus,80628,CHEMBL619841,,1,BAO_0000218,F,10090.0,N,Intermediate,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,In vivo,,,
4392,Mus musculus,80628,CHEMBL857704,,1,BAO_0000218,F,10090.0,N,Expert,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,,,
4393,Mus musculus,80628,CHEMBL619842,,1,BAO_0000218,F,10090.0,N,Intermediate,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,,,
4394,Mus musculus,80628,CHEMBL619843,,1,BAO_0000218,F,10090.0,N,Expert,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,,,
4395,Staphylococcus aureus,22226,CHEMBL619844,,1,BAO_0000019,B,1280.0,U,Autocuration,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,,
4396,Rattus norvegicus,22226,CHEMBL857855,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,,Liver
4397,Rattus norvegicus,22226,CHEMBL619845,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,,Liver
4398,Rattus norvegicus,22226,CHEMBL619846,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,,Liver
4399,Rattus norvegicus,22226,CHEMBL619847,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,,Liver
4400,Rattus norvegicus,22226,CHEMBL619848,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,,Liver
4401,Rattus norvegicus,22226,CHEMBL620893,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,,Liver
4402,Rattus norvegicus,22226,CHEMBL620894,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,,Liver
4403,Rattus norvegicus,22226,CHEMBL620895,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,,Liver
4404,Rattus norvegicus,22226,CHEMBL620896,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,,Liver
4405,Rattus norvegicus,22226,CHEMBL620897,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,,Liver
4406,Rattus norvegicus,22226,CHEMBL620898,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,,Liver
4407,Rattus norvegicus,22226,CHEMBL620899,,1,BAO_0000251,B,10116.0,U,Autocuration,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,,Liver
4408,Cercopithecidae,22224,CHEMBL620900,,1,BAO_0000218,A,9527.0,U,Autocuration,347,The apparent total plasma clearance in monkey,In vivo,,,Plasma
4409,Cercopithecidae,22224,CHEMBL620901,,1,BAO_0000218,A,9527.0,U,Autocuration,3341,Compound was evaluated for Hepatic clearance in monkey,In vivo,,,
4410,Cercopithecidae,22224,CHEMBL620902,,1,BAO_0000218,A,9527.0,U,Autocuration,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,In vivo,,,
4411,Cercopithecidae,22224,CHEMBL620903,,1,BAO_0000218,A,9527.0,U,Autocuration,4514,Plasma clearance in rhesus monkey,In vivo,,,
4412,Cercopithecidae,22224,CHEMBL620904,,1,BAO_0000218,A,9527.0,U,Autocuration,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,In vivo,,,
4413,Cercopithecidae,22224,CHEMBL620905,,1,BAO_0000218,A,9527.0,U,Autocuration,6821,Plasma clearance of compound was determined in monkey,In vivo,,,
4414,Cercopithecidae,22224,CHEMBL620906,,1,BAO_0000218,A,9527.0,U,Autocuration,6057,Plasma clearance was calculated in rhesus monkey,In vivo,,,
4415,Cercopithecidae,22224,CHEMBL875420,,1,BAO_0000218,A,9527.0,U,Autocuration,5145,Plasma clearance in rhesus monkey,In vivo,,,
4416,Cercopithecidae,22224,CHEMBL620907,,1,BAO_0000218,A,9527.0,U,Autocuration,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
4417,Cercopithecidae,22224,CHEMBL620908,,1,BAO_0000218,A,9527.0,U,Autocuration,5472,Plasma clearance was evaluated in rhesus,In vivo,,,
4418,Cercopithecidae,22224,CHEMBL620909,,1,BAO_0000218,A,9527.0,U,Autocuration,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,In vivo,,,
4419,Cercopithecidae,22224,CHEMBL620910,,1,BAO_0000218,A,9527.0,U,Autocuration,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,,,
4420,Cercopithecidae,22224,CHEMBL620911,,1,BAO_0000218,A,9527.0,U,Autocuration,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,,
4421,Cercopithecidae,22224,CHEMBL620912,,1,BAO_0000218,A,9527.0,U,Autocuration,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,,
4422,Cercopithecidae,22224,CHEMBL620913,,1,BAO_0000218,A,9527.0,U,Autocuration,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,In vivo,,,
4423,Cercopithecidae,22224,CHEMBL620914,,1,BAO_0000218,A,9527.0,U,Autocuration,6535,Cmax in monkey after administration of 1 mg/kg iv,In vivo,,,
4424,Cercopithecidae,22224,CHEMBL620915,,1,BAO_0000218,A,9527.0,U,Autocuration,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,In vivo,,,
4425,Cercopithecidae,22224,CHEMBL620916,,1,BAO_0000218,A,9527.0,U,Autocuration,5922,Cmax in cynomolgus monkey by iv administration,In vivo,,,
4426,Cercopithecidae,22224,CHEMBL620917,,1,BAO_0000218,A,9527.0,U,Autocuration,5922,Cmax in cynomolgus monkey by po administration,In vivo,,,
4427,Cercopithecidae,22224,CHEMBL620918,,1,BAO_0000218,A,9527.0,U,Autocuration,6078,Cmax value evaluated in monkey,In vivo,,,
4428,Cercopithecidae,22224,CHEMBL620919,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,,
4429,Cercopithecidae,22224,CHEMBL620920,,1,BAO_0000218,A,9527.0,U,Autocuration,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,In vivo,,,Plasma
4430,Cercopithecidae,22224,CHEMBL620921,,1,BAO_0000218,A,9527.0,U,Autocuration,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,In vivo,,,Plasma
4431,Cercopithecidae,22224,CHEMBL620922,,1,BAO_0000218,A,9527.0,U,Autocuration,5553,Maximal plasma concentration in squirrel monkeys,In vivo,,,Plasma
4432,Cercopithecidae,22224,CHEMBL620923,,1,BAO_0000218,A,9527.0,U,Autocuration,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,,
4433,Cercopithecidae,22224,CHEMBL620924,,1,BAO_0000218,A,9527.0,U,Autocuration,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,In vivo,,,Plasma
4434,Cercopithecidae,22224,CHEMBL620925,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,,
4435,Cercopithecidae,22224,CHEMBL620926,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,,,
4436,Cercopithecidae,22224,CHEMBL620927,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,,,
4437,Cercopithecidae,22224,CHEMBL620928,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,In vivo,,,
4438,Cercopithecidae,22224,CHEMBL620929,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,In vivo,,,
4439,Cercopithecidae,22224,CHEMBL620930,,1,BAO_0000218,A,9527.0,U,Autocuration,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,In vivo,,,Plasma
4440,Cercopithecidae,22224,CHEMBL620931,,1,BAO_0000218,A,9527.0,U,Autocuration,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,,
4441,Cercopithecidae,22224,CHEMBL620932,,1,BAO_0000218,A,9527.0,U,Autocuration,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,,
4442,monkey,22224,CHEMBL620933,,1,BAO_0000218,A,9443.0,U,Autocuration,4257,Absolute bioavailability was evaluated in monkey,In vivo,,,
4443,monkey,22224,CHEMBL620934,,1,BAO_0000218,A,9443.0,U,Autocuration,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,,
4444,monkey,22224,CHEMBL620935,,1,BAO_0000218,A,9443.0,U,Autocuration,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,In vivo,,,
4445,Macaca mulatta,22224,CHEMBL620936,,1,BAO_0000218,A,9544.0,U,Autocuration,17267,Bioavailability of compound was determined in rhesus monkey,In vivo,,,
4446,marmosets,22224,CHEMBL620937,,1,BAO_0000218,A,38020.0,U,Autocuration,4256,Bioavailability determined after oral administration in marmoset,In vivo,,,
4447,Macaca fascicularis,22224,CHEMBL620938,,1,BAO_0000218,A,9541.0,U,Autocuration,4256,Oral bioavailability in cynomolgus monkey,In vivo,,,
4448,monkey,22224,CHEMBL620939,,1,BAO_0000218,A,9443.0,U,Autocuration,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,In vivo,,,
4449,monkey,22224,CHEMBL620940,,1,BAO_0000218,A,9443.0,U,Autocuration,16365,Bioavailability was evaluated after oral administration in monkey,In vivo,,,
4450,Macaca fascicularis,22224,CHEMBL620941,,1,BAO_0000218,A,9541.0,U,Autocuration,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,,
4451,Macaca mulatta,22224,CHEMBL620942,,1,BAO_0000218,A,9544.0,U,Autocuration,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,,
4452,Macaca mulatta,22224,CHEMBL620943,,1,BAO_0000218,A,9544.0,U,Autocuration,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,,
4453,monkey,22224,CHEMBL620944,,1,BAO_0000218,A,9443.0,U,Autocuration,17592,Bioavailability of the compound was determined in monkey,In vivo,,,
4454,Saimiri sciureus,22224,CHEMBL620945,,1,BAO_0000218,A,9521.0,U,Autocuration,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),In vivo,,,
4455,monkey,22224,CHEMBL620946,,1,BAO_0000218,A,9443.0,U,Autocuration,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,,
4456,monkey,22224,CHEMBL620947,,1,BAO_0000218,A,9443.0,U,Autocuration,3341,Oral bioavailability in monkey,In vivo,,,
4457,Saimiri sciureus,22224,CHEMBL620948,,1,BAO_0000218,A,9521.0,U,Autocuration,64,Compound was tested for bioavailability in squirrel monkey,In vivo,,,
4458,Macaca mulatta,22224,CHEMBL620949,,1,BAO_0000218,A,9544.0,U,Autocuration,5005,Oral bioavailability in Rhesus monkey,In vivo,,,
4459,Macaca mulatta,22224,CHEMBL620950,,1,BAO_0000218,A,9544.0,U,Autocuration,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),In vivo,,,
4460,Macaca fascicularis,22224,CHEMBL620951,,1,BAO_0000218,A,9541.0,U,Autocuration,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,In vivo,,,
4461,Macaca fascicularis,22224,CHEMBL620952,,1,BAO_0000218,A,9541.0,U,Autocuration,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,In vivo,,,
4462,monkey,22224,CHEMBL875421,,1,BAO_0000218,A,9443.0,U,Autocuration,5302,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,,,
4463,monkey,22224,CHEMBL620953,,1,BAO_0000218,A,9443.0,U,Autocuration,17667,Oral bioavailability of compound at 5 mg/kg in monkey,In vivo,,,
4464,Canis lupus familiaris,50588,CHEMBL873491,,1,BAO_0000218,A,9615.0,N,Intermediate,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,,,
4465,Canis lupus familiaris,50588,CHEMBL620954,,1,BAO_0000218,A,9615.0,N,Intermediate,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,,,
4466,Canis lupus familiaris,50588,CHEMBL620955,,1,BAO_0000218,A,9615.0,N,Intermediate,3854,Plasma half life determined,,,,Plasma
4467,Canis lupus familiaris,50588,CHEMBL618097,,1,BAO_0000218,A,9615.0,N,Intermediate,993,Plasma half life in dog,,,,Plasma
4468,Canis lupus familiaris,50588,CHEMBL618268,,1,BAO_0000218,A,9615.0,N,Intermediate,4514,Plasma half-life in Beagle dogs,,,,Plasma
4469,Canis lupus familiaris,50588,CHEMBL618269,,1,BAO_0000218,A,9615.0,N,Intermediate,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,,Plasma
4470,Canis lupus familiaris,50588,CHEMBL618270,,1,BAO_0000218,A,9615.0,N,Intermediate,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),In vivo,,,Plasma
4471,Canis lupus familiaris,50588,CHEMBL618271,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,,
4472,Canis lupus familiaris,50588,CHEMBL873493,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,,
4473,Canis lupus familiaris,50588,CHEMBL621031,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,Tested for the half life period in dog,,,,
4474,Canis lupus familiaris,50588,CHEMBL621032,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,Tested for the half life period in dog at dosage of 10 mpk,In vivo,,,
4475,Canis lupus familiaris,50588,CHEMBL621033,,1,BAO_0000218,A,9615.0,N,Intermediate,3880,The compound was tested for half life in dog,,,,
4476,Canis lupus familiaris,50588,CHEMBL621034,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,,Plasma
4477,Canis lupus familiaris,50588,CHEMBL621035,,1,BAO_0000218,A,9615.0,N,Intermediate,3880,The half life was determined,,,,
4478,Canis lupus familiaris,50588,CHEMBL621036,,1,BAO_0000218,A,9615.0,N,Intermediate,3918,The plasma half-life in dogs,,,,Plasma
4479,Canis lupus familiaris,50588,CHEMBL621037,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,,Plasma
4480,Canis lupus familiaris,50588,CHEMBL619812,,1,BAO_0000218,A,9615.0,N,Intermediate,17796,Half life in dog,,,,
4481,Canis lupus familiaris,50588,CHEMBL619813,,1,BAO_0000218,A,9615.0,N,Intermediate,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,,,
4482,Canis lupus familiaris,50588,CHEMBL873335,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,,
4483,Canis lupus familiaris,50588,CHEMBL619814,,1,BAO_0000218,A,9615.0,N,Intermediate,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,,
4484,Mustela putorius furo,50506,CHEMBL619815,,1,BAO_0000218,A,9669.0,N,Expert,6113,Cmax in ferrets after 30 mg/kg oral dose,In vivo,,,
4485,Mustela putorius furo,50506,CHEMBL619816,,1,BAO_0000218,F,9669.0,N,Expert,6113,Emesis in ferrets at 30 mg/kg oral dose,In vivo,,,
4486,Macaca fascicularis,22224,CHEMBL619817,,1,BAO_0000218,A,9541.0,U,Autocuration,17796,Bioavailability in cynomolgus monkey,In vivo,,,
4487,Macaca fascicularis,100710,CHEMBL619818,,1,BAO_0000218,A,9541.0,N,Intermediate,17796,Volume of distribution in cynomolgus,In vivo,,,
4488,Cavia porcellus,22224,CHEMBL619819,,1,BAO_0000218,A,10141.0,U,Autocuration,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,,Plasma
4489,Cavia porcellus,22224,CHEMBL619820,,1,BAO_0000218,A,10141.0,U,Autocuration,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,,
4490,Cavia porcellus,22224,CHEMBL875419,,1,BAO_0000218,A,10141.0,U,Autocuration,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,,
4491,Cavia porcellus,22224,CHEMBL619821,,1,BAO_0000218,A,10141.0,U,Autocuration,4878,AUC in guinea pig after 3mg/kg oral dose,In vivo,,,Plasma
4492,Cavia porcellus,22224,CHEMBL619822,,1,BAO_0000218,A,10141.0,U,Autocuration,5308,Bioavailability in guinea pig was tested,In vivo,,,
4493,Cavia porcellus,22224,CHEMBL619823,,1,BAO_0000218,A,10141.0,U,Autocuration,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,In vivo,,,
4494,Cavia porcellus,22224,CHEMBL619824,,1,BAO_0000218,A,10141.0,U,Autocuration,4876,Tested for the oral bioavailability of the compound,In vivo,,,
4495,Cavia porcellus,22224,CHEMBL619825,,1,BAO_0000218,A,10141.0,U,Autocuration,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,In vivo,,,
4496,Cavia porcellus,22224,CHEMBL619826,,1,BAO_0000218,A,10141.0,U,Autocuration,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,In vivo,,,
4497,Cavia porcellus,22224,CHEMBL619827,,1,BAO_0000218,A,10141.0,U,Autocuration,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,In vivo,,,Lung
4498,Cavia porcellus,22224,CHEMBL618167,,1,BAO_0000218,A,10141.0,U,Autocuration,4878,Cmax in guinea pig after 3mg/kg oral dose,In vivo,,,
4499,Cavia porcellus,22224,CHEMBL618168,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,,Blood
4500,Cavia porcellus,22224,CHEMBL618169,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,,Brain
4501,Cavia porcellus,22224,CHEMBL618170,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,,
4502,Cavia porcellus,22224,CHEMBL618171,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,,Intestine
4503,Cavia porcellus,22224,CHEMBL618172,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,,Kidney
4504,Cavia porcellus,22224,CHEMBL618173,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,,Liver
4505,Cavia porcellus,22224,CHEMBL618174,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,,
4506,Cavia porcellus,22224,CHEMBL875408,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,,Spleen
4507,Cavia porcellus,22224,CHEMBL839827,,1,BAO_0000218,A,10141.0,U,Autocuration,14465,Elimination T1/2 in Guinea pig (PO dose),In vivo,,,
4508,Cavia porcellus,22224,CHEMBL618175,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Partition coefficient was measured as -log (counts per min ),,,,
4509,Cavia porcellus,22224,CHEMBL618176,,1,BAO_0000218,A,10141.0,U,Autocuration,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,,,
4510,Cavia porcellus,22224,CHEMBL618177,,1,BAO_0000218,A,10141.0,U,Autocuration,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,In vivo,,,
4511,Cavia porcellus,22224,CHEMBL618178,,1,BAO_0000218,A,10141.0,U,Autocuration,14465,Elimination T1/2 in Guinea pig (PO dose),In vivo,,,
4512,Cavia porcellus,22224,CHEMBL618179,,1,BAO_0000218,A,10141.0,U,Autocuration,4876,"Tested for the half life period of the compound, intravenously",In vivo,,,
4513,Cavia porcellus,22224,CHEMBL873489,,1,BAO_0000019,A,10141.0,U,Autocuration,5689,Half-life was measured,,,,
4514,Cavia porcellus,22224,CHEMBL618180,,1,BAO_0000019,A,10141.0,U,Autocuration,7515,The time required for onset of inotropy after addition of a single dose of delta F75,,,,
4515,Cavia porcellus,22224,CHEMBL618181,,1,BAO_0000218,A,10141.0,U,Autocuration,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,In vivo,,,
4516,Cavia porcellus,22224,CHEMBL618182,,1,BAO_0000218,A,10141.0,U,Autocuration,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,In vivo,,,
4517,Cricetulus griseus,22224,CHEMBL618183,,1,BAO_0000218,A,10029.0,U,Autocuration,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,,,
4518,Mus musculus,50594,CHEMBL618184,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,
4519,Mus musculus,50594,CHEMBL618185,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,
4520,Mus musculus,50594,CHEMBL618186,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,
4521,Mus musculus,50594,CHEMBL618187,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,
4522,Mus musculus,50594,CHEMBL618188,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,In vivo,,,
4523,Mus musculus,50594,CHEMBL875409,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,
4524,Mus musculus,50594,CHEMBL618189,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,
4525,Mus musculus,50594,CHEMBL618190,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,In vivo,,,Blood
4526,Mus musculus,50594,CHEMBL618191,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,In vivo,,,Blood
4527,Mus musculus,50594,CHEMBL618192,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,In vivo,,,Blood
4528,Mus musculus,50594,CHEMBL618193,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,In vivo,,,Bone
4529,Mus musculus,50594,CHEMBL618194,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,In vivo,,,Bone
4530,Mus musculus,50594,CHEMBL618195,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,In vivo,,,Bone
4531,Mus musculus,50594,CHEMBL618196,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,In vivo,,,Brain
4532,Mus musculus,50594,CHEMBL618197,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,In vivo,,,Brain
4533,Mus musculus,50594,CHEMBL618198,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,In vivo,,,Brain
4534,Mus musculus,50594,CHEMBL618199,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,In vivo,,,Heart
4535,Mus musculus,50594,CHEMBL618200,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,In vivo,,,Heart
4536,Mus musculus,50594,CHEMBL618201,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,In vivo,,,Heart
4537,Mus musculus,50594,CHEMBL618202,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,In vivo,,,Intestine
4538,Mus musculus,50594,CHEMBL618203,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,In vivo,,,Intestine
4539,Mus musculus,50594,CHEMBL618204,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,In vivo,,,Intestine
4540,Mus musculus,50594,CHEMBL618205,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,In vivo,,,Kidney
4541,Mus musculus,50594,CHEMBL618206,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,In vivo,,,Kidney
4542,Mus musculus,50594,CHEMBL618207,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,In vivo,,,Kidney
4543,Mus musculus,50594,CHEMBL618208,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,In vivo,,,Liver
4544,Mus musculus,50594,CHEMBL618932,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,In vivo,,,Liver
4545,Mus musculus,50594,CHEMBL618933,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,In vivo,,,Liver
4546,Mus musculus,50594,CHEMBL618934,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,In vivo,,,Lung
4547,Mus musculus,50594,CHEMBL618935,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,In vivo,,,Lung
4548,Mus musculus,50594,CHEMBL618936,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,In vivo,,,Lung
4549,Mus musculus,50594,CHEMBL618937,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,In vivo,,,Muscle tissue
4550,Mus musculus,50594,CHEMBL618938,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,In vivo,,,Muscle tissue
4551,Mus musculus,50594,CHEMBL619104,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,In vivo,,,Muscle tissue
4552,Mus musculus,50594,CHEMBL619105,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,In vivo,,,Spleen
4553,Mus musculus,50594,CHEMBL619106,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,In vivo,,,Spleen
4554,Mus musculus,50594,CHEMBL619107,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,In vivo,,,Spleen
4555,Mus musculus,50594,CHEMBL875410,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,In vivo,,,Stomach
4556,Mus musculus,50594,CHEMBL619108,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,In vivo,,,Stomach
4557,Mus musculus,50594,CHEMBL619109,,1,BAO_0000218,A,10090.0,N,Intermediate,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,In vivo,,,Stomach
4558,Mus musculus,50594,CHEMBL619110,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,,,
4559,Mus musculus,50594,CHEMBL619111,,1,BAO_0000218,F,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,In vivo,,,
4560,Mus musculus,50594,CHEMBL619112,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,,
4561,Mus musculus,50594,CHEMBL619113,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,,
4562,Mus musculus,50594,CHEMBL619114,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,In vivo,,,
4563,Mus musculus,50594,CHEMBL619115,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,In vivo,,,
4564,Homo sapiens,81034,CHEMBL619116,,1,BAO_0000219,F,9606.0,N,Intermediate,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,,,
4565,Homo sapiens,81034,CHEMBL619117,,1,BAO_0000219,F,9606.0,N,Intermediate,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,,,
4566,Homo sapiens,81034,CHEMBL619118,,1,BAO_0000219,F,9606.0,N,Intermediate,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,,,,
4567,Homo sapiens,81034,CHEMBL619119,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,,,
4568,Homo sapiens,81034,CHEMBL619120,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,,
4569,Homo sapiens,81034,CHEMBL619121,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,,
4570,Homo sapiens,81034,CHEMBL619122,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,,
4571,Homo sapiens,81034,CHEMBL619123,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,,
4572,Homo sapiens,81034,CHEMBL619124,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,,
4573,Homo sapiens,81034,CHEMBL619125,,1,BAO_0000219,F,9606.0,N,Intermediate,2859,Compound was evaluated for cytotoxicity against A2780 cell line,,,,
4574,Homo sapiens,81034,CHEMBL875411,,1,BAO_0000219,F,9606.0,N,Intermediate,5618,In vitro inhibitory activity against human tumor cell line A2780,,,,
4575,Homo sapiens,81034,CHEMBL619126,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,,,
4576,Homo sapiens,81034,CHEMBL619127,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,,,
4577,Homo sapiens,81034,CHEMBL619128,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,,,
4578,Homo sapiens,81034,CHEMBL619129,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,,,
4579,Homo sapiens,81034,CHEMBL619130,,1,BAO_0000219,F,9606.0,N,Intermediate,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,,,
4580,Homo sapiens,81034,CHEMBL619131,,1,BAO_0000219,F,9606.0,N,Intermediate,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,,,
4581,Homo sapiens,81034,CHEMBL619132,,1,BAO_0000219,F,9606.0,N,Intermediate,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,,,
4582,Homo sapiens,81034,CHEMBL619133,,1,BAO_0000218,F,9606.0,N,Expert,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,,
4583,Homo sapiens,81034,CHEMBL619134,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,,,
4584,Homo sapiens,81034,CHEMBL619135,,1,BAO_0000219,F,9606.0,N,Intermediate,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,,,
4585,Homo sapiens,81034,CHEMBL619136,,1,BAO_0000219,F,9606.0,N,Intermediate,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,,,
4586,Homo sapiens,81034,CHEMBL619137,,1,BAO_0000219,F,9606.0,N,Intermediate,2040,Relative resistance factor in A2780 cisplatin-resistant line,,,,
4587,Homo sapiens,81034,CHEMBL883713,,1,BAO_0000219,F,9606.0,N,Intermediate,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,,,
4588,Homo sapiens,81034,CHEMBL875412,,1,BAO_0000219,F,9606.0,N,Intermediate,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,,,
4589,Homo sapiens,81034,CHEMBL619138,,1,BAO_0000218,F,9606.0,N,Expert,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,,
4590,Homo sapiens,81034,CHEMBL619262,,1,BAO_0000218,F,9606.0,N,Expert,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,,,
4591,Homo sapiens,81034,CHEMBL619139,,1,BAO_0000219,F,9606.0,N,Intermediate,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,,,
4592,Homo sapiens,81034,CHEMBL619140,,1,BAO_0000219,F,9606.0,N,Intermediate,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,,,
4593,Homo sapiens,81034,CHEMBL619141,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,,,
4594,Homo sapiens,81034,CHEMBL619142,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,,,
4595,Homo sapiens,81034,CHEMBL619143,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,,,
4596,Homo sapiens,81034,CHEMBL619144,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,,,
4597,Homo sapiens,81034,CHEMBL619145,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,,,
4598,Homo sapiens,81034,CHEMBL619146,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,,,
4599,Homo sapiens,81034,CHEMBL619147,,1,BAO_0000219,F,9606.0,N,Intermediate,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,,,
4600,Homo sapiens,81034,CHEMBL619148,,1,BAO_0000219,F,9606.0,N,Intermediate,17420,Antiproliferative effect of compound on A2780/DX cell line,,,,
4601,Homo sapiens,81034,CHEMBL619149,,1,BAO_0000219,F,9606.0,N,Intermediate,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,,,
4602,Homo sapiens,81034,CHEMBL619150,,1,BAO_0000219,F,9606.0,N,Intermediate,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,,,
4603,Homo sapiens,81034,CHEMBL619151,,1,BAO_0000219,F,9606.0,N,Intermediate,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,,,
4604,Homo sapiens,81034,CHEMBL883794,,1,BAO_0000219,F,9606.0,N,Intermediate,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,,,
4605,Homo sapiens,81034,CHEMBL619152,,1,BAO_0000219,F,9606.0,N,Intermediate,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,,,
4606,Homo sapiens,81034,CHEMBL619153,,1,BAO_0000219,F,9606.0,N,Intermediate,17270,In vitro cytotoxicity against A2780ADR cell line,,,,
4607,Homo sapiens,81034,CHEMBL619154,,1,BAO_0000219,F,9606.0,N,Intermediate,17270,In vitro cytotoxicity against A2780CIS cell line,,,,
4608,Homo sapiens,81034,CHEMBL619155,,1,BAO_0000219,F,9606.0,N,Intermediate,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,,,
4609,Homo sapiens,81034,CHEMBL619156,,1,BAO_0000219,F,9606.0,N,Intermediate,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,,,
4610,Homo sapiens,81034,CHEMBL619157,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,,,
4611,Homo sapiens,81034,CHEMBL619797,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,,,
4612,Macaca mulatta,22224,CHEMBL619798,,1,BAO_0000218,A,9544.0,U,Autocuration,17839,Oral bioavailability of compound in rhesus macaques,In vivo,,,
4613,monkey,22224,CHEMBL619799,,1,BAO_0000218,A,9443.0,U,Autocuration,6821,Oral bioavailability in monkey,In vivo,,,
4614,monkey,22224,CHEMBL619800,,1,BAO_0000218,A,9443.0,U,Autocuration,6078,Oral bioavailability evaluated in monkey,In vivo,,,
4615,monkey,22224,CHEMBL619801,,1,BAO_0000218,A,9443.0,U,Autocuration,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),In vivo,,,
4616,Macaca mulatta,22224,CHEMBL619802,,1,BAO_0000218,A,9544.0,U,Autocuration,4449,Oral bioavailability in Rhesus monkey,In vivo,,,
4617,Macaca mulatta,22224,CHEMBL619803,,1,BAO_0000218,A,9544.0,U,Autocuration,6057,Oral bioavailability was calculated in rhesus monkey,In vivo,,,
4618,Macaca fascicularis,22224,CHEMBL619965,,1,BAO_0000218,A,9541.0,U,Autocuration,5922,Oral bioavailability in cynomolgus monkey,In vivo,,,
4619,monkey,22224,CHEMBL619966,,1,BAO_0000218,A,9443.0,U,Autocuration,5940,Oral bioavailability in monkey,In vivo,,,
4620,monkey,22224,CHEMBL619967,,1,BAO_0000218,A,9443.0,U,Autocuration,6265,Oral bioavailability in monkey,In vivo,,,
4621,monkey,22224,CHEMBL620073,,1,BAO_0000218,A,9443.0,U,Autocuration,6265,Oral bioavailability in monkey (dose 1 mg/kg),In vivo,,,
4622,monkey,22224,CHEMBL620074,,1,BAO_0000218,A,9443.0,U,Autocuration,6265,Oral bioavailability in monkey (dose 5 mg/kg),In vivo,,,
4623,monkey,22224,CHEMBL620075,,1,BAO_0000218,A,9443.0,U,Autocuration,5940,Oral bioavailability in monkey,In vivo,,,
4624,monkey,22224,CHEMBL620076,,1,BAO_0000218,A,9443.0,U,Autocuration,5940,Oral bioavailability in monkey,In vivo,,,
4625,Macaca mulatta,22224,CHEMBL620077,,1,BAO_0000218,A,9544.0,U,Autocuration,4514,Oral bioavailability in rhesus monkey,In vivo,,,
4626,Macaca mulatta,22224,CHEMBL620078,,1,BAO_0000218,A,9544.0,U,Autocuration,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,In vivo,,,
4627,Saimiri sciureus,22224,CHEMBL620079,,1,BAO_0000218,A,9521.0,U,Autocuration,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,In vivo,,,
4628,monkey,22224,CHEMBL620080,,1,BAO_0000218,A,9443.0,U,Autocuration,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
4629,Macaca mulatta,22224,CHEMBL620081,,1,BAO_0000218,A,9544.0,U,Autocuration,5472,Oral bioavailability in Rhesus monkey,In vivo,,,
4630,Macaca mulatta,22224,CHEMBL620082,,1,BAO_0000218,A,9544.0,U,Autocuration,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),In vivo,,,
4631,monkey,22224,CHEMBL620083,,1,BAO_0000218,A,9443.0,U,Autocuration,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,In vivo,,,
4632,Macaca mulatta,22224,CHEMBL620084,,1,BAO_0000218,A,9544.0,U,Autocuration,5145,Bioavailability in Rhesus monkey,In vivo,,,
4633,Cercopithecidae,22224,CHEMBL620085,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,
4634,Cercopithecidae,22224,CHEMBL874595,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,
4635,Cercopithecidae,22224,CHEMBL873352,,1,BAO_0000218,A,9527.0,U,Autocuration,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,In vivo,,,
4636,Cercopithecidae,22224,CHEMBL620086,,1,BAO_0000218,A,9527.0,U,Autocuration,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,In vivo,,,
4637,Cercopithecidae,22224,CHEMBL620087,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,In vivo,,,
4638,Cercopithecidae,22224,CHEMBL620088,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,,
4639,Cercopithecidae,22224,CHEMBL620089,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,,
4640,Cercopithecidae,22224,CHEMBL620090,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,,
4641,Cercopithecidae,22224,CHEMBL620091,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,,
4642,Cercopithecidae,22224,CHEMBL620092,,1,BAO_0000251,A,9527.0,U,Autocuration,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,,
4643,Cercopithecidae,22224,CHEMBL620093,,1,BAO_0000251,A,9527.0,U,Autocuration,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,,
4644,Cercopithecidae,22224,CHEMBL620094,,1,BAO_0000251,A,9527.0,U,Autocuration,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,,
4645,Cercopithecidae,22224,CHEMBL620095,,1,BAO_0000251,A,9527.0,U,Autocuration,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,,
4646,Cercopithecidae,22224,CHEMBL620096,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,,
4647,Cercopithecidae,22224,CHEMBL620097,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,,
4648,Cercopithecidae,22224,CHEMBL620098,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,,
4649,Cercopithecidae,22224,CHEMBL620099,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,
4650,Cercopithecidae,22224,CHEMBL620100,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,
4651,Cercopithecidae,22224,CHEMBL620101,,1,BAO_0000019,A,9527.0,U,Autocuration,6821,Elimination Half-life of compound was determined in monkey,,,,
4652,Cercopithecidae,22224,CHEMBL620102,,1,BAO_0000019,A,9527.0,U,Autocuration,17267,Half life of compound was determined in rhesus monkey,,,,
4653,Cercopithecidae,22224,CHEMBL620103,,1,BAO_0000366,A,9527.0,U,Autocuration,5819,Half life in monkey plasma,,,,Plasma
4654,Cercopithecidae,22224,CHEMBL620104,,1,BAO_0000366,A,9527.0,U,Autocuration,5819,Half life in monkey plasma; Not detected,,,,Plasma
4655,Cercopithecidae,22224,CHEMBL874596,,1,BAO_0000218,A,9527.0,U,Autocuration,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,,
4656,Cercopithecidae,22224,CHEMBL873490,,1,BAO_0000218,A,9527.0,U,Autocuration,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,In vivo,,,
4657,Cercopithecidae,22224,CHEMBL620105,,1,BAO_0000019,A,9527.0,U,Autocuration,1399,Terminal half life of the compound.,,,,
4658,Cercopithecidae,22224,CHEMBL620780,,1,BAO_0000218,A,9527.0,U,Autocuration,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,In vivo,,,
4659,Cercopithecidae,22224,CHEMBL620781,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),In vivo,,,
4660,Cercopithecidae,22224,CHEMBL620956,,1,BAO_0000218,A,9527.0,U,Autocuration,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,,
4661,Cercopithecidae,22224,CHEMBL620957,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Urine
4662,Cercopithecidae,22224,CHEMBL620958,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Urine
4663,Cercopithecidae,22224,CHEMBL620959,,1,BAO_0000218,A,9527.0,U,Autocuration,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,In vivo,,,
4664,Cercopithecidae,22224,CHEMBL620960,,1,BAO_0000218,A,9527.0,U,Autocuration,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,,
4665,Cercopithecidae,22224,CHEMBL620961,,1,BAO_0000218,A,9527.0,U,Autocuration,5472,Volume of distribution was evaluated in rhesus,In vivo,,,
4666,Cricetulus griseus,22224,CHEMBL620962,,1,BAO_0000218,A,10029.0,U,Autocuration,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,In vivo,,,
4667,Cricetulus griseus,22224,CHEMBL620963,,1,BAO_0000218,A,10029.0,U,Autocuration,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,In vivo,,,
4668,Cricetulus griseus,22224,CHEMBL620964,,1,BAO_0000218,A,10029.0,U,Autocuration,4727,Bioavailability in hamster was determined,In vivo,,,
4669,Cricetulus griseus,22224,CHEMBL620965,,1,BAO_0000218,A,10029.0,U,Autocuration,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,In vivo,,,
4670,Cricetulus griseus,22224,CHEMBL620966,,1,BAO_0000218,A,10029.0,U,Autocuration,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,In vivo,,,
4671,Cricetulus griseus,22224,CHEMBL620967,,1,BAO_0000221,A,10029.0,U,Autocuration,4727,Half life of compound was determined in hamster blood,,,,Blood
4672,Sus scrofa,22224,CHEMBL620968,,1,BAO_0000019,A,9823.0,U,Autocuration,1452,Michaelis-Menten constant of the compound.,,,,
4673,Sus scrofa,22224,CHEMBL874597,,1,BAO_0000019,A,9823.0,U,Autocuration,1452,Vmax value was measured at 0 uM concentration of silyl ether.,,,,
4674,Sus scrofa,22224,CHEMBL620969,,1,BAO_0000019,A,9823.0,U,Autocuration,1452,Vmax value was measured at 10 uM concentration of silyl ether.,,,,
4675,Sus scrofa,22224,CHEMBL620970,,1,BAO_0000019,A,9823.0,U,Autocuration,1452,Vmax value was measured at 5 uM concentration of silyl ether.,,,,
4676,Homo sapiens,235,CHEMBL620971,,1,BAO_0000357,B,9606.0,D,Expert,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,,
4677,Homo sapiens,22224,CHEMBL620972,,1,BAO_0000218,A,9606.0,U,Autocuration,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,,
4678,Homo sapiens,22224,CHEMBL620973,,1,BAO_0000019,A,9606.0,U,Autocuration,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,,
4679,Homo sapiens,22224,CHEMBL618243,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Active metabolite of ifosfamide determined in humans; A-Active,,,,
4680,Homo sapiens,22224,CHEMBL618244,,1,BAO_0000019,A,9606.0,U,Autocuration,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,,
4681,Homo sapiens,22224,CHEMBL618245,,1,BAO_0000019,A,9606.0,U,Autocuration,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,,
4682,Homo sapiens,22224,CHEMBL618246,,1,BAO_0000019,A,9606.0,U,Autocuration,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,,
4683,Homo sapiens,22224,CHEMBL618247,,1,BAO_0000019,A,9606.0,U,Autocuration,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,,
4684,Homo sapiens,22224,CHEMBL618248,,1,BAO_0000218,A,9606.0,U,Autocuration,17791,Compound was evaluated for oral bioavailability in human,,,,
4685,Homo sapiens,22224,CHEMBL618249,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Metabolite of ifosfamide determined in urine; NF-Not found,,,,Urine
4686,Homo sapiens,22224,CHEMBL618250,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,,
4687,Homo sapiens,22224,CHEMBL874598,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,,
4688,Homo sapiens,22224,CHEMBL618251,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,,
4689,Homo sapiens,22224,CHEMBL618252,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,,
4690,Homo sapiens,22224,CHEMBL618253,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,,
4691,Homo sapiens,22224,CHEMBL618254,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,,
4692,Homo sapiens,22224,CHEMBL618255,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent of compound in healthy individuals (Group D),,,,
4693,Homo sapiens,22224,CHEMBL618983,,1,BAO_0000251,A,9606.0,U,Autocuration,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,,Liver
4694,Homo sapiens,22224,CHEMBL618984,,1,BAO_0000019,A,9606.0,U,Autocuration,17409,Binding towards human plasma protein at 10 uM,,,,
4695,Homo sapiens,22224,CHEMBL618985,,1,BAO_0000019,A,9606.0,U,Autocuration,17409,Binding towards human plasma protein at 100 uM,,,,
4696,Homo sapiens,22224,CHEMBL618986,,1,BAO_0000019,A,9606.0,U,Autocuration,17176,Human plasma protein binding activity was determined,,,,
4697,Homo sapiens,22224,CHEMBL618987,,1,BAO_0000019,A,9606.0,U,Autocuration,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,,
4698,Homo sapiens,22224,CHEMBL618988,,1,BAO_0000019,A,9606.0,U,Autocuration,17267,Percent binding of compound towards human plasma protein was determined,,,,
4699,Homo sapiens,22224,CHEMBL618989,,1,BAO_0000251,A,9606.0,U,Autocuration,5944,Plasma clearance in human liver microsomes,In vitro,,,Liver
4700,Homo sapiens,22224,CHEMBL618990,,1,BAO_0000251,A,9606.0,U,Autocuration,5668,In vitro intrinsic clearance in human liver microsome,In vitro,,,Liver
4701,Homo sapiens,22224,CHEMBL618991,,1,BAO_0000251,A,9606.0,U,Autocuration,5669,In vitro intrinsic clearance in human liver microsome,In vitro,,,Liver
4702,Homo sapiens,22224,CHEMBL876725,,1,BAO_0000251,A,9606.0,U,Autocuration,5041,In vitro microsome metabolism clearance in human was determined,In vitro,,,
4703,Homo sapiens,22224,CHEMBL618992,,1,BAO_0000251,A,9606.0,U,Autocuration,5041,In vitro microsome metabolism clearance in human was determined; High,In vitro,,,
4704,Homo sapiens,22224,CHEMBL618993,,1,BAO_0000251,A,9606.0,U,Autocuration,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,In vitro,,,
4705,Homo sapiens,22224,CHEMBL618994,,1,BAO_0000251,A,9606.0,U,Autocuration,5676,Pharmacokinetic property (clearance) in human liver microsome,In vitro,,,Liver
4706,Homo sapiens,22224,CHEMBL618995,,1,BAO_0000251,A,9606.0,U,Autocuration,5944,Plasma clearance in human liver microsomes,In vitro,,,Liver
4707,Homo sapiens,22224,CHEMBL618996,,1,BAO_0000251,A,9606.0,U,Autocuration,17538,In vitro clearance in human liver microsomes,In vitro,,,Liver
4708,Homo sapiens,22224,CHEMBL618997,,1,BAO_0000251,A,9606.0,U,Autocuration,6331,Intrinsic clearance in human liver microsomes was determined,In vitro,,,Liver
4709,Homo sapiens,22224,CHEMBL618998,,1,BAO_0000251,A,9606.0,U,Autocuration,5948,Intrinsic clearance in human liver microsomes was determined,In vitro,,,Liver
4710,Homo sapiens,22224,CHEMBL618999,,1,BAO_0000218,A,9606.0,U,Autocuration,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,In vivo,,,
4711,Homo sapiens,22224,CHEMBL620223,,1,BAO_0000218,A,9606.0,U,Autocuration,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,,
4712,Homo sapiens,22224,CHEMBL620224,,1,BAO_0000218,A,9606.0,U,Autocuration,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,,
4713,Homo sapiens,22224,CHEMBL620225,,1,BAO_0000019,A,9606.0,U,Autocuration,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,,
4714,Homo sapiens,22224,CHEMBL620226,,1,BAO_0000019,A,9606.0,U,Autocuration,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,,
4715,Homo sapiens,22224,CHEMBL620227,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4716,Homo sapiens,22224,CHEMBL876726,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4717,Homo sapiens,22224,CHEMBL620228,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4718,Homo sapiens,22224,CHEMBL620229,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4719,Mus musculus,50594,CHEMBL620230,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,In vivo,,,
4720,Mus musculus,50594,CHEMBL620231,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,In vivo,,,
4721,Mus musculus,50594,CHEMBL620232,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,In vivo,,,
4722,Mus musculus,50594,CHEMBL620233,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,In vivo,,,
4723,Mus musculus,50594,CHEMBL620234,,1,BAO_0000218,A,10090.0,N,Intermediate,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,,
4724,Mus musculus,50594,CHEMBL620235,,1,BAO_0000218,A,10090.0,N,Intermediate,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,,
4725,Mus musculus,50594,CHEMBL620236,,1,BAO_0000218,A,10090.0,N,Intermediate,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,,
4726,Mus musculus,50594,CHEMBL620237,,1,BAO_0000218,A,10090.0,N,Intermediate,6251,In vitro metabolic potential in mouse liver microsomes,,,,Liver
4727,Mus musculus,50594,CHEMBL620238,,1,BAO_0000218,A,10090.0,N,Intermediate,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,,
4728,Mus musculus,50594,CHEMBL620239,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,,Adrenal gland
4729,Mus musculus,50594,CHEMBL620240,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,,Brain
4730,Mus musculus,50594,CHEMBL620241,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,,Brain
4731,Mus musculus,50594,CHEMBL876727,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,,
4732,Mus musculus,50594,CHEMBL620242,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,,Kidney
4733,Mus musculus,50594,CHEMBL620243,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,,
4734,Mus musculus,50594,CHEMBL620244,,1,BAO_0000218,A,10090.0,N,Intermediate,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,,
4735,Mus musculus,50594,CHEMBL620245,,1,BAO_0000218,A,10090.0,N,Intermediate,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,,Serum
4736,Mus musculus,50594,CHEMBL620246,,1,BAO_0000218,A,10090.0,N,Intermediate,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,,Serum
4737,Mus musculus,50594,CHEMBL620247,,1,BAO_0000218,A,10090.0,N,Intermediate,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,,Serum
4738,Mus musculus,50594,CHEMBL620248,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,In vivo,,,Plasma
4739,Mus musculus,50594,CHEMBL873497,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,In vivo,,,Plasma
4740,Mus musculus,50594,CHEMBL620249,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,In vivo,,,Plasma
4741,Mus musculus,50594,CHEMBL620250,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,In vivo,,,
4742,Mus musculus,50594,CHEMBL620251,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,In vivo,,,
4743,Mus musculus,50594,CHEMBL620252,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,In vivo,,,
4744,Mus musculus,50594,CHEMBL620253,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,In vivo,,,
4745,Mus musculus,50594,CHEMBL620254,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Half life after intravenous administration in mice at 23 uM/kg,In vivo,,,
4746,Mus musculus,50594,CHEMBL620255,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Half life after intravenous administration in mice at 24 uM/kg,In vivo,,,
4747,Mus musculus,50594,CHEMBL620256,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,,,
4748,Mus musculus,50594,CHEMBL876728,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,In vivo,,,
4749,Mus musculus,50594,CHEMBL620257,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,In vivo,,,
4750,Mus musculus,50594,CHEMBL620258,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),In vivo,,,
4751,Mus musculus,50594,CHEMBL620259,,1,BAO_0000218,A,10090.0,N,Intermediate,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",In vivo,,,
4752,Mus musculus,50594,CHEMBL620260,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,In vivo,,,
4753,Mus musculus,50594,CHEMBL620261,,1,BAO_0000218,A,10090.0,N,Intermediate,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,,,Blood
4754,Mus musculus,50594,CHEMBL620262,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,,
4755,Mus musculus,50594,CHEMBL620263,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,In vivo,,,
4756,Mus musculus,50594,CHEMBL620264,,1,BAO_0000218,A,10090.0,N,Intermediate,6619,Half life in ob/ob mice,,,,
4757,Mus musculus,50594,CHEMBL620265,,1,BAO_0000218,A,10090.0,N,Intermediate,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,,
4758,Mus musculus,50594,CHEMBL620266,,1,BAO_0000218,A,10090.0,N,Intermediate,4239,Half-life was measured in mouse,,,,
4759,Mus musculus,50594,CHEMBL620267,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,In vivo,,,
4760,Mus musculus,50594,CHEMBL619364,,1,BAO_0000218,A,10090.0,N,Intermediate,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,,
4761,Mus musculus,50594,CHEMBL619365,,1,BAO_0000218,A,10090.0,N,Intermediate,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,,
4762,Mus musculus,50594,CHEMBL619366,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,T2 in brain of mice at the oral dose of 50 mg/kg,,,,Brain
4763,Mus musculus,50594,CHEMBL619367,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,,,,Kidney
4764,Mus musculus,50594,CHEMBL619368,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,T2 in liver of mice at the oral dose of 50 mg/kg,,,,Liver
4765,Mus musculus,50594,CHEMBL619369,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,,,,Lung
4766,Mus musculus,50594,CHEMBL876729,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,,,,Spleen
4767,Mus musculus,50594,CHEMBL619370,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,In vivo,,,
4768,Mus musculus,50594,CHEMBL619371,,1,BAO_0000218,A,10090.0,N,Intermediate,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",In vivo,,,
4769,Mus musculus,50594,CHEMBL619372,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,In vivo,,,
4770,Mus musculus,50594,CHEMBL620012,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,In vivo,,,
4771,Mus musculus,50594,CHEMBL620013,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,In vivo,,,
4772,Homo sapiens,81034,CHEMBL620014,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,,
4773,Homo sapiens,81034,CHEMBL620015,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,,,
4774,Homo sapiens,81034,CHEMBL621010,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,,
4775,Homo sapiens,81034,CHEMBL621011,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,,
4776,Homo sapiens,81034,CHEMBL621012,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,,
4777,Homo sapiens,81034,CHEMBL621013,,1,BAO_0000219,F,9606.0,N,Intermediate,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,,,
4778,Homo sapiens,81034,CHEMBL621014,,1,BAO_0000219,F,9606.0,N,Intermediate,17270,In vitro cytotoxicity against A2780TAX cell line,,,,
4779,Homo sapiens,80017,CHEMBL618154,,1,BAO_0000219,F,9606.0,N,Intermediate,5618,In vitro inhibitory activity against human tumor cell line A2780cis,,,,
4780,Homo sapiens,81034,CHEMBL618155,,1,BAO_0000219,F,9606.0,N,Expert,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,,,
4781,Homo sapiens,80017,CHEMBL618156,,1,BAO_0000219,F,9606.0,N,Intermediate,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,,,
4782,Homo sapiens,80017,CHEMBL618157,,1,BAO_0000219,F,9606.0,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,,
4783,Homo sapiens,81034,CHEMBL618328,,1,BAO_0000219,F,9606.0,N,Intermediate,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,,,
4784,Homo sapiens,81034,CHEMBL618329,,1,BAO_0000219,F,9606.0,N,Intermediate,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,,,
4785,Homo sapiens,81034,CHEMBL618330,,1,BAO_0000219,F,9606.0,N,Intermediate,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,,,
4786,Homo sapiens,81034,CHEMBL618331,,1,BAO_0000219,F,9606.0,N,Expert,12989,In vitro antitumor activity against A2780cisR cell line.,,,,
4787,Homo sapiens,81034,CHEMBL618332,,1,BAO_0000219,F,9606.0,N,Intermediate,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,,,
4788,Homo sapiens,81034,CHEMBL618333,,1,BAO_0000219,F,9606.0,N,Expert,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,,,
4789,Homo sapiens,80017,CHEMBL618334,,1,BAO_0000219,F,9606.0,N,Intermediate,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,,,
4790,Homo sapiens,81034,CHEMBL618335,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,,,
4791,Rattus norvegicus,11736,CHEMBL618336,,1,BAO_0000019,B,10116.0,D,Expert,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,,
4792,,11736,CHEMBL618337,,1,BAO_0000019,F,,H,Expert,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,
4793,Rattus norvegicus,11736,CHEMBL618338,,1,BAO_0000019,F,10116.0,D,Expert,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,
4794,Homo sapiens,278,CHEMBL618339,,1,BAO_0000219,F,9606.0,D,Expert,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,,,
4795,Homo sapiens,278,CHEMBL618340,,1,BAO_0000219,F,9606.0,D,Expert,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,,,
4796,Mus musculus,11831,CHEMBL618341,,1,BAO_0000019,B,10090.0,D,Expert,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,,
4797,,11831,CHEMBL618342,,1,BAO_0000019,F,,H,Expert,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,
4798,Mus musculus,11831,CHEMBL618343,,1,BAO_0000019,F,10090.0,D,Expert,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,
4799,,280,CHEMBL621038,,1,BAO_0000357,B,,H,Expert,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,,
4800,Homo sapiens,22226,CHEMBL621039,,1,BAO_0000219,F,9606.0,U,Autocuration,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,,,
4801,Homo sapiens,22226,CHEMBL621040,,1,BAO_0000219,F,9606.0,U,Autocuration,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,,,
4802,Homo sapiens,80018,CHEMBL621041,,1,BAO_0000219,F,9606.0,N,Intermediate,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,,,
4803,Homo sapiens,80018,CHEMBL621042,,1,BAO_0000219,F,9606.0,N,Intermediate,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,,,
4804,Homo sapiens,80018,CHEMBL621043,,1,BAO_0000219,F,9606.0,N,Intermediate,2683,In vitro antitumor activity against A375cell line extracted form melanoma,,,,
4805,Homo sapiens,80018,CHEMBL621044,,1,BAO_0000219,F,9606.0,N,Expert,15313,Inhibition of cell growth in (A375) melan cell line,,,,
4806,Homo sapiens,80018,CHEMBL621045,,1,BAO_0000219,F,9606.0,N,Intermediate,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,,,
4807,Homo sapiens,80018,CHEMBL621046,,1,BAO_0000219,F,9606.0,N,Intermediate,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,,,
4808,Homo sapiens,80018,CHEMBL621047,,1,BAO_0000219,F,9606.0,N,Intermediate,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,,,
4809,Homo sapiens,80019,CHEMBL621048,,1,BAO_0000219,F,9606.0,N,Intermediate,14777,Antiproliferative activity measured against A427 human lung carcinoma,,,,
4810,Homo sapiens,80019,CHEMBL883798,,1,BAO_0000219,F,9606.0,N,Intermediate,14777,Antiproliferative activity measured against A427 human lung carcinoma,,,,
4811,Homo sapiens,80019,CHEMBL621049,,1,BAO_0000219,F,9606.0,N,Intermediate,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,,,,
4812,Homo sapiens,80019,CHEMBL621050,,1,BAO_0000219,F,9606.0,N,Intermediate,14368,Inhibition of large cell lung carcinoma (A427),,,,
4813,Homo sapiens,80019,CHEMBL621051,,1,BAO_0000219,F,9606.0,N,Intermediate,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,,,
4814,Homo sapiens,80019,CHEMBL621052,,1,BAO_0000219,F,9606.0,N,Intermediate,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,,
4815,Homo sapiens,80019,CHEMBL621053,,1,BAO_0000219,F,9606.0,N,Intermediate,2545,Inhibitory concentration in human lung carcinoma A427 cell line,,,,
4816,Homo sapiens,80019,CHEMBL621054,,1,BAO_0000219,F,9606.0,N,Intermediate,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,,,
4817,Cercopithecidae,22224,CHEMBL621055,,1,BAO_0000218,A,9527.0,U,Autocuration,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,,,
4818,Cercopithecidae,22224,CHEMBL876398,,1,BAO_0000218,A,9527.0,U,Autocuration,4578,Tested for volume of distribution upon iv administration to african green monkey,In vivo,,,
4819,Cercopithecidae,22224,CHEMBL621056,,1,BAO_0000218,A,9527.0,U,Autocuration,17592,Volume of distribution in monkey,In vivo,,,
4820,Macaca mulatta,22224,CHEMBL621057,,1,BAO_0000218,A,9544.0,U,Autocuration,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,,
4821,Macaca mulatta,22224,CHEMBL621058,,1,BAO_0000218,A,9544.0,U,Autocuration,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,In vivo,,,
4822,Cercopithecidae,22224,CHEMBL621059,,1,BAO_0000218,A,9527.0,U,Autocuration,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,In vivo,,,
4823,Cercopithecidae,22224,CHEMBL621060,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The distribution volume after intravenous administration in cynomolgus monkeys,In vivo,,,
4824,Cercopithecidae,22224,CHEMBL621061,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,,
4825,Cercopithecidae,22224,CHEMBL621062,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,,
4826,Cercopithecidae,22224,CHEMBL621063,,1,BAO_0000218,A,9527.0,U,Autocuration,6057,Volume displacement was calculated in rhesus monkey,In vivo,,,
4827,Cercopithecidae,22224,CHEMBL621064,,1,BAO_0000218,A,9527.0,U,Autocuration,5145,Volume of distribution in steady state was determined in rhesus monkey,In vivo,,,
4828,Cercopithecidae,22224,CHEMBL621065,,1,BAO_0000218,A,9527.0,U,Autocuration,6821,Volume of distribution of compound was determined in monkey,In vivo,,,
4829,Cercopithecidae,22224,CHEMBL621066,,1,BAO_0000218,A,9527.0,U,Autocuration,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,,
4830,Cercopithecidae,22224,CHEMBL621067,,1,BAO_0000218,A,9527.0,U,Autocuration,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,,
4831,Cercopithecidae,22224,CHEMBL621068,,1,BAO_0000218,A,9527.0,U,Autocuration,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
4832,Cercopithecidae,22224,CHEMBL876399,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,,
4833,Cercopithecidae,22224,CHEMBL621069,,1,BAO_0000218,A,9527.0,U,Autocuration,6535,Volume distribution in monkey after administration of 1 mg/kg iv,In vivo,,,
4834,Cercopithecidae,22224,CHEMBL621070,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,,
4835,Cercopithecidae,22224,CHEMBL621071,,1,BAO_0000218,A,9527.0,U,Autocuration,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,In vivo,,,
4836,Cercopithecidae,22224,CHEMBL621072,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,,
4837,Cercopithecidae,22224,CHEMBL618209,,1,BAO_0000218,A,9527.0,U,Autocuration,4578,Oral systemic bioavailability upon iv administration to african green monkey,In vivo,,,
4838,Cercopithecidae,22224,CHEMBL618210,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,,
4839,Cercopithecidae,22224,CHEMBL618211,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Baboon plasma free fraction. ,,,,
4840,Cercopithecidae,22224,CHEMBL618212,,1,BAO_0000218,A,9527.0,U,Autocuration,6057,Area under the curve was calculated in rhesus monkey after iv administration,,,,
4841,Cercopithecidae,22224,CHEMBL618213,,1,BAO_0000019,A,9527.0,U,Autocuration,6057,Area under the curve was calculated in rhesus monkey after peroral administration,,,,
4842,Cercopithecidae,22224,CHEMBL618214,,1,BAO_0000019,A,9527.0,U,Autocuration,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,,
4843,Cercopithecidae,22224,CHEMBL873492,,1,BAO_0000218,A,9527.0,U,Autocuration,5302,Half life period in monkey after 5 mg/kg dose,In vivo,,,
4844,Cercopithecidae,22224,CHEMBL618272,,1,BAO_0000218,A,9527.0,U,Autocuration,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,In vivo,,,
4845,Cercopithecidae,22224,CHEMBL618273,,1,BAO_0000218,A,9527.0,U,Autocuration,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,In vivo,,,
4846,Cercopithecidae,22224,CHEMBL618274,,1,BAO_0000218,A,9527.0,U,Autocuration,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,,,Plasma
4847,Cercopithecidae,22224,CHEMBL618275,,1,BAO_0000218,A,9527.0,U,Autocuration,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,In vivo,,,
4848,Cercopithecidae,22224,CHEMBL618276,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,,
4849,Cercopithecidae,22224,CHEMBL618277,,1,BAO_0000019,A,9527.0,U,Autocuration,3341,Compound was evaluated for terminal half life in monkey,,,,
4850,Cercopithecidae,22224,CHEMBL618278,,1,BAO_0000218,A,9527.0,U,Autocuration,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,In vivo,,,
4851,Macaca mulatta,22224,CHEMBL618279,,1,BAO_0000218,A,9544.0,U,Autocuration,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,,Plasma
4852,Cercopithecidae,22224,CHEMBL618280,,1,BAO_0000019,A,9527.0,U,Autocuration,4847,Half life of compound was determined in squirrel monkey,,,,
4853,Macaca fascicularis,22224,CHEMBL618281,,1,BAO_0000218,A,9541.0,U,Autocuration,4256,Half life after iv administration in cynomolgus monkey,In vivo,,,
4854,Cercopithecidae,22224,CHEMBL618282,,1,BAO_0000218,A,9527.0,U,Autocuration,6535,Half life in monkey plasma after administration of 1 mg/kg iv,In vivo,,,Plasma
4855,Cercopithecidae,22224,CHEMBL618283,,1,BAO_0000019,A,9527.0,U,Autocuration,6057,Half life was calculated in rhesus monkey,,,,
4856,Cercopithecidae,22224,CHEMBL618284,,1,BAO_0000019,A,9527.0,U,Autocuration,17592,Half life in monkey,,,,
4857,Cercopithecidae,22224,CHEMBL618285,,1,BAO_0000218,A,9527.0,U,Autocuration,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
4858,Cercopithecidae,22224,CHEMBL618286,,1,BAO_0000019,A,9527.0,U,Autocuration,5472,Half life was evaluated in rhesus,,,,
4859,Cercopithecidae,22224,CHEMBL618287,,1,BAO_0000218,A,9527.0,U,Autocuration,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,,
4860,Cercopithecidae,22224,CHEMBL618288,,1,BAO_0000218,A,9527.0,U,Autocuration,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,In vivo,,,
4861,Cercopithecidae,22224,CHEMBL876393,,1,BAO_0000218,A,9527.0,U,Autocuration,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),In vivo,,,
4862,Cercopithecidae,22224,CHEMBL618289,,1,BAO_0000218,A,9527.0,U,Autocuration,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,In vivo,,,
4863,Cercopithecidae,22224,CHEMBL618290,,1,BAO_0000218,A,9527.0,U,Autocuration,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,In vivo,,,
4864,Cercopithecidae,22224,CHEMBL618291,,1,BAO_0000019,A,9527.0,U,Autocuration,6078,Half-life was calculated in monkey,,,,
4865,Cercopithecidae,22224,CHEMBL618292,,1,BAO_0000019,A,9527.0,U,Autocuration,5147,Half-life in Squirrel monkey,,,,
4866,Cercopithecidae,22224,CHEMBL618293,,1,BAO_0000019,A,9527.0,U,Autocuration,5145,Half-life in rhesus monkey,,,,
4867,Cercopithecidae,22224,CHEMBL618294,,1,BAO_0000218,A,9527.0,U,Autocuration,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,In vivo,,,
4868,Cercopithecidae,22224,CHEMBL618295,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Half-life period after intravenous administration in cynomolgus monkeys,In vivo,,,
4869,Cercopithecidae,22224,CHEMBL618296,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Half-life period after oral administration in cynomolgus monkeys,In vivo,,,
4870,Cercopithecidae,22224,CHEMBL618297,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,In vivo,,,
4871,Homo sapiens,22224,CHEMBL618298,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4872,Homo sapiens,22224,CHEMBL618299,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4873,Homo sapiens,22224,CHEMBL618300,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4874,Homo sapiens,22224,CHEMBL618301,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,,Urine
4875,Homo sapiens,22224,CHEMBL618302,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,,Urine
4876,Homo sapiens,22224,CHEMBL876394,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,,Urine
4877,Homo sapiens,22224,CHEMBL618303,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,,Urine
4878,Homo sapiens,22224,CHEMBL618304,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,,Urine
4879,Homo sapiens,22224,CHEMBL618305,,1,BAO_0000218,A,9606.0,U,Autocuration,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,In vivo,,,
4880,Homo sapiens,22224,CHEMBL618306,,1,BAO_0000218,A,9606.0,U,Autocuration,16643,Oral bioavailability in human,In vivo,,,
4881,Homo sapiens,22224,CHEMBL618307,,1,BAO_0000019,A,9606.0,U,Autocuration,17248,Compound was tested for human plasma protein binding,,,,
4882,Homo sapiens,22224,CHEMBL618308,,1,BAO_0000019,A,9606.0,U,Autocuration,17248,Compound was tested for human plasma protein binding; Not determined,,,,
4883,Homo sapiens,22224,CHEMBL618309,,1,BAO_0000019,A,9606.0,U,Autocuration,6241,Protein binding activity of compound in human plasma; % Free,,,,
4884,Homo sapiens,22224,CHEMBL618310,,1,BAO_0000019,A,9606.0,U,Autocuration,17716,Unbound fraction (plasma),,,,
4885,Homo sapiens,22224,CHEMBL873353,,1,BAO_0000366,A,9606.0,U,Autocuration,17605,Half life for the hydrolysis of compound in human blood serum,,,,Plasma
4886,Homo sapiens,22224,CHEMBL618311,,1,BAO_0000366,A,9606.0,U,Autocuration,17625,Half life period in human plasma using phosphate buffer (0.08 M),,,,Plasma
4887,Homo sapiens,22224,CHEMBL618312,,1,BAO_0000366,A,9606.0,U,Autocuration,17625,Half life period in human plasma using phosphate buffer (0.1 M),,,,Plasma
4888,Homo sapiens,22224,CHEMBL618313,,1,BAO_0000366,A,9606.0,U,Autocuration,17747,Half-life in human plasma was determined,,,,Plasma
4889,Homo sapiens,22224,CHEMBL618314,,1,BAO_0000019,A,9606.0,U,Autocuration,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,,
4890,Homo sapiens,22224,CHEMBL618315,,1,BAO_0000019,A,9606.0,U,Autocuration,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,,
4891,Homo sapiens,22224,CHEMBL618316,,1,BAO_0000019,A,9606.0,U,Autocuration,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,,
4892,Homo sapiens,22224,CHEMBL618317,,1,BAO_0000019,A,9606.0,U,Autocuration,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,,
4893,Homo sapiens,22224,CHEMBL620138,,1,BAO_0000019,A,9606.0,U,Autocuration,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,,
4894,Homo sapiens,22224,CHEMBL858280,,1,BAO_0000019,A,9606.0,U,Autocuration,17599,Partition coefficient (logP),,,,
4895,Homo sapiens,22224,CHEMBL620139,,1,BAO_0000019,A,9606.0,U,Autocuration,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,,
4896,Homo sapiens,22224,CHEMBL620140,,1,BAO_0000251,A,9606.0,U,Autocuration,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,,
4897,Homo sapiens,22224,CHEMBL620141,,1,BAO_0000019,A,9606.0,U,Autocuration,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,,
4898,Homo sapiens,22224,CHEMBL620142,,1,BAO_0000019,A,9606.0,U,Autocuration,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,,
4899,Homo sapiens,22224,CHEMBL620143,,1,BAO_0000019,A,9606.0,U,Autocuration,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,,
4900,Homo sapiens,22224,CHEMBL620144,,1,BAO_0000251,A,9606.0,U,Autocuration,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,,
4901,Homo sapiens,22224,CHEMBL620145,,1,BAO_0000251,A,9606.0,U,Autocuration,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,,
4902,Homo sapiens,22224,CHEMBL620146,,1,BAO_0000251,A,9606.0,U,Autocuration,14294,Metabolism of compound in human microsomes; Trace,,,,
4903,Homo sapiens,22224,CHEMBL620147,,1,BAO_0000251,A,9606.0,U,Autocuration,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,,Liver
4904,Homo sapiens,22224,CHEMBL620148,,1,BAO_0000251,A,9606.0,U,Autocuration,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,,
4905,Homo sapiens,22224,CHEMBL620149,,1,BAO_0000251,A,9606.0,U,Autocuration,6251,In vitro metabolic potential in human liver microsomes,,,,Liver
4906,Homo sapiens,22224,CHEMBL876412,,1,BAO_0000019,A,9606.0,U,Autocuration,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,,
4907,Homo sapiens,22224,CHEMBL619352,,1,BAO_0000019,A,9606.0,U,Autocuration,17313,Tested for human plasma protein binding of the compound; Not tested,,,,
4908,Homo sapiens,22224,CHEMBL619353,,1,BAO_0000019,A,9606.0,U,Autocuration,6227,Compound was tested for percent protein binding (PB) in human,,,,
4909,Homo sapiens,22224,CHEMBL619354,,1,BAO_0000019,A,9606.0,U,Autocuration,5530,Protein binding in human plasma,,,,Plasma
4910,Homo sapiens,22224,CHEMBL619355,,1,BAO_0000019,A,9606.0,U,Autocuration,6108,Permeability coefficient (B to A) in Caco-2 cell,,,,
4911,Homo sapiens,22224,CHEMBL619356,,1,BAO_0000019,A,9606.0,U,Autocuration,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,,
4912,Homo sapiens,22224,CHEMBL619357,,1,BAO_0000019,A,9606.0,U,Autocuration,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,,
4913,Homo sapiens,22224,CHEMBL619358,,1,BAO_0000019,A,9606.0,U,Autocuration,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,,,,
4914,Homo sapiens,22224,CHEMBL619359,,1,BAO_0000219,A,9606.0,U,Autocuration,17582,Cellular permeability of compound was determined in Caco-2 cells; High,,,,
4915,Homo sapiens,22224,CHEMBL619360,,1,BAO_0000219,A,9606.0,U,Autocuration,6838,Permeability in Caco-2 cells of compound,,,,
4916,Homo sapiens,22224,CHEMBL619361,,1,BAO_0000019,A,9606.0,U,Autocuration,6108,Permeability coefficient (A to B) in Caco-2 cell,,,,
4917,Homo sapiens,22224,CHEMBL619362,,1,BAO_0000019,A,9606.0,U,Autocuration,6108,Permeability coefficient (B to A) in Caco-2 cell,,,,
4918,Homo sapiens,22224,CHEMBL619363,,1,BAO_0000019,A,9606.0,U,Autocuration,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,,
4919,Homo sapiens,22224,CHEMBL618942,,1,BAO_0000019,A,9606.0,U,Autocuration,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,,
4920,Homo sapiens,22224,CHEMBL618943,,1,BAO_0000019,A,9606.0,U,Autocuration,4514,Compound was tested for protein binding in human plasma,,,,
4921,Homo sapiens,22224,CHEMBL618944,,1,BAO_0000019,A,9606.0,U,Autocuration,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,,
4922,Homo sapiens,22224,CHEMBL618945,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,,Urine
4923,Mus musculus,50594,CHEMBL618946,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,In vivo,,,
4924,Mus musculus,50594,CHEMBL876413,,1,BAO_0000218,A,10090.0,N,Intermediate,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,,
4925,Mus musculus,50594,CHEMBL618947,,1,BAO_0000218,A,10090.0,N,Intermediate,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,,,
4926,Mus musculus,50594,CHEMBL618948,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,In vivo,,,Plasma
4927,Mus musculus,50594,CHEMBL618949,,1,BAO_0000218,A,10090.0,N,Intermediate,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,,Plasma
4928,Mus musculus,50594,CHEMBL618950,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,In vivo,,,
4929,Mus musculus,50594,CHEMBL618951,,1,BAO_0000218,A,10090.0,N,Intermediate,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,In vivo,,,
4930,Mus musculus,50594,CHEMBL618952,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Tmax after peroral administration in mice at 2.4 uM/kg,In vivo,,,
4931,Mus musculus,50594,CHEMBL618953,,1,BAO_0000218,A,10090.0,N,Intermediate,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,,
4932,Mus musculus,50594,CHEMBL618954,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,In vivo,,,Brain
4933,Mus musculus,50594,CHEMBL618955,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,,,Kidney
4934,Mus musculus,50594,CHEMBL618956,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,In vivo,,,Liver
4935,Mus musculus,50594,CHEMBL618957,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,,,Lung
4936,Mus musculus,50594,CHEMBL618958,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Tmax in mice at 18 uM/kg i.p. administration,In vivo,,,
4937,Mus musculus,50594,CHEMBL618959,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Tmax in mice at 23 uM/kg i.v. administration,In vivo,,,
4938,Mus musculus,50594,CHEMBL618960,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Tmax in mice at 25 uM/kg i.p. administration,In vivo,,,
4939,Mus musculus,50594,CHEMBL876723,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Tmax in mice at 26 uM/kg i.p. administration,In vivo,,,
4940,Mus musculus,50594,CHEMBL618961,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,,,Spleen
4941,Mus musculus,50594,CHEMBL618962,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,,
4942,Mus musculus,50594,CHEMBL618963,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,,
4943,Mus musculus,50594,CHEMBL618964,,1,BAO_0000218,A,10090.0,N,Intermediate,5951,Tmax value in IRC mice,,,,
4944,Mus musculus,50594,CHEMBL618965,,1,BAO_0000218,A,10090.0,N,Intermediate,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,,,
4945,Mus musculus,50594,CHEMBL618966,,1,BAO_0000218,A,10090.0,N,Intermediate,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,,,
4946,Mus musculus,50594,CHEMBL618967,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,,Urine
4947,Mus musculus,50594,CHEMBL618968,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,,Urine
4948,Mus musculus,50594,CHEMBL618969,,1,BAO_0000218,A,10090.0,N,Intermediate,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,,Urine
4949,Mus musculus,50594,CHEMBL618970,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,,
4950,Mus musculus,50594,CHEMBL618971,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,,
4951,Mus musculus,50594,CHEMBL618972,,1,BAO_0000218,A,10090.0,N,Intermediate,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,,,
4952,Mus musculus,50594,CHEMBL618973,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,In vivo,,,
4953,Mus musculus,50594,CHEMBL618974,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,In vivo,,,
4954,Mus musculus,50594,CHEMBL618975,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,,,
4955,Mus musculus,50594,CHEMBL618976,,1,BAO_0000218,A,10090.0,N,Intermediate,5980,Vd in mice,In vivo,,,
4956,Mus musculus,50594,CHEMBL618977,,1,BAO_0000218,A,10090.0,N,Intermediate,17592,Volume of distribution in mouse,In vivo,,,
4957,Mus musculus,50594,CHEMBL876724,,1,BAO_0000218,A,10090.0,N,Intermediate,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,,
4958,Mus musculus,50594,CHEMBL618978,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,In vivo,,,
4959,Mus musculus,50594,CHEMBL618979,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,In vivo,,,
4960,Mus musculus,50594,CHEMBL618980,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,In vivo,,,
4961,Mus musculus,50594,CHEMBL618981,,1,BAO_0000218,A,10090.0,N,Intermediate,4239,Pharmacokinetic property (vdss) was measured in mouse,In vivo,,,
4962,Mus musculus,50594,CHEMBL618982,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Value distribution upon iv administration in mouse,In vivo,,,
4963,Mus musculus,50594,CHEMBL620150,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,In vivo,,,
4964,Mus musculus,50594,CHEMBL620151,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Volume of distribution was evaluated in mice after intravenous administration,In vivo,,,
4965,Mus musculus,50594,CHEMBL620152,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Volume of distribution was evaluated in mice after oral administration,In vivo,,,
4966,Mus musculus,50594,CHEMBL620153,,1,BAO_0000218,A,10090.0,N,Intermediate,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,In vivo,,,
4967,Mus musculus,50594,CHEMBL876395,,1,BAO_0000218,A,10090.0,N,Intermediate,5727,Steady state volume of distribution was determined in mice,In vivo,,,
4968,Mus musculus,50594,CHEMBL620154,,1,BAO_0000218,A,10090.0,N,Intermediate,17852,Volume distribution (steady state) of compound was determined in mouse,In vivo,,,
4969,Mus musculus,50594,CHEMBL620155,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,In vivo,,,
4970,Mus musculus,50594,CHEMBL620156,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,,
4971,Mus musculus,50594,CHEMBL620157,,1,BAO_0000218,A,10090.0,N,Intermediate,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,In vivo,,,
4972,Mus musculus,50594,CHEMBL620158,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution of compound (oxidized form) in in kidney tissue,In vivo,,,Kidney
4973,Mus musculus,50594,CHEMBL620159,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,,Blood
4974,Mus musculus,50594,CHEMBL620160,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,,Blood
4975,Mus musculus,50594,CHEMBL620161,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Blood
4976,Homo sapiens,80019,CHEMBL620162,,1,BAO_0000219,F,9606.0,N,Intermediate,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,,,
4977,Homo sapiens,80852,CHEMBL620163,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,,,,
4978,Homo sapiens,80852,CHEMBL620833,,1,BAO_0000219,F,9606.0,N,Expert,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,,,
4979,Homo sapiens,80852,CHEMBL876396,,1,BAO_0000219,F,9606.0,N,Expert,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,,,
4980,Homo sapiens,80852,CHEMBL620834,,1,BAO_0000219,F,9606.0,N,Expert,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,,,
4981,Homo sapiens,80852,CHEMBL620835,,1,BAO_0000219,F,9606.0,N,Expert,6700,Inhibition of A431 human carcinoma cell proliferation,,,,
4982,Homo sapiens,80852,CHEMBL620836,,1,BAO_0000219,F,9606.0,N,Expert,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,,,
4983,Homo sapiens,80852,CHEMBL620837,,1,BAO_0000219,F,9606.0,N,Intermediate,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,,,
4984,Homo sapiens,80852,CHEMBL621017,,1,BAO_0000219,F,9606.0,N,Intermediate,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,,,,
4985,Homo sapiens,9,CHEMBL621018,,1,BAO_0000218,F,9606.0,D,Expert,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,,,
4986,Homo sapiens,80852,CHEMBL621019,,1,BAO_0000219,F,9606.0,N,Intermediate,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,,,,
4987,Homo sapiens,80852,CHEMBL621020,,1,BAO_0000219,F,9606.0,N,Intermediate,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,,,
4988,Homo sapiens,80852,CHEMBL621021,,1,BAO_0000219,F,9606.0,N,Intermediate,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,,,
4989,,9,CHEMBL621022,,1,BAO_0000219,F,,H,Expert,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,,,
4990,Homo sapiens,80852,CHEMBL621023,,1,BAO_0000219,F,9606.0,N,Expert,6333,Tested for antiproliferative activity against human A431 cells,,,,
4991,Homo sapiens,9,CHEMBL621024,,1,BAO_0000219,F,9606.0,D,Expert,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,,,
4992,Homo sapiens,80852,CHEMBL621025,,1,BAO_0000219,F,9606.0,N,Expert,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,,,
4993,Homo sapiens,80852,CHEMBL621026,,1,BAO_0000219,F,9606.0,N,Expert,5126,Inhibition of A431 cell proliferation,,,,
4994,Homo sapiens,80852,CHEMBL621027,,1,BAO_0000219,F,9606.0,N,Expert,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,,,,
4995,Homo sapiens,80852,CHEMBL876397,,1,BAO_0000219,F,9606.0,N,Expert,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,,,
4996,Homo sapiens,80852,CHEMBL883797,,1,BAO_0000219,F,9606.0,N,Intermediate,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,,,
4997,Homo sapiens,80852,CHEMBL621028,,1,BAO_0000219,F,9606.0,N,Intermediate,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,,,
4998,Homo sapiens,80852,CHEMBL621029,,1,BAO_0000219,F,9606.0,N,Intermediate,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,,,
4999,Homo sapiens,80852,CHEMBL621030,,1,BAO_0000219,F,9606.0,N,Intermediate,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,,,
5000,,9,CHEMBL621147,,1,BAO_0000219,F,,H,Expert,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,,,
5001,Homo sapiens,80852,CHEMBL621148,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,In vivo antiproliferative activity against A431 cell line,,,,
5002,Homo sapiens,9,CHEMBL621149,,1,BAO_0000219,F,9606.0,D,Expert,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,,,
5003,Homo sapiens,80852,CHEMBL621150,,1,BAO_0000219,F,9606.0,N,Expert,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,,,,
5004,Homo sapiens,9,CHEMBL621151,,1,BAO_0000219,F,9606.0,D,Expert,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,,,
5005,Homo sapiens,80852,CHEMBL621152,,1,BAO_0000219,F,9606.0,N,Intermediate,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,,,
5006,Homo sapiens,80852,CHEMBL621153,,1,BAO_0000219,F,9606.0,N,Intermediate,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,,,
5007,Homo sapiens,80852,CHEMBL884000,,1,BAO_0000219,F,9606.0,N,Intermediate,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,,,
5008,Homo sapiens,9,CHEMBL621154,,1,BAO_0000019,F,9606.0,D,Expert,5296,Inhibition of EGFR overexpressing A431 cell proliferation,,,,
5009,Homo sapiens,80852,CHEMBL621155,,1,BAO_0000219,F,9606.0,N,Expert,12624,Inhibition of A431 cell proliferation,,,,
5010,Homo sapiens,9,CHEMBL621156,,1,BAO_0000219,F,9606.0,D,Expert,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,,,
5011,Homo sapiens,9,CHEMBL621157,,1,BAO_0000219,F,9606.0,D,Expert,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,,,
5012,,9,CHEMBL621158,,1,BAO_0000219,F,,H,Expert,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,,,
5013,Homo sapiens,80852,CHEMBL621159,,1,BAO_0000219,F,9606.0,N,Intermediate,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,,
5014,Homo sapiens,80852,CHEMBL621160,,1,BAO_0000219,F,9606.0,N,Intermediate,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,,,
5015,Homo sapiens,80852,CHEMBL621161,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,,,
5016,Homo sapiens,80852,CHEMBL621162,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,,,
5017,Homo sapiens,80852,CHEMBL621163,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,,
5018,Homo sapiens,80852,CHEMBL621164,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,,,
5019,Homo sapiens,80852,CHEMBL621165,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,,,
5020,Cercopithecidae,22224,CHEMBL619159,,1,BAO_0000019,A,9527.0,U,Autocuration,5922,Half-life period in cynomolgus monkey,,,,
5021,Cercopithecidae,22224,CHEMBL619160,,1,BAO_0000366,A,9527.0,U,Autocuration,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",In vitro,,,Plasma
5022,Cercopithecidae,22224,CHEMBL619161,,1,BAO_0000218,A,9527.0,U,Autocuration,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,In vivo,,,
5023,Cercopithecidae,22224,CHEMBL619162,,1,BAO_0000366,A,9527.0,U,Autocuration,993,Plasma half life in monkey,,,,Plasma
5024,Cercopithecidae,22224,CHEMBL619163,,1,BAO_0000366,A,9527.0,U,Autocuration,4514,Plasma half-life in rhesus monkey,,,,Plasma
5025,Cercopithecidae,22224,CHEMBL619164,,1,BAO_0000218,A,9527.0,U,Autocuration,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),In vivo,,,Plasma
5026,Cercopithecidae,22224,CHEMBL619320,,1,BAO_0000218,A,9527.0,U,Autocuration,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),In vivo,,,Plasma
5027,Cercopithecidae,22224,CHEMBL619321,,1,BAO_0000218,A,9527.0,U,Autocuration,4578,Tested for half life upon iv administration to african green monkey,In vivo,,,
5028,Cercopithecidae,22224,CHEMBL873336,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,,
5029,Cercopithecidae,22224,CHEMBL619322,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,In vivo,,,
5030,Cercopithecidae,22224,CHEMBL619323,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,In vivo,,,
5031,Cercopithecidae,22224,CHEMBL619324,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,In vivo,,,
5032,Cercopithecidae,22224,CHEMBL619325,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,,
5033,Cercopithecidae,22224,CHEMBL876411,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,,
5034,Cercopithecidae,22224,CHEMBL619326,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,,
5035,Cercopithecidae,22224,CHEMBL619327,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,,
5036,Cercopithecidae,22224,CHEMBL619328,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,,
5037,Cercopithecidae,22224,CHEMBL619329,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,,
5038,Cercopithecidae,22224,CHEMBL619330,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,,
5039,Cercopithecidae,22224,CHEMBL619331,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,,
5040,Cercopithecidae,22224,CHEMBL619332,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,,
5041,Cercopithecidae,22224,CHEMBL619333,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,,
5042,Cercopithecidae,22224,CHEMBL619334,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,,
5043,Cercopithecidae,22224,CHEMBL619335,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,,
5044,Cercopithecidae,22224,CHEMBL619336,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,,
5045,Cercopithecidae,22224,CHEMBL619337,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,,
5046,Cercopithecidae,22224,CHEMBL619338,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,,
5047,Cercopithecidae,22224,CHEMBL619339,,1,BAO_0000019,A,9527.0,U,Autocuration,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,,
5048,Rattus norvegicus,50597,CHEMBL619340,,1,BAO_0000218,A,10116.0,N,Intermediate,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),In vivo,,,
5049,Rattus norvegicus,50597,CHEMBL873496,,1,BAO_0000218,A,10116.0,N,Intermediate,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,In vivo,,,Plasma
5050,Rattus norvegicus,50597,CHEMBL619341,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,,,,Plasma
5051,Rattus norvegicus,50597,CHEMBL619342,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,,,,Plasma
5052,Rattus norvegicus,50597,CHEMBL619343,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,,,
5053,Rattus norvegicus,50597,CHEMBL619344,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,In vivo,,,
5054,Rattus norvegicus,50597,CHEMBL619345,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,In vivo,,,
5055,Rattus norvegicus,50597,CHEMBL619346,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,,,,
5056,Rattus norvegicus,50597,CHEMBL619347,,1,BAO_0000218,A,10116.0,N,Intermediate,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,In vivo,,,
5057,Papio hamadryas,22224,CHEMBL619348,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,,
5058,Papio hamadryas,22224,CHEMBL619349,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,,
5059,Papio hamadryas,22224,CHEMBL619350,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,,
5060,Papio hamadryas,22224,CHEMBL619351,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,,
5061,Papio hamadryas,22224,CHEMBL875953,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,,
5062,Papio hamadryas,22224,CHEMBL621716,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,,
5063,Papio hamadryas,22224,CHEMBL621717,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,,
5064,Papio hamadryas,22224,CHEMBL621718,,1,BAO_0000019,A,9557.0,U,Autocuration,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,,
5065,beagle,22224,CHEMBL621719,,1,BAO_0000019,A,9615.0,U,Autocuration,3510,Area under curve after 1 mpk peroral administration to beagles,,,,
5066,beagle,22224,CHEMBL621720,,1,BAO_0000019,A,9615.0,U,Autocuration,3510,Area under curve after 2 mpk peroral administration to beagles,,,,
5067,beagle,22224,CHEMBL621721,,1,BAO_0000218,A,9615.0,U,Autocuration,3510,Cmax value after 1 mpk peroral administration to beagles,In vivo,,,
5068,Homo sapiens,22224,CHEMBL621722,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,,Urine
5069,Homo sapiens,22224,CHEMBL621723,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,,Urine
5070,Homo sapiens,22224,CHEMBL621724,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,,Urine
5071,Homo sapiens,22224,CHEMBL623443,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,,Urine
5072,Homo sapiens,22224,CHEMBL623444,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,,Urine
5073,Homo sapiens,22224,CHEMBL623445,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,,Urine
5074,Homo sapiens,22224,CHEMBL623446,,1,BAO_0000019,A,9606.0,U,Autocuration,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,,Urine
5075,Homo sapiens,22224,CHEMBL623447,,1,BAO_0000251,A,9606.0,U,Autocuration,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,,,,Liver
5076,Homo sapiens,22224,CHEMBL623448,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,,
5077,Homo sapiens,22224,CHEMBL623449,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,,
5078,Homo sapiens,22224,CHEMBL623450,,1,BAO_0000019,A,9606.0,U,Autocuration,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,,
5079,Homo sapiens,22224,CHEMBL623451,,1,BAO_0000251,A,9606.0,U,Autocuration,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,,Liver
5080,Homo sapiens,22224,CHEMBL623452,,1,BAO_0000019,A,9606.0,U,Autocuration,6570,Metabolic stability (% remaining at 30 mins) in human S9.,,,,
5081,Homo sapiens,22224,CHEMBL623453,,1,BAO_0000019,A,9606.0,U,Autocuration,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,,
5082,Homo sapiens,22224,CHEMBL623454,,1,BAO_0000251,A,9606.0,U,Autocuration,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,,Liver
5083,Homo sapiens,22224,CHEMBL623455,,1,BAO_0000251,A,9606.0,U,Autocuration,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,,Liver
5084,Homo sapiens,22224,CHEMBL624371,,1,BAO_0000251,A,9606.0,U,Autocuration,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,,Liver
5085,Homo sapiens,22224,CHEMBL624372,,1,BAO_0000218,A,9606.0,U,Autocuration,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,,
5086,Homo sapiens,22224,CHEMBL624373,,1,BAO_0000019,A,9606.0,U,Autocuration,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,,
5087,Homo sapiens,22224,CHEMBL624374,,1,BAO_0000019,A,9606.0,U,Autocuration,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,,
5088,Homo sapiens,22224,CHEMBL624556,,1,BAO_0000019,A,9606.0,U,Autocuration,3956,The percent remaining in human plasma after 30 min was determined,,,,
5089,Homo sapiens,22224,CHEMBL624557,,1,BAO_0000366,A,9606.0,U,Autocuration,5074,Conversion rate of the prodrug in human plasma,,,,Plasma
5090,Homo sapiens,22224,CHEMBL624558,,1,BAO_0000366,A,9606.0,U,Autocuration,5074,Conversion rate of the prodrug in human plasma; ND means no data,,,,Plasma
5091,Homo sapiens,22224,CHEMBL624559,,1,BAO_0000221,A,9606.0,U,Autocuration,4727,Half life of compound was determined in human blood,,,,Blood
5092,Homo sapiens,22224,CHEMBL624560,,1,BAO_0000019,A,9606.0,U,Autocuration,5965,Half life of compound was determined in man with once daily dosing,,,,
5093,Homo sapiens,22224,CHEMBL624561,,1,BAO_0000251,A,9606.0,U,Autocuration,5732,Half life in human microsomes,In vitro,,,
5094,Homo sapiens,22224,CHEMBL624562,,1,BAO_0000366,A,9606.0,U,Autocuration,5819,Half life in human plasma,,,,Plasma
5095,Homo sapiens,22224,CHEMBL624563,,1,BAO_0000366,A,9606.0,U,Autocuration,5819,Half life in human plasma; Not detected,,,,Plasma
5096,Homo sapiens,22224,CHEMBL624564,,1,BAO_0000218,A,9606.0,U,Autocuration,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,,
5097,Homo sapiens,22224,CHEMBL624565,,1,BAO_0000251,A,9606.0,U,Autocuration,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,In vitro,,,Liver
5098,Homo sapiens,22224,CHEMBL875152,,1,BAO_0000366,A,9606.0,U,Autocuration,5229,Half-life in human plasma,,,,Plasma
5099,Homo sapiens,22224,CHEMBL624566,,1,BAO_0000366,A,9606.0,U,Autocuration,5229,Half-life of the parent prodrug in plasma,,,,Plasma
5100,Homo sapiens,22224,CHEMBL873805,,1,BAO_0000366,A,9606.0,U,Autocuration,2192,In vitro half life in human plasma was determined,In vitro,,,Plasma
5101,Homo sapiens,22224,CHEMBL624567,,1,BAO_0000251,A,9606.0,U,Autocuration,3032,The compound was tested In Vitro for half life in human liver microsomes.,In vitro,,,Liver
5102,Homo sapiens,22224,CHEMBL624568,,1,BAO_0000218,A,9606.0,U,Autocuration,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,In vivo,,,
5103,Homo sapiens,22224,CHEMBL624569,,1,BAO_0000218,A,9606.0,U,Autocuration,17716,Observed volume of distribution,In vivo,,,
5104,Homo sapiens,22224,CHEMBL624570,,1,BAO_0000218,A,9606.0,U,Autocuration,15778,Oral bioavailability in human,In vivo,,,
5105,Homo sapiens,22224,CHEMBL624571,,1,BAO_0000019,A,9606.0,U,Autocuration,17313,Tested for human plasma protein binding of the compound,,,,
5106,Homo sapiens,22224,CHEMBL624572,,1,BAO_0000019,A,9606.0,U,Autocuration,4231,"First order rate constant, k was determined in human plasma",,,,
5107,Homo sapiens,22224,CHEMBL624573,,1,BAO_0000019,A,9606.0,U,Autocuration,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,,
5108,Homo sapiens,22224,CHEMBL875153,,1,BAO_0000019,A,9606.0,U,Autocuration,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,,
5109,Homo sapiens,22224,CHEMBL624574,,1,BAO_0000251,A,9606.0,U,Autocuration,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,,Liver
5110,Homo sapiens,22224,CHEMBL624575,,1,BAO_0000019,A,9606.0,U,Autocuration,10839,The compound was tested for the plasma binding in human,,,,
5111,Homo sapiens,22224,CHEMBL624576,,1,BAO_0000019,A,9606.0,U,Autocuration,10839,Plasma protein binding (human),,,,
5112,Homo sapiens,22224,CHEMBL624577,,1,BAO_0000251,A,9606.0,U,Autocuration,3199,Compound was evaluated for half-life in human liver microsomes,In vitro,,,Liver
5113,Homo sapiens,22224,CHEMBL624578,,1,BAO_0000221,A,9606.0,U,Autocuration,1345,Half life measured in vitro for its stability in human blood,In vitro,,,Blood
5114,Homo sapiens,22224,CHEMBL622796,,1,BAO_0000019,A,9606.0,U,Autocuration,4297,Half life in human serum,,,,Serum
5115,Homo sapiens,22224,CHEMBL622797,,1,BAO_0000019,A,9606.0,U,Autocuration,4297,Half life in human serum; ND=not determined,,,,Serum
5116,Homo sapiens,22224,CHEMBL622798,,1,BAO_0000019,A,9606.0,U,Autocuration,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,,,,
5117,Homo sapiens,22224,CHEMBL622799,,1,BAO_0000019,A,9606.0,U,Autocuration,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,,,,
5118,Homo sapiens,22224,CHEMBL622800,,1,BAO_0000366,A,9606.0,U,Autocuration,4231,Half life of the in human plasma,,,,Plasma
5119,Homo sapiens,22224,CHEMBL622801,,1,BAO_0000220,A,9606.0,U,Autocuration,5633,Half life period in human hepatic S9 fraction was determined,In vitro,,,
5120,Homo sapiens,22224,CHEMBL622802,,1,BAO_0000251,A,9606.0,U,Autocuration,5633,Half life period in human liver microsome was determined,In vitro,,,Liver
5121,Homo sapiens,22224,CHEMBL622803,,1,BAO_0000019,A,9606.0,U,Autocuration,17791,Half life period was determined; 6-7,,,,
5122,Homo sapiens,22224,CHEMBL875154,,1,BAO_0000019,A,9606.0,U,Autocuration,17791,Half life period was evaluated in human,,,,
5123,Homo sapiens,22224,CHEMBL622804,,1,BAO_0000366,A,9606.0,U,Autocuration,3160,Half life time in human plasma,,,,Plasma
5124,Mus musculus,50594,CHEMBL622805,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Brain
5125,Mus musculus,50594,CHEMBL622611,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Heart
5126,Mus musculus,50594,CHEMBL622612,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Heart
5127,Mus musculus,50594,CHEMBL875160,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Kidney
5128,Mus musculus,50594,CHEMBL622613,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,,Kidney
5129,Mus musculus,50594,CHEMBL622614,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Kidney
5130,Mus musculus,50594,CHEMBL622615,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Liver
5131,Mus musculus,50594,CHEMBL622616,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,,Liver
5132,Mus musculus,50594,CHEMBL622617,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Liver
5133,Mus musculus,50594,CHEMBL622618,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,In vivo,,,Spleen
5134,Mus musculus,50594,CHEMBL622619,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",In vivo,,,Spleen
5135,Mus musculus,50594,CHEMBL622620,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Spleen
5136,Mus musculus,50594,CHEMBL622621,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,,Brain
5137,Mus musculus,50594,CHEMBL622622,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution of compound (oxidized form) in blood tissue,In vivo,,,Blood
5138,Mus musculus,50594,CHEMBL622623,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Blood
5139,Mus musculus,50594,CHEMBL622624,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,,Blood
5140,Mus musculus,50594,CHEMBL622625,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,,Blood
5141,Mus musculus,50594,CHEMBL622626,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Blood
5142,Mus musculus,50594,CHEMBL622627,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,,Blood
5143,Mus musculus,50594,CHEMBL622628,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,In vivo,,,Brain
5144,Mus musculus,50594,CHEMBL622629,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Brain
5145,Mus musculus,50594,CHEMBL622630,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,,Brain
5146,Mus musculus,50594,CHEMBL622631,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Brain
5147,Mus musculus,50594,CHEMBL622632,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,,Brain
5148,Mus musculus,50594,CHEMBL622633,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,,Brain
5149,Mus musculus,50594,CHEMBL622634,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,In vivo,,,Heart
5150,Mus musculus,50594,CHEMBL622635,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Heart
5151,Mus musculus,50594,CHEMBL875161,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Heart
5152,Mus musculus,50594,CHEMBL622636,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,,Heart
5153,Mus musculus,50594,CHEMBL623335,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Heart
5154,Mus musculus,50594,CHEMBL623336,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,,Heart
5155,Mus musculus,50594,CHEMBL623337,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Kidney
5156,Mus musculus,50594,CHEMBL623338,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",In vivo,,,Kidney
5157,Mus musculus,50594,CHEMBL623339,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,,Kidney
5158,Mus musculus,50594,CHEMBL623524,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",In vivo,,,Kidney
5159,Mus musculus,50594,CHEMBL623525,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",In vivo,,,Kidney
5160,Mus musculus,50594,CHEMBL623526,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,Biodistribution of compound (oxidized form) in liver tissue,In vivo,,,Liver
5161,Mus musculus,50594,CHEMBL623527,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",In vivo,,,Liver
5162,Mus musculus,50594,CHEMBL623528,,1,BAO_0000218,A,10090.0,N,Intermediate,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",In vivo,,,Liver
5163,Homo sapiens,80852,CHEMBL624615,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,,,
5164,Homo sapiens,80852,CHEMBL621672,,1,BAO_0000219,F,9606.0,N,Intermediate,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,,,
5165,,80852,CHEMBL621673,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,,,
5166,,80852,CHEMBL621674,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,,,
5167,Homo sapiens,9,CHEMBL884002,,1,BAO_0000219,F,9606.0,D,Expert,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,,
5168,Homo sapiens,80852,CHEMBL621850,,1,BAO_0000219,F,9606.0,N,Intermediate,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,,,
5169,Homo sapiens,80852,CHEMBL621851,,1,BAO_0000219,F,9606.0,N,Intermediate,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,,,
5170,Homo sapiens,9,CHEMBL621852,,1,BAO_0000219,F,9606.0,D,Expert,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,,,
5171,Homo sapiens,9,CHEMBL621853,,1,BAO_0000219,F,9606.0,D,Expert,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,,,
5172,,80852,CHEMBL621854,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,,,
5173,,80852,CHEMBL621855,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,
5174,,80852,CHEMBL623724,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,,,
5175,,80852,CHEMBL623725,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,,,
5176,,80852,CHEMBL623726,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,,,
5177,Homo sapiens,9,CHEMBL623727,,1,BAO_0000219,F,9606.0,D,Expert,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,,,
5178,,9,CHEMBL623728,,1,BAO_0000219,F,,H,Expert,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,,,
5179,,80852,CHEMBL623729,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,,,
5180,,80852,CHEMBL623730,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,
5181,,80852,CHEMBL623731,,1,BAO_0000218,F,,N,Expert,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,,,
5182,Mus musculus,80852,CHEMBL623732,,1,BAO_0000218,F,10090.0,N,Expert,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,,,
5183,Mus musculus,80852,CHEMBL623733,,1,BAO_0000218,F,10090.0,N,Expert,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,,,
5184,Mus musculus,80852,CHEMBL623734,,1,BAO_0000218,F,10090.0,N,Expert,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,,
5185,Mus musculus,80852,CHEMBL623735,,1,BAO_0000218,F,10090.0,N,Expert,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,,,
5186,Homo sapiens,80852,CHEMBL623736,,1,BAO_0000219,F,9606.0,N,Expert,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,,,
5187,Homo sapiens,80852,CHEMBL623737,,1,BAO_0000219,F,9606.0,N,Intermediate,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,,,
5188,Homo sapiens,80852,CHEMBL623738,,1,BAO_0000219,F,9606.0,N,Intermediate,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,,,
5189,Homo sapiens,80852,CHEMBL875168,,1,BAO_0000219,F,9606.0,N,Intermediate,3558,Dose giving a 50% decrease in the living cell number (A437 cells),,,,
5190,Homo sapiens,80682,CHEMBL623739,,1,BAO_0000219,F,9606.0,N,Expert,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,,,,
5191,Homo sapiens,80682,CHEMBL623740,,1,BAO_0000219,F,9606.0,N,Intermediate,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,,,
5192,Homo sapiens,80682,CHEMBL624424,,1,BAO_0000219,F,9606.0,N,Intermediate,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,,,
5193,Homo sapiens,80021,CHEMBL624425,,1,BAO_0000219,F,9606.0,N,Intermediate,17229,In vitro antitumor activity against renal A498 tumor cell lines,,,,
5194,Homo sapiens,80021,CHEMBL624426,,1,BAO_0000219,F,9606.0,N,Intermediate,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,,,
5195,Homo sapiens,80021,CHEMBL624427,,1,BAO_0000219,F,9606.0,N,Intermediate,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,,,
5196,Homo sapiens,80021,CHEMBL624428,,1,BAO_0000219,F,9606.0,N,Intermediate,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,,,
5197,Homo sapiens,80021,CHEMBL624429,,1,BAO_0000219,F,9606.0,N,Intermediate,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,,,
5198,Homo sapiens,80021,CHEMBL624620,,1,BAO_0000219,F,9606.0,N,Intermediate,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,,,
5199,Homo sapiens,80021,CHEMBL624621,,1,BAO_0000219,F,9606.0,N,Intermediate,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,,,,
5200,Homo sapiens,80021,CHEMBL624622,,1,BAO_0000219,F,9606.0,N,Intermediate,15403,Compound was evaluated against Human cell line renal A498,,,,
5201,Homo sapiens,80021,CHEMBL624623,,1,BAO_0000219,F,9606.0,N,Intermediate,1009,Compound was tested for inhibition of A498 human renal cancer cell line,,,,
5202,Homo sapiens,80021,CHEMBL874365,,1,BAO_0000219,F,9606.0,N,Intermediate,1043,Growth inhibitory activity against A498 human cancer cell line,,,,
5203,Homo sapiens,80021,CHEMBL624624,,1,BAO_0000219,F,9606.0,N,Intermediate,5858,In vitro antitumor activity against human renal A498 cell line,,,,
5204,Homo sapiens,80021,CHEMBL624625,,1,BAO_0000219,F,9606.0,N,Intermediate,5958,In vitro cytotoxic activity against renal (A498) cell line,,,,
5205,Homo sapiens,80021,CHEMBL624626,,1,BAO_0000219,F,9606.0,N,Intermediate,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,,,,
5206,Homo sapiens,80021,CHEMBL624627,,1,BAO_0000219,F,9606.0,N,Intermediate,12781,Tested for cytostatic activity against renal A498 cell line,,,,
5207,Homo sapiens,80021,CHEMBL883157,,1,BAO_0000219,F,9606.0,N,Intermediate,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,,,
5208,Homo sapiens,80021,CHEMBL624628,,1,BAO_0000219,F,9606.0,N,Expert,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,,,
5209,beagle,22224,CHEMBL624629,,1,BAO_0000218,A,9615.0,U,Autocuration,3510,Cmax value after 2 mpk peroral administration to beagles,In vivo,,,
5210,Canis lupus familiaris,22224,CHEMBL623551,,1,BAO_0000218,A,9615.0,U,Autocuration,3510,Bioavailability,In vivo,,beagle,
5211,Canis lupus familiaris,22224,CHEMBL623552,,1,BAO_0000218,A,9615.0,U,Autocuration,3510,Bioavailability after 1 mpk peroral administration to beagles,In vivo,,beagle,
5212,Canis lupus familiaris,22224,CHEMBL623553,,1,BAO_0000218,A,9615.0,U,Autocuration,3510,Bioavailability after 2 mpk peroral administration to beagles,In vivo,,beagle,
5213,Bos taurus,22224,CHEMBL623554,,1,BAO_0000019,A,9913.0,U,Autocuration,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,,
5214,Bos taurus,22224,CHEMBL623555,,1,BAO_0000019,A,9913.0,U,Autocuration,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,,
5215,Bos taurus,22224,CHEMBL623556,,1,BAO_0000019,A,9913.0,U,Autocuration,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,,
5216,Bos taurus,22224,CHEMBL623557,,1,BAO_0000019,A,9913.0,U,Autocuration,9372,Solubility against bovine alpha-chymotrypsin,,,,
5217,Bos taurus,22224,CHEMBL623558,,1,BAO_0000019,A,9913.0,U,Autocuration,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,,
5218,Bos taurus,22224,CHEMBL623559,,1,BAO_0000019,A,9913.0,U,Autocuration,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,,
5219,Bos taurus,22224,CHEMBL623560,,1,BAO_0000221,A,9913.0,U,Autocuration,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,,Spleen
5220,Bos taurus,22224,CHEMBL623561,,1,BAO_0000019,A,9913.0,U,Autocuration,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,,
5221,Bos taurus,22224,CHEMBL623562,,1,BAO_0000019,A,9913.0,U,Autocuration,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,,
5222,Bos taurus,22224,CHEMBL623563,,1,BAO_0000019,A,9913.0,U,Autocuration,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,,
5223,Bos taurus,22224,CHEMBL623564,,1,BAO_0000221,A,9913.0,U,Autocuration,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,,Spleen
5224,Bos taurus,22224,CHEMBL873806,,1,BAO_0000019,A,9913.0,U,Autocuration,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,,,,
5225,Bos taurus,22224,CHEMBL623565,,1,BAO_0000019,A,9913.0,U,Autocuration,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,,
5226,Bos taurus,22224,CHEMBL623566,,1,BAO_0000019,A,9913.0,U,Autocuration,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,,
5227,Bos taurus,22224,CHEMBL623567,,1,BAO_0000019,A,9913.0,U,Autocuration,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,,
5228,Bos taurus,22224,CHEMBL623568,,1,BAO_0000019,A,9913.0,U,Autocuration,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,,
5229,Canis lupus familiaris,50588,CHEMBL623569,,1,BAO_0000218,A,9615.0,N,Intermediate,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,,Plasma
5230,Canis lupus familiaris,50588,CHEMBL623570,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,AUC after administration at 100 mg/kg/day in dogs,,,,Plasma
5231,Canis lupus familiaris,50588,CHEMBL624254,,1,BAO_0000218,A,9615.0,N,Intermediate,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,,Plasma
5232,Canis lupus familiaris,50588,CHEMBL624255,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,AUC value after 15 mg/kg iv dose in Dogs,,,,Plasma
5233,Canis lupus familiaris,50588,CHEMBL624256,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,AUC value after 30 mg/kg po dose in Dogs,,,,Plasma
5234,Canis lupus familiaris,50588,CHEMBL624257,,1,BAO_0000218,A,9615.0,N,Intermediate,2959,AUC value after administration of 4 mg/Kg oral dose in dog,,,,Plasma
5235,Canis lupus familiaris,50588,CHEMBL624258,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,,Plasma
5236,Canis lupus familiaris,50588,CHEMBL875277,,1,BAO_0000218,A,9615.0,N,Intermediate,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,,
5237,Canis lupus familiaris,50588,CHEMBL622667,,1,BAO_0000218,A,9615.0,N,Intermediate,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,,
5238,Canis lupus familiaris,50588,CHEMBL622668,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,,
5239,Canis lupus familiaris,50588,CHEMBL622669,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,,
5240,Canis lupus familiaris,50588,CHEMBL622670,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,,
5241,Canis lupus familiaris,50588,CHEMBL622671,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,,,,
5242,Canis lupus familiaris,50588,CHEMBL622672,,1,BAO_0000218,A,9615.0,N,Intermediate,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,,
5243,Canis lupus familiaris,50588,CHEMBL622673,,1,BAO_0000218,A,9615.0,N,Expert,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,,
5244,Canis lupus familiaris,50588,CHEMBL622674,,1,BAO_0000218,A,9615.0,N,Expert,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,,
5245,Canis lupus familiaris,50588,CHEMBL622675,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,,
5246,Canis lupus familiaris,50588,CHEMBL622676,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,,
5247,Canis lupus familiaris,50588,CHEMBL622677,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,,
5248,Canis lupus familiaris,50588,CHEMBL622678,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,,
5249,Canis lupus familiaris,50588,CHEMBL622679,,1,BAO_0000218,A,9615.0,N,Intermediate,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,,
5250,Canis lupus familiaris,50588,CHEMBL622680,,1,BAO_0000218,A,9615.0,N,Intermediate,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,,
5251,Canis lupus familiaris,50588,CHEMBL622681,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Area under curve was determine after peroral administration at 10 mpk in dog,,,,
5252,Canis lupus familiaris,50588,CHEMBL875278,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Area under curve was determine after peroral administration at 5 mpk in dog,,,,
5253,Canis lupus familiaris,50588,CHEMBL622682,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Area under curve was determined,,,,
5254,Canis lupus familiaris,50588,CHEMBL622683,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Area under curve in dogs,,,,
5255,Canis lupus familiaris,50588,CHEMBL622684,,1,BAO_0000218,A,9615.0,N,Intermediate,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,,
5256,Canis lupus familiaris,50588,CHEMBL622685,,1,BAO_0000218,A,9615.0,N,Intermediate,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,,
5257,Canis lupus familiaris,50588,CHEMBL622686,,1,BAO_0000218,A,9615.0,N,Intermediate,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,,
5258,Canis lupus familiaris,50588,CHEMBL618344,,1,BAO_0000218,A,9615.0,N,Intermediate,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,,
5259,Canis lupus familiaris,50588,CHEMBL875582,,1,BAO_0000218,A,9615.0,N,Intermediate,5302,Area under curve value in dog at a dose of 5 mg/kg,,,,
5260,Canis lupus familiaris,50588,CHEMBL618345,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,,
5261,Canis lupus familiaris,50588,CHEMBL618346,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,,,,
5262,Canis lupus familiaris,50588,CHEMBL618347,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,,
5263,Canis lupus familiaris,50588,CHEMBL618348,,1,BAO_0000218,A,9615.0,N,Intermediate,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,,
5264,Homo sapiens,22224,CHEMBL618349,,1,BAO_0000019,A,9606.0,U,Autocuration,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,,
5265,Homo sapiens,22224,CHEMBL618350,,1,BAO_0000019,A,9606.0,U,Autocuration,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,,
5266,Homo sapiens,22224,CHEMBL618351,,1,BAO_0000019,A,9606.0,U,Autocuration,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,,
5267,Homo sapiens,22224,CHEMBL618352,,1,BAO_0000019,A,9606.0,U,Autocuration,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,,
5268,Homo sapiens,22224,CHEMBL873494,,1,BAO_0000221,A,9606.0,U,Autocuration,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,,,,Blood
5269,Homo sapiens,22224,CHEMBL618353,,1,BAO_0000366,A,9606.0,U,Autocuration,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,,Plasma
5270,Homo sapiens,22224,CHEMBL618354,,1,BAO_0000366,A,9606.0,U,Autocuration,6787,Half life in human plasma,,,,Plasma
5271,Homo sapiens,22224,CHEMBL875583,,1,BAO_0000366,A,9606.0,U,Autocuration,4898,Half life in human plasma was reported,,,,Plasma
5272,Homo sapiens,22224,CHEMBL618355,,1,BAO_0000019,A,9606.0,U,Autocuration,6072,Half life in human serum,,,,Serum
5273,Homo sapiens,22224,CHEMBL618356,,1,BAO_0000366,A,9606.0,U,Autocuration,16907,Half life upon exposure to human plasma,,,,Plasma
5274,Homo sapiens,22224,CHEMBL618357,,1,BAO_0000251,A,9606.0,U,Autocuration,5656,t1/2 in human microsomes,In vitro,,,
5275,Homo sapiens,22224,CHEMBL618358,,1,BAO_0000366,A,9606.0,U,Autocuration,4755,Half life period in 80% human plasma at 37 degree Centigrade,,,,Plasma
5276,Homo sapiens,22224,CHEMBL618359,,1,BAO_0000221,A,9606.0,U,Autocuration,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,,Zone of skin
5277,Homo sapiens,22224,CHEMBL618360,,1,BAO_0000366,A,9606.0,U,Autocuration,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,In vitro,,,Plasma
5278,Homo sapiens,22224,CHEMBL618361,,1,BAO_0000019,A,9606.0,U,Autocuration,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,,
5279,Homo sapiens,22224,CHEMBL618362,,1,BAO_0000251,A,9606.0,U,Autocuration,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,In vitro,,,Liver
5280,Homo sapiens,22224,CHEMBL618363,,1,BAO_0000366,A,9606.0,U,Autocuration,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,,Plasma
5281,Homo sapiens,22224,CHEMBL618364,,1,BAO_0000366,A,9606.0,U,Autocuration,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,,Plasma
5282,Homo sapiens,22224,CHEMBL875584,,1,BAO_0000366,A,9606.0,U,Autocuration,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,,Plasma
5283,Homo sapiens,22224,CHEMBL618365,,1,BAO_0000019,A,9606.0,U,Autocuration,1540,Half-life in the CEM cell extracts,,,,
5284,Homo sapiens,22224,CHEMBL873495,,1,BAO_0000366,A,9606.0,U,Autocuration,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,,Plasma
5285,Homo sapiens,22224,CHEMBL618366,,1,BAO_0000366,A,9606.0,U,Autocuration,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,,Plasma
5286,Homo sapiens,22224,CHEMBL618367,,1,BAO_0000019,A,9606.0,U,Autocuration,5523,Half-life was determined,,,,
5287,Homo sapiens,22224,CHEMBL618368,,1,BAO_0000221,A,9606.0,U,Autocuration,1499,Half-life (human blood stability),,,,Blood
5288,Homo sapiens,22224,CHEMBL618369,,1,BAO_0000221,A,9606.0,U,Autocuration,1499,Half-life (human blood stability); no data,,,,Blood
5289,Homo sapiens,22224,CHEMBL618370,,1,BAO_0000366,A,9606.0,U,Autocuration,17065,Half-life in human plasma,,,,Plasma
5290,Homo sapiens,22224,CHEMBL618371,,1,BAO_0000019,A,9606.0,U,Autocuration,6861,CYP3A4 metabolism half-life (t1/2),,,,
5291,Homo sapiens,22224,CHEMBL618372,,1,BAO_0000221,A,9606.0,U,Autocuration,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,,Blood
5292,Homo sapiens,22224,CHEMBL618373,,1,BAO_0000366,A,9606.0,U,Autocuration,530,In vitro half life in human plasma,In vitro,,,Plasma
5293,Homo sapiens,22224,CHEMBL618374,,1,BAO_0000366,A,9606.0,U,Autocuration,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",In vitro,,,Plasma
5294,Homo sapiens,22224,CHEMBL618375,,1,BAO_0000366,A,9606.0,U,Autocuration,6695,In vitro hydrolysis in human plasma,In vitro,,,Plasma
5295,Homo sapiens,22224,CHEMBL618376,,1,BAO_0000366,A,9606.0,U,Autocuration,6695,In vitro hydrolysis in human plasma; no data,In vitro,,,Plasma
5296,Homo sapiens,22224,CHEMBL618377,,1,BAO_0000251,A,9606.0,U,Autocuration,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,In vitro,,,Liver
5297,Homo sapiens,22224,CHEMBL618378,,1,BAO_0000366,A,9606.0,U,Autocuration,993,Plasma half life in human,,,,Plasma
5298,Homo sapiens,22224,CHEMBL618379,,1,BAO_0000366,A,9606.0,U,Autocuration,15429,Stability after incubation with human plasma (at 37 degree C),,,,Plasma
5299,Homo sapiens,22224,CHEMBL618380,,1,BAO_0000366,A,9606.0,U,Autocuration,1675,T1/2 was evaluated in human plasma,,,,Plasma
5300,Homo sapiens,22224,CHEMBL618381,,1,BAO_0000366,A,9606.0,U,Autocuration,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,,Plasma
5301,Homo sapiens,22224,CHEMBL618382,,1,BAO_0000366,A,9606.0,U,Autocuration,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,,Plasma
5302,Homo sapiens,22224,CHEMBL618383,,1,BAO_0000019,A,9606.0,U,Autocuration,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,,
5303,Homo sapiens,22224,CHEMBL618384,,1,BAO_0000019,A,9606.0,U,Autocuration,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,In vitro,,,
5304,Homo sapiens,22224,CHEMBL618385,,1,BAO_0000019,A,9606.0,U,Autocuration,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,In vitro,,,
5305,Homo sapiens,22224,CHEMBL619099,,1,BAO_0000366,A,9606.0,U,Autocuration,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,,Plasma
5306,Homo sapiens,22224,CHEMBL619100,,1,BAO_0000366,A,9606.0,U,Autocuration,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,,Plasma
5307,Homo sapiens,22224,CHEMBL619101,,1,BAO_0000019,A,9606.0,U,Autocuration,5495,Time taken for 50% to be consumed by serum PON1 was determined,,,,
5308,Homo sapiens,22224,CHEMBL619102,,1,BAO_0000019,A,9606.0,U,Autocuration,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,,
5309,Homo sapiens,22224,CHEMBL619103,,1,BAO_0000251,A,9606.0,U,Autocuration,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,,Liver
5310,Mus sp.,22224,CHEMBL619268,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,
5311,Mus sp.,22224,CHEMBL619269,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,
5312,Mus sp.,22224,CHEMBL619270,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,
5313,Mus sp.,22224,CHEMBL619271,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,
5314,Mus sp.,22224,CHEMBL875585,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,
5315,Mus sp.,22224,CHEMBL619272,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,
5316,Homo sapiens,80640,CHEMBL619273,,1,BAO_0000219,F,9606.0,N,Intermediate,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,,,,
5317,Homo sapiens,80640,CHEMBL619274,,1,BAO_0000219,F,9606.0,N,Intermediate,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,,,
5318,Homo sapiens,80640,CHEMBL619275,,1,BAO_0000219,F,9606.0,N,Expert,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,,,
5319,Homo sapiens,80640,CHEMBL619276,,1,BAO_0000219,F,9606.0,N,Intermediate,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,,,
5320,Homo sapiens,80640,CHEMBL619277,,1,BAO_0000219,F,9606.0,N,Intermediate,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,,,
5321,Homo sapiens,80640,CHEMBL619278,,1,BAO_0000219,F,9606.0,N,Intermediate,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,,,
5322,Homo sapiens,80640,CHEMBL619279,,1,BAO_0000219,F,9606.0,N,Intermediate,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,,,
5323,Homo sapiens,80640,CHEMBL858458,,1,BAO_0000219,F,9606.0,N,Intermediate,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,,,
5324,Homo sapiens,80640,CHEMBL619280,,1,BAO_0000219,F,9606.0,N,Expert,12888,Cytotoxic effect on renal cancer line 786-0,,,,
5325,Homo sapiens,80640,CHEMBL619281,,1,BAO_0000219,F,9606.0,N,Intermediate,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,,,
5326,Homo sapiens,80640,CHEMBL619282,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,,,
5327,Homo sapiens,80640,CHEMBL619283,,1,BAO_0000219,F,9606.0,N,Intermediate,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,,,
5328,Homo sapiens,80640,CHEMBL619284,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,,,
5329,Homo sapiens,80640,CHEMBL619285,,1,BAO_0000219,F,9606.0,N,Intermediate,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,,
5330,Homo sapiens,80640,CHEMBL619286,,1,BAO_0000219,F,9606.0,N,Intermediate,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,,,
5331,Homo sapiens,80640,CHEMBL619287,,1,BAO_0000219,F,9606.0,N,Intermediate,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,,,
5332,Homo sapiens,80640,CHEMBL857455,,1,BAO_0000219,F,9606.0,N,Intermediate,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,,
5333,Homo sapiens,80640,CHEMBL883801,,1,BAO_0000219,F,9606.0,N,Intermediate,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,,,
5334,Homo sapiens,80641,CHEMBL619288,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,,,
5335,Homo sapiens,80641,CHEMBL619289,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,,,
5336,Homo sapiens,80641,CHEMBL619290,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,,,
5337,Homo sapiens,80641,CHEMBL619291,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,,,
5338,Homo sapiens,80641,CHEMBL619292,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,,,
5339,Homo sapiens,80641,CHEMBL619293,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,,,
5340,Homo sapiens,80641,CHEMBL619294,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,,,
5341,Homo sapiens,80641,CHEMBL619295,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,,,
5342,Homo sapiens,80641,CHEMBL619296,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,,,
5343,Homo sapiens,80641,CHEMBL619297,,1,BAO_0000219,F,9606.0,N,Intermediate,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,,,
5344,Homo sapiens,80640,CHEMBL619298,,1,BAO_0000219,F,9606.0,N,Intermediate,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,,,
5345,,22226,CHEMBL619299,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,,
5346,Homo sapiens,80433,CHEMBL619300,,1,BAO_0000219,F,9606.0,N,Expert,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,,,
5347,Homo sapiens,80433,CHEMBL619301,,1,BAO_0000219,F,9606.0,N,Expert,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,,,
5348,Homo sapiens,80433,CHEMBL619302,,1,BAO_0000219,F,9606.0,N,Intermediate,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,,,
5349,Homo sapiens,80433,CHEMBL619303,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,,
5350,Homo sapiens,80433,CHEMBL619304,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,,
5351,Homo sapiens,80433,CHEMBL857706,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,,
5352,Homo sapiens,80433,CHEMBL619305,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,,
5353,Homo sapiens,80433,CHEMBL619306,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,,
5354,Homo sapiens,80433,CHEMBL619307,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,,
5355,Homo sapiens,80433,CHEMBL619308,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,,
5356,Homo sapiens,80433,CHEMBL619309,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,,
5357,Homo sapiens,80433,CHEMBL619310,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,,
5358,Homo sapiens,80021,CHEMBL619311,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,,
5359,Homo sapiens,80021,CHEMBL619312,,1,BAO_0000219,F,9606.0,N,Intermediate,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,,,,
5360,Homo sapiens,80021,CHEMBL619313,,1,BAO_0000219,F,9606.0,N,Intermediate,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,,,
5361,Homo sapiens,80021,CHEMBL619314,,1,BAO_0000219,F,9606.0,N,Intermediate,4337,In vitro inhibitory concentration against renal cancer cell line A498,,,,
5362,Homo sapiens,80021,CHEMBL619959,,1,BAO_0000219,F,9606.0,N,Intermediate,15277,Cytotoxicity against A 498 tumor cell line,,,,
5363,Homo sapiens,80021,CHEMBL619960,,1,BAO_0000219,F,9606.0,N,Intermediate,4812,In vitro antitumor activity against A498 human cancer cell line,,,,
5364,Homo sapiens,80021,CHEMBL619961,,1,BAO_0000219,F,9606.0,N,Intermediate,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,,,
5365,Homo sapiens,80021,CHEMBL619962,,1,BAO_0000219,F,9606.0,N,Intermediate,4995,Inhibitory dose required against A498 human tumor cell lines,,,,
5366,Homo sapiens,80021,CHEMBL875586,,1,BAO_0000219,F,9606.0,N,Intermediate,5847,Anticancer activity against one renal cancer (A498 cell line),,,,
5367,Homo sapiens,80021,CHEMBL619963,,1,BAO_0000219,F,9606.0,N,Intermediate,6557,In vitro cytotoxicity against melanoma A498 cell line,,,,
5368,Homo sapiens,80021,CHEMBL619964,,1,BAO_0000219,F,9606.0,N,Intermediate,2597,Compound was tested for growth inhibitory activity against A498 cell line,,,,
5369,Homo sapiens,80021,CHEMBL620108,,1,BAO_0000219,F,9606.0,N,Intermediate,6058,Compound tested for growth inhibition of renal cancer cell line A498,,,,
5370,Homo sapiens,80021,CHEMBL620109,,1,BAO_0000219,F,9606.0,N,Intermediate,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,,,
5371,Homo sapiens,80021,CHEMBL620110,,1,BAO_0000219,F,9606.0,N,Intermediate,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,,,
5372,Homo sapiens,80021,CHEMBL620111,,1,BAO_0000219,F,9606.0,N,Intermediate,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,,,
5373,Homo sapiens,80021,CHEMBL620112,,1,BAO_0000219,F,9606.0,N,Intermediate,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,,,,
5374,Homo sapiens,80021,CHEMBL620113,,1,BAO_0000219,F,9606.0,N,Intermediate,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,,,
5375,Homo sapiens,80021,CHEMBL620114,,1,BAO_0000219,F,9606.0,N,Expert,12888,Cytotoxic effect on renal cancer lines A498,,,,
5376,Homo sapiens,80021,CHEMBL620115,,1,BAO_0000219,F,9606.0,N,Intermediate,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,,,
5377,Homo sapiens,80021,CHEMBL620116,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,,,
5378,Homo sapiens,80021,CHEMBL620117,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,,,
5379,Homo sapiens,80021,CHEMBL620118,,1,BAO_0000219,F,9606.0,N,Intermediate,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,,,
5380,Homo sapiens,80021,CHEMBL620119,,1,BAO_0000219,F,9606.0,N,Intermediate,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,,,
5381,Homo sapiens,80021,CHEMBL620120,,1,BAO_0000219,F,9606.0,N,Intermediate,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,,,
5382,Homo sapiens,80682,CHEMBL620121,,1,BAO_0000219,F,9606.0,N,Expert,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,,,
5383,Homo sapiens,80682,CHEMBL620122,,1,BAO_0000219,F,9606.0,N,Intermediate,10196,Antitumor activity against A549 human lung carcinoma cell line,,,,
5384,Homo sapiens,80682,CHEMBL620123,,1,BAO_0000219,F,9606.0,N,Intermediate,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,,,
5385,Homo sapiens,80682,CHEMBL620124,,1,BAO_0000219,F,9606.0,N,Intermediate,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,,,
5386,Homo sapiens,80682,CHEMBL620125,,1,BAO_0000219,F,9606.0,N,Intermediate,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,,,
5387,Homo sapiens,80682,CHEMBL620126,,1,BAO_0000219,F,9606.0,N,Expert,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,,,
5388,Homo sapiens,80682,CHEMBL883027,,1,BAO_0000219,F,9606.0,N,Intermediate,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,,
5389,Homo sapiens,80682,CHEMBL620127,,1,BAO_0000219,F,9606.0,N,Expert,16470,In vitro cytotoxic activity against human lung A549 cell line,,,,
5390,Homo sapiens,80682,CHEMBL620128,,1,BAO_0000219,F,9606.0,N,Intermediate,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,,,
5391,Homo sapiens,80682,CHEMBL620129,,1,BAO_0000219,F,9606.0,N,Intermediate,16470,In vitro cytotoxic activity against human lung A549 cell line),,,,
5392,Homo sapiens,80682,CHEMBL620130,,1,BAO_0000219,F,9606.0,N,Intermediate,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,,,
5393,Homo sapiens,80682,CHEMBL620131,,1,BAO_0000219,F,9606.0,N,Expert,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,,,
5394,Homo sapiens,80682,CHEMBL620132,,1,BAO_0000219,F,9606.0,N,Intermediate,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,,,
5395,Homo sapiens,80682,CHEMBL620133,,1,BAO_0000219,F,9606.0,N,Intermediate,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,,,
5396,Homo sapiens,80682,CHEMBL620134,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of A549 human lung carcinoma cell proliferation,,,,
5397,Homo sapiens,80682,CHEMBL620135,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,,,,
5398,Homo sapiens,80682,CHEMBL620136,,1,BAO_0000219,F,9606.0,N,Intermediate,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,,,
5399,Homo sapiens,80682,CHEMBL620137,,1,BAO_0000219,F,9606.0,N,Intermediate,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,,,
5400,Homo sapiens,80682,CHEMBL620268,,1,BAO_0000219,F,9606.0,N,Intermediate,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,,,
5401,Homo sapiens,80682,CHEMBL620269,,1,BAO_0000219,F,9606.0,N,Intermediate,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,,
5402,Homo sapiens,80682,CHEMBL620270,,1,BAO_0000219,F,9606.0,N,Intermediate,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,,,
5403,Homo sapiens,80682,CHEMBL620271,,1,BAO_0000219,F,9606.0,N,Intermediate,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,,
5404,Homo sapiens,80682,CHEMBL620272,,1,BAO_0000219,F,9606.0,N,Expert,4090,Inhibition of A549 cancer cell proliferation,,,,
5405,Homo sapiens,80682,CHEMBL620273,,1,BAO_0000219,F,9606.0,N,Expert,4090,Inhibition of A549 cancer cell proliferation (Not tested),,,,
5406,Homo sapiens,80682,CHEMBL620274,,1,BAO_0000219,F,9606.0,N,Intermediate,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,,,
5407,Homo sapiens,80682,CHEMBL620275,,1,BAO_0000219,F,9606.0,N,Intermediate,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,,,
5408,Homo sapiens,80682,CHEMBL620276,,1,BAO_0000219,F,9606.0,N,Intermediate,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,,,,
5409,Homo sapiens,80682,CHEMBL620277,,1,BAO_0000219,F,9606.0,N,Intermediate,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,,,
5410,Homo sapiens,80682,CHEMBL620278,,1,BAO_0000219,F,9606.0,N,Intermediate,5194,Cytotoxicity against Renal cell lines A549 was determined,,,,
5411,Canis lupus familiaris,50588,CHEMBL620279,,1,BAO_0000218,A,9615.0,N,Intermediate,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,,
5412,Canis lupus familiaris,50588,CHEMBL620280,,1,BAO_0000218,A,9615.0,N,Intermediate,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,,,,
5413,Canis lupus familiaris,50588,CHEMBL620281,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,,
5414,Canis lupus familiaris,50588,CHEMBL620282,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,,
5415,Canis lupus familiaris,50588,CHEMBL621134,,1,BAO_0000218,A,9615.0,N,Intermediate,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,,
5416,Canis lupus familiaris,50588,CHEMBL621135,,1,BAO_0000218,A,9615.0,N,Intermediate,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,,
5417,Canis lupus familiaris,50588,CHEMBL621136,,1,BAO_0000218,A,9615.0,N,Intermediate,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,,
5418,Canis lupus familiaris,50588,CHEMBL621137,,1,BAO_0000218,A,9615.0,N,Intermediate,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,,
5419,Canis lupus familiaris,50588,CHEMBL621138,,1,BAO_0000218,A,9615.0,N,Intermediate,17657,Area under plasma concentration time curve in dog upon oral administration,,,,Plasma
5420,Canis lupus familiaris,50588,CHEMBL875587,,1,BAO_0000218,A,9615.0,N,Intermediate,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,,Plasma
5421,Canis lupus familiaris,50588,CHEMBL621139,,1,BAO_0000218,A,9615.0,N,Intermediate,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,,
5422,Canis lupus familiaris,50588,CHEMBL621140,,1,BAO_0000218,A,9615.0,N,Intermediate,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,,
5423,Canis lupus familiaris,50588,CHEMBL621141,,1,BAO_0000218,A,9615.0,N,Intermediate,3132,Area under the curve for the compound was obtained when tested in dog,,,,
5424,Canis lupus familiaris,50588,CHEMBL621142,,1,BAO_0000218,A,9615.0,N,Intermediate,5473,Area under the curve at a dose of 1 mg/kg,,,,
5425,Canis lupus familiaris,50588,CHEMBL621143,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Area under the curve at a dose of 1 mg/kg (oral),,,,
5426,Canis lupus familiaris,50588,CHEMBL621144,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Area under the curve at i.v. dose of 0.2 mg/kg,,,,
5427,Canis lupus familiaris,50588,CHEMBL621145,,1,BAO_0000218,A,9615.0,N,Intermediate,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,,
5428,Canis lupus familiaris,50588,CHEMBL621146,,1,BAO_0000218,A,9615.0,N,Intermediate,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,,
5429,Canis lupus familiaris,50588,CHEMBL622567,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,,
5430,Canis lupus familiaris,50588,CHEMBL622568,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,,
5431,Canis lupus familiaris,50588,CHEMBL622569,,1,BAO_0000218,A,9615.0,N,Intermediate,2877,Compound was evaluated for area under the curve in dog blood.,,,,
5432,Canis lupus familiaris,50588,CHEMBL622570,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,,
5433,Canis lupus familiaris,50588,CHEMBL622571,,1,BAO_0000218,A,9615.0,N,Intermediate,5130,AUC in dog after oral dose (1 mg/kg),,,,Plasma
5434,Canis lupus familiaris,50588,CHEMBL622572,,1,BAO_0000218,A,9615.0,N,Intermediate,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,,
5435,Canis lupus familiaris,50588,CHEMBL622573,,1,BAO_0000218,A,9615.0,N,Intermediate,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,,
5436,Canis lupus familiaris,50588,CHEMBL622574,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,,
5437,Canis lupus familiaris,50588,CHEMBL622575,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Pharmacokinetic parameter AUC after oral administration to dogs,,,,
5438,Canis lupus familiaris,50588,CHEMBL622576,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,,
5439,Canis lupus familiaris,50588,CHEMBL622577,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,,
5440,Canis lupus familiaris,50588,CHEMBL622578,,1,BAO_0000218,A,9615.0,N,Intermediate,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,,
5441,Canis lupus familiaris,50588,CHEMBL622579,,1,BAO_0000218,A,9615.0,N,Intermediate,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,,
5442,Canis lupus familiaris,50588,CHEMBL622580,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,,
5443,Canis lupus familiaris,50588,CHEMBL622581,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,,
5444,Canis lupus familiaris,50588,CHEMBL622582,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,
5445,Canis lupus familiaris,50588,CHEMBL622583,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,
5446,Canis lupus familiaris,50588,CHEMBL622584,,1,BAO_0000218,A,9615.0,N,Intermediate,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,,
5447,Canis lupus familiaris,50588,CHEMBL622585,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,,
5448,Canis lupus familiaris,50588,CHEMBL622586,,1,BAO_0000218,A,9615.0,N,Intermediate,17791,Compound was evaluated for oral bioavailability in dog; 90-100,,,,
5449,Canis lupus familiaris,50588,CHEMBL623281,,1,BAO_0000218,A,9615.0,N,Intermediate,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,,
5450,Canis lupus familiaris,50588,CHEMBL623282,,1,BAO_0000218,A,9615.0,N,Intermediate,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,,
5451,Canis lupus familiaris,50588,CHEMBL623283,,1,BAO_0000218,A,9615.0,N,Intermediate,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,,
5452,Canis lupus familiaris,50588,CHEMBL623284,,1,BAO_0000218,A,9615.0,N,Intermediate,3880,Oral bioavailability in dog,,,,
5453,Canis lupus familiaris,50588,CHEMBL623285,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,,
5454,Canis lupus familiaris,50588,CHEMBL623463,,1,BAO_0000218,A,9615.0,N,Intermediate,17409,Plasma protein binding towards dog plasma at 10 uM,,,,Plasma
5455,Canis lupus familiaris,50588,CHEMBL875952,,1,BAO_0000218,A,9615.0,N,Intermediate,17409,Plasma protein binding towards dog plasma at 100 uM,,,,Plasma
5456,Canis lupus familiaris,50588,CHEMBL621705,,1,BAO_0000218,A,9615.0,N,Intermediate,2959,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,,,
5457,Canis lupus familiaris,50588,CHEMBL621706,,1,BAO_0000218,A,9615.0,N,Intermediate,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,In vivo,,,
5458,Canis lupus familiaris,50588,CHEMBL621707,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,,
5459,Canis lupus familiaris,50588,CHEMBL621708,,1,BAO_0000218,A,9615.0,N,Intermediate,15145,Bioavailability in dogs,In vivo,,,
5460,Canis lupus familiaris,50588,CHEMBL621709,,1,BAO_0000218,A,9615.0,N,Intermediate,4219,Bioavailability,In vivo,,,
5461,Canis lupus familiaris,50588,CHEMBL621710,,1,BAO_0000218,A,9615.0,N,Intermediate,17538,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,,
5462,Canis lupus familiaris,50588,CHEMBL621711,,1,BAO_0000218,A,9615.0,N,Intermediate,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,In vivo,,,
5463,Canis lupus familiaris,50588,CHEMBL621712,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),In vivo,,,
5464,Canis lupus familiaris,50588,CHEMBL621713,,1,BAO_0000218,A,9615.0,N,Intermediate,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,In vivo,,,
5465,Canis lupus familiaris,50588,CHEMBL621714,,1,BAO_0000218,A,9615.0,N,Intermediate,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,In vivo,,,
5466,Mus sp.,22224,CHEMBL621715,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,
5467,Mus sp.,22224,CHEMBL623717,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Liver
5468,Mus sp.,22224,CHEMBL623718,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,Liver
5469,Mus sp.,22224,CHEMBL623719,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Liver
5470,Mus sp.,22224,CHEMBL623720,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,
5471,Mus sp.,22224,CHEMBL623721,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,
5472,Mus sp.,22224,CHEMBL623722,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Muscle tissue
5473,Mus sp.,22224,CHEMBL623723,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,Muscle tissue
5474,Mus sp.,22224,CHEMBL618543,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Muscle tissue
5475,Mus sp.,22224,CHEMBL618544,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Spleen
5476,Mus sp.,22224,CHEMBL875155,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Spleen
5477,Mus sp.,22224,CHEMBL618545,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,
5478,Mus sp.,22224,CHEMBL618546,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,
5479,Mus sp.,22224,CHEMBL623529,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,
5480,Mus sp.,22224,CHEMBL623530,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,
5481,Mus sp.,22224,CHEMBL621764,,1,BAO_0000218,A,10095.0,U,Autocuration,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,
5482,Cercopithecidae,22224,CHEMBL621765,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,,
5483,Cercopithecidae,22224,CHEMBL621766,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,,Cerebellum
5484,Cercopithecidae,22224,CHEMBL621767,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,,Frontal cortex
5485,Cercopithecidae,22224,CHEMBL621768,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,,
5486,Cercopithecidae,22224,CHEMBL621769,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,,Striatum
5487,Cercopithecidae,22224,CHEMBL621770,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,,
5488,Cercopithecidae,22224,CHEMBL621771,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,,Cerebellum
5489,Cercopithecidae,22224,CHEMBL621772,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,,Frontal cortex
5490,Cercopithecidae,22224,CHEMBL621773,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,,
5491,Cercopithecidae,22224,CHEMBL621774,,1,BAO_0000019,A,9527.0,U,Autocuration,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,,Striatum
5492,Cercopithecidae,22224,CHEMBL621775,,1,BAO_0000218,A,9527.0,U,Autocuration,17791,Compound was evaluated for oral bioavailability in rats,,,,
5493,Cercopithecidae,22224,CHEMBL621776,,1,BAO_0000218,A,9527.0,U,Autocuration,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,In vivo,,,Plasma
5494,Cercopithecidae,22224,CHEMBL621777,,1,BAO_0000019,A,9527.0,U,Autocuration,17791,Half life period was evaluated in monkey,,,,
5495,Cercopithecidae,22224,CHEMBL875162,,1,BAO_0000218,A,9527.0,U,Autocuration,110,Half-life in rhesus monkeys by intravenous administration of dose,In vivo,,,
5496,Mus musculus,50594,CHEMBL621778,,1,BAO_0000218,A,10090.0,N,Intermediate,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,,Plasma
5497,Mus musculus,50594,CHEMBL621779,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,,,,Plasma
5498,Mus musculus,50594,CHEMBL622479,,1,BAO_0000218,A,10090.0,N,Intermediate,17718,AUC value was determined after oral administration,,,,Plasma
5499,Mus musculus,50594,CHEMBL622480,,1,BAO_0000218,A,10090.0,N,Intermediate,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,,
5500,Mus musculus,50594,CHEMBL622481,,1,BAO_0000218,A,10090.0,N,Intermediate,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,,
5501,Mus musculus,50594,CHEMBL622482,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Area under curve by ioral administration in mouse,,,,
5502,Mus musculus,50594,CHEMBL622483,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Area under curve by iv administration in mouse,,,,
5503,Mus musculus,50594,CHEMBL622484,,1,BAO_0000218,A,10090.0,N,Intermediate,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,,,,
5504,Mus musculus,50594,CHEMBL622641,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,,
5505,Mus musculus,50594,CHEMBL622642,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,,
5506,Mus musculus,50594,CHEMBL622643,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,,
5507,Mus musculus,50594,CHEMBL622644,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,,
5508,Homo sapiens,80433,CHEMBL622645,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,,
5509,Homo sapiens,80433,CHEMBL622646,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,,
5510,Homo sapiens,80433,CHEMBL621238,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,,
5511,Homo sapiens,80433,CHEMBL621239,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,,
5512,Homo sapiens,80433,CHEMBL621240,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,,
5513,Homo sapiens,80433,CHEMBL621241,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,,
5514,Homo sapiens,80433,CHEMBL621242,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,,
5515,Homo sapiens,80433,CHEMBL620350,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,,
5516,Homo sapiens,80433,CHEMBL620351,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,,,
5517,Homo sapiens,80433,CHEMBL620352,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,,,
5518,Homo sapiens,80433,CHEMBL620353,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,,,
5519,Homo sapiens,80433,CHEMBL620354,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,,,
5520,Homo sapiens,80433,CHEMBL620355,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,,,
5521,Homo sapiens,80433,CHEMBL620356,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,,,
5522,Homo sapiens,80433,CHEMBL620357,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,,,
5523,Homo sapiens,80433,CHEMBL620358,,1,BAO_0000219,F,9606.0,N,Intermediate,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,,,
5524,Homo sapiens,80433,CHEMBL620359,,1,BAO_0000219,F,9606.0,N,Expert,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,,,
5525,Homo sapiens,80433,CHEMBL620360,,1,BAO_0000219,F,9606.0,N,Intermediate,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,,,
5526,Homo sapiens,80433,CHEMBL620361,,1,BAO_0000219,F,9606.0,N,Intermediate,17378,Cytotoxicity of compound against 8226/DOX1V cells,,,,
5527,Homo sapiens,80433,CHEMBL620362,,1,BAO_0000219,F,9606.0,N,Intermediate,17378,Cytotoxicity of compound against 8226/S cells,,,,
5528,Homo sapiens,80433,CHEMBL620363,,1,BAO_0000219,F,9606.0,N,Intermediate,17079,Inhibitory concentration against 8226 myeloma cancer cell line,,,,
5529,Homo sapiens,80433,CHEMBL620364,,1,BAO_0000219,F,9606.0,N,Intermediate,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,,,
5530,Homo sapiens,80647,CHEMBL620365,,1,BAO_0000219,F,9606.0,N,Intermediate,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,,,
5531,Homo sapiens,80647,CHEMBL620366,,1,BAO_0000219,F,9606.0,N,Intermediate,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,,,
5532,Homo sapiens,80647,CHEMBL620367,,1,BAO_0000219,F,9606.0,N,Expert,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,,,
5533,Homo sapiens,80647,CHEMBL620368,,1,BAO_0000219,F,9606.0,N,Intermediate,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,,,
5534,,22226,CHEMBL620369,,1,BAO_0000019,B,,U,Autocuration,6608,Inhibitory activity against caspase-1,,,,
5535,Enterococcus faecalis,45,CHEMBL620370,,1,BAO_0000357,B,1351.0,H,Autocuration,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,,
5536,Homo sapiens,80648,CHEMBL620371,,1,BAO_0000219,F,9606.0,N,Intermediate,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,,,
5537,Homo sapiens,80648,CHEMBL620372,,1,BAO_0000219,F,9606.0,N,Intermediate,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,,,
5538,,22226,CHEMBL876492,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,,
5539,,22226,CHEMBL620373,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,,
5540,,22226,CHEMBL620374,,1,BAO_0000019,F,,U,Intermediate,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,,
5541,,22226,CHEMBL620375,,1,BAO_0000019,B,,U,Autocuration,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,,
5542,Streptococcus pyogenes,22226,CHEMBL857902,,1,BAO_0000019,F,1314.0,U,Autocuration,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,,
5543,Streptococcus pyogenes,22226,CHEMBL620376,,1,BAO_0000019,F,1314.0,U,Autocuration,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,,
5544,,11922,CHEMBL620377,,1,BAO_0000357,B,,H,Autocuration,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,,
5545,Homo sapiens,81115,CHEMBL620378,,1,BAO_0000219,F,9606.0,N,Intermediate,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,,
5546,Homo sapiens,81115,CHEMBL620379,,1,BAO_0000219,A,9606.0,N,Intermediate,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,,,,
5547,Homo sapiens,22226,CHEMBL620380,,1,BAO_0000219,F,9606.0,U,Autocuration,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,,,,
5548,Rattus norvegicus,80653,CHEMBL884006,,1,BAO_0000219,F,10116.0,N,Intermediate,12446,Cytotoxic concentration against 9L cells was determined on day 3,,,,
5549,Rattus norvegicus,80653,CHEMBL620381,,1,BAO_0000219,F,10116.0,N,Expert,15345,Tested in vitro for anticancer activity against 9L cells,,,,
5550,Rattus norvegicus,80653,CHEMBL620382,,1,BAO_0000219,F,10116.0,N,Expert,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,,,,
5551,Homo sapiens,80682,CHEMBL620383,,1,BAO_0000219,F,9606.0,N,Intermediate,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,,,
5552,Homo sapiens,80682,CHEMBL876493,,1,BAO_0000219,F,9606.0,N,Intermediate,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,,,
5553,Homo sapiens,80682,CHEMBL620384,,1,BAO_0000219,F,9606.0,N,Intermediate,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,,,
5554,Homo sapiens,80682,CHEMBL620385,,1,BAO_0000219,F,9606.0,N,Intermediate,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,,,
5555,Homo sapiens,80682,CHEMBL620386,,1,BAO_0000219,F,9606.0,N,Expert,13330,Cytotoxicity against human lung carcinoma A549 cell line,,,,
5556,Homo sapiens,25,CHEMBL620387,,1,BAO_0000219,F,9606.0,D,Expert,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,,,
5557,Homo sapiens,25,CHEMBL621404,,1,BAO_0000219,F,9606.0,D,Expert,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,,,
5558,Homo sapiens,80682,CHEMBL621405,,1,BAO_0000219,F,9606.0,N,Intermediate,14425,"In vitro growth inhibition of A549, lung carcinoma",,,,
5559,Homo sapiens,80682,CHEMBL621406,,1,BAO_0000219,F,9606.0,N,Intermediate,14425,"In vitro growth inhibition of A549, lung carcinoma.",,,,
5560,Homo sapiens,80682,CHEMBL621407,,1,BAO_0000219,F,9606.0,N,Expert,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,,
5561,Homo sapiens,80682,CHEMBL621408,,1,BAO_0000219,F,9606.0,N,Intermediate,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,,,,
5562,Homo sapiens,80682,CHEMBL885345,,1,BAO_0000219,F,9606.0,N,Expert,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,,,
5563,Homo sapiens,80682,CHEMBL621409,,1,BAO_0000219,F,9606.0,N,Intermediate,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,,,
5564,Homo sapiens,80682,CHEMBL876034,,1,BAO_0000219,F,9606.0,N,Expert,5677,Cytotoxicity in A549 (human carcinoma) cell line.,,,,
5565,Homo sapiens,80682,CHEMBL621410,,1,BAO_0000219,F,9606.0,N,Intermediate,13788,Cytotoxicity on lung carcinoma (A-549) cell line,,,,
5566,Homo sapiens,80682,CHEMBL621411,,1,BAO_0000219,F,9606.0,N,Expert,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,,,
5567,Homo sapiens,80682,CHEMBL621412,,1,BAO_0000219,F,9606.0,N,Intermediate,6726,Effective dose of compound against replication of A549 cell line was evaluated,,,,
5568,Homo sapiens,80682,CHEMBL621413,,1,BAO_0000219,F,9606.0,N,Expert,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,,,
5569,Homo sapiens,80682,CHEMBL621414,,1,BAO_0000219,F,9606.0,N,Intermediate,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,,,
5570,Homo sapiens,80682,CHEMBL621415,,1,BAO_0000219,F,9606.0,N,Intermediate,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,,,
5571,Homo sapiens,80682,CHEMBL621416,,1,BAO_0000219,F,9606.0,N,Intermediate,3936,The compound was evaluated for antiproliferative activity against A549 cell line,,,,
5572,Homo sapiens,80682,CHEMBL621417,,1,BAO_0000219,F,9606.0,N,Intermediate,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,,,
5573,Homo sapiens,80682,CHEMBL621418,,1,BAO_0000219,F,9606.0,N,Intermediate,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,,,,
5574,Homo sapiens,80682,CHEMBL621419,,1,BAO_0000219,F,9606.0,N,Intermediate,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,,,
5575,Homo sapiens,80682,CHEMBL621420,,1,BAO_0000219,F,9606.0,N,Intermediate,6776,Growth inhibition against A549 cell line was evaluated,,,,
5576,Homo sapiens,80682,CHEMBL875823,,1,BAO_0000219,F,9606.0,N,Intermediate,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,,,
5577,Homo sapiens,80682,CHEMBL621421,,1,BAO_0000219,F,9606.0,N,Expert,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,,,
5578,Homo sapiens,80682,CHEMBL621422,,1,BAO_0000219,F,9606.0,N,Intermediate,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,,,
5579,Homo sapiens,80682,CHEMBL884014,,1,BAO_0000219,F,9606.0,N,Expert,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,,,,
5580,Homo sapiens,80682,CHEMBL621423,,1,BAO_0000219,F,9606.0,N,Intermediate,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,,,
5581,Homo sapiens,80682,CHEMBL621424,,1,BAO_0000219,F,9606.0,N,Expert,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,,,
5582,Homo sapiens,80682,CHEMBL621425,,1,BAO_0000219,F,9606.0,N,Intermediate,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,,,
5583,Homo sapiens,80682,CHEMBL621426,,1,BAO_0000219,F,9606.0,N,Expert,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,,,
5584,Homo sapiens,80682,CHEMBL621427,,1,BAO_0000219,F,9606.0,N,Intermediate,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,,,
5585,Homo sapiens,80682,CHEMBL621428,,1,BAO_0000219,F,9606.0,N,Intermediate,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,,
5586,Homo sapiens,80682,CHEMBL621429,,1,BAO_0000219,F,9606.0,N,Expert,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,,,
5587,Homo sapiens,80682,CHEMBL621430,,1,BAO_0000219,F,9606.0,N,Intermediate,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,,,
5588,Homo sapiens,80682,CHEMBL621431,,1,BAO_0000219,F,9606.0,N,Intermediate,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,,,
5589,Homo sapiens,80682,CHEMBL621432,,1,BAO_0000219,F,9606.0,N,Intermediate,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,,,
5590,Homo sapiens,80682,CHEMBL621433,,1,BAO_0000219,F,9606.0,N,Expert,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,,,
5591,Homo sapiens,80682,CHEMBL875824,,1,BAO_0000219,F,9606.0,N,Intermediate,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,,
5592,Homo sapiens,80682,CHEMBL621434,,1,BAO_0000219,F,9606.0,N,Intermediate,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,,
5593,Homo sapiens,80682,CHEMBL621435,,1,BAO_0000219,F,9606.0,N,Intermediate,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,,,
5594,Homo sapiens,80682,CHEMBL621436,,1,BAO_0000219,F,9606.0,N,Intermediate,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,,,
5595,Homo sapiens,80682,CHEMBL621437,,1,BAO_0000219,F,9606.0,N,Intermediate,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,,,
5596,Homo sapiens,80682,CHEMBL621438,,1,BAO_0000219,F,9606.0,N,Intermediate,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,,,,
5597,Homo sapiens,80682,CHEMBL621439,,1,BAO_0000219,F,9606.0,N,Expert,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,,,
5598,Homo sapiens,80682,CHEMBL621440,,1,BAO_0000219,F,9606.0,N,Intermediate,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,,,
5599,Canis lupus familiaris,50588,CHEMBL621441,,1,BAO_0000218,A,9615.0,N,Intermediate,3043,Oral bioavailability in dog (conscious),In vivo,,,
5600,Canis lupus familiaris,50588,CHEMBL621442,,1,BAO_0000218,A,9615.0,N,Intermediate,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,In vivo,,,
5601,Canis lupus familiaris,50588,CHEMBL621443,,1,BAO_0000218,A,9615.0,N,Intermediate,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,In vivo,,,
5602,Canis lupus familiaris,50588,CHEMBL621444,,1,BAO_0000218,A,9615.0,N,Intermediate,4453,Oral bioavailability in dog,In vivo,,,
5603,Canis lupus familiaris,50588,CHEMBL625133,,1,BAO_0000218,A,9615.0,N,Intermediate,1696,Oral bioavailability in dog,In vivo,,,
5604,Canis lupus familiaris,50588,CHEMBL625134,,1,BAO_0000218,A,9615.0,N,Intermediate,5045,Oral bioavailability in dog,In vivo,,,
5605,Canis lupus familiaris,50588,CHEMBL625135,,1,BAO_0000218,A,9615.0,N,Intermediate,5356,Oral bioavailability in dog (fasted),In vivo,,,
5606,Canis lupus familiaris,50588,CHEMBL625136,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,In vivo,,,
5607,Canis lupus familiaris,50588,CHEMBL625137,,1,BAO_0000218,A,9615.0,N,Intermediate,6448,Oral bioavailability in dog,In vivo,,,
5608,Canis lupus familiaris,50588,CHEMBL625138,,1,BAO_0000218,A,9615.0,N,Intermediate,1475,Oral bioavailability in dog,In vivo,,,
5609,Canis lupus familiaris,50588,CHEMBL625139,,1,BAO_0000218,A,9615.0,N,Intermediate,3788,Percent bioavailability in dog,In vivo,,,
5610,Canis lupus familiaris,50588,CHEMBL872264,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,In vivo,,,
5611,Canis lupus familiaris,50588,CHEMBL625140,,1,BAO_0000218,A,9615.0,N,Intermediate,13397,Oral bioavailability in dog,In vivo,,,
5612,Canis lupus familiaris,50588,CHEMBL624436,,1,BAO_0000218,A,9615.0,N,Intermediate,2137,The compound was evaluated for bioavailability in dogs; 34-44,In vivo,,,
5613,Canis lupus familiaris,50588,CHEMBL624437,,1,BAO_0000218,A,9615.0,N,Intermediate,2959,Bioavailability in dog (dose 4 mg/kg p.o.),In vivo,,,
5614,Canis lupus familiaris,50588,CHEMBL872261,,1,BAO_0000218,A,9615.0,N,Intermediate,6448,Oral bioavailability in dog,In vivo,,,
5615,Canis lupus familiaris,50588,CHEMBL624438,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,8 hour trough Blood level in dog was measured after administration of compound,,,,
5616,Canis lupus familiaris,50588,CHEMBL624439,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,In vivo,,,Plasma
5617,Canis lupus familiaris,50588,CHEMBL624440,,1,BAO_0000218,A,9615.0,N,Intermediate,6316,C24 after oral administration at 5 mg/kg,,,,
5618,Canis lupus familiaris,50588,CHEMBL624441,,1,BAO_0000218,A,9615.0,N,Intermediate,5238,Clearance after oral and iv dosing in dogs,,,,
5619,Canis lupus familiaris,50588,CHEMBL624442,,1,BAO_0000218,A,9615.0,N,Intermediate,17796,Clearance of the drug was measured in the plasma of dog,,,,Plasma
5620,Canis lupus familiaris,50588,CHEMBL624443,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,,
5621,Canis lupus familiaris,50588,CHEMBL624444,,1,BAO_0000218,A,9615.0,N,Intermediate,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,,
5622,Canis lupus familiaris,50588,CHEMBL624445,,1,BAO_0000218,A,9615.0,N,Intermediate,6621,Clearance of compound was determined in dogs,In vivo,,,
5623,Canis lupus familiaris,50588,CHEMBL624446,,1,BAO_0000218,A,9615.0,N,Intermediate,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,In vivo,,,
5624,Canis lupus familiaris,50588,CHEMBL624447,,1,BAO_0000218,A,9615.0,N,Intermediate,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,,
5625,Canis lupus familiaris,50588,CHEMBL624448,,1,BAO_0000218,A,9615.0,N,Intermediate,17267,Plasma clearance in dog was determined,In vivo,,,
5626,Canis lupus familiaris,50588,CHEMBL624449,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,,
5627,Canis lupus familiaris,50588,CHEMBL624450,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,In vivo,,,
5628,Canis lupus familiaris,50588,CHEMBL875942,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Plasma clearance in dog after administration of 1 mg/kg iv,In vivo,,,
5629,Canis lupus familiaris,50588,CHEMBL624451,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Plasma clearance in dogs,In vivo,,,
5630,Canis lupus familiaris,50588,CHEMBL624452,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,In vivo,,,
5631,Canis lupus familiaris,50588,CHEMBL624453,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,,
5632,Canis lupus familiaris,50588,CHEMBL624454,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,In vivo,,,
5633,Canis lupus familiaris,50588,CHEMBL624455,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Plasma clearance after 30 mg/kg po dose in Dogs,In vivo,,,
5634,Canis lupus familiaris,50588,CHEMBL624456,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Plasma administration to dogs,In vivo,,,
5635,Canis lupus familiaris,50588,CHEMBL624457,,1,BAO_0000218,A,9615.0,N,Intermediate,5505,Plasma clearance was determined,In vivo,,,
5636,Canis lupus familiaris,50588,CHEMBL624458,,1,BAO_0000218,A,9615.0,N,Intermediate,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,,
5637,Canis lupus familiaris,50588,CHEMBL624459,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,,
5638,Homo sapiens,102164,CHEMBL624460,,1,BAO_0000251,A,9606.0,S,Intermediate,5007,Intrinsic clearance in human liver microsomes,In vitro,,,Liver
5639,Homo sapiens,102164,CHEMBL624461,,1,BAO_0000251,A,9606.0,S,Intermediate,5007,Intrinsic clearance in human liver microsomes,In vitro,,,Liver
5640,Canis lupus familiaris,50588,CHEMBL875943,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,,
5641,Canis lupus familiaris,50588,CHEMBL624462,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,,
5642,Canis lupus familiaris,50588,CHEMBL624463,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Clearance in dog (dose 1 mg/kg i.v.),In vivo,,,
5643,Canis lupus familiaris,50588,CHEMBL624464,,1,BAO_0000218,A,9615.0,N,Intermediate,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,In vivo,,,
5644,Canis lupus familiaris,50588,CHEMBL624465,,1,BAO_0000218,A,9615.0,N,Intermediate,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,,
5645,Canis lupus familiaris,50588,CHEMBL624466,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Plasma clearance after peroral administration at 10 mpk in dog,In vivo,,,
5646,Canis lupus familiaris,50588,CHEMBL624467,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Plasma clearance after peroral administration at 5 mpk in dog,In vivo,,,
5647,Canis lupus familiaris,50588,CHEMBL624468,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,In vivo,,,
5648,Canis lupus familiaris,50588,CHEMBL624469,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Plasma clearance was measured in dog,In vivo,,,
5649,Canis lupus familiaris,50588,CHEMBL624470,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Plasma clearance was measured in dog,In vivo,,,
5650,Canis lupus familiaris,50588,CHEMBL624471,,1,BAO_0000218,A,9615.0,N,Intermediate,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,In vivo,,,
5651,Canis lupus familiaris,50588,CHEMBL624472,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,In vivo,,,
5652,Canis lupus familiaris,50588,CHEMBL622775,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,,,
5653,Canis lupus familiaris,50588,CHEMBL622776,,1,BAO_0000218,A,9615.0,N,Intermediate,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,,,
5654,Canis lupus familiaris,50588,CHEMBL622777,,1,BAO_0000218,A,9615.0,N,Intermediate,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,,,
5655,Canis lupus familiaris,50588,CHEMBL622778,,1,BAO_0000218,A,9615.0,N,Intermediate,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,In vivo,,,
5656,Canis lupus familiaris,50588,CHEMBL622779,,1,BAO_0000218,A,9615.0,N,Intermediate,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,In vivo,,,
5657,Canis lupus familiaris,50588,CHEMBL622780,,1,BAO_0000218,A,9615.0,N,Intermediate,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,In vivo,,,
5658,Canis lupus familiaris,50588,CHEMBL622781,,1,BAO_0000218,A,9615.0,N,Intermediate,1918,Clearance value was evaluated in dog plasma,In vivo,,,Plasma
5659,Canis lupus familiaris,50588,CHEMBL622782,,1,BAO_0000218,A,9615.0,N,Intermediate,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,,,
5660,Canis lupus familiaris,50588,CHEMBL622783,,1,BAO_0000218,A,9615.0,N,Intermediate,4839,Compound was tested for plasma clearance in dog,In vivo,,,Plasma
5661,Canis lupus familiaris,50588,CHEMBL622784,,1,BAO_0000218,A,9615.0,N,Intermediate,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,In vivo,,,
5662,Mus musculus,50594,CHEMBL622785,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,,
5663,Mus musculus,50594,CHEMBL622786,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,,
5664,Mus musculus,50594,CHEMBL622787,,1,BAO_0000218,A,10090.0,N,Intermediate,5302,Area under curve value in mouse at a dose of 10 mg/kg,,,,
5665,Mus musculus,50594,CHEMBL875949,,1,BAO_0000218,A,10090.0,N,Intermediate,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,,
5666,Mus musculus,50594,CHEMBL622788,,1,BAO_0000218,A,10090.0,N,Intermediate,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,,
5667,Mus musculus,50594,CHEMBL622789,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,,
5668,Mus musculus,50594,CHEMBL622790,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,,
5669,Mus musculus,50594,CHEMBL622791,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,,
5670,Mus musculus,50594,CHEMBL622792,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,,
5671,Mus musculus,50594,CHEMBL622793,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,,
5672,Mus musculus,50594,CHEMBL622794,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Area under curve was determined for the compound at 24 mg/Kg,,,,
5673,Mus musculus,50594,CHEMBL622795,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Area under curve was determined for the compound at 40 mg/Kg,,,,
5674,Mus musculus,50594,CHEMBL621803,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Area under curve was determined for the compound at 5 mg/Kg,,,,
5675,Mus musculus,50594,CHEMBL621804,,1,BAO_0000218,A,10090.0,N,Intermediate,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,,,,
5676,Mus musculus,50594,CHEMBL621805,,1,BAO_0000218,A,10090.0,N,Intermediate,3132,Area under the curve for the compound was obtained when tested in mouse,,,,
5677,Mus musculus,50594,CHEMBL621806,,1,BAO_0000218,A,10090.0,N,Intermediate,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,,
5678,Mus musculus,50594,CHEMBL621807,,1,BAO_0000218,A,10090.0,N,Intermediate,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,,
5679,Mus musculus,50594,CHEMBL621808,,1,BAO_0000218,A,10090.0,N,Intermediate,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,,
5680,Mus musculus,50594,CHEMBL621809,,1,BAO_0000218,A,10090.0,N,Intermediate,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,,
5681,Mus musculus,50594,CHEMBL621810,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,,
5682,Mus musculus,50594,CHEMBL875164,,1,BAO_0000218,A,10090.0,N,Intermediate,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,,
5683,Mus musculus,50594,CHEMBL621811,,1,BAO_0000218,A,10090.0,N,Intermediate,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,,
5684,Mus musculus,50594,CHEMBL621812,,1,BAO_0000218,A,10090.0,N,Intermediate,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,,
5685,Mus musculus,50594,CHEMBL621813,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,,
5686,Mus musculus,50594,CHEMBL621814,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,,
5687,Mus musculus,50594,CHEMBL621815,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,,
5688,Mus musculus,50594,CHEMBL621816,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,,
5689,Mus musculus,50594,CHEMBL621817,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,,
5690,Mus musculus,50594,CHEMBL621818,,1,BAO_0000218,A,10090.0,N,Intermediate,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,,
5691,Mus musculus,50594,CHEMBL621819,,1,BAO_0000218,A,10090.0,N,Intermediate,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,,
5692,Mus musculus,50594,CHEMBL621820,,1,BAO_0000218,A,10090.0,N,Intermediate,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,,
5693,Mus musculus,50594,CHEMBL621821,,1,BAO_0000218,A,10090.0,N,Intermediate,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,,
5694,Mus musculus,50594,CHEMBL621822,,1,BAO_0000218,A,10090.0,N,Intermediate,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,,
5695,Mus musculus,50594,CHEMBL619474,,1,BAO_0000218,A,10090.0,N,Intermediate,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,,
5696,Mus musculus,50594,CHEMBL619475,,1,BAO_0000218,A,10090.0,N,Intermediate,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,,
5697,Mus musculus,50594,CHEMBL619476,,1,BAO_0000218,A,10090.0,N,Intermediate,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,,
5698,Mus musculus,50594,CHEMBL619477,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,,
5699,Mus musculus,50594,CHEMBL619478,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,,
5700,Mus musculus,50594,CHEMBL619479,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,,
5701,Mus musculus,50594,CHEMBL619480,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,,
5702,Mus musculus,50594,CHEMBL619481,,1,BAO_0000218,A,10090.0,N,Intermediate,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,,
5703,Mus musculus,50594,CHEMBL619482,,1,BAO_0000218,A,10090.0,N,Intermediate,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,,
5704,Mus musculus,50594,CHEMBL619483,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Area under the curve was evaluated in mice after intravenous administration,,,,
5705,Mus musculus,50594,CHEMBL619484,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Area under the curve was evaluated in mice after oral administration,,,,
5706,Mus musculus,50594,CHEMBL619485,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,,Plasma
5707,Mus musculus,50594,CHEMBL619486,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,,Plasma
5708,Mus musculus,50594,CHEMBL619487,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,,
5709,Mus musculus,50594,CHEMBL619488,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,,
5710,Mus musculus,50594,CHEMBL620106,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,In vivo,,,Blood
5711,,80653,CHEMBL620107,,1,BAO_0000219,F,,N,Intermediate,15345,The compound was tested in vitro for anticancer activity against 9L cells,,,,
5712,Rattus norvegicus,22226,CHEMBL620283,,1,BAO_0000019,F,10116.0,U,Autocuration,2181,Anti proliferation activity determined; Weak effect,,,,
5713,Rattus norvegicus,22226,CHEMBL875176,,1,BAO_0000219,F,10116.0,U,Autocuration,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,,
5714,Rattus norvegicus,22226,CHEMBL620284,,1,BAO_0000219,F,10116.0,U,Autocuration,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,,
5715,Rattus norvegicus,22226,CHEMBL623515,,1,BAO_0000219,F,10116.0,U,Autocuration,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,,
5716,Mus musculus,22226,CHEMBL623516,,1,BAO_0000019,F,10090.0,U,Autocuration,10486,The cytotoxic activity was in vitro tested by 9PS assay method,,,,
5717,Mus musculus,22226,CHEMBL623517,,1,BAO_0000019,F,10090.0,U,Autocuration,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,,,,
5718,,22224,CHEMBL857878,,1,BAO_0000019,A,,U,Autocuration,15508,Partition coefficient (logD6.5),,,,
5719,Homo sapiens,81034,CHEMBL623518,,1,BAO_0000219,F,9606.0,N,Expert,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,,,
5720,Homo sapiens,80018,CHEMBL624195,,1,BAO_0000219,F,9606.0,N,Intermediate,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,,,
5721,Homo sapiens,80852,CHEMBL624196,,1,BAO_0000219,F,9606.0,N,Expert,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,,,
5722,Homo sapiens,9,CHEMBL624197,,1,BAO_0000219,F,9606.0,D,Expert,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,,,
5723,Homo sapiens,80021,CHEMBL624198,,1,BAO_0000219,F,9606.0,N,Intermediate,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,,,
5724,Homo sapiens,80021,CHEMBL621287,,1,BAO_0000219,F,9606.0,N,Intermediate,2596,in vitro cytotoxicity against A 498 cancer cell line,,,,
5725,Homo sapiens,80021,CHEMBL621288,,1,BAO_0000219,F,9606.0,N,Intermediate,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,,,
5726,Homo sapiens,80021,CHEMBL876496,,1,BAO_0000219,F,9606.0,N,Intermediate,1847,Cytotoxic activity against A 498 renal cancer cell lines.,,,,
5727,Homo sapiens,80021,CHEMBL621289,,1,BAO_0000219,F,9606.0,N,Intermediate,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,,,
5728,Staphylococcus aureus,22226,CHEMBL621290,,1,BAO_0000019,F,1280.0,U,Autocuration,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,,
5729,Staphylococcus aureus,22226,CHEMBL621291,,1,BAO_0000019,F,1280.0,U,Autocuration,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,,
5730,Staphylococcus aureus,22226,CHEMBL621292,,1,BAO_0000019,F,1280.0,U,Autocuration,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,,
5731,Staphylococcus aureus,22226,CHEMBL621293,,1,BAO_0000019,F,1280.0,U,Autocuration,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,,
5732,Homo sapiens,80682,CHEMBL621294,,1,BAO_0000219,F,9606.0,N,Intermediate,4782,Inhibitory concentration required against A 549 lung cancer cell line,,,,
5733,Homo sapiens,80682,CHEMBL621295,,1,BAO_0000219,F,9606.0,N,Intermediate,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,,,
5734,Homo sapiens,80682,CHEMBL884007,,1,BAO_0000219,F,9606.0,N,Intermediate,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,,,
5735,Homo sapiens,80682,CHEMBL621296,,1,BAO_0000219,F,9606.0,N,Intermediate,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,,,,
5736,Homo sapiens,80682,CHEMBL621297,,1,BAO_0000219,F,9606.0,N,Intermediate,4594,Compound was tested for its cytotoxicity against A 549 cell line,,,,
5737,Homo sapiens,80682,CHEMBL839828,,1,BAO_0000219,F,9606.0,N,Expert,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,,,
5738,Homo sapiens,80682,CHEMBL620397,,1,BAO_0000219,F,9606.0,N,Intermediate,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,,,
5739,Homo sapiens,80682,CHEMBL620398,,1,BAO_0000219,F,9606.0,N,Expert,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,,,
5740,Homo sapiens,80682,CHEMBL620399,,1,BAO_0000219,F,9606.0,N,Intermediate,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,,
5741,Homo sapiens,80682,CHEMBL620400,,1,BAO_0000219,F,9606.0,N,Expert,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,,,,
5742,Homo sapiens,80682,CHEMBL620401,,1,BAO_0000219,F,9606.0,N,Intermediate,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,,,
5743,Homo sapiens,80682,CHEMBL620402,,1,BAO_0000219,F,9606.0,N,Expert,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,,,
5744,Homo sapiens,80682,CHEMBL620403,,1,BAO_0000219,F,9606.0,N,Expert,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,,,
5745,,22226,CHEMBL620404,,1,BAO_0000218,F,,U,Autocuration,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,,
5746,,104694,CHEMBL620405,,1,BAO_0000218,F,,H,Autocuration,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,In vivo,,,
5747,,104694,CHEMBL620406,,1,BAO_0000218,F,,H,Autocuration,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,In vivo,,,
5748,,104694,CHEMBL620407,,1,BAO_0000218,F,,H,Autocuration,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,In vivo,,,
5749,,104694,CHEMBL620408,,1,BAO_0000218,F,,H,Autocuration,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,In vivo,,,
5750,,104694,CHEMBL620409,,1,BAO_0000218,F,,H,Autocuration,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,In vivo,,,
5751,Homo sapiens,80021,CHEMBL620410,,1,BAO_0000219,F,9606.0,N,Expert,3600,Inhibition of A-498 human Renal cell proliferation,,,,
5752,Rattus norvegicus,22226,CHEMBL620411,,1,BAO_0000019,F,10116.0,U,Autocuration,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,,
5753,Rattus norvegicus,22226,CHEMBL620412,,1,BAO_0000019,F,10116.0,U,Autocuration,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,,
5754,Rattus norvegicus,22226,CHEMBL876596,,1,BAO_0000019,F,10116.0,U,Autocuration,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,,
5755,Homo sapiens,80012,CHEMBL620413,,1,BAO_0000219,F,9606.0,N,Expert,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,,,
5756,Homo sapiens,80012,CHEMBL620414,,1,BAO_0000219,F,9606.0,N,Intermediate,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,,
5757,Homo sapiens,80012,CHEMBL620415,,1,BAO_0000219,F,9606.0,N,Intermediate,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,,
5758,Homo sapiens,80682,CHEMBL620416,,1,BAO_0000219,F,9606.0,N,Expert,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,,,
5759,Homo sapiens,80682,CHEMBL620417,,1,BAO_0000219,F,9606.0,N,Intermediate,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,,,
5760,Homo sapiens,80682,CHEMBL620418,,1,BAO_0000219,F,9606.0,N,Expert,13799,Cytotoxic activity evaluated against A549 tumor cells,,,,
5761,Homo sapiens,80682,CHEMBL620419,,1,BAO_0000219,F,9606.0,N,Intermediate,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,,,
5762,Homo sapiens,80682,CHEMBL620420,,1,BAO_0000219,F,9606.0,N,Intermediate,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,,,
5763,Homo sapiens,80682,CHEMBL620421,,1,BAO_0000219,F,9606.0,N,Intermediate,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,,,
5764,Homo sapiens,80682,CHEMBL620422,,1,BAO_0000219,F,9606.0,N,Intermediate,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,,,
5765,Homo sapiens,80682,CHEMBL620423,,1,BAO_0000219,F,9606.0,N,Intermediate,6851,Cytotoxicity of compound against A549 cell line,,,,
5766,Homo sapiens,80682,CHEMBL620424,,1,BAO_0000219,F,9606.0,N,Expert,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,,,,
5767,Homo sapiens,80682,CHEMBL620425,,1,BAO_0000219,F,9606.0,N,Intermediate,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,,,
5768,Homo sapiens,80682,CHEMBL620426,,1,BAO_0000219,F,9606.0,N,Intermediate,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,,,
5769,Homo sapiens,80682,CHEMBL620427,,1,BAO_0000219,F,9606.0,N,Intermediate,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,,,
5770,Homo sapiens,80682,CHEMBL620428,,1,BAO_0000219,F,9606.0,N,Intermediate,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,,,
5771,Homo sapiens,80682,CHEMBL620429,,1,BAO_0000219,F,9606.0,N,Intermediate,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,,,
5772,Homo sapiens,80682,CHEMBL620430,,1,BAO_0000219,F,9606.0,N,Expert,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,,,
5773,Homo sapiens,80682,CHEMBL839887,,1,BAO_0000219,F,9606.0,N,Expert,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,,
5774,Homo sapiens,80682,CHEMBL620431,,1,BAO_0000219,F,9606.0,N,Intermediate,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,,,
5775,Homo sapiens,80682,CHEMBL884010,,1,BAO_0000219,F,9606.0,N,Intermediate,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,,,
5776,Homo sapiens,80682,CHEMBL620538,,1,BAO_0000219,F,9606.0,N,Intermediate,5895,In vitro cytotoxicity against A549 (human lung cancer),,,,
5777,Homo sapiens,80682,CHEMBL620539,,1,BAO_0000219,F,9606.0,N,Expert,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,,
5778,Homo sapiens,80682,CHEMBL623373,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,In vivo antiproliferative activity against A549 cell line,,,,
5779,Homo sapiens,80682,CHEMBL623374,,1,BAO_0000219,F,9606.0,N,Intermediate,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),,,,
5780,Homo sapiens,80682,CHEMBL623375,,1,BAO_0000219,F,9606.0,N,Intermediate,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,,,
5781,Homo sapiens,80682,CHEMBL623376,,1,BAO_0000219,F,9606.0,N,Intermediate,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,,,
5782,Homo sapiens,80682,CHEMBL623377,,1,BAO_0000219,F,9606.0,N,Intermediate,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,,,
5783,Homo sapiens,80682,CHEMBL623378,,1,BAO_0000219,F,9606.0,N,Intermediate,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,,,
5784,Homo sapiens,80682,CHEMBL623379,,1,BAO_0000219,F,9606.0,N,Intermediate,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,,,
5785,Homo sapiens,80682,CHEMBL623380,,1,BAO_0000219,F,9606.0,N,Intermediate,4862,Inhibitory activity against A549 lung cancer cell line,,,,
5786,Homo sapiens,80682,CHEMBL623381,,1,BAO_0000219,F,9606.0,N,Intermediate,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,,,
5787,Homo sapiens,80682,CHEMBL623382,,1,BAO_0000219,F,9606.0,N,Intermediate,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,,,
5788,Homo sapiens,80682,CHEMBL623383,,1,BAO_0000219,F,9606.0,N,Intermediate,15970,Inhibitory concentration against A549 (lung cancer) cell line,,,,
5789,Homo sapiens,80682,CHEMBL623384,,1,BAO_0000219,F,9606.0,N,Expert,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,,,
5790,Homo sapiens,80682,CHEMBL623385,,1,BAO_0000219,F,9606.0,N,Intermediate,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,,,
5791,Homo sapiens,80682,CHEMBL623386,,1,BAO_0000219,F,9606.0,N,Expert,13736,Activity against A549 cancer cell line.,,,,
5792,Homo sapiens,80682,CHEMBL884105,,1,BAO_0000219,F,9606.0,N,Intermediate,4312,The compound was evaluated for cytotoxicity against A549 cell line,,,,
5793,Homo sapiens,80682,CHEMBL623387,,1,BAO_0000219,F,9606.0,N,Intermediate,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,,,
5794,Homo sapiens,80682,CHEMBL621568,,1,BAO_0000219,F,9606.0,N,Intermediate,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,,,
5795,Homo sapiens,80682,CHEMBL621569,,1,BAO_0000219,F,9606.0,N,Intermediate,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,,,,
5796,Homo sapiens,80682,CHEMBL621570,,1,BAO_0000219,F,9606.0,N,Intermediate,4634,Inhibitory activity against A549 lung cancer cell line,,,,
5797,Homo sapiens,80682,CHEMBL621571,,1,BAO_0000219,F,9606.0,N,Intermediate,1149,Inhibitory activity against A549 cell line; inactive,,,,
5798,Homo sapiens,80682,CHEMBL621572,,1,BAO_0000219,F,9606.0,N,Expert,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,,
5799,Homo sapiens,80682,CHEMBL621573,,1,BAO_0000219,F,9606.0,N,Expert,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,,,
5800,Homo sapiens,80682,CHEMBL621574,,1,BAO_0000219,F,9606.0,N,Intermediate,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,,,
5801,Homo sapiens,80682,CHEMBL621575,,1,BAO_0000219,F,9606.0,N,Intermediate,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,,,
5802,Homo sapiens,80682,CHEMBL621576,,1,BAO_0000219,F,9606.0,N,Intermediate,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,,,
5803,Homo sapiens,80682,CHEMBL621577,,1,BAO_0000219,F,9606.0,N,Intermediate,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,,,
5804,Homo sapiens,80682,CHEMBL621578,,1,BAO_0000219,F,9606.0,N,Intermediate,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,,,
5805,Homo sapiens,80682,CHEMBL621579,,1,BAO_0000219,F,9606.0,N,Intermediate,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,,,
5806,Homo sapiens,80682,CHEMBL621580,,1,BAO_0000219,F,9606.0,N,Intermediate,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,,,
5807,Canis lupus familiaris,50588,CHEMBL621581,,1,BAO_0000218,A,9615.0,N,Intermediate,17800,Plasma clearance (in vivo) in mongrel dogs was determined,In vivo,,,
5808,Canis lupus familiaris,50588,CHEMBL621582,,1,BAO_0000218,A,9615.0,N,Intermediate,5985,Plasma clearance was measured in dog,In vivo,,,
5809,Canis lupus familiaris,50588,CHEMBL621583,,1,BAO_0000218,A,9615.0,N,Intermediate,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,,,
5810,Canis lupus familiaris,50588,CHEMBL621584,,1,BAO_0000218,A,9615.0,N,Intermediate,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,,,
5811,Canis lupus familiaris,50588,CHEMBL621585,,1,BAO_0000218,A,9615.0,N,Intermediate,4839,Tested for plasma clearance in dog,In vivo,,,Plasma
5812,Canis lupus familiaris,50588,CHEMBL621586,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,The compound was tested for clearance in dog plasma.,In vivo,,,
5813,Canis lupus familiaris,50588,CHEMBL875835,,1,BAO_0000218,A,9615.0,N,Intermediate,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",In vivo,,,
5814,Canis lupus familiaris,50588,CHEMBL621587,,1,BAO_0000218,A,9615.0,N,Intermediate,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,In vivo,,,
5815,Canis lupus familiaris,50588,CHEMBL621588,,1,BAO_0000218,A,9615.0,N,Intermediate,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,,,Plasma
5816,Canis lupus familiaris,50588,CHEMBL621589,,1,BAO_0000218,A,9615.0,N,Intermediate,17538,In vitro clearance in dog liver microsomes,In vitro,,,Liver
5817,Canis lupus familiaris,50588,CHEMBL621590,,1,BAO_0000218,A,9615.0,N,Intermediate,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,In vivo,,,
5818,Canis lupus familiaris,50588,CHEMBL621591,,1,BAO_0000218,A,9615.0,N,Intermediate,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,In vivo,,,
5819,Canis lupus familiaris,50588,CHEMBL621592,,1,BAO_0000218,A,9615.0,N,Intermediate,1696,Plasma clearance in dog,In vivo,,,
5820,Canis lupus familiaris,50588,CHEMBL621593,,1,BAO_0000218,A,9615.0,N,Intermediate,6762,Clearance rate in dog,In vivo,,,
5821,Canis lupus familiaris,50588,CHEMBL621594,,1,BAO_0000218,A,9615.0,N,Intermediate,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,In vivo,,,Plasma
5822,Canis lupus familiaris,50588,CHEMBL621595,,1,BAO_0000218,A,9615.0,N,Intermediate,6305,Clearance in dogs,In vivo,,,
5823,Canis lupus familiaris,50588,CHEMBL621596,,1,BAO_0000218,A,9615.0,N,Intermediate,4942,Plasma clearance in dogs,In vivo,,,
5824,Canis lupus familiaris,50588,CHEMBL621597,,1,BAO_0000218,A,9615.0,N,Intermediate,4219,Plasma clearance was determined,In vivo,,,
5825,Canis lupus familiaris,50588,CHEMBL621598,,1,BAO_0000218,A,9615.0,N,Intermediate,17853,Lower clearance in dog (i.v.) at 0.5 mpk,In vivo,,,
5826,Canis lupus familiaris,50588,CHEMBL621599,,1,BAO_0000218,A,9615.0,N,Intermediate,4514,Plasma clearance in Beagle dogs,In vivo,,,
5827,Canis lupus familiaris,50588,CHEMBL875836,,1,BAO_0000218,A,9615.0,N,Intermediate,6448,Plasma clearance (Clp) in dog,In vivo,,,
5828,Canis lupus familiaris,50588,CHEMBL621600,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,In vivo,,,
5829,Canis lupus familiaris,50588,CHEMBL621601,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,In vivo,,,
5830,Canis lupus familiaris,50588,CHEMBL618474,,1,BAO_0000218,A,9615.0,N,Intermediate,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,In vivo,,,
5831,Canis lupus familiaris,50588,CHEMBL618475,,1,BAO_0000218,A,9615.0,N,Intermediate,6821,Plasma clearance of compound was determined in dog,In vivo,,,
5832,Canis lupus familiaris,50588,CHEMBL624524,,1,BAO_0000218,A,9615.0,N,Intermediate,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,In vivo,,,
5833,Canis lupus familiaris,50588,CHEMBL624525,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,,
5834,Canis lupus familiaris,50588,CHEMBL624526,,1,BAO_0000218,A,9615.0,N,Intermediate,5374,Plasma clearance in dog was determined,In vivo,,,
5835,Canis lupus familiaris,50588,CHEMBL624527,,1,BAO_0000218,A,9615.0,N,Intermediate,6057,Plasma clearance was calculated in dog,In vivo,,,
5836,Canis lupus familiaris,50588,CHEMBL624528,,1,BAO_0000218,A,9615.0,N,Intermediate,4727,Plasma clearance at the dose of 2 mg/kg in dog,In vivo,,,
5837,Canis lupus familiaris,50588,CHEMBL624529,,1,BAO_0000218,A,9615.0,N,Intermediate,5145,Plasma clearance in dog,In vivo,,,
5838,Canis lupus familiaris,50588,CHEMBL624530,,1,BAO_0000218,A,9615.0,N,Intermediate,17657,Plasma clearance in dog,In vivo,,,
5839,Canis lupus familiaris,50588,CHEMBL624531,,1,BAO_0000218,A,9615.0,N,Intermediate,17657,Plasma clearance in dog; Unable to calculate,In vivo,,,
5840,Canis lupus familiaris,50588,CHEMBL624532,,1,BAO_0000218,A,9615.0,N,Intermediate,5145,Plasma clearance in rhesus monkey,In vivo,,,
5841,Canis lupus familiaris,50588,CHEMBL624533,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,,
5842,Canis lupus familiaris,50588,CHEMBL624534,,1,BAO_0000218,A,9615.0,N,Intermediate,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
5843,Canis lupus familiaris,50588,CHEMBL624535,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
5844,Canis lupus familiaris,50588,CHEMBL624536,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Plasma clearance was evaluated in dog,In vivo,,,
5845,Canis lupus familiaris,50588,CHEMBL624537,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Plasma clearance was evaluated in dog; Not tested,In vivo,,,
5846,Canis lupus familiaris,50588,CHEMBL624538,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Plasma clearance was evaluated in rhesus,In vivo,,,
5847,Canis lupus familiaris,50588,CHEMBL624539,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Plasma clearance was evaluated in rhesus; Not tested,In vivo,,,
5848,Canis lupus familiaris,50588,CHEMBL624540,,1,BAO_0000218,A,9615.0,N,Intermediate,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,In vivo,,,
5849,Canis lupus familiaris,50588,CHEMBL624541,,1,BAO_0000218,A,9615.0,N,Intermediate,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,,
5850,Canis lupus familiaris,50588,CHEMBL624542,,1,BAO_0000218,A,9615.0,N,Intermediate,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,,,
5851,Canis lupus familiaris,50588,CHEMBL624543,,1,BAO_0000218,A,9615.0,N,Intermediate,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,,
5852,Canis lupus familiaris,50588,CHEMBL624544,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Clearance value at a dose of 0.2 mg/kg i.v.,In vivo,,,
5853,Canis lupus familiaris,50588,CHEMBL624545,,1,BAO_0000218,A,9615.0,N,Intermediate,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,In vivo,,,Plasma
5854,Canis lupus familiaris,50588,CHEMBL624546,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,In vivo,,,
5855,Canis lupus familiaris,50588,CHEMBL875957,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,In vivo,,,
5856,Canis lupus familiaris,50588,CHEMBL624547,,1,BAO_0000218,A,9615.0,N,Intermediate,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,,
5857,Canis lupus familiaris,50588,CHEMBL624548,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,,,
5858,Canis lupus familiaris,50588,CHEMBL624549,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Cmax in dog after administration of 1 mg/kg iv,In vivo,,,
5859,Canis lupus familiaris,50588,CHEMBL624550,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,In vivo,,,Plasma
5860,Canis lupus familiaris,50588,CHEMBL621613,,1,BAO_0000218,A,9615.0,N,Intermediate,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,In vivo,,,
5861,Canis lupus familiaris,50588,CHEMBL621614,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Cmax was determine after peroral administration at 10 mpk in dog,In vivo,,,
5862,Canis lupus familiaris,50588,CHEMBL623431,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Cmax was determine after peroral administration at 5 mpk in dog,In vivo,,,
5863,Canis lupus familiaris,50588,CHEMBL623432,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,In vivo,,,
5864,Canis lupus familiaris,50588,CHEMBL623433,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Cmax after 0.3 mg/kg po administration in dog,In vivo,,,
5865,Canis lupus familiaris,50588,CHEMBL623434,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,In vivo,,,
5866,Canis lupus familiaris,50588,CHEMBL623435,,1,BAO_0000218,A,9615.0,N,Intermediate,6123,Cmax in dog after oral administration at 1 mg/kg,In vivo,,,
5867,Canis lupus familiaris,50588,CHEMBL623436,,1,BAO_0000218,A,9615.0,N,Intermediate,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,In vivo,,,
5868,Canis lupus familiaris,50588,CHEMBL875958,,1,BAO_0000218,A,9615.0,N,Intermediate,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,In vivo,,,
5869,Canis lupus familiaris,50588,CHEMBL623437,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Cmax value after 15 mg/kg iv dose in Dogs,In vivo,,,
5870,Mus musculus,50594,CHEMBL623438,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Blood
5871,Mus musculus,50594,CHEMBL623439,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Blood
5872,Mus musculus,50594,CHEMBL623440,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Bone
5873,Mus musculus,50594,CHEMBL623441,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Bone
5874,Mus musculus,50594,CHEMBL623442,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Bone
5875,Mus musculus,50594,CHEMBL623469,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,
5876,Mus musculus,50594,CHEMBL623470,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,
5877,Mus musculus,50594,CHEMBL623471,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,
5878,Mus musculus,50594,CHEMBL623472,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Heart
5879,Mus musculus,50594,CHEMBL623473,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Heart
5880,Mus musculus,50594,CHEMBL623474,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Heart
5881,Mus musculus,50594,CHEMBL623475,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Kidney
5882,Mus musculus,50594,CHEMBL623476,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Kidney
5883,Mus musculus,50594,CHEMBL623477,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Kidney
5884,Mus musculus,50594,CHEMBL621896,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Intestine
5885,Mus musculus,50594,CHEMBL621897,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Intestine
5886,Mus musculus,50594,CHEMBL621898,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Intestine
5887,Mus musculus,50594,CHEMBL621899,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Liver
5888,Mus musculus,50594,CHEMBL621900,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Liver
5889,Mus musculus,50594,CHEMBL621901,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Liver
5890,Mus musculus,50594,CHEMBL621902,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Lung
5891,Mus musculus,50594,CHEMBL621903,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Lung
5892,Mus musculus,50594,CHEMBL622587,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Lung
5893,Mus musculus,50594,CHEMBL620285,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Muscle tissue
5894,Mus musculus,50594,CHEMBL875285,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Muscle tissue
5895,Mus musculus,50594,CHEMBL620286,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Muscle tissue
5896,Mus musculus,50594,CHEMBL620287,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,
5897,Mus musculus,50594,CHEMBL620288,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,
5898,Mus musculus,50594,CHEMBL620289,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,
5899,Mus musculus,50594,CHEMBL620290,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Intestine
5900,Mus musculus,50594,CHEMBL620291,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Intestine
5901,Mus musculus,50594,CHEMBL620292,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Intestine
5902,Mus musculus,50594,CHEMBL620293,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Spleen
5903,Mus musculus,50594,CHEMBL620294,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Spleen
5904,Mus musculus,50594,CHEMBL618614,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Spleen
5905,Mus musculus,50594,CHEMBL618615,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Stomach
5906,Mus musculus,50594,CHEMBL618616,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,In vivo,,,Stomach
5907,Homo sapiens,80012,CHEMBL618617,,1,BAO_0000219,F,9606.0,N,Expert,2036,Cytotoxicity against A-172 human tumor cell lines,,,,
5908,Homo sapiens,80012,CHEMBL618618,,1,BAO_0000219,F,9606.0,N,Intermediate,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,,,
5909,Homo sapiens,80014,CHEMBL618619,,1,BAO_0000219,F,9606.0,N,Intermediate,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,,,
5910,Homo sapiens,81034,CHEMBL618620,,1,BAO_0000219,F,9606.0,N,Intermediate,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,,,,
5911,Homo sapiens,80018,CHEMBL618621,,1,BAO_0000219,F,9606.0,N,Intermediate,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,,,
5912,Homo sapiens,80018,CHEMBL618622,,1,BAO_0000219,F,9606.0,N,Intermediate,12152,Tested in vitro against A-375 cell line human melanoma,,,,
5913,Homo sapiens,80019,CHEMBL618623,,1,BAO_0000219,F,9606.0,N,Expert,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,,,
5914,Homo sapiens,80019,CHEMBL618624,,1,BAO_0000219,F,9606.0,N,Intermediate,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,,
5915,Homo sapiens,80019,CHEMBL618625,,1,BAO_0000219,F,9606.0,N,Expert,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,,,
5916,Homo sapiens,80019,CHEMBL618626,,1,BAO_0000219,F,9606.0,N,Intermediate,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,,,
5917,Homo sapiens,80019,CHEMBL618627,,1,BAO_0000219,F,9606.0,N,Intermediate,10413,Antitumor activity on A-427 lung carcinoma cell lines,,,,
5918,Homo sapiens,80019,CHEMBL618628,,1,BAO_0000219,F,9606.0,N,Intermediate,6418,Cytotoxic activity against human A-427 lung tumor cell line,,,,
5919,Homo sapiens,80019,CHEMBL618629,,1,BAO_0000219,F,9606.0,N,Expert,17134,In vitro antitumor effects against human A-427 cell lines.,,,,
5920,Homo sapiens,80019,CHEMBL618630,,1,BAO_0000219,F,9606.0,N,Expert,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,,,,
5921,Homo sapiens,80019,CHEMBL618631,,1,BAO_0000219,F,9606.0,N,Intermediate,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,,,
5922,Homo sapiens,80019,CHEMBL618632,,1,BAO_0000219,F,9606.0,N,Intermediate,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,,,,
5923,Homo sapiens,80852,CHEMBL618633,,1,BAO_0000219,F,9606.0,N,Expert,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,,,
5924,Homo sapiens,80021,CHEMBL619315,,1,BAO_0000219,F,9606.0,N,Intermediate,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,,,
5925,Homo sapiens,80021,CHEMBL619316,,1,BAO_0000219,F,9606.0,N,Expert,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,,,
5926,Homo sapiens,80021,CHEMBL619317,,1,BAO_0000219,F,9606.0,N,Intermediate,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,,,,
5927,Homo sapiens,80021,CHEMBL619318,,1,BAO_0000219,F,9606.0,N,Intermediate,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,,,
5928,Homo sapiens,80021,CHEMBL619319,,1,BAO_0000219,F,9606.0,N,Intermediate,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,,,
5929,Homo sapiens,80021,CHEMBL619739,,1,BAO_0000219,F,9606.0,N,Intermediate,4461,Antitumor cytotoxic activity against A-498 cell line was determined,,,,
5930,Homo sapiens,80021,CHEMBL619740,,1,BAO_0000219,F,9606.0,N,Intermediate,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,,,
5931,Homo sapiens,80021,CHEMBL883158,,1,BAO_0000219,F,9606.0,N,Intermediate,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,,,
5932,Homo sapiens,80021,CHEMBL884012,,1,BAO_0000219,F,9606.0,N,Intermediate,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,,,
5933,Homo sapiens,80021,CHEMBL619741,,1,BAO_0000219,F,9606.0,N,Intermediate,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,,,
5934,Homo sapiens,80021,CHEMBL619742,,1,BAO_0000219,F,9606.0,N,Intermediate,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,,,
5935,Homo sapiens,80682,CHEMBL876610,,1,BAO_0000219,F,9606.0,N,Intermediate,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,,,
5936,Homo sapiens,80682,CHEMBL619743,,1,BAO_0000219,F,9606.0,N,Intermediate,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,,,
5937,Homo sapiens,80682,CHEMBL619744,,1,BAO_0000219,F,9606.0,N,Intermediate,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,,,,
5938,Homo sapiens,80682,CHEMBL619745,,1,BAO_0000219,F,9606.0,N,Intermediate,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,,,
5939,Homo sapiens,80682,CHEMBL619746,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,,,
5940,Homo sapiens,80682,CHEMBL619747,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,,,
5941,Homo sapiens,80682,CHEMBL619748,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,,,
5942,Homo sapiens,80682,CHEMBL619749,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,,,
5943,Homo sapiens,80682,CHEMBL619750,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,,,
5944,Homo sapiens,80682,CHEMBL624014,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,,,
5945,Homo sapiens,80682,CHEMBL624015,,1,BAO_0000219,F,9606.0,N,Intermediate,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,,,
5946,Homo sapiens,80682,CHEMBL885344,,1,BAO_0000219,F,9606.0,N,Expert,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,,,
5947,Homo sapiens,80682,CHEMBL623224,,1,BAO_0000219,F,9606.0,N,Intermediate,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,,,
5948,Homo sapiens,80682,CHEMBL623225,,1,BAO_0000219,F,9606.0,N,Intermediate,6513,Cytotoxic activity against A-549 cell line,,,,
5949,Homo sapiens,80682,CHEMBL622698,,1,BAO_0000219,F,9606.0,N,Intermediate,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,,,
5950,Homo sapiens,80682,CHEMBL622699,,1,BAO_0000219,F,9606.0,N,Intermediate,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,,,
5951,Homo sapiens,80682,CHEMBL622700,,1,BAO_0000219,F,9606.0,N,Expert,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,,,
5952,Homo sapiens,80682,CHEMBL622701,,1,BAO_0000219,F,9606.0,N,Intermediate,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,,,
5953,Homo sapiens,80682,CHEMBL622702,,1,BAO_0000219,F,9606.0,N,Intermediate,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,,,
5954,Homo sapiens,80682,CHEMBL622703,,1,BAO_0000219,F,9606.0,N,Intermediate,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,,,,
5955,Homo sapiens,80682,CHEMBL622704,,1,BAO_0000219,F,9606.0,N,Expert,5771,Cytotoxic activity towards A-549 cells,,,,
5956,Homo sapiens,80682,CHEMBL622705,,1,BAO_0000219,F,9606.0,N,Intermediate,14425,"In vitro percent inhibition of A549, lung carcinoma.",,,,
5957,Homo sapiens,80682,CHEMBL622706,,1,BAO_0000219,F,9606.0,N,Intermediate,14425,"In vitro percent inhibition of A549, lung carcinoma",,,,
5958,Homo sapiens,80682,CHEMBL622707,,1,BAO_0000219,F,9606.0,N,Intermediate,14425,"In vitro percent inhibition of A549, lung carcinoma.",,,,
5959,Homo sapiens,80682,CHEMBL622708,,1,BAO_0000219,F,9606.0,N,Intermediate,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,,,
5960,Homo sapiens,80682,CHEMBL622709,,1,BAO_0000219,F,9606.0,N,Intermediate,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,,,
5961,Homo sapiens,80682,CHEMBL622710,,1,BAO_0000219,F,9606.0,N,Intermediate,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,,,
5962,Homo sapiens,80682,CHEMBL622711,,1,BAO_0000219,F,9606.0,N,Intermediate,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,,,
5963,Homo sapiens,80682,CHEMBL622712,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,,
5964,Homo sapiens,80682,CHEMBL622713,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,,
5965,Homo sapiens,80682,CHEMBL622714,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,,
5966,Homo sapiens,80682,CHEMBL622715,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,,
5967,Homo sapiens,80682,CHEMBL622716,,1,BAO_0000218,F,9606.0,N,Intermediate,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,,,
5968,Homo sapiens,80682,CHEMBL622717,,1,BAO_0000219,F,9606.0,N,Intermediate,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,,,
5969,Homo sapiens,80682,CHEMBL622718,,1,BAO_0000218,F,9606.0,N,Intermediate,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,,,
5970,Homo sapiens,80682,CHEMBL622719,,1,BAO_0000219,F,9606.0,N,Expert,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,,,
5971,Homo sapiens,80682,CHEMBL622720,,1,BAO_0000219,F,9606.0,N,Intermediate,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,,
5972,Homo sapiens,80682,CHEMBL622721,,1,BAO_0000219,F,9606.0,N,Intermediate,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,,,
5973,Homo sapiens,80682,CHEMBL622722,,1,BAO_0000219,F,9606.0,N,Intermediate,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,,,
5974,Homo sapiens,80682,CHEMBL876030,,1,BAO_0000219,F,9606.0,N,Intermediate,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,,
5975,Homo sapiens,80682,CHEMBL620206,,1,BAO_0000219,F,9606.0,N,Intermediate,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,,,
5976,Homo sapiens,80682,CHEMBL620207,,1,BAO_0000219,F,9606.0,N,Expert,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,,,
5977,Homo sapiens,80682,CHEMBL620208,,1,BAO_0000219,F,9606.0,N,Expert,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,,,
5978,Homo sapiens,80682,CHEMBL620209,,1,BAO_0000219,F,9606.0,N,Expert,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,,,
5979,Homo sapiens,80682,CHEMBL620210,,1,BAO_0000219,F,9606.0,N,Expert,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,,,
5980,Homo sapiens,80682,CHEMBL621639,,1,BAO_0000219,F,9606.0,N,Expert,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,,,
5981,Homo sapiens,80682,CHEMBL621640,,1,BAO_0000219,F,9606.0,N,Intermediate,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,,,
5982,Homo sapiens,80682,CHEMBL621641,,1,BAO_0000219,F,9606.0,N,Expert,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,,
5983,Homo sapiens,80682,CHEMBL621642,,1,BAO_0000219,F,9606.0,N,Expert,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,,,
5984,Homo sapiens,80682,CHEMBL621643,,1,BAO_0000219,F,9606.0,N,Intermediate,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,,,
5985,Homo sapiens,80682,CHEMBL621644,,1,BAO_0000219,F,9606.0,N,Intermediate,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,,,
5986,Homo sapiens,80682,CHEMBL621645,,1,BAO_0000219,F,9606.0,N,Intermediate,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,,,
5987,Mus musculus,80682,CHEMBL621646,,1,BAO_0000219,F,10090.0,N,Intermediate,17737,In vitro antiproliferative activity against A549 cell line,,,,
5988,,80682,CHEMBL621647,,1,BAO_0000219,F,,N,Intermediate,6630,Synergism with indomethacin in A549 cells,,,,
5989,,80682,CHEMBL621648,,1,BAO_0000219,F,,N,Intermediate,6630,Synergism with tolmetin in A549 cells,,,,
5990,,80682,CHEMBL621649,,1,BAO_0000219,F,,N,Intermediate,6630,Synergism with sulindac in A549 cells,,,,
5991,,80682,CHEMBL621650,,1,BAO_0000219,F,,N,Intermediate,6630,Antagonism of indomethacin in A549 cells,,,,
5992,,80682,CHEMBL621651,,1,BAO_0000219,F,,N,Intermediate,6630,Antagonism of sulindac in A549 cells,,,,
5993,,80682,CHEMBL621652,,1,BAO_0000219,F,,N,Intermediate,6630,Antagonism of tolmetin in A549 cells,,,,
5994,,80682,CHEMBL621653,,1,BAO_0000219,F,,N,Intermediate,6630,Synergism with indomethacin in A549 cells,,,,
5995,,80682,CHEMBL621654,,1,BAO_0000219,F,,N,Intermediate,6630,Synergism with sulindac in A549 cells,,,,
5996,,80682,CHEMBL621655,,1,BAO_0000219,F,,N,Intermediate,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,,,
5997,Canis lupus familiaris,50588,CHEMBL621656,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Cmax value after 30 mg/kg po dose in Dogs,In vivo,,,
5998,Canis lupus familiaris,50588,CHEMBL621657,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,,,
5999,Canis lupus familiaris,50588,CHEMBL621658,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,In vivo,,,
6000,Canis lupus familiaris,50588,CHEMBL621659,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),In vivo,,,
6001,Canis lupus familiaris,50588,CHEMBL621660,,1,BAO_0000218,A,9615.0,N,Intermediate,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,In vivo,,,
6002,Canis lupus familiaris,50588,CHEMBL621661,,1,BAO_0000218,A,9615.0,N,Intermediate,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,In vivo,,,
6003,Canis lupus familiaris,50588,CHEMBL621662,,1,BAO_0000218,A,9615.0,N,Intermediate,6241,Cmax value in dog,In vivo,,,
6004,Canis lupus familiaris,50588,CHEMBL621663,,1,BAO_0000218,A,9615.0,N,Intermediate,6241,Cmax value in dogs after oral administration at 1 mg/kg,In vivo,,,
6005,Canis lupus familiaris,50588,CHEMBL621664,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,In vivo,,,
6006,Canis lupus familiaris,50588,CHEMBL621665,,1,BAO_0000218,A,9615.0,N,Intermediate,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,,,Plasma
6007,Canis lupus familiaris,50588,CHEMBL621666,,1,BAO_0000218,A,9615.0,N,Intermediate,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,,,Plasma
6008,Canis lupus familiaris,50588,CHEMBL621667,,1,BAO_0000218,A,9615.0,N,Intermediate,1021,Concentration maxima after oral dosing in dogs,In vivo,,,
6009,Canis lupus familiaris,50588,CHEMBL876738,,1,BAO_0000218,A,9615.0,N,Intermediate,1021,Concentration maxima after oral dosing in dogs; not available,In vivo,,,
6010,Canis lupus familiaris,50588,CHEMBL621668,,1,BAO_0000218,A,9615.0,N,Intermediate,1021,Concentration maxima after oral dosing in dogs; not available,In vivo,,,
6011,Canis lupus familiaris,50588,CHEMBL621669,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,In vivo,,,
6012,Canis lupus familiaris,50588,CHEMBL621670,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,In vivo,,,
6013,Canis lupus familiaris,50588,CHEMBL621671,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,In vivo,,,
6014,Canis lupus familiaris,50588,CHEMBL622360,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,In vivo,,,
6015,Canis lupus familiaris,50588,CHEMBL622361,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,In vivo,,,
6016,Canis lupus familiaris,50588,CHEMBL622362,,1,BAO_0000218,A,9615.0,N,Intermediate,5130,Cmax in dog plasma after oral dose (1 mg/kg),In vivo,,,Plasma
6017,Canis lupus familiaris,50588,CHEMBL622363,,1,BAO_0000218,A,9615.0,N,Intermediate,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,In vivo,,,Plasma
6018,Canis lupus familiaris,50588,CHEMBL622364,,1,BAO_0000218,A,9615.0,N,Intermediate,5473,Maximal plasma concentration at a dose of 1 mg/kg,In vivo,,,Plasma
6019,Canis lupus familiaris,50588,CHEMBL622365,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),In vivo,,,Plasma
6020,Canis lupus familiaris,50588,CHEMBL622533,,1,BAO_0000218,A,9615.0,N,Intermediate,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,In vivo,,,Plasma
6021,Canis lupus familiaris,50588,CHEMBL622534,,1,BAO_0000218,A,9615.0,N,Intermediate,3031,Maximum concentration of compound in dog was evaluated.,In vivo,,,
6022,Canis lupus familiaris,50588,CHEMBL622535,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,,
6023,Canis lupus familiaris,50588,CHEMBL876739,,1,BAO_0000218,A,9615.0,N,Intermediate,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,In vivo,,,
6024,Canis lupus familiaris,50588,CHEMBL622536,,1,BAO_0000218,A,9615.0,N,Intermediate,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,,
6025,Canis lupus familiaris,50588,CHEMBL622537,,1,BAO_0000218,A,9615.0,N,Intermediate,3132,Maximum concentration obtained in dog plasma was determined,In vivo,,,Plasma
6026,Canis lupus familiaris,50588,CHEMBL622538,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Maximum concentration was determined,In vivo,,,
6027,Canis lupus familiaris,50588,CHEMBL627867,,1,BAO_0000218,A,9615.0,N,Intermediate,4727,Maximum concentration at the dose of 2 mg/kg in dog,In vivo,,,
6028,Canis lupus familiaris,50588,CHEMBL627868,,1,BAO_0000218,A,9615.0,N,Intermediate,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,,
6029,Canis lupus familiaris,50588,CHEMBL627869,,1,BAO_0000218,A,9615.0,N,Intermediate,1918,Maximum concentration was evaluated in dog plasma,In vivo,,,Plasma
6030,Canis lupus familiaris,50588,CHEMBL627870,,1,BAO_0000218,A,9615.0,N,Intermediate,3045,Maximum concentration was evaluated after 75 min after administration in dog,In vivo,,,
6031,Canis lupus familiaris,50588,CHEMBL627871,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Maximum plasma concentration determined in dog after oral administration of 17b,In vivo,,,Plasma
6032,Canis lupus familiaris,50588,CHEMBL627872,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Maximum plasma concentration determined in dog after oral administration of 2b,In vivo,,,Plasma
6033,Canis lupus familiaris,50588,CHEMBL627873,,1,BAO_0000218,A,9615.0,N,Intermediate,933,Maximum plasma concentration in dog,In vivo,,,Plasma
6034,Canis lupus familiaris,50588,CHEMBL627874,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,,,Plasma
6035,Canis lupus familiaris,50588,CHEMBL627875,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,,,Plasma
6036,Canis lupus familiaris,50588,CHEMBL627876,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,,,Plasma
6037,Canis lupus familiaris,50588,CHEMBL627877,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,In vivo,,,Plasma
6038,Canis lupus familiaris,50588,CHEMBL627878,,1,BAO_0000218,A,9615.0,N,Intermediate,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,,Plasma
6039,Canis lupus familiaris,50588,CHEMBL627879,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,In vivo,,,Plasma
6040,Canis lupus familiaris,50588,CHEMBL875355,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,,Plasma
6041,Canis lupus familiaris,50588,CHEMBL627880,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,,Plasma
6042,Canis lupus familiaris,50588,CHEMBL627881,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,,,Plasma
6043,Canis lupus familiaris,50588,CHEMBL627882,,1,BAO_0000218,A,9615.0,N,Intermediate,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,,,Plasma
6044,Canis lupus familiaris,50588,CHEMBL627883,,1,BAO_0000218,A,9615.0,N,Intermediate,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,In vivo,,,Plasma
6045,Canis lupus familiaris,50588,CHEMBL628526,,1,BAO_0000218,A,9615.0,N,Intermediate,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,In vivo,,,Plasma
6046,Canis lupus familiaris,50588,CHEMBL628527,,1,BAO_0000218,A,9615.0,N,Intermediate,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,In vivo,,,Plasma
6047,Canis lupus familiaris,50588,CHEMBL628528,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,In vivo,,,Plasma
6048,Canis lupus familiaris,50588,CHEMBL628529,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,In vivo,,,Plasma
6049,Canis lupus familiaris,50588,CHEMBL628530,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,In vivo,,,Plasma
6050,Canis lupus familiaris,50588,CHEMBL625243,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,In vivo,,,Plasma
6051,Canis lupus familiaris,50588,CHEMBL625244,,1,BAO_0000218,A,9615.0,N,Expert,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,,Plasma
6052,Canis lupus familiaris,50588,CHEMBL625245,,1,BAO_0000218,A,9615.0,N,Intermediate,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,In vivo,,,
6053,Canis lupus familiaris,50588,CHEMBL625246,,1,BAO_0000218,A,9615.0,N,Intermediate,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,In vivo,,,
6054,Mus musculus,50594,CHEMBL625247,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,In vivo,,,Stomach
6055,Mus musculus,50594,CHEMBL625248,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,In vivo,,,Urine
6056,Mus musculus,50594,CHEMBL625249,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,,,Urine
6057,Mus musculus,50594,CHEMBL625250,,1,BAO_0000218,A,10090.0,N,Intermediate,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,In vivo,,,Urine
6058,Mus musculus,50594,CHEMBL625251,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,,
6059,Mus musculus,50594,CHEMBL875356,,1,BAO_0000218,A,10090.0,N,Intermediate,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,,
6060,Mus musculus,50594,CHEMBL625252,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,,
6061,Mus musculus,50594,CHEMBL625253,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,,Blood
6062,Mus musculus,50594,CHEMBL625254,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,,
6063,Mus musculus,50594,CHEMBL625255,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,,
6064,Mus musculus,50594,CHEMBL625256,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,,
6065,Mus musculus,50594,CHEMBL625257,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,,Blood
6066,Mus musculus,50594,CHEMBL625258,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,,Blood
6067,Mus musculus,50594,CHEMBL625259,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,,
6068,Mus musculus,50594,CHEMBL625260,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,,
6069,Mus musculus,50594,CHEMBL625261,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,,
6070,Mus musculus,50594,CHEMBL625262,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,,
6071,Mus musculus,50594,CHEMBL622639,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,,
6072,Mus musculus,50594,CHEMBL622640,,1,BAO_0000218,A,10090.0,N,Intermediate,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,,
6073,Mus musculus,50594,CHEMBL622812,,1,BAO_0000218,A,10090.0,N,Intermediate,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,,
6074,Mus musculus,50594,CHEMBL622813,,1,BAO_0000218,A,10090.0,N,Intermediate,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,,
6075,Mus musculus,50594,CHEMBL622814,,1,BAO_0000218,A,10090.0,N,Intermediate,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,,
6076,Mus musculus,50594,CHEMBL622815,,1,BAO_0000218,A,10090.0,N,Intermediate,17827,Time at maximum activity in mice (Radiolabeled compound),,,,
6077,Mus musculus,50594,CHEMBL625342,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,,
6078,Mus musculus,50594,CHEMBL625343,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,,
6079,Mus musculus,50594,CHEMBL877591,,1,BAO_0000218,A,10090.0,N,Intermediate,17409,Binding towards mouse plasma protein at 10 uM,,,,
6080,Mus musculus,50594,CHEMBL625344,,1,BAO_0000218,A,10090.0,N,Intermediate,17409,Binding towards mouse plasma protein at 100 uM,,,,
6081,Mus musculus,50594,CHEMBL625345,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Bioavailability was evaluated in mice after intravenous administration,In vivo,,,
6082,Mus musculus,50594,CHEMBL625346,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Bioavailability was evaluated in mice after oral administration,In vivo,,,
6083,Mus musculus,50594,CHEMBL625347,,1,BAO_0000218,A,10090.0,N,Intermediate,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,In vivo,,,
6084,Mus musculus,50594,CHEMBL625348,,1,BAO_0000218,A,10090.0,N,Intermediate,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,In vivo,,,
6085,Mus musculus,50594,CHEMBL625349,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,In vivo,,,
6086,Mus musculus,50594,CHEMBL625350,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Oral bioavailability in mouse,In vivo,,,
6087,Mus musculus,50594,CHEMBL882952,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,In vivo,,,
6088,Mus musculus,50594,CHEMBL625351,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Brain
6089,Mus musculus,50594,CHEMBL625352,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Brain
6090,Mus musculus,50594,CHEMBL877592,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Brain
6091,Mus musculus,50594,CHEMBL625353,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Brain
6092,Mus musculus,50594,CHEMBL625354,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Brain
6093,Mus musculus,50594,CHEMBL626019,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Brain
6094,Mus musculus,50594,CHEMBL626020,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Heart
6095,Mus musculus,50594,CHEMBL626021,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Heart
6096,Mus musculus,50594,CHEMBL626022,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Heart
6097,Mus musculus,50594,CHEMBL626192,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Heart
6098,Homo sapiens,80682,CHEMBL626193,,1,BAO_0000219,F,9606.0,N,Intermediate,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,,,
6099,Homo sapiens,80682,CHEMBL626194,,1,BAO_0000219,F,9606.0,N,Expert,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,,,
6100,Homo sapiens,80682,CHEMBL626195,,1,BAO_0000219,F,9606.0,N,Intermediate,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,,,,
6101,Homo sapiens,80682,CHEMBL626196,,1,BAO_0000219,F,9606.0,N,Intermediate,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,,,
6102,Homo sapiens,80682,CHEMBL626197,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,,,,
6103,Homo sapiens,80682,CHEMBL626198,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,,,
6104,Homo sapiens,80682,CHEMBL626199,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,,,
6105,Homo sapiens,80682,CHEMBL626200,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,,,
6106,Homo sapiens,80682,CHEMBL626201,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,,,
6107,Homo sapiens,80682,CHEMBL626202,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,,,
6108,Homo sapiens,80682,CHEMBL626203,,1,BAO_0000219,F,9606.0,N,Intermediate,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,,,
6109,Homo sapiens,80682,CHEMBL626204,,1,BAO_0000219,F,9606.0,N,Intermediate,15167,In vitro cytotoxicity against A-549 human lung cancer cells,,,,
6110,Homo sapiens,80682,CHEMBL624701,,1,BAO_0000219,F,9606.0,N,Intermediate,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,,,
6111,Homo sapiens,80682,CHEMBL624702,,1,BAO_0000219,F,9606.0,N,Intermediate,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,,,
6112,Homo sapiens,80682,CHEMBL624703,,1,BAO_0000219,F,9606.0,N,Expert,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,,
6113,Homo sapiens,80682,CHEMBL624704,,1,BAO_0000219,F,9606.0,N,Intermediate,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,,,
6114,Homo sapiens,80682,CHEMBL624705,,1,BAO_0000219,F,9606.0,N,Intermediate,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,,,
6115,Homo sapiens,80682,CHEMBL624706,,1,BAO_0000219,F,9606.0,N,Expert,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,,,
6116,Homo sapiens,80682,CHEMBL624707,,1,BAO_0000219,F,9606.0,N,Intermediate,4461,Antitumor cytotoxic activity against A-549 cell line was determined,,,,
6117,Homo sapiens,80682,CHEMBL624708,,1,BAO_0000219,F,9606.0,N,Intermediate,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,,,
6118,Homo sapiens,80682,CHEMBL624709,,1,BAO_0000219,F,9606.0,N,Intermediate,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,,
6119,Homo sapiens,80682,CHEMBL884107,,1,BAO_0000219,F,9606.0,N,Expert,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,,
6120,Homo sapiens,80682,CHEMBL624710,,1,BAO_0000219,F,9606.0,N,Intermediate,3265,Antitumoral activity was assayed against A-549 cell line,,,,
6121,Homo sapiens,80682,CHEMBL624711,,1,BAO_0000219,F,9606.0,N,Intermediate,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,,,
6122,Homo sapiens,80682,CHEMBL624712,,1,BAO_0000219,F,9606.0,N,Intermediate,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,,,
6123,Homo sapiens,80682,CHEMBL624713,,1,BAO_0000219,F,9606.0,N,Expert,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,,,
6124,Homo sapiens,80682,CHEMBL624714,,1,BAO_0000219,F,9606.0,N,Intermediate,1481,Compound was tested for inhibition of cell growth of A-549 cells,,,,
6125,Homo sapiens,80682,CHEMBL624715,,1,BAO_0000219,F,9606.0,N,Intermediate,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,,,
6126,Homo sapiens,80682,CHEMBL624716,,1,BAO_0000219,F,9606.0,N,Intermediate,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,,,
6127,Homo sapiens,80682,CHEMBL619505,,1,BAO_0000219,F,9606.0,N,Expert,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,,,,
6128,Homo sapiens,80682,CHEMBL619506,,1,BAO_0000219,F,9606.0,N,Expert,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,,,
6129,Homo sapiens,80682,CHEMBL619507,,1,BAO_0000219,F,9606.0,N,Intermediate,1847,Cytotoxic activity against A-549 cell lines.,,,,
6130,Homo sapiens,80682,CHEMBL619508,,1,BAO_0000219,F,9606.0,N,Expert,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,,,
6131,Homo sapiens,80682,CHEMBL619509,,1,BAO_0000219,F,9606.0,N,Intermediate,1003,Cytotoxicity against human A549 non small cell lung cell lines,,,,
6132,Homo sapiens,80682,CHEMBL619510,,1,BAO_0000219,F,9606.0,N,Expert,15313,Inhibition of cell growth in (A-549) lung cell line,,,,
6133,Homo sapiens,80682,CHEMBL619511,,1,BAO_0000219,F,9606.0,N,Intermediate,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,,,
6134,Homo sapiens,80682,CHEMBL619512,,1,BAO_0000219,F,9606.0,N,Intermediate,16049,In vitro antitumor activity against A-549 tumor cells.,,,,
6135,Homo sapiens,80682,CHEMBL619513,,1,BAO_0000219,F,9606.0,N,Expert,17134,In vitro antitumor effects against human A-549 cell lines.,,,,
6136,Homo sapiens,80682,CHEMBL619514,,1,BAO_0000219,F,9606.0,N,Intermediate,6406,In vitro cytotoxic activity of compound against A-549 cell line,,,,
6137,Homo sapiens,80682,CHEMBL619515,,1,BAO_0000219,F,9606.0,N,Intermediate,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,,,
6138,Homo sapiens,80682,CHEMBL619516,,1,BAO_0000219,F,9606.0,N,Intermediate,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,,,
6139,Homo sapiens,80682,CHEMBL884005,,1,BAO_0000219,F,9606.0,N,Intermediate,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,,,
6140,Homo sapiens,80682,CHEMBL619517,,1,BAO_0000219,F,9606.0,N,Expert,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,,,
6141,Homo sapiens,80682,CHEMBL619518,,1,BAO_0000219,F,9606.0,N,Intermediate,6663,Inhibitory concentration of compound against A-549 cell line,,,,
6142,Homo sapiens,80682,CHEMBL619519,,1,BAO_0000219,F,9606.0,N,Intermediate,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,,,
6143,Homo sapiens,80682,CHEMBL876489,,1,BAO_0000219,F,9606.0,N,Intermediate,14709,cytotoxic activity against leukemia (A-549) cancer cell line,,,,
6144,Homo sapiens,80682,CHEMBL619520,,1,BAO_0000219,F,9606.0,N,Expert,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,,,
6145,Homo sapiens,80682,CHEMBL619521,,1,BAO_0000219,F,9606.0,N,Intermediate,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,,,
6146,Homo sapiens,80682,CHEMBL619522,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,,,
6147,Homo sapiens,80682,CHEMBL619523,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,,,
6148,Homo sapiens,80682,CHEMBL619524,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,,,
6149,Homo sapiens,80682,CHEMBL619525,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,,,
6150,,80682,CHEMBL619526,,1,BAO_0000219,F,,N,Intermediate,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,,,
6151,Homo sapiens,80682,CHEMBL619527,,1,BAO_0000219,F,9606.0,N,Intermediate,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,,,
6152,Homo sapiens,80682,CHEMBL619528,,1,BAO_0000219,F,9606.0,N,Intermediate,17846,Cytotoxicity against A549 cells; No cytotoxicity,,,,
6153,Homo sapiens,80682,CHEMBL619529,,1,BAO_0000219,F,9606.0,N,Expert,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,,,,
6154,Homo sapiens,80682,CHEMBL619530,,1,BAO_0000219,F,9606.0,N,Expert,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,,,
6155,Homo sapiens,80682,CHEMBL876490,,1,BAO_0000219,F,9606.0,N,Intermediate,5609,In vitro anticancer activity against human lung (A549) cell line,,,,
6156,Homo sapiens,80682,CHEMBL619531,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,,,
6157,Homo sapiens,80682,CHEMBL619532,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,,,
6158,Homo sapiens,80682,CHEMBL619533,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,,,
6159,Homo sapiens,80682,CHEMBL619534,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,,,
6160,Homo sapiens,80682,CHEMBL620164,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,,,
6161,Homo sapiens,80682,CHEMBL620165,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,,
6162,Homo sapiens,80682,CHEMBL620166,,1,BAO_0000219,F,9606.0,N,Expert,16295,Inhibition of A549 human lung tumor cell proliferation,,,,
6163,Homo sapiens,80682,CHEMBL620167,,1,BAO_0000219,F,9606.0,N,Intermediate,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,,,
6164,Homo sapiens,80682,CHEMBL620168,,1,BAO_0000219,F,9606.0,N,Expert,3439,In vitro cytotoxicity against human tumor cell line A549,,,,
6165,Homo sapiens,80682,CHEMBL620338,,1,BAO_0000219,F,9606.0,N,Intermediate,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,,,
6166,Homo sapiens,80682,CHEMBL620339,,1,BAO_0000219,F,9606.0,N,Intermediate,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,,,
6167,Homo sapiens,80682,CHEMBL620340,,1,BAO_0000219,F,9606.0,N,Intermediate,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,,,
6168,Homo sapiens,80682,CHEMBL620341,,1,BAO_0000219,F,9606.0,N,Intermediate,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,,,
6169,Homo sapiens,80682,CHEMBL876491,,1,BAO_0000219,F,9606.0,N,Intermediate,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,,,
6170,Homo sapiens,80682,CHEMBL620342,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,,
6171,Homo sapiens,80682,CHEMBL620343,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,,
6172,Homo sapiens,80682,CHEMBL620344,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,,
6173,Homo sapiens,80682,CHEMBL620345,,1,BAO_0000219,F,9606.0,N,Intermediate,5609,In vitro anticancer activity against human lung (A549) cell line,,,,
6174,Homo sapiens,80682,CHEMBL620346,,1,BAO_0000219,F,9606.0,N,Intermediate,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,,,
6175,Homo sapiens,80682,CHEMBL620347,,1,BAO_0000219,F,9606.0,N,Intermediate,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,,,
6176,Homo sapiens,80682,CHEMBL620348,,1,BAO_0000219,F,9606.0,N,Intermediate,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,,,
6177,Homo sapiens,80682,CHEMBL620349,,1,BAO_0000219,F,9606.0,N,Intermediate,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,,,
6178,Homo sapiens,80682,CHEMBL618667,,1,BAO_0000219,F,9606.0,N,Intermediate,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,,,
6179,Homo sapiens,80682,CHEMBL618668,,1,BAO_0000219,F,9606.0,N,Expert,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,,,,
6180,Homo sapiens,80682,CHEMBL876031,,1,BAO_0000219,F,9606.0,N,Intermediate,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,,,
6181,Homo sapiens,80682,CHEMBL618759,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,,,
6182,Homo sapiens,80682,CHEMBL618760,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,,
6183,Homo sapiens,80682,CHEMBL619000,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,,,
6184,Homo sapiens,80682,CHEMBL619001,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,,,
6185,Homo sapiens,80682,CHEMBL619002,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,,,
6186,Homo sapiens,80682,CHEMBL619003,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,,,
6187,Homo sapiens,80682,CHEMBL619597,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,,,
6188,Homo sapiens,80682,CHEMBL619598,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,,,
6189,Homo sapiens,80682,CHEMBL619599,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,,,
6190,Homo sapiens,80682,CHEMBL619600,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,,,
6191,Homo sapiens,80682,CHEMBL619601,,1,BAO_0000219,F,9606.0,N,Intermediate,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,,,
6192,Homo sapiens,80682,CHEMBL619602,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,,,
6193,Homo sapiens,80682,CHEMBL619603,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,,,
6194,Homo sapiens,80682,CHEMBL619604,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,,,
6195,Homo sapiens,80682,CHEMBL619605,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,,,
6196,Canis lupus familiaris,50588,CHEMBL619606,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,In vivo,,,
6197,Canis lupus familiaris,50588,CHEMBL876032,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Pharmacokinetic activity (Cmax) in dog,In vivo,,,
6198,Canis lupus familiaris,50588,CHEMBL619607,,1,BAO_0000218,A,9615.0,N,Intermediate,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,,
6199,Canis lupus familiaris,50588,CHEMBL619608,,1,BAO_0000218,A,9615.0,N,Intermediate,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,In vivo,,,
6200,Canis lupus familiaris,50588,CHEMBL619609,,1,BAO_0000218,A,9615.0,N,Intermediate,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,In vivo,,,
6201,Canis lupus familiaris,50588,CHEMBL619610,,1,BAO_0000218,A,9615.0,N,Intermediate,5932,Cmax in dog plasma after 30mg/kg oral dose,In vivo,,,Plasma
6202,Canis lupus familiaris,50588,CHEMBL619611,,1,BAO_0000218,A,9615.0,N,Intermediate,4273,Tested for the peak blood level in dog,In vivo,,,Blood
6203,Canis lupus familiaris,50588,CHEMBL619612,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",In vivo,,,
6204,Canis lupus familiaris,50588,CHEMBL619613,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",In vivo,,,
6205,Canis lupus familiaris,50588,CHEMBL619614,,1,BAO_0000218,A,9615.0,N,Intermediate,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,In vivo,,,Blood
6206,Canis lupus familiaris,50588,CHEMBL619615,,1,BAO_0000218,A,9615.0,N,Intermediate,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,,
6207,Canis lupus familiaris,50588,CHEMBL619616,,1,BAO_0000218,A,9615.0,N,Intermediate,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,,
6208,Canis lupus familiaris,50588,CHEMBL619617,,1,BAO_0000218,A,9615.0,N,Intermediate,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,,Plasma
6209,Canis lupus familiaris,50588,CHEMBL619618,,1,BAO_0000218,A,9615.0,N,Intermediate,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,,
6210,Canis lupus familiaris,50588,CHEMBL876033,,1,BAO_0000218,A,9615.0,N,Intermediate,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,,
6211,Canis lupus familiaris,50588,CHEMBL619619,,1,BAO_0000218,A,9615.0,N,Intermediate,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,,
6212,Canis lupus familiaris,50588,CHEMBL619620,,1,BAO_0000218,A,9615.0,N,Intermediate,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,,
6213,Canis lupus familiaris,50588,CHEMBL619621,,1,BAO_0000218,A,9615.0,N,Intermediate,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,,Urine
6214,Canis lupus familiaris,50588,CHEMBL619622,,1,BAO_0000218,A,9615.0,N,Intermediate,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,,Urine
6215,Canis lupus familiaris,50588,CHEMBL618874,,1,BAO_0000218,A,9615.0,N,Intermediate,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,,Urine
6216,Canis lupus familiaris,50588,CHEMBL618875,,1,BAO_0000218,A,9615.0,N,Intermediate,4257,Absolute bioavailability was evaluated in dog,In vivo,,,
6217,Canis lupus familiaris,50588,CHEMBL618876,,1,BAO_0000218,A,9615.0,N,Intermediate,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,In vivo,,,
6218,Canis lupus familiaris,50588,CHEMBL618877,,1,BAO_0000218,A,9615.0,N,Intermediate,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,In vivo,,,
6219,Canis lupus familiaris,50588,CHEMBL618878,,1,BAO_0000218,A,9615.0,N,Intermediate,17267,Bioavailability in dog,In vivo,,,
6220,Canis lupus familiaris,50588,CHEMBL618879,,1,BAO_0000218,A,9615.0,N,Intermediate,6621,Bioavailability in dog,In vivo,,,
6221,Canis lupus familiaris,50588,CHEMBL618880,,1,BAO_0000218,A,9615.0,N,Intermediate,3854,Bioavailability after intravenous administration in dogs,In vivo,,,
6222,Canis lupus familiaris,50588,CHEMBL618881,,1,BAO_0000218,A,9615.0,N,Intermediate,3854,Bioavailability after peroral administration in dogs,In vivo,,,
6223,Canis lupus familiaris,50588,CHEMBL618882,,1,BAO_0000218,A,9615.0,N,Intermediate,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,,,
6224,Canis lupus familiaris,50588,CHEMBL624226,,1,BAO_0000218,A,9615.0,N,Intermediate,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,In vivo,,,
6225,Canis lupus familiaris,50588,CHEMBL624227,,1,BAO_0000218,A,9615.0,N,Intermediate,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,In vivo,,,Plasma
6226,Canis lupus familiaris,50588,CHEMBL624228,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Bioavailability,In vivo,,,
6227,Canis lupus familiaris,50588,CHEMBL624229,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Bioavailability,In vivo,,,
6228,Canis lupus familiaris,50588,CHEMBL624230,,1,BAO_0000218,A,9615.0,N,Intermediate,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,In vivo,,,
6229,Canis lupus familiaris,50588,CHEMBL624231,,1,BAO_0000218,A,9615.0,N,Intermediate,3771,Bioavailability in dog,In vivo,,,
6230,Canis lupus familiaris,50588,CHEMBL624232,,1,BAO_0000218,A,9615.0,N,Intermediate,4953,Bioavailability in dog,In vivo,,,
6231,Canis lupus familiaris,50588,CHEMBL625127,,1,BAO_0000218,A,9615.0,N,Intermediate,5064,Bioavailability in dog,In vivo,,,
6232,Canis lupus familiaris,50588,CHEMBL625128,,1,BAO_0000218,A,9615.0,N,Intermediate,17657,Bioavailability in dog,In vivo,,,
6233,Canis lupus familiaris,50588,CHEMBL621675,,1,BAO_0000218,A,9615.0,N,Intermediate,17796,Bioavailability in dog,In vivo,,,
6234,Canis lupus familiaris,50588,CHEMBL621676,,1,BAO_0000218,A,9615.0,N,Intermediate,17853,Bioavailability in dog (p.o.) at 2.0 mpk,In vivo,,,
6235,Canis lupus familiaris,50588,CHEMBL621677,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),In vivo,,,
6236,Canis lupus familiaris,50588,CHEMBL621678,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,,
6237,Canis lupus familiaris,50588,CHEMBL621679,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Bioavailability in dog,In vivo,,,
6238,Canis lupus familiaris,50588,CHEMBL621680,,1,BAO_0000218,A,9615.0,N,Intermediate,16365,Bioavailability was evaluated after oral administration in dog,In vivo,,,
6239,Canis lupus familiaris,50588,CHEMBL621681,,1,BAO_0000218,A,9615.0,N,Intermediate,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,,
6240,Canis lupus familiaris,50588,CHEMBL876740,,1,BAO_0000218,A,9615.0,N,Intermediate,1918,Bioavailability was evaluated in dog,In vivo,,,
6241,Canis lupus familiaris,50588,CHEMBL621682,,1,BAO_0000218,A,9615.0,N,Intermediate,4239,Bioavailability in dog,In vivo,,,
6242,Canis lupus familiaris,50588,CHEMBL621683,,1,BAO_0000218,A,9615.0,N,Intermediate,6505,Bioavailability in dog,In vivo,,,
6243,Canis lupus familiaris,50588,CHEMBL621684,,1,BAO_0000218,A,9615.0,N,Intermediate,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,,
6244,Canis lupus familiaris,50588,CHEMBL621685,,1,BAO_0000218,A,9615.0,N,Intermediate,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,,,
6245,Canis lupus familiaris,50588,CHEMBL621686,,1,BAO_0000218,A,9615.0,N,Intermediate,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,,
6246,Canis lupus familiaris,50588,CHEMBL621687,,1,BAO_0000218,A,9615.0,N,Intermediate,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,,
6247,Canis lupus familiaris,50588,CHEMBL621688,,1,BAO_0000218,A,9615.0,N,Intermediate,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,In vivo,,,
6248,Canis lupus familiaris,50588,CHEMBL621689,,1,BAO_0000218,A,9615.0,N,Intermediate,17804,Bioavailability of compound in dog was determined after peroral administration,In vivo,,,
6249,Canis lupus familiaris,50588,CHEMBL621690,,1,BAO_0000218,A,9615.0,N,Intermediate,3184,Oral bioavailability in dog,In vivo,,,
6250,Canis lupus familiaris,50588,CHEMBL621691,,1,BAO_0000218,A,9615.0,N,Intermediate,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,In vivo,,,
6251,Canis lupus familiaris,50588,CHEMBL875941,,1,BAO_0000218,A,9615.0,N,Intermediate,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,In vivo,,,
6252,Canis lupus familiaris,50588,CHEMBL621692,,1,BAO_0000218,A,9615.0,N,Intermediate,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,In vivo,,,
6253,Canis lupus familiaris,50588,CHEMBL621693,,1,BAO_0000218,A,9615.0,N,Intermediate,4839,Bioavailability in dog,In vivo,,,
6254,Canis lupus familiaris,50588,CHEMBL621694,,1,BAO_0000218,A,9615.0,N,Intermediate,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),In vivo,,,
6255,Mus musculus,50594,CHEMBL621695,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Heart
6256,Mus musculus,50594,CHEMBL621696,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Heart
6257,Mus musculus,50594,CHEMBL621697,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Kidney
6258,Mus musculus,50594,CHEMBL621698,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Kidney
6259,Mus musculus,50594,CHEMBL623420,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Kidney
6260,Mus musculus,50594,CHEMBL623421,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Kidney
6261,Mus musculus,50594,CHEMBL623422,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Kidney
6262,Mus musculus,50594,CHEMBL623423,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Kidney
6263,Mus musculus,50594,CHEMBL623424,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Liver
6264,Mus musculus,50594,CHEMBL623425,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Liver
6265,Mus musculus,50594,CHEMBL623426,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Liver
6266,Mus musculus,50594,CHEMBL623427,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Liver
6267,Mus musculus,50594,CHEMBL623428,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Liver
6268,Mus musculus,50594,CHEMBL875947,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Liver
6269,Mus musculus,50594,CHEMBL623429,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Lung
6270,Mus musculus,50594,CHEMBL623430,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Lung
6271,Mus musculus,50594,CHEMBL622588,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Lung
6272,Mus musculus,50594,CHEMBL622589,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Lung
6273,Mus musculus,50594,CHEMBL622751,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Lung
6274,Mus musculus,50594,CHEMBL622752,,1,BAO_0000218,A,10090.0,N,Intermediate,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,In vivo,,,Lung
6275,Mus musculus,50594,CHEMBL622753,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,,,
6276,Mus musculus,50594,CHEMBL622647,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,,,
6277,Mus musculus,50594,CHEMBL875163,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,,,
6278,Mus musculus,50594,CHEMBL622648,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,,,
6279,Mus musculus,50594,CHEMBL622649,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,,,
6280,Mus musculus,50594,CHEMBL622650,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,,,Brain
6281,Mus musculus,50594,CHEMBL622651,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,,,Brain
6282,Mus musculus,50594,CHEMBL622652,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,,,Brain
6283,Mus musculus,50594,CHEMBL622653,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,,,Brain
6284,Mus musculus,50594,CHEMBL622654,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,,,Brain
6285,Mus musculus,50594,CHEMBL622655,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,,,Heart
6286,Mus musculus,50594,CHEMBL622656,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,,,Heart
6287,Mus musculus,50594,CHEMBL622657,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,,,Heart
6288,Mus musculus,50594,CHEMBL622658,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,,,Heart
6289,Mus musculus,50594,CHEMBL622659,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,,,Heart
6290,Mus musculus,50594,CHEMBL624630,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,,,Kidney
6291,Mus musculus,50594,CHEMBL624631,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,,,Kidney
6292,Mus musculus,50594,CHEMBL624632,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,,,Kidney
6293,Homo sapiens,80682,CHEMBL624633,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,,,
6294,Homo sapiens,80682,CHEMBL624634,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,,,
6295,Homo sapiens,80682,CHEMBL624635,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,,,
6296,Homo sapiens,80682,CHEMBL624636,,1,BAO_0000219,F,9606.0,N,Intermediate,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,,,
6297,Homo sapiens,80682,CHEMBL857055,,1,BAO_0000219,F,9606.0,N,Expert,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,,,
6298,Homo sapiens,80682,CHEMBL624637,,1,BAO_0000219,F,9606.0,N,Expert,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,,,
6299,Homo sapiens,80682,CHEMBL624638,,1,BAO_0000219,F,9606.0,N,Expert,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,,,
6300,Homo sapiens,80682,CHEMBL874366,,1,BAO_0000219,F,9606.0,N,Expert,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,,,
6301,Homo sapiens,80682,CHEMBL624639,,1,BAO_0000219,F,9606.0,N,Expert,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,,,
6302,Homo sapiens,80682,CHEMBL624640,,1,BAO_0000219,F,9606.0,N,Expert,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,,,
6303,Homo sapiens,80682,CHEMBL624641,,1,BAO_0000219,F,9606.0,N,Intermediate,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,,,
6304,Homo sapiens,80682,CHEMBL624642,,1,BAO_0000219,F,9606.0,N,Intermediate,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,,,
6305,Homo sapiens,80682,CHEMBL624643,,1,BAO_0000219,F,9606.0,N,Intermediate,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,,,
6306,Homo sapiens,80682,CHEMBL624644,,1,BAO_0000219,F,9606.0,N,Intermediate,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,,,
6307,Homo sapiens,80682,CHEMBL624645,,1,BAO_0000219,F,9606.0,N,Intermediate,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,,,
6308,Homo sapiens,80682,CHEMBL619445,,1,BAO_0000219,F,9606.0,N,Intermediate,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,,,,
6309,Homo sapiens,80682,CHEMBL839886,,1,BAO_0000219,F,9606.0,N,Expert,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,,,
6310,Homo sapiens,80682,CHEMBL619446,,1,BAO_0000219,F,9606.0,N,Intermediate,5076,Cytotoxic activity of compound against A-549 tumor cell line.,,,,
6311,Homo sapiens,80682,CHEMBL619447,,1,BAO_0000219,F,9606.0,N,Intermediate,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,,,
6312,Homo sapiens,80682,CHEMBL619448,,1,BAO_0000219,F,9606.0,N,Intermediate,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,,,
6313,Homo sapiens,80682,CHEMBL619449,,1,BAO_0000219,F,9606.0,N,Intermediate,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,,,
6314,Homo sapiens,80682,CHEMBL619450,,1,BAO_0000219,F,9606.0,N,Intermediate,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,,,
6315,Homo sapiens,80682,CHEMBL619451,,1,BAO_0000219,F,9606.0,N,Intermediate,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,,,
6316,Homo sapiens,80682,CHEMBL619452,,1,BAO_0000219,F,9606.0,N,Expert,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,,,
6317,Homo sapiens,80682,CHEMBL619453,,1,BAO_0000219,F,9606.0,N,Intermediate,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,,,
6318,Homo sapiens,80682,CHEMBL874367,,1,BAO_0000219,F,9606.0,N,Intermediate,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,,,
6319,Homo sapiens,80682,CHEMBL619454,,1,BAO_0000219,F,9606.0,N,Intermediate,11333,Cytotoxic concentration against A-549 tumor cells.,,,,
6320,Homo sapiens,80682,CHEMBL619455,,1,BAO_0000219,F,9606.0,N,Intermediate,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,,,
6321,Homo sapiens,80682,CHEMBL619456,,1,BAO_0000219,F,9606.0,N,Intermediate,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,,,
6322,Acinetobacter baumannii,50191,CHEMBL619457,,1,BAO_0000218,F,470.0,N,Expert,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,,
6323,Acinetobacter calcoaceticus,50192,CHEMBL619458,,1,BAO_0000218,F,471.0,N,Intermediate,10624,Activity against Acinetobacter calcoaceticus (AC54),,,,
6324,Aspergillus flavus,50274,CHEMBL619459,,1,BAO_0000218,F,5059.0,N,Expert,16717,In vitro antifungal activity against Aspergillus flavus CM74,,,,
6325,Aspergillus flavus,50274,CHEMBL619460,,1,BAO_0000218,F,5059.0,N,Expert,16717,In vitro antifungal activity against Aspergillus flavus CM74,,,,
6326,Aspergillus fumigatus,50416,CHEMBL619461,,1,BAO_0000218,F,746128.0,N,Intermediate,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,,
6327,Aspergillus fumigatus,50416,CHEMBL619462,,1,BAO_0000218,F,746128.0,N,Intermediate,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,,
6328,Aspergillus fumigatus,50416,CHEMBL620388,,1,BAO_0000218,F,746128.0,N,Intermediate,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),,,,
6329,Aspergillus fumigatus,50416,CHEMBL620389,,1,BAO_0000218,F,746128.0,N,Intermediate,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),,,,
6330,Aspergillus fumigatus,50416,CHEMBL620390,,1,BAO_0000218,F,746128.0,N,Intermediate,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,,
6331,Aspergillus fumigatus,50416,CHEMBL620391,,1,BAO_0000218,F,746128.0,N,Expert,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,,
6332,Aspergillus fumigatus,50416,CHEMBL621073,,1,BAO_0000218,F,746128.0,N,Expert,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,,
6333,Actinomyces naeslundii,50296,CHEMBL621074,,1,BAO_0000218,F,1655.0,N,Intermediate,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,,
6334,Actinomyces viscosus,50366,CHEMBL621075,,1,BAO_0000218,F,1656.0,N,Intermediate,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,,
6335,Acanthocheilonema viteae,50535,CHEMBL619554,,1,BAO_0000218,F,6277.0,N,Intermediate,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,,
6336,Acanthocheilonema viteae,50535,CHEMBL619555,,1,BAO_0000218,F,6277.0,N,Intermediate,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,,
6337,Aggregatibacter actinomycetemcomitans,50169,CHEMBL619556,,1,BAO_0000218,F,714.0,N,Intermediate,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,,
6338,Aggregatibacter actinomycetemcomitans,50169,CHEMBL619557,,1,BAO_0000218,F,714.0,N,Intermediate,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,,
6339,Aggregatibacter actinomycetemcomitans,50169,CHEMBL619558,,1,BAO_0000218,F,714.0,N,Intermediate,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,,
6340,Homo sapiens,80682,CHEMBL619559,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,,,
6341,Homo sapiens,80682,CHEMBL619560,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,,,
6342,Homo sapiens,80682,CHEMBL619561,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,,,
6343,Homo sapiens,80682,CHEMBL619562,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,,,
6344,Homo sapiens,80682,CHEMBL619563,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,,,
6345,Homo sapiens,80682,CHEMBL857457,,1,BAO_0000219,F,9606.0,N,Intermediate,16381,GI values against A549 cells (lung cancer),,,,
6346,Homo sapiens,80682,CHEMBL619564,,1,BAO_0000219,F,9606.0,N,Intermediate,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,,,
6347,Homo sapiens,80682,CHEMBL619565,,1,BAO_0000219,F,9606.0,N,Intermediate,16325,Inhibitory activity against A549 human adenocarcinoma,,,,
6348,Homo sapiens,80682,CHEMBL619566,,1,BAO_0000218,F,9606.0,N,Intermediate,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,,,
6349,Homo sapiens,80682,CHEMBL619567,,1,BAO_0000218,F,9606.0,N,Intermediate,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,,,
6350,Homo sapiens,80682,CHEMBL619568,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,,,,
6351,Homo sapiens,80682,CHEMBL619569,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,,,
6352,Homo sapiens,80682,CHEMBL619570,,1,BAO_0000219,F,9606.0,N,Intermediate,17488,Cytotoxicity against human A549 lung cells,,,,
6353,Homo sapiens,80682,CHEMBL619571,,1,BAO_0000218,F,9606.0,N,Intermediate,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,,,
6354,Homo sapiens,80682,CHEMBL619572,,1,BAO_0000219,F,9606.0,N,Expert,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,,,,
6355,Homo sapiens,80682,CHEMBL619573,,1,BAO_0000219,F,9606.0,N,Expert,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,,,,
6356,Homo sapiens,80682,CHEMBL619574,,1,BAO_0000219,F,9606.0,N,Intermediate,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,,,
6357,Homo sapiens,80682,CHEMBL619575,,1,BAO_0000219,F,9606.0,N,Intermediate,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,,,
6358,Homo sapiens,80682,CHEMBL619576,,1,BAO_0000219,F,9606.0,N,Expert,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,,,
6359,Homo sapiens,80682,CHEMBL619577,,1,BAO_0000219,F,9606.0,N,Intermediate,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,,,
6360,Homo sapiens,80682,CHEMBL619578,,1,BAO_0000219,F,9606.0,N,Intermediate,2525,In vitro inhibitory activity against A549 tumor cell culture,,,,
6361,Homo sapiens,80682,CHEMBL884009,,1,BAO_0000219,F,9606.0,N,Intermediate,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,,,
6362,Homo sapiens,80682,CHEMBL619579,,1,BAO_0000219,F,9606.0,N,Intermediate,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,,,
6363,Homo sapiens,80682,CHEMBL619580,,1,BAO_0000219,F,9606.0,N,Intermediate,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,,,
6364,Homo sapiens,80682,CHEMBL619581,,1,BAO_0000219,F,9606.0,N,Intermediate,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,,,
6365,Homo sapiens,80682,CHEMBL619582,,1,BAO_0000219,F,9606.0,N,Intermediate,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,,,
6366,Homo sapiens,80682,CHEMBL619583,,1,BAO_0000219,F,9606.0,N,Intermediate,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,,,
6367,Homo sapiens,80682,CHEMBL876502,,1,BAO_0000219,F,9606.0,N,Intermediate,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,,,
6368,Homo sapiens,80682,CHEMBL619584,,1,BAO_0000219,F,9606.0,N,Intermediate,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,,,
6369,Homo sapiens,80682,CHEMBL619585,,1,BAO_0000219,F,9606.0,N,Intermediate,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,,
6370,Homo sapiens,80682,CHEMBL619586,,1,BAO_0000219,F,9606.0,N,Intermediate,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,,
6371,Homo sapiens,80682,CHEMBL619587,,1,BAO_0000219,F,9606.0,N,Intermediate,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,,,
6372,Homo sapiens,80682,CHEMBL619588,,1,BAO_0000219,F,9606.0,N,Intermediate,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,,,
6373,Homo sapiens,80682,CHEMBL619589,,1,BAO_0000219,F,9606.0,N,Intermediate,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,,,
6374,Homo sapiens,80682,CHEMBL619590,,1,BAO_0000219,F,9606.0,N,Intermediate,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,,,
6375,Homo sapiens,80682,CHEMBL619591,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,,,
6376,Homo sapiens,80682,CHEMBL619592,,1,BAO_0000219,F,9606.0,N,Intermediate,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,,,
6377,Homo sapiens,80682,CHEMBL619593,,1,BAO_0000219,F,9606.0,N,Intermediate,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,,,
6378,Homo sapiens,80682,CHEMBL620217,,1,BAO_0000219,F,9606.0,N,Intermediate,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,,,
6379,Homo sapiens,80682,CHEMBL620218,,1,BAO_0000219,F,9606.0,N,Intermediate,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,,,
6380,Homo sapiens,80682,CHEMBL620219,,1,BAO_0000219,F,9606.0,N,Intermediate,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,,,
6381,Homo sapiens,80682,CHEMBL620220,,1,BAO_0000219,F,9606.0,N,Intermediate,12301,Antitumor activity against A549/ATCC cell line,,,,
6382,Homo sapiens,80682,CHEMBL625141,,1,BAO_0000219,F,9606.0,N,Intermediate,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,,,
6383,Homo sapiens,80682,CHEMBL625142,,1,BAO_0000219,F,9606.0,N,Expert,11818,In vitro cytotoxicity against A549/ATCC cell line.,,,,
6384,Homo sapiens,80682,CHEMBL625143,,1,BAO_0000219,F,9606.0,N,Intermediate,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,,,
6385,Homo sapiens,80682,CHEMBL625144,,1,BAO_0000219,F,9606.0,N,Intermediate,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,,,
6386,Homo sapiens,80682,CHEMBL622474,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,,,
6387,Homo sapiens,80682,CHEMBL884104,,1,BAO_0000219,F,9606.0,N,Intermediate,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,,,
6388,Homo sapiens,22226,CHEMBL622475,,1,BAO_0000219,F,9606.0,U,Autocuration,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,,
6389,Canis lupus familiaris,22224,CHEMBL622476,,1,BAO_0000218,A,9615.0,U,Intermediate,5005,Compound was tested for oral bioavailability in dogs,In vivo,,,
6390,Canis lupus familiaris,50588,CHEMBL875831,,1,BAO_0000218,A,9615.0,N,Intermediate,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,In vivo,,,
6391,Canis lupus familiaris,50588,CHEMBL622477,,1,BAO_0000218,A,9615.0,N,Intermediate,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,In vivo,,,
6392,Canis lupus familiaris,50588,CHEMBL622478,,1,BAO_0000218,A,9615.0,N,Intermediate,5374,Oral bioavailability in dog,In vivo,,,
6393,Canis lupus familiaris,50588,CHEMBL623172,,1,BAO_0000218,A,9615.0,N,Intermediate,5374,Compound was tested for the oral bioavailability in dog; No availability,In vivo,,,
6394,Canis lupus familiaris,50588,CHEMBL623173,,1,BAO_0000218,A,9615.0,N,Intermediate,6265,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,,
6395,Canis lupus familiaris,50588,CHEMBL623174,,1,BAO_0000218,A,9615.0,N,Intermediate,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,,,
6396,Canis lupus familiaris,50588,CHEMBL623175,,1,BAO_0000218,A,9615.0,N,Intermediate,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,In vivo,,,
6397,Canis lupus familiaris,50588,CHEMBL623340,,1,BAO_0000218,A,9615.0,N,Intermediate,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),In vivo,,,
6398,Canis lupus familiaris,50588,CHEMBL623341,,1,BAO_0000218,A,9615.0,N,Intermediate,5302,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,,
6399,Canis lupus familiaris,50588,CHEMBL623342,,1,BAO_0000218,A,9615.0,N,Intermediate,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),In vivo,,,
6400,Canis lupus familiaris,50588,CHEMBL623343,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Oral bioavailability of active FTIs in dogs,In vivo,,,
6401,Canis lupus familiaris,50588,CHEMBL623344,,1,BAO_0000218,A,9615.0,N,Intermediate,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),In vivo,,,
6402,Canis lupus familiaris,50588,CHEMBL623345,,1,BAO_0000218,A,9615.0,N,Expert,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,,
6403,Canis lupus familiaris,50588,CHEMBL875832,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Oral bioavailability in dog,In vivo,,,
6404,Canis lupus familiaris,50588,CHEMBL623346,,1,BAO_0000218,A,9615.0,N,Intermediate,6762,Oral bioavailability in dog,In vivo,,,
6405,Canis lupus familiaris,50588,CHEMBL623347,,1,BAO_0000218,A,9615.0,N,Intermediate,6821,Oral bioavailability in dog,In vivo,,,
6406,Canis lupus familiaris,50588,CHEMBL623348,,1,BAO_0000218,A,9615.0,N,Intermediate,6821,Oral bioavailability of compound was determined in dog; Not tested,In vivo,,,
6407,Canis lupus familiaris,50588,CHEMBL623349,,1,BAO_0000218,A,9615.0,N,Intermediate,5210,Oral bioavailability in dog,In vivo,,,
6408,Canis lupus familiaris,50588,CHEMBL623350,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Oral bioavailability (10 mg/kg) was determined in dog,In vivo,,,
6409,Canis lupus familiaris,50588,CHEMBL623351,,1,BAO_0000218,A,9615.0,N,Intermediate,761,Oral bioavailability,In vivo,,,
6410,Canis lupus familiaris,50588,CHEMBL623352,,1,BAO_0000218,A,9615.0,N,Intermediate,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),In vivo,,,
6411,Canis lupus familiaris,50588,CHEMBL623353,,1,BAO_0000218,A,9615.0,N,Intermediate,761,Oral bioavailability administered in solution in rats,In vivo,,,
6412,Canis lupus familiaris,50588,CHEMBL875833,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,In vivo,,,
6413,Canis lupus familiaris,50588,CHEMBL623354,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,In vivo,,,
6414,Canis lupus familiaris,50588,CHEMBL623355,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),In vivo,,,
6415,Canis lupus familiaris,50588,CHEMBL623356,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Oral bioavailability in Dog; ND = not determined,In vivo,,,
6416,Canis lupus familiaris,50588,CHEMBL623357,,1,BAO_0000218,A,9615.0,N,Intermediate,3352,Oral bioavailability in dog,In vivo,,,
6417,Canis lupus familiaris,50588,CHEMBL623358,,1,BAO_0000218,A,9615.0,N,Intermediate,6168,Oral bioavailability in dog,In vivo,,,
6418,Canis lupus familiaris,50588,CHEMBL623359,,1,BAO_0000218,A,9615.0,N,Intermediate,5988,Oral bioavailability in dog,In vivo,,,
6419,Canis lupus familiaris,50588,CHEMBL623360,,1,BAO_0000218,A,9615.0,N,Intermediate,4942,Oral bioavailability in dog,In vivo,,,
6420,Canis lupus familiaris,50588,CHEMBL623361,,1,BAO_0000218,A,9615.0,N,Intermediate,4942,Oral bioavailability in dogs; No data,In vivo,,,
6421,Canis lupus familiaris,50588,CHEMBL623362,,1,BAO_0000218,A,9615.0,N,Intermediate,14541,Oral bioavailability measured in dogs,In vivo,,,
6422,Canis lupus familiaris,50588,CHEMBL623363,,1,BAO_0000218,A,9615.0,N,Intermediate,4449,Oral bioavailability in dog,In vivo,,,
6423,Canis lupus familiaris,50588,CHEMBL623364,,1,BAO_0000218,A,9615.0,N,Intermediate,6057,Oral bioavailability was calculated in dog,In vivo,,,
6424,Canis lupus familiaris,50588,CHEMBL875834,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,In vivo,,,
6425,Canis lupus familiaris,50588,CHEMBL623365,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,Oral bioavailability in dog (i.v. dosing),In vivo,,,
6426,Canis lupus familiaris,50588,CHEMBL623366,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,Oral bioavailability in dog,In vivo,,,
6427,Canis lupus familiaris,50588,CHEMBL623367,,1,BAO_0000218,A,9615.0,N,Intermediate,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,In vivo,,,
6428,Canis lupus familiaris,50588,CHEMBL623368,,1,BAO_0000218,A,9615.0,N,Intermediate,4514,Oral bioavailability in Beagle dogs,In vivo,,,
6429,Canis lupus familiaris,50588,CHEMBL623369,,1,BAO_0000218,A,9615.0,N,Intermediate,3624,Oral bioavailability in dog,In vivo,,,
6430,Canis lupus familiaris,50588,CHEMBL623370,,1,BAO_0000218,A,9615.0,N,Intermediate,3854,Oral bioavailability in dog,In vivo,,,
6431,Canis lupus familiaris,50588,CHEMBL623371,,1,BAO_0000218,A,9615.0,N,Intermediate,5836,Oral bioavailability in dog,In vivo,,,
6432,Canis lupus familiaris,50588,CHEMBL623372,,1,BAO_0000218,A,9615.0,N,Intermediate,5940,Oral bioavailability in dog,In vivo,,,
6433,Canis lupus familiaris,50588,CHEMBL621351,,1,BAO_0000218,A,9615.0,N,Intermediate,6168,Oral bioavailability in dog,In vivo,,,
6434,Canis lupus familiaris,50588,CHEMBL621352,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Oral bioavailability in dog,In vivo,,,
6435,Canis lupus familiaris,50588,CHEMBL621353,,1,BAO_0000218,A,9615.0,N,Intermediate,6251,Oral bioavailability in dog,In vivo,,,
6436,Canis lupus familiaris,50588,CHEMBL621354,,1,BAO_0000218,A,9615.0,N,Intermediate,6448,Oral bioavailability in dog,In vivo,,,
6437,Canis lupus familiaris,50588,CHEMBL621355,,1,BAO_0000218,A,9615.0,N,Intermediate,6647,Oral bioavailability in dog,In vivo,,,
6438,Canis lupus familiaris,50588,CHEMBL621356,,1,BAO_0000218,A,9615.0,N,Intermediate,5940,Oral bioavailability in dog,In vivo,,,
6439,Canis lupus familiaris,50588,CHEMBL621357,,1,BAO_0000218,A,9615.0,N,Intermediate,933,Oral bioavailability in dog,In vivo,,,
6440,Canis lupus familiaris,50588,CHEMBL621358,,1,BAO_0000218,A,9615.0,N,Intermediate,5210,Oral bioavailability in dog,In vivo,,,
6441,Canis lupus familiaris,50588,CHEMBL621359,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),In vivo,,,
6442,Canis lupus familiaris,50588,CHEMBL621360,,1,BAO_0000218,A,9615.0,N,Intermediate,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,,,
6443,Canis lupus familiaris,50588,CHEMBL621361,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),In vivo,,,
6444,Canis lupus familiaris,50588,CHEMBL621362,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Oral bioavailability in dog,In vivo,,,
6445,Canis lupus familiaris,50588,CHEMBL621363,,1,BAO_0000218,A,9615.0,N,Intermediate,5985,Oral bioavailability in dog,In vivo,,,
6446,Canis lupus familiaris,50588,CHEMBL621364,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Oral bioavailability in dog,In vivo,,,
6447,Canis lupus familiaris,50588,CHEMBL621166,,1,BAO_0000218,A,9615.0,N,Intermediate,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),In vivo,,,
6448,Canis lupus familiaris,50588,CHEMBL621167,,1,BAO_0000218,A,9615.0,N,Intermediate,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,,
6449,Canis lupus familiaris,50588,CHEMBL621168,,1,BAO_0000218,A,9615.0,N,Intermediate,6305,Oral bioavailability (F) in dogs,In vivo,,,
6450,Canis lupus familiaris,50588,CHEMBL621169,,1,BAO_0000218,A,9615.0,N,Intermediate,5210,Oral bioavailability in dog,In vivo,,,
6451,Canis lupus familiaris,50588,CHEMBL875950,,1,BAO_0000218,A,9615.0,N,Intermediate,5238,Bioavailability in dog,In vivo,,,
6452,Canis lupus familiaris,50588,CHEMBL621170,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,,
6453,Canis lupus familiaris,50588,CHEMBL621171,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,In vivo,,,
6454,Canis lupus familiaris,50588,CHEMBL621172,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Oral bioavailability in dog (dose 5 mg/kg),In vivo,,,
6455,Canis lupus familiaris,50588,CHEMBL621173,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,,
6456,Mus musculus,50594,CHEMBL621174,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,,,Kidney
6457,Mus musculus,50594,CHEMBL621175,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,,,Kidney
6458,Mus musculus,50594,CHEMBL621176,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,,,Liver
6459,Mus musculus,50594,CHEMBL621177,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,,,Liver
6460,Mus musculus,50594,CHEMBL621178,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,,,Liver
6461,Mus musculus,50594,CHEMBL621179,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,,,Liver
6462,Mus musculus,50594,CHEMBL621180,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,,,Liver
6463,Mus musculus,50594,CHEMBL875951,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,,,Lung
6464,Mus musculus,50594,CHEMBL621181,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,,,Lung
6465,Mus musculus,50594,CHEMBL621182,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,,,Lung
6466,Mus musculus,50594,CHEMBL621183,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,,,Lung
6467,Mus musculus,50594,CHEMBL621184,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,,,Lung
6468,Mus musculus,50594,CHEMBL621185,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,,,
6469,Mus musculus,50594,CHEMBL621186,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,,,
6470,Mus musculus,50594,CHEMBL621187,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,,,
6471,Mus musculus,50594,CHEMBL621188,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,,,
6472,Mus musculus,50594,CHEMBL621189,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,,,
6473,Mus musculus,50594,CHEMBL621190,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,,,Spleen
6474,Mus musculus,50594,CHEMBL618520,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,,,Spleen
6475,Mus musculus,50594,CHEMBL621739,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,,,Spleen
6476,Mus musculus,50594,CHEMBL621740,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,,,Spleen
6477,Mus musculus,50594,CHEMBL621741,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,,,Spleen
6478,Mus musculus,50594,CHEMBL621742,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,,,
6479,Mus musculus,50594,CHEMBL621743,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,,,
6480,Mus musculus,50594,CHEMBL621744,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,,,
6481,Mus musculus,50594,CHEMBL621745,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,,,
6482,Mus musculus,50594,CHEMBL621746,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,,,
6483,Mus musculus,50594,CHEMBL621747,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,,,
6484,Mus musculus,50594,CHEMBL621748,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,,,
6485,Mus musculus,50594,CHEMBL621749,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,,,
6486,Mus musculus,50594,CHEMBL621750,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,,,
6487,Mus musculus,50594,CHEMBL621751,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,,,
6488,Mus musculus,50594,CHEMBL621752,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,,,Heart
6489,Mus musculus,50594,CHEMBL621753,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,,,Heart
6490,Mus musculus,50594,CHEMBL875955,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,,,Heart
6491,Mus musculus,50594,CHEMBL621754,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,,,Heart
6492,Mus musculus,50594,CHEMBL621755,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,,,Heart
6493,Mus musculus,50594,CHEMBL621756,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,,,Liver
6494,Mus musculus,50594,CHEMBL624199,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,,,Liver
6495,Mus musculus,50594,CHEMBL624200,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,,,Liver
6496,Mus musculus,50594,CHEMBL624375,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,,,Liver
6497,Mus musculus,50594,CHEMBL624376,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,,,Liver
6498,Mus musculus,50594,CHEMBL624377,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,,,Lung
6499,Mus musculus,50594,CHEMBL624378,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,,,Lung
6500,aeinetobacter anitrotap,50067,CHEMBL857901,,1,BAO_0000218,F,107673.0,N,Intermediate,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,
6501,Acinetobacter calcoaceticus subsp. anitratus,50067,CHEMBL875274,,1,BAO_0000218,F,107673.0,N,Intermediate,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,
6502,Acinetobacter calcoaceticus subsp. anitratus,50067,CHEMBL624379,,1,BAO_0000218,F,107673.0,N,Intermediate,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,
6503,aeinetobacter anitrotap,50067,CHEMBL624380,,1,BAO_0000218,F,107673.0,N,Intermediate,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,
6504,Acinetobacter calcoaceticus,50192,CHEMBL624381,,1,BAO_0000218,F,471.0,N,Intermediate,10624,Activity against Acinetobacter calcoaceticus (AC54),,,,
6505,Anolis carolinensis,50714,CHEMBL624382,,1,BAO_0000218,F,28377.0,N,Intermediate,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,,
6506,Anolis carolinensis,50714,CHEMBL624383,,1,BAO_0000218,F,28377.0,N,Intermediate,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,,
6507,Actinomyces naeslundii,50296,CHEMBL624384,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,,
6508,Actinomyces naeslundii,50296,CHEMBL624385,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,,
6509,Actinomyces naeslundii,50296,CHEMBL624386,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,,
6510,Actinomyces naeslundii,50296,CHEMBL624387,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,,
6511,Actinomyces naeslundii,50296,CHEMBL624388,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces naeslundii 631,,,,
6512,Actinomyces naeslundii,50296,CHEMBL624389,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,,,,
6513,Actinomyces naeslundii,50296,CHEMBL624390,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces naeslundii B74,,,,
6514,Actinomyces naeslundii,50296,CHEMBL875275,,1,BAO_0000218,F,1655.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,,,,
6515,Artemia salina,50056,CHEMBL624391,,1,BAO_0000218,F,85549.0,N,Intermediate,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,,
6516,Artemia salina,50056,CHEMBL623636,,1,BAO_0000218,F,85549.0,N,Intermediate,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,,
6517,Ascaris suum,50532,CHEMBL623637,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,,
6518,Ascaris suum,50532,CHEMBL623638,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,,
6519,Ascaris suum,50532,CHEMBL623639,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,,
6520,Ascaris suum,50532,CHEMBL623640,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,,
6521,Ascaris suum,50532,CHEMBL623641,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,,
6522,Ascaris suum,50532,CHEMBL623642,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,,
6523,Ascaris suum,50532,CHEMBL623643,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,,
6524,Ascaris suum,50532,CHEMBL623644,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,,
6525,Ascaris suum,50532,CHEMBL623645,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,,
6526,Ascaris suum,50532,CHEMBL623646,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,,
6527,Ascaris suum,50532,CHEMBL623647,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,,
6528,Ascaris suum,50532,CHEMBL623648,,1,BAO_0000218,F,6253.0,N,Intermediate,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,,
6529,Actinomyces viscosus,50366,CHEMBL623649,,1,BAO_0000218,F,1656.0,N,Intermediate,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,,
6530,Actinomyces viscosus,50366,CHEMBL623650,,1,BAO_0000218,F,1656.0,N,Intermediate,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,,
6531,Actinomyces viscosus,50366,CHEMBL623651,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,,
6532,Actinomyces viscosus,50366,CHEMBL623652,,1,BAO_0000218,F,1656.0,N,Expert,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,,
6533,Actinomyces viscosus,50366,CHEMBL623653,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,,
6534,Actinomyces viscosus,50366,CHEMBL623654,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,,
6535,Actinomyces viscosus,50366,CHEMBL623655,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,,,,
6536,Actinomyces viscosus,50366,CHEMBL623656,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces viscosus M-100,,,,
6537,Actinomyces viscosus,50366,CHEMBL623657,,1,BAO_0000218,F,1656.0,N,Expert,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,,
6538,Actinomyces viscosus,50366,CHEMBL623658,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,,
6539,Actinomyces viscosus,50366,CHEMBL623659,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,,
6540,Actinomyces viscosus,50366,CHEMBL623660,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces viscosus 626,,,,
6541,Actinomyces viscosus,50366,CHEMBL623661,,1,BAO_0000218,F,1656.0,N,Intermediate,9560,Plaque bactericidal index against Actinomyces viscosus T14V,,,,
6542,Acanthocheilonema viteae,50535,CHEMBL875281,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,,
6543,Acanthocheilonema viteae,50535,CHEMBL623662,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,,
6544,Acanthocheilonema viteae,50535,CHEMBL623663,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,,
6545,Acanthocheilonema viteae,50535,CHEMBL623664,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,,
6546,Acanthocheilonema viteae,50535,CHEMBL623665,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,,
6547,Homo sapiens,80023,CHEMBL621856,,1,BAO_0000219,F,9606.0,N,Intermediate,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,,,
6548,Homo sapiens,80661,CHEMBL620432,,1,BAO_0000219,F,9606.0,N,Intermediate,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,,,
6549,Rattus norvegicus,22226,CHEMBL620433,,1,BAO_0000219,F,10116.0,U,Autocuration,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,,
6550,Mus musculus,80024,CHEMBL620434,,1,BAO_0000219,F,10090.0,N,Intermediate,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,,
6551,Mus musculus,80024,CHEMBL620435,,1,BAO_0000219,F,10090.0,N,Intermediate,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,,,
6552,Homo sapiens,80024,CHEMBL620436,,1,BAO_0000219,F,9606.0,N,Intermediate,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,,,
6553,Homo sapiens,80024,CHEMBL876597,,1,BAO_0000219,F,9606.0,N,Intermediate,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,,,
6554,Homo sapiens,81037,CHEMBL620437,,1,BAO_0000219,F,9606.0,N,Expert,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,,,
6555,Mus musculus,80024,CHEMBL620438,,1,BAO_0000219,F,10090.0,N,Expert,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,,,
6556,Mus musculus,80024,CHEMBL620439,,1,BAO_0000219,F,10090.0,N,Expert,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,,,
6557,Mus musculus,80024,CHEMBL619657,,1,BAO_0000219,F,10090.0,N,Expert,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,,,
6558,Mus musculus,80024,CHEMBL619658,,1,BAO_0000219,F,10090.0,N,Intermediate,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,,,
6559,Mus musculus,80024,CHEMBL619659,,1,BAO_0000219,F,10090.0,N,Intermediate,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,,,
6560,,10649,CHEMBL619660,,1,BAO_0000019,F,,H,Expert,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,,
6561,Mus musculus,80024,CHEMBL619661,,1,BAO_0000219,F,10090.0,N,Intermediate,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,,,
6562,Mus musculus,80024,CHEMBL619662,,1,BAO_0000219,F,10090.0,N,Intermediate,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,,,
6563,Cricetulus griseus,80663,CHEMBL619663,,1,BAO_0000219,F,10029.0,N,Intermediate,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,,,
6564,Homo sapiens,22226,CHEMBL619664,,1,BAO_0000219,F,9606.0,U,Autocuration,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,,
6565,Homo sapiens,22226,CHEMBL619665,,1,BAO_0000219,F,9606.0,U,Autocuration,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,,
6566,Homo sapiens,80662,CHEMBL883244,,1,BAO_0000219,F,9606.0,N,Intermediate,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,,,
6567,Homo sapiens,80662,CHEMBL884011,,1,BAO_0000219,F,9606.0,N,Intermediate,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),,,,
6568,Homo sapiens,80662,CHEMBL619666,,1,BAO_0000219,F,9606.0,N,Intermediate,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,,,
6569,Homo sapiens,80566,CHEMBL619667,,1,BAO_0000219,F,9606.0,N,Intermediate,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,,,
6570,Cricetulus griseus,80578,CHEMBL619668,,1,BAO_0000219,F,10029.0,N,Intermediate,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,,,
6571,Cricetulus griseus,80089,CHEMBL619669,,1,BAO_0000219,F,10029.0,N,Expert,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,,
6572,Cricetulus griseus,80089,CHEMBL876608,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Average intracellular compound concentration when the hypoxic SER=1.6,,,,
6573,Cricetulus griseus,80089,CHEMBL619670,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,,,,
6574,Cricetulus griseus,80089,CHEMBL619671,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,,,
6575,Cricetulus griseus,80089,CHEMBL619672,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,,,
6576,Cricetulus griseus,80089,CHEMBL619673,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,,,
6577,Cricetulus griseus,80089,CHEMBL619674,,1,BAO_0000219,F,10029.0,N,Intermediate,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,,,
6578,Cricetulus griseus,80089,CHEMBL619675,,1,BAO_0000219,F,10029.0,N,Intermediate,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,,,
6579,Cricetulus griseus,80089,CHEMBL619676,,1,BAO_0000219,F,10029.0,N,Intermediate,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,,,
6580,Cricetulus griseus,80089,CHEMBL619677,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,,
6581,Cricetulus griseus,80089,CHEMBL619678,,1,BAO_0000219,A,10029.0,N,Intermediate,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,,,
6582,Cricetulus griseus,80089,CHEMBL619679,,1,BAO_0000219,A,10029.0,N,Intermediate,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,,,
6583,Cricetulus griseus,80089,CHEMBL619680,,1,BAO_0000219,A,10029.0,N,Expert,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,,,
6584,Cricetulus griseus,80089,CHEMBL621457,,1,BAO_0000219,A,10029.0,N,Intermediate,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,,,
6585,Cricetulus griseus,80089,CHEMBL876609,,1,BAO_0000219,F,10029.0,N,Expert,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,,,
6586,Cricetulus griseus,80089,CHEMBL621458,,1,BAO_0000219,F,10029.0,N,Intermediate,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,,,
6587,hampster,80089,CHEMBL621459,,1,BAO_0000219,F,36483.0,N,Expert,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,,,
6588,Cricetulus griseus,80089,CHEMBL621460,,1,BAO_0000219,F,10029.0,N,Expert,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,,,,
6589,Cricetulus griseus,80089,CHEMBL621461,,1,BAO_0000219,F,10029.0,N,Expert,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,,,
6590,Cricetulus griseus,80089,CHEMBL621462,,1,BAO_0000219,F,10029.0,N,Expert,13436,Inhibition of growth under aerobic conditions in AA8 cells,,,,
6591,Canis lupus familiaris,50588,CHEMBL621463,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,,
6592,Canis lupus familiaris,50588,CHEMBL621464,,1,BAO_0000218,A,9615.0,N,Intermediate,5711,Oral bioavailability in dog at 10 mg/kg of the compound,In vivo,,,
6593,Canis lupus familiaris,50588,CHEMBL621465,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,,
6594,Canis lupus familiaris,50588,CHEMBL621466,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,,
6595,Canis lupus familiaris,50588,CHEMBL621467,,1,BAO_0000218,A,9615.0,N,Intermediate,17800,Oral bioavailability in dog (mongrel),In vivo,,,
6596,Canis lupus familiaris,50588,CHEMBL621468,,1,BAO_0000218,A,9615.0,N,Intermediate,3994,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,,
6597,Canis lupus familiaris,50588,CHEMBL876734,,1,BAO_0000218,F,9615.0,N,Intermediate,3994,Oral bioavailability in dog (dose 10 mg/kg),In vivo,,,
6598,Canis lupus familiaris,50588,CHEMBL618476,,1,BAO_0000218,A,9615.0,N,Intermediate,5145,Bioavailability in dog,In vivo,,,
6599,Canis lupus familiaris,50588,CHEMBL618477,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,,
6600,Canis lupus familiaris,50588,CHEMBL618478,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),In vivo,,,
6601,Canis lupus familiaris,50588,CHEMBL618479,,1,BAO_0000218,A,9615.0,N,Intermediate,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,In vivo,,,
6602,Canis lupus familiaris,50588,CHEMBL618480,,1,BAO_0000218,A,9615.0,N,Intermediate,4273,Bioavailability in dog,In vivo,,,
6603,Canis lupus familiaris,50588,CHEMBL618481,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,Bioavailability in dog (dose 3-10 mg/kg),In vivo,,,
6604,Canis lupus familiaris,50588,CHEMBL618482,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,In vivo,,,Plasma
6605,Canis lupus familiaris,50588,CHEMBL618483,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,Oral bioavailability in dog,In vivo,,,
6606,Canis lupus familiaris,50588,CHEMBL618484,,1,BAO_0000218,A,9615.0,N,Intermediate,3880,Oral bioavailability in dog,In vivo,,,
6607,Canis lupus familiaris,50588,CHEMBL618485,,1,BAO_0000218,A,9615.0,N,Intermediate,4838,Bioavailability in dog,In vivo,,,
6608,Canis lupus familiaris,50588,CHEMBL618486,,1,BAO_0000218,A,9615.0,N,Intermediate,15600,oral bioavailability was measured in dogs,In vivo,,,
6609,Canis lupus familiaris,50588,CHEMBL618487,,1,BAO_0000218,A,9615.0,N,Intermediate,17248,Compound was tested for plasma protein binding in dog; Not determined,,,,
6610,Canis lupus familiaris,50588,CHEMBL618488,,1,BAO_0000218,A,9615.0,N,Intermediate,17248,Compound was tested for plasma protein binding of dog,,,,
6611,Canis lupus familiaris,50588,CHEMBL876735,,1,BAO_0000218,A,9615.0,N,Intermediate,17248,Compound was tested for plasma protein binding of dog; Not determined,,,,
6612,Canis lupus familiaris,50588,CHEMBL618489,,1,BAO_0000218,A,9615.0,N,Intermediate,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,,
6613,Canis lupus familiaris,50588,CHEMBL618490,,1,BAO_0000218,A,9615.0,N,Intermediate,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,In vivo,,,
6614,Canis lupus familiaris,50588,CHEMBL618491,,1,BAO_0000218,A,9615.0,N,Intermediate,3749,Half life was determined,,,,
6615,Canis lupus familiaris,50588,CHEMBL618492,,1,BAO_0000218,A,9615.0,N,Intermediate,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,In vivo,,,
6616,Canis lupus familiaris,50588,CHEMBL873354,,1,BAO_0000218,A,9615.0,N,Intermediate,3022,Half life was evaluated in dog,,,,
6617,Canis lupus familiaris,50588,CHEMBL618493,,1,BAO_0000218,A,9615.0,N,Intermediate,3749,Half life was determined,,,,
6618,Canis lupus familiaris,50588,CHEMBL618494,,1,BAO_0000218,A,9615.0,N,Intermediate,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,,
6619,Canis lupus familiaris,50588,CHEMBL618495,,1,BAO_0000218,A,9615.0,N,Intermediate,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,,Heart
6620,Canis lupus familiaris,50588,CHEMBL618496,,1,BAO_0000218,A,9615.0,N,Intermediate,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,,Kidney
6621,Canis lupus familiaris,50588,CHEMBL618497,,1,BAO_0000218,A,9615.0,N,Intermediate,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,,Liver
6622,Canis lupus familiaris,50588,CHEMBL618498,,1,BAO_0000218,A,9615.0,N,Intermediate,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,,Lung
6623,Canis lupus familiaris,50588,CHEMBL618499,,1,BAO_0000218,A,9615.0,N,Intermediate,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),In vivo,,,Spleen
6624,Canis lupus familiaris,50588,CHEMBL876736,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,LogP in dog,,,,
6625,Canis lupus familiaris,50588,CHEMBL618500,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Partition coefficient (logP),,,,
6626,Canis lupus familiaris,50588,CHEMBL857831,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Partition coefficient in dog,,,,
6627,Canis lupus familiaris,50588,CHEMBL618501,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,In vivo,,,
6628,Canis lupus familiaris,50588,CHEMBL618502,,1,BAO_0000218,A,9615.0,N,Intermediate,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),In vivo,,,
6629,Canis lupus familiaris,50588,CHEMBL618503,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,,
6630,Canis lupus familiaris,50588,CHEMBL618504,,1,BAO_0000218,A,9615.0,N,Intermediate,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,,
6631,Canis lupus familiaris,50588,CHEMBL618505,,1,BAO_0000218,A,9615.0,N,Intermediate,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,,
6632,Canis lupus familiaris,50588,CHEMBL618506,,1,BAO_0000218,A,9615.0,N,Intermediate,14294,Metabolism of compound in dog S9 microsomes; Trace,,,,
6633,Canis lupus familiaris,50588,CHEMBL618507,,1,BAO_0000218,A,9615.0,N,Intermediate,6251,In vitro metabolic potential in dog liver microsomes,,,,Liver
6634,Canis lupus familiaris,50588,CHEMBL876737,,1,BAO_0000218,A,9615.0,N,Intermediate,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,In vivo,,,
6635,Canis lupus familiaris,50588,CHEMBL618508,,1,BAO_0000218,A,9615.0,N,Intermediate,2713,Oral bioavailability in dog,In vivo,,,
6636,Canis lupus familiaris,50588,CHEMBL618509,,1,BAO_0000218,A,9615.0,N,Intermediate,6512,Oral bioavailability in dog,In vivo,,,
6637,Canis lupus familiaris,50588,CHEMBL618510,,1,BAO_0000218,A,9615.0,N,Intermediate,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,,
6638,Canis lupus familiaris,50588,CHEMBL618511,,1,BAO_0000218,A,9615.0,N,Intermediate,3749,The compound was tested for bioavailability in dogs,In vivo,,,
6639,Canis lupus familiaris,50588,CHEMBL618512,,1,BAO_0000218,A,9615.0,N,Intermediate,3749,The compound was tested for oral bioavailability in dogs,In vivo,,,
6640,Canis lupus familiaris,50588,CHEMBL618513,,1,BAO_0000218,A,9615.0,N,Intermediate,6742,Oral bioavailability in dog,In vivo,,,
6641,Canis lupus familiaris,50588,CHEMBL618514,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Compound was tested for percent protein binding (PB) in dog,,,,
6642,Canis lupus familiaris,50588,CHEMBL620052,,1,BAO_0000218,A,9615.0,N,Intermediate,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,,
6643,Canis lupus familiaris,50588,CHEMBL620053,,1,BAO_0000218,A,9615.0,N,Intermediate,2877,Compound was evaluated for plasma clearance.,In vivo,,,Plasma
6644,Canis lupus familiaris,50588,CHEMBL620054,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,The compound was tested for plasma clearance in dog,In vivo,,,Plasma
6645,Canis lupus familiaris,50588,CHEMBL620055,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,In vivo,,,Plasma
6646,Canis lupus familiaris,50588,CHEMBL620056,,1,BAO_0000218,A,9615.0,N,Intermediate,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,,
6647,Canis lupus familiaris,50588,CHEMBL620057,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,,,,Liver
6648,Canis lupus familiaris,50588,CHEMBL618939,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,In vivo,,,
6649,Canis lupus familiaris,50588,CHEMBL618940,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,,,
6650,Canis lupus familiaris,50588,CHEMBL618941,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,In vivo,,,
6651,Mus musculus,50594,CHEMBL624473,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,,,Lung
6652,Mus musculus,50594,CHEMBL624474,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,,,Lung
6653,Mus musculus,50594,CHEMBL624475,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,,,Lung
6654,Mus musculus,50594,CHEMBL624476,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,,,
6655,Mus musculus,50594,CHEMBL623478,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,,,
6656,Mus musculus,50594,CHEMBL623479,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,,,
6657,Mus musculus,50594,CHEMBL623480,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,,,
6658,Mus musculus,50594,CHEMBL623481,,1,BAO_0000218,A,10090.0,N,Intermediate,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,,,
6659,Mus musculus,50594,CHEMBL623482,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,C2 in brain of mice at the oral dose of 50 mg/kg,,,,Brain
6660,Mus musculus,50594,CHEMBL623483,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,,,,Kidney
6661,Mus musculus,50594,CHEMBL623484,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,C2 in liver of mice at the oral dose of 50 mg/kg,,,,Liver
6662,Mus musculus,50594,CHEMBL623485,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,,,,Lung
6663,Mus musculus,50594,CHEMBL623486,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,,,,Spleen
6664,Mus musculus,50594,CHEMBL623487,,1,BAO_0000218,A,10090.0,N,Intermediate,17852,Plasma clearance in mouse,In vivo,,,
6665,Mus musculus,50594,CHEMBL623488,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,In vivo,,,
6666,Mus musculus,50594,CHEMBL623489,,1,BAO_0000218,A,10090.0,N,Intermediate,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,In vivo,,,
6667,Mus musculus,50594,CHEMBL875157,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Clearance was evaluated in mice after intravenous administration,In vivo,,,
6668,Mus musculus,50594,CHEMBL623490,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Clearance was evaluated in mice after oral administration,In vivo,,,
6669,Mus musculus,50594,CHEMBL623491,,1,BAO_0000218,A,10090.0,N,Intermediate,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,In vivo,,,
6670,Mus musculus,50594,CHEMBL623492,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Plasma clearance of compound was determined at 40 mg/Kg,In vivo,,,
6671,Mus musculus,50594,CHEMBL623493,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Plasma clearance of at 24 mg/Kg,In vivo,,,
6672,Mus musculus,50594,CHEMBL623494,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Plasma clearance at 24 mg/Kg,In vivo,,,
6673,Mus musculus,50594,CHEMBL623495,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Plasma clearance at 5 mg/Kg,In vivo,,,
6674,Mus musculus,50594,CHEMBL623496,,1,BAO_0000218,A,10090.0,N,Intermediate,5727,Plasma clearance in mice,In vivo,,,
6675,Mus musculus,50594,CHEMBL623497,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Plasma clearance value upon iv administration in mouse,In vivo,,,
6676,Mus musculus,50594,CHEMBL623498,,1,BAO_0000218,A,10090.0,N,Intermediate,5980,Total plasma clearance in mice,In vivo,,,Plasma
6677,Mus musculus,50594,CHEMBL623499,,1,BAO_0000218,A,10090.0,N,Intermediate,17592,Clearance in mouse,In vivo,,,
6678,Mus musculus,50594,CHEMBL623500,,1,BAO_0000218,A,10090.0,N,Intermediate,17718,Clearance value was determined,In vivo,,,
6679,Mus musculus,50594,CHEMBL623501,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,,
6680,,22229,CHEMBL875158,,1,BAO_0000100,P,,U,Intermediate,17384,Calculated partition coefficient (clogP),,,,
6681,Mus musculus,50594,CHEMBL623502,,1,BAO_0000218,A,10090.0,N,Intermediate,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,In vivo,,,
6682,Mus musculus,50594,CHEMBL623503,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,In vivo,,,
6683,Mus musculus,50594,CHEMBL623504,,1,BAO_0000218,A,10090.0,N,Intermediate,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,,
6684,Mus musculus,50594,CHEMBL623505,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,In vivo,,,
6685,Mus musculus,50594,CHEMBL623506,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,In vivo,,,
6686,Mus musculus,50594,CHEMBL623507,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,In vivo,,,
6687,Mus musculus,50594,CHEMBL623508,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,In vivo,,,
6688,Mus musculus,50594,CHEMBL623509,,1,BAO_0000218,A,10090.0,N,Intermediate,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,In vivo,,,
6689,Mus musculus,50594,CHEMBL875159,,1,BAO_0000218,A,10090.0,N,Intermediate,17764,Cmax after peroral administration in mice at 2.4 uM/kg,In vivo,,,
6690,Mus musculus,50594,CHEMBL623510,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,In vivo,,,Brain
6691,Mus musculus,50594,CHEMBL623511,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,In vivo,,,Kidney
6692,Mus musculus,50594,CHEMBL623512,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,In vivo,,,Liver
6693,Mus musculus,50594,CHEMBL623513,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,In vivo,,,Lung
6694,Mus musculus,50594,CHEMBL623514,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Cmax in mice at 18 uM/kg i.p. administration,In vivo,,,
6695,Mus musculus,50594,CHEMBL622609,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Cmax in mice at 23 uM/kg i.v. administration,In vivo,,,
6696,Mus musculus,50594,CHEMBL622610,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Cmax in mice at 24 uM/kg i.p. administration,In vivo,,,
6697,Mus musculus,50594,CHEMBL621823,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Cmax in mice at 25 uM/kg i.p. administration,In vivo,,,
6698,Mus musculus,50594,CHEMBL621824,,1,BAO_0000218,F,10090.0,N,Intermediate,17764,Cmax in mice at 26 uM/kg i.p. administration,In vivo,,,
6699,Mus musculus,50594,CHEMBL621825,,1,BAO_0000218,A,10090.0,N,Intermediate,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,In vivo,,,Spleen
6700,Mus musculus,50594,CHEMBL621826,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,In vivo,,,
6701,Mus musculus,50594,CHEMBL621827,,1,BAO_0000218,A,10090.0,N,Intermediate,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,In vivo,,,
6702,Mus musculus,50594,CHEMBL621828,,1,BAO_0000218,A,10090.0,N,Intermediate,5727,Cmax value was determined,In vivo,,,
6703,Mus musculus,50594,CHEMBL621829,,1,BAO_0000218,A,10090.0,N,Intermediate,5951,Cmax value in IRC mice,In vivo,,,
6704,Mus musculus,50594,CHEMBL621830,,1,BAO_0000218,A,10090.0,N,Intermediate,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,In vivo,,,
6705,Mus musculus,50594,CHEMBL621831,,1,BAO_0000218,A,10090.0,N,Intermediate,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,In vivo,,,
6706,Mus musculus,50594,CHEMBL621832,,1,BAO_0000218,A,10090.0,N,Intermediate,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,In vivo,,,Plasma
6707,Mus musculus,50594,CHEMBL624579,,1,BAO_0000218,A,10090.0,N,Intermediate,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",In vivo,,,Plasma
6708,Mus musculus,50594,CHEMBL624580,,1,BAO_0000218,A,10090.0,N,Intermediate,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,In vivo,,,
6709,Acanthocheilonema viteae,50535,CHEMBL624581,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,,
6710,Acanthocheilonema viteae,50535,CHEMBL624582,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,,
6711,Acanthocheilonema viteae,50535,CHEMBL624583,,1,BAO_0000218,F,6277.0,N,Intermediate,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,,
6712,Homo sapiens,80018,CHEMBL624584,,1,BAO_0000219,F,9606.0,N,Intermediate,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,,,,
6713,Rattus norvegicus,12512,CHEMBL624585,,1,BAO_0000249,B,10116.0,D,Expert,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,,
6714,Homo sapiens,114,CHEMBL875165,,1,BAO_0000019,F,9606.0,D,Expert,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,,,,
6715,,114,CHEMBL619490,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,,,
6716,,114,CHEMBL619491,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,,
6717,,114,CHEMBL619492,,1,BAO_0000219,F,,H,Expert,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,,,
6718,,114,CHEMBL619493,,1,BAO_0000219,F,,H,Expert,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,,,
6719,,114,CHEMBL619494,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,,,
6720,,114,CHEMBL619495,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,,,
6721,,114,CHEMBL619496,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,,,
6722,Homo sapiens,114,CHEMBL619497,,1,BAO_0000219,F,9606.0,D,Expert,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,,,
6723,,114,CHEMBL619498,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,,,
6724,,114,CHEMBL619499,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,,,
6725,,114,CHEMBL619500,,1,BAO_0000219,F,,H,Expert,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,,,
6726,,114,CHEMBL619501,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,,,
6727,,114,CHEMBL619502,,1,BAO_0000219,F,,H,Expert,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,,,
6728,,114,CHEMBL619503,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,,,
6729,,114,CHEMBL619504,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,
6730,,114,CHEMBL621298,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,,,
6731,,114,CHEMBL621299,,1,BAO_0000219,F,,H,Expert,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,,,
6732,,114,CHEMBL621300,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,,,
6733,,114,CHEMBL621301,,1,BAO_0000219,F,,H,Autocuration,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,,,
6734,,114,CHEMBL621302,,1,BAO_0000219,F,,H,Expert,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,,,
6735,Oryctolagus cuniculus,80013,CHEMBL621303,,1,BAO_0000219,F,9986.0,N,Intermediate,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,,,
6736,Rattus norvegicus,22226,CHEMBL621304,,1,BAO_0000219,F,10116.0,U,Autocuration,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,,,
6737,Rattus norvegicus,22226,CHEMBL621305,,1,BAO_0000219,F,10116.0,U,Autocuration,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,,,
6738,Rattus norvegicus,80013,CHEMBL621306,,1,BAO_0000219,F,10116.0,N,Intermediate,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,,,
6739,Rattus norvegicus,80013,CHEMBL618444,,1,BAO_0000219,F,10116.0,N,Intermediate,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,,,
6740,Rattus norvegicus,80013,CHEMBL618445,,1,BAO_0000219,F,10116.0,N,Intermediate,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,,,
6741,Cricetulus griseus,80089,CHEMBL618446,,1,BAO_0000219,F,10029.0,N,Intermediate,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,,,
6742,Cricetulus griseus,80089,CHEMBL618447,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,,,
6743,Cricetulus griseus,80089,CHEMBL618448,,1,BAO_0000219,F,10029.0,N,Intermediate,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,,,
6744,Cricetulus griseus,80089,CHEMBL618449,,1,BAO_0000219,F,10029.0,N,Intermediate,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,,,
6745,Cricetulus griseus,80089,CHEMBL618637,,1,BAO_0000219,F,10029.0,N,Intermediate,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,,
6746,Cricetulus griseus,80089,CHEMBL618638,,1,BAO_0000219,F,10029.0,N,Intermediate,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,,,
6747,Cricetulus griseus,80089,CHEMBL618639,,1,BAO_0000219,F,10029.0,N,Intermediate,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,,,
6748,Cricetulus griseus,80089,CHEMBL618640,,1,BAO_0000219,F,10029.0,N,Expert,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,,,
6749,Cricetulus griseus,80089,CHEMBL618641,,1,BAO_0000219,F,10029.0,N,Expert,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,,,
6750,Cricetulus griseus,80089,CHEMBL618642,,1,BAO_0000219,F,10029.0,N,Intermediate,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,,,
6751,Cricetulus griseus,80089,CHEMBL618643,,1,BAO_0000219,F,10029.0,N,Intermediate,13435,Inhibitory activity against aerobic growth of AA8 cells.,,,,
6752,Cricetulus griseus,80089,CHEMBL884013,,1,BAO_0000219,A,10029.0,N,Intermediate,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,,
6753,Cricetulus griseus,80089,CHEMBL622723,,1,BAO_0000219,F,10029.0,N,Expert,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,,
6754,Cricetulus griseus,80089,CHEMBL622724,,1,BAO_0000219,F,10029.0,N,Intermediate,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,,,
6755,Cricetulus griseus,80089,CHEMBL622725,,1,BAO_0000219,F,10029.0,N,Expert,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,,,
6756,Cricetulus griseus,80089,CHEMBL622726,,1,BAO_0000219,F,10029.0,N,Expert,10368,Cytotoxicity against AA8 cell line,,,,
6757,Cricetulus griseus,80089,CHEMBL622727,,1,BAO_0000219,F,10029.0,N,Intermediate,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,,,
6758,Cricetulus griseus,80089,CHEMBL622728,,1,BAO_0000219,A,10029.0,N,Intermediate,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,,
6759,Cricetulus griseus,80089,CHEMBL622729,,1,BAO_0000219,F,10029.0,N,Intermediate,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,,
6760,Cricetulus griseus,80089,CHEMBL622730,,1,BAO_0000219,A,10029.0,N,Intermediate,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,,,
6761,Cricetulus griseus,80089,CHEMBL622731,,1,BAO_0000219,F,10029.0,N,Intermediate,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,,,
6762,Cricetulus griseus,80089,CHEMBL622732,,1,BAO_0000219,F,10029.0,N,Intermediate,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,,
6763,Cricetulus griseus,80089,CHEMBL622733,,1,BAO_0000219,F,10029.0,N,Intermediate,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,,,
6764,Cricetulus griseus,22224,CHEMBL622734,,1,BAO_0000218,F,10029.0,U,Autocuration,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,,
6765,Cricetulus griseus,80089,CHEMBL622735,,1,BAO_0000219,F,10029.0,N,Expert,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,,,
6766,Cricetulus griseus,22224,CHEMBL618746,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,,,
6767,Cricetulus griseus,22224,CHEMBL618747,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,,,
6768,Cricetulus griseus,22224,CHEMBL620540,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,,,
6769,Cricetulus griseus,22224,CHEMBL620541,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,,,
6770,Cricetulus griseus,22224,CHEMBL620542,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,,,
6771,Cricetulus griseus,22224,CHEMBL620543,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,,,
6772,Cricetulus griseus,22224,CHEMBL618832,,1,BAO_0000219,F,10029.0,U,Autocuration,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,,,
6773,Cricetulus griseus,80089,CHEMBL618833,,1,BAO_0000219,F,10029.0,N,Expert,11616,Concentration required to reduce AA8 cell survival by 10%,,,,
6774,Cricetulus griseus,22224,CHEMBL618834,,1,BAO_0000219,F,10029.0,U,Autocuration,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,,,
6775,Cricetulus griseus,22224,CHEMBL618835,,1,BAO_0000219,F,10029.0,U,Autocuration,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,,
6776,Cricetulus griseus,22224,CHEMBL618836,,1,BAO_0000219,F,10029.0,U,Autocuration,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,,,
6777,Cricetulus griseus,22224,CHEMBL618837,,1,BAO_0000219,F,10029.0,U,Autocuration,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,,,
6778,Cricetulus griseus,22224,CHEMBL618838,,1,BAO_0000219,F,10029.0,U,Autocuration,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,,,
6779,Cricetulus griseus,22224,CHEMBL618839,,1,BAO_0000219,F,10029.0,U,Autocuration,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,,,
6780,Cricetulus griseus,22224,CHEMBL618840,,1,BAO_0000219,F,10029.0,U,Autocuration,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,,,
6781,Cricetulus griseus,22224,CHEMBL618841,,1,BAO_0000019,F,10029.0,U,Autocuration,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,,
6782,Cricetulus griseus,22224,CHEMBL618842,,1,BAO_0000219,F,10029.0,U,Autocuration,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,,,
6783,Cricetulus griseus,22224,CHEMBL618843,,1,BAO_0000219,F,10029.0,U,Autocuration,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,,,
6784,Canis lupus familiaris,50588,CHEMBL618844,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Half life period after 15 mg/kg iv dose in Dogs,In vivo,,,
6785,Canis lupus familiaris,50588,CHEMBL618845,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Half life period after 30 mg/kg po dose in Dogs,In vivo,,,
6786,Canis lupus familiaris,50588,CHEMBL618846,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Half life was measured after oral 2b administration (tested in 6 dogs),In vivo,,,
6787,Canis lupus familiaris,50588,CHEMBL618847,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Half life was measured in dog after oral 17b administration,In vivo,,,
6788,Canis lupus familiaris,50588,CHEMBL618848,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,In vivo,,,
6789,Canis lupus familiaris,50588,CHEMBL618849,,1,BAO_0000218,A,9615.0,N,Intermediate,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,In vivo,,,
6790,Canis lupus familiaris,50588,CHEMBL618850,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Tmax value after 15 mg/kg iv dose in Dogs,In vivo,,,
6791,Canis lupus familiaris,50588,CHEMBL618851,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Tmax value after 30 mg/kg po dose in Dogs,In vivo,,,
6792,Canis lupus familiaris,50588,CHEMBL873815,,1,BAO_0000218,A,9615.0,N,Intermediate,3184,Compound was evaluated for its half life when administered intravenously in dog,In vivo,,,
6793,Canis lupus familiaris,50588,CHEMBL618852,,1,BAO_0000218,A,9615.0,N,Intermediate,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),In vivo,,,Plasma
6794,Canis lupus familiaris,50588,CHEMBL618853,,1,BAO_0000218,A,9615.0,N,Intermediate,6821,Elimination Half-life of compound was determined in dog,,,,
6795,Canis lupus familiaris,50588,CHEMBL618854,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Half life of compound in dog following oral administration,In vivo,,,
6796,Canis lupus familiaris,50588,CHEMBL618855,,1,BAO_0000218,A,9615.0,N,Intermediate,17267,Half life of compound was determined in dog,,,,
6797,Canis lupus familiaris,50588,CHEMBL618856,,1,BAO_0000218,A,9615.0,N,Intermediate,4727,Half life of compound was determined in dog blood,,,,Blood
6798,Canis lupus familiaris,50588,CHEMBL875827,,1,BAO_0000218,A,9615.0,N,Intermediate,5238,Half life after oral and iv dosing in dogs,In vivo,,,
6799,Canis lupus familiaris,50588,CHEMBL618857,,1,BAO_0000218,A,9615.0,N,Intermediate,4942,Half life in dogs in hours,,,,
6800,Canis lupus familiaris,50588,CHEMBL618858,,1,BAO_0000218,A,9615.0,N,Intermediate,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,In vivo,,,
6801,Canis lupus familiaris,50588,CHEMBL618859,,1,BAO_0000218,A,9615.0,N,Intermediate,5130,t1/2 in dog after oral dose (1 mg/kg),In vivo,,,
6802,Canis lupus familiaris,50588,CHEMBL618860,,1,BAO_0000218,A,9615.0,N,Intermediate,1475,Half life was evaluated in dog,,,,
6803,Canis lupus familiaris,50588,CHEMBL618861,,1,BAO_0000218,A,9615.0,N,Intermediate,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,In vivo,,,
6804,Canis lupus familiaris,50588,CHEMBL622539,,1,BAO_0000218,A,9615.0,N,Intermediate,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,In vivo,,,
6805,Canis lupus familiaris,50588,CHEMBL622540,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Half life period (10 mg/kg) was determined in dog,In vivo,,,
6806,Canis lupus familiaris,50588,CHEMBL873803,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Half life period (10 mg/kg) was determined in dog,In vivo,,,
6807,Canis lupus familiaris,50588,CHEMBL873804,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,In vivo,,,
6808,Canis lupus familiaris,50588,CHEMBL624311,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,In vivo,,,
6809,Canis lupus familiaris,50588,CHEMBL624312,,1,BAO_0000218,A,9615.0,N,Intermediate,6084,Half life period in dog,,,,
6810,Canis lupus familiaris,50588,CHEMBL624313,,1,BAO_0000218,A,9615.0,N,Intermediate,6241,Half life period in dogs after oral administration at 1 mg/kg,In vivo,,,
6811,Canis lupus familiaris,50588,CHEMBL624314,,1,BAO_0000218,A,9615.0,N,Intermediate,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,,
6812,Canis lupus familiaris,50588,CHEMBL624315,,1,BAO_0000218,A,9615.0,N,Intermediate,6621,Half-life of compound was determined in dogs,,,,
6813,Canis lupus familiaris,50588,CHEMBL624316,,1,BAO_0000218,A,9615.0,N,Intermediate,1696,Half-life in dog plasma,,,,Plasma
6814,Canis lupus familiaris,50588,CHEMBL624317,,1,BAO_0000218,A,9615.0,N,Intermediate,17800,Half-life in mongrel dogs was determined,,,,
6815,Canis lupus familiaris,50588,CHEMBL624318,,1,BAO_0000218,A,9615.0,N,Intermediate,17657,Half-life in dog upon oral administration,In vivo,,,
6816,Canis lupus familiaris,50588,CHEMBL624319,,1,BAO_0000218,A,9615.0,N,Intermediate,17657,Half-life in dog upon oral administration; Unable to calculate,In vivo,,,
6817,Canis lupus familiaris,50588,CHEMBL624496,,1,BAO_0000218,A,9615.0,N,Intermediate,4239,Half-life was measured in dog,,,,
6818,Canis lupus familiaris,50588,CHEMBL624497,,1,BAO_0000218,A,9615.0,N,Intermediate,5985,Half-life was measured in dog,,,,
6819,Canis lupus familiaris,50588,CHEMBL624498,,1,BAO_0000218,A,9615.0,N,Intermediate,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,,
6820,Canis lupus familiaris,50588,CHEMBL624499,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Oral half life was determined,In vivo,,,
6821,Canis lupus familiaris,50588,CHEMBL624500,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,In vivo,,,Plasma
6822,Canis lupus familiaris,50588,CHEMBL624501,,1,BAO_0000218,A,9615.0,N,Intermediate,1475,Plasma half life was evaluated,,,,Plasma
6823,Canis lupus familiaris,50588,CHEMBL623666,,1,BAO_0000218,A,9615.0,N,Intermediate,1475,Plasma half life was evaluated in Dog,,,,Plasma
6824,Canis lupus familiaris,50588,CHEMBL623667,,1,BAO_0000218,A,9615.0,N,Intermediate,1475,Plasma half life was evaluated in dog,,,,Plasma
6825,Canis lupus familiaris,50588,CHEMBL623668,,1,BAO_0000218,A,9615.0,N,Intermediate,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,In vivo,,,
6826,Canis lupus familiaris,50588,CHEMBL623669,,1,BAO_0000218,A,9615.0,N,Intermediate,4883,Tested for the half life value in dog,,,,
6827,Canis lupus familiaris,50588,CHEMBL623670,,1,BAO_0000218,A,9615.0,N,Intermediate,4727,Maximum time at the dose of 2 mg/kg in dog,In vivo,,,
6828,Canis lupus familiaris,50588,CHEMBL623671,,1,BAO_0000218,A,9615.0,N,Intermediate,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,In vivo,,,
6829,Canis lupus familiaris,50588,CHEMBL875945,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,,Blood
6830,Canis lupus familiaris,50588,CHEMBL623672,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,,Blood
6831,Canis lupus familiaris,50588,CHEMBL623673,,1,BAO_0000218,A,9615.0,N,Intermediate,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,In vivo,,,
6832,Canis lupus familiaris,50588,CHEMBL623674,,1,BAO_0000218,A,9615.0,N,Intermediate,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),In vivo,,,
6833,Canis lupus familiaris,50588,CHEMBL623675,,1,BAO_0000218,A,9615.0,N,Intermediate,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,In vivo,,,
6834,Canis lupus familiaris,50588,CHEMBL872526,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,,
6835,Canis lupus familiaris,50588,CHEMBL623676,,1,BAO_0000218,A,9615.0,N,Intermediate,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",In vivo,,,
6836,Canis lupus familiaris,50588,CHEMBL623677,,1,BAO_0000218,A,9615.0,N,Intermediate,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,In vivo,,,Plasma
6837,Canis lupus familiaris,50588,CHEMBL623678,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,In vivo,,,Plasma
6838,Canis lupus familiaris,50588,CHEMBL623679,,1,BAO_0000218,A,9615.0,N,Intermediate,933,Time taken for maximum plasma concentration in dog,,,,Plasma
6839,Canis lupus familiaris,50588,CHEMBL623680,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Time to reach Cmax after oral administration to dogs,In vivo,,,
6840,Canis lupus familiaris,50588,CHEMBL623681,,1,BAO_0000218,A,9615.0,N,Intermediate,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,,Plasma
6841,Canis lupus familiaris,50588,CHEMBL623682,,1,BAO_0000218,A,9615.0,N,Intermediate,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,In vivo,,,
6842,Canis lupus familiaris,50588,CHEMBL623683,,1,BAO_0000218,A,9615.0,N,Intermediate,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,In vivo,,,
6843,Canis lupus familiaris,50588,CHEMBL623684,,1,BAO_0000218,A,9615.0,N,Expert,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,In vivo,,,
6844,Canis lupus familiaris,50588,CHEMBL622745,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,,
6845,Canis lupus familiaris,50588,CHEMBL622746,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,In vivo,,,
6846,Mus musculus,50594,CHEMBL622747,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo Cmax in mice at dose of 100 mg/kg,In vivo,,,
6847,Mus musculus,50594,CHEMBL622748,,1,BAO_0000218,A,10090.0,N,Intermediate,5969,In vivo Cmax in mice at dose of 50 mg/kg,In vivo,,,
6848,Mus musculus,50594,CHEMBL622749,,1,BAO_0000218,A,10090.0,N,Intermediate,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,In vivo,,,
6849,Mus musculus,50594,CHEMBL622750,,1,BAO_0000218,A,10090.0,N,Intermediate,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),In vivo,,,Plasma
6850,Mus musculus,50594,CHEMBL623411,,1,BAO_0000218,A,10090.0,N,Intermediate,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,In vivo,,,Plasma
6851,Mus musculus,50594,CHEMBL875946,,1,BAO_0000218,A,10090.0,N,Intermediate,3132,Maximum concentration obtained in mouse plasma was determined,In vivo,,,Plasma
6852,Mus musculus,50594,CHEMBL623412,,1,BAO_0000218,A,10090.0,N,Intermediate,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,In vivo,,,Plasma
6853,Mus musculus,50594,CHEMBL623413,,1,BAO_0000218,A,10090.0,N,Intermediate,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,,Plasma
6854,Mus musculus,50594,CHEMBL623414,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,In vivo,,,Plasma
6855,Mus musculus,50594,CHEMBL623415,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,In vivo,,,Plasma
6856,Mus musculus,50594,CHEMBL623416,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,In vivo,,,Plasma
6857,Mus musculus,50594,CHEMBL623417,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,In vivo,,,Plasma
6858,Mus musculus,50594,CHEMBL623418,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,In vivo,,,Plasma
6859,Mus musculus,50594,CHEMBL623419,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,In vivo,,,Plasma
6860,Mus musculus,50594,CHEMBL622816,,1,BAO_0000218,A,10090.0,N,Intermediate,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,In vivo,,,
6861,Mus musculus,50594,CHEMBL623313,,1,BAO_0000218,A,10090.0,N,Intermediate,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,In vivo,,,
6862,Mus musculus,50594,CHEMBL623314,,1,BAO_0000218,A,10090.0,N,Intermediate,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,In vivo,,,
6863,Mus musculus,50594,CHEMBL876788,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,In vivo,,,
6864,Mus musculus,50594,CHEMBL623315,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,In vivo,,,
6865,Mus musculus,50594,CHEMBL623316,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,In vivo,,,
6866,Mus musculus,50594,CHEMBL623317,,1,BAO_0000218,A,10090.0,N,Intermediate,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,In vivo,,,
6868,Mus musculus,50594,CHEMBL623319,,1,BAO_0000218,A,10090.0,N,Intermediate,5961,Cmax in male mice after 2 mg/kg oral dose,In vivo,,,
6869,Mus musculus,50594,CHEMBL623320,,1,BAO_0000218,A,10090.0,N,Intermediate,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,In vivo,,,
6870,Mus musculus,50594,CHEMBL623321,,1,BAO_0000218,A,10090.0,N,Intermediate,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,In vivo,,,
6871,Mus musculus,50594,CHEMBL623322,,1,BAO_0000218,A,10090.0,N,Intermediate,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,,
6872,Mus musculus,50594,CHEMBL623323,,1,BAO_0000218,A,10090.0,N,Intermediate,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,,
6873,Mus musculus,50594,CHEMBL623324,,1,BAO_0000218,A,10090.0,N,Intermediate,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,,
6874,Mus musculus,50594,CHEMBL623325,,1,BAO_0000218,A,10090.0,N,Intermediate,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,,
6875,Mus musculus,50594,CHEMBL623326,,1,BAO_0000218,A,10090.0,N,Intermediate,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,,
6876,Mus musculus,50594,CHEMBL623327,,1,BAO_0000218,A,10090.0,N,Intermediate,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,,
6877,Mus musculus,50594,CHEMBL623328,,1,BAO_0000218,A,10090.0,N,Intermediate,2862,Maximum concentration in plasma upon oral administration in mouse,,,,Plasma
6878,Mus musculus,50594,CHEMBL623329,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Maximum plasma concentration was evaluated in mice after oral administration,,,,Plasma
6879,Mus musculus,50594,CHEMBL623330,,1,BAO_0000218,A,10090.0,N,Intermediate,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,In vivo,,,Plasma
6880,Mus musculus,50594,CHEMBL876789,,1,BAO_0000218,A,10090.0,N,Intermediate,5399,Dose at which the compound induced fecal excretion in mice,,,,
6893,Rattus norvegicus,80013,CHEMBL623333,,1,BAO_0000219,F,10116.0,N,Expert,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,,,
6894,Rattus norvegicus,80013,CHEMBL623334,,1,BAO_0000219,F,10116.0,N,Expert,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,,,
6895,Rattus norvegicus,80013,CHEMBL627536,,1,BAO_0000219,F,10116.0,N,Expert,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,,,
6896,Rattus norvegicus,80013,CHEMBL627537,,1,BAO_0000219,F,10116.0,N,Expert,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,,,
6897,Rattus norvegicus,80013,CHEMBL627538,,1,BAO_0000219,F,10116.0,N,Intermediate,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,,,
6898,Homo sapiens,80655,CHEMBL884106,,1,BAO_0000219,F,9606.0,N,Intermediate,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,,,
6899,Homo sapiens,80655,CHEMBL625294,,1,BAO_0000219,F,9606.0,N,Intermediate,10404,Anticancer activity against human ovarian carcinoma A121 cells,,,,
6900,Homo sapiens,80655,CHEMBL625295,,1,BAO_0000219,F,9606.0,N,Intermediate,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,,,
6901,Homo sapiens,80655,CHEMBL625296,,1,BAO_0000219,F,9606.0,N,Intermediate,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,,,
6902,Homo sapiens,80655,CHEMBL625297,,1,BAO_0000219,F,9606.0,N,Expert,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,,,,
6903,Homo sapiens,80655,CHEMBL625298,,1,BAO_0000219,F,9606.0,N,Expert,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,,,
6904,Homo sapiens,80655,CHEMBL625960,,1,BAO_0000219,F,9606.0,N,Intermediate,1003,Cytotoxicity against human A121 ovarian cells,,,,
6905,Homo sapiens,80655,CHEMBL625961,,1,BAO_0000219,F,9606.0,N,Intermediate,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,,,
6906,Homo sapiens,80655,CHEMBL625962,,1,BAO_0000219,F,9606.0,N,Intermediate,12307,In vitro cytotoxicity against human ovarian carcinoma A21,,,,
6907,Homo sapiens,80655,CHEMBL624717,,1,BAO_0000219,F,9606.0,N,Intermediate,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,,,
6908,Homo sapiens,80655,CHEMBL624718,,1,BAO_0000219,F,9606.0,N,Intermediate,13370,Inhibitory activity of compound against human A121 ovarian cell line.,,,,
6909,Homo sapiens,80655,CHEMBL624719,,1,BAO_0000219,F,9606.0,N,Intermediate,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,,,
6910,Homo sapiens,80655,CHEMBL624720,,1,BAO_0000219,F,9606.0,N,Intermediate,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,,,
6911,Homo sapiens,80012,CHEMBL624721,,1,BAO_0000219,F,9606.0,N,Intermediate,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,,,
6912,Homo sapiens,80012,CHEMBL624722,,1,BAO_0000219,F,9606.0,N,Expert,2037,In vitro cytotoxicity against A172 human tumor cell lines.,,,,
6913,Homo sapiens,80012,CHEMBL877597,,1,BAO_0000219,F,9606.0,N,Intermediate,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,,,
6914,Homo sapiens,80012,CHEMBL624723,,1,BAO_0000219,F,9606.0,N,Intermediate,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,,,
6915,Homo sapiens,80012,CHEMBL624724,,1,BAO_0000219,F,9606.0,N,Intermediate,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,,,
6916,Canis lupus familiaris,104729,CHEMBL624725,,1,BAO_0000224,B,9615.0,H,Autocuration,8975,Association constant against A2 adenosine receptor,,,,
6917,fish,80656,CHEMBL624726,,1,BAO_0000219,F,,N,Intermediate,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,,,
6918,Rattus norvegicus,104713,CHEMBL857535,,1,BAO_0000224,B,10116.0,D,Autocuration,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,,,,
6919,Homo sapiens,80014,CHEMBL624727,,1,BAO_0000219,F,9606.0,N,Expert,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,,,
6920,Homo sapiens,80014,CHEMBL624728,,1,BAO_0000219,F,9606.0,N,Expert,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,,,
6921,Homo sapiens,80015,CHEMBL624729,,1,BAO_0000219,F,9606.0,N,Intermediate,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,,,
6922,Homo sapiens,80657,CHEMBL624730,,1,BAO_0000219,F,9606.0,N,Intermediate,13160,Growth inhibition against Human squamous cell line(A 253),,,,
6923,Homo sapiens,80657,CHEMBL624731,,1,BAO_0000219,F,9606.0,N,Intermediate,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,,,
6924,Homo sapiens,80657,CHEMBL624732,,1,BAO_0000219,F,9606.0,N,Intermediate,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,,,
6925,Homo sapiens,80657,CHEMBL883245,,1,BAO_0000219,F,9606.0,N,Intermediate,15984,Growth inhibition of A253 cell lines.,,,,
6926,Homo sapiens,80657,CHEMBL624733,,1,BAO_0000219,F,9606.0,N,Intermediate,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,,,
6927,Homo sapiens,80657,CHEMBL624734,,1,BAO_0000219,F,9606.0,N,Intermediate,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,,
6928,Homo sapiens,80657,CHEMBL624735,,1,BAO_0000219,F,9606.0,N,Intermediate,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,,,
6929,Homo sapiens,81034,CHEMBL621780,,1,BAO_0000219,F,9606.0,N,Intermediate,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,,,
6930,Homo sapiens,81034,CHEMBL877598,,1,BAO_0000219,F,9606.0,N,Intermediate,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,,,
6931,Homo sapiens,81034,CHEMBL621781,,1,BAO_0000219,F,9606.0,N,Expert,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,,,
6932,Homo sapiens,81034,CHEMBL621782,,1,BAO_0000219,F,9606.0,N,Intermediate,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),,,,
6933,Homo sapiens,81034,CHEMBL621783,,1,BAO_0000219,F,9606.0,N,Expert,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,,,
6934,Homo sapiens,81034,CHEMBL621784,,1,BAO_0000219,F,9606.0,N,Intermediate,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,,,
6935,Homo sapiens,81034,CHEMBL621785,,1,BAO_0000219,F,9606.0,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,,
6936,Homo sapiens,81034,CHEMBL621968,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,,,
6937,Homo sapiens,81034,CHEMBL621969,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,,,
6938,Homo sapiens,81034,CHEMBL621970,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,,,
6939,Homo sapiens,81034,CHEMBL621971,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,,,
6940,Homo sapiens,81034,CHEMBL621972,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,,,
6941,Homo sapiens,81034,CHEMBL884108,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,,,
6942,Cricetulus griseus,22224,CHEMBL623826,,1,BAO_0000019,F,10029.0,U,Autocuration,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,,
6943,Cricetulus griseus,22224,CHEMBL623827,,1,BAO_0000219,A,10029.0,U,Autocuration,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,,,
6944,Cricetulus griseus,22224,CHEMBL623828,,1,BAO_0000219,F,10029.0,U,Autocuration,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,,,
6945,Cricetulus griseus,22224,CHEMBL623829,,1,BAO_0000219,F,10029.0,U,Autocuration,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,,,
6946,Cricetulus griseus,22224,CHEMBL623830,,1,BAO_0000219,F,10029.0,U,Autocuration,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,,,
6947,Cricetulus griseus,22224,CHEMBL623831,,1,BAO_0000019,F,10029.0,U,Autocuration,11858,Growth inhibition against CHO-derived cell line AA8,,,,
6948,Cricetulus griseus,22224,CHEMBL623832,,1,BAO_0000219,F,10029.0,U,Autocuration,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,,,
6949,hampster,80089,CHEMBL623833,,1,BAO_0000219,F,36483.0,N,Expert,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,,,
6950,Cricetulus griseus,80089,CHEMBL623834,,1,BAO_0000219,F,10029.0,N,Expert,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,,,
6951,Cricetulus griseus,22224,CHEMBL623835,,1,BAO_0000219,F,10029.0,U,Autocuration,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,,,
6952,Cricetulus griseus,22224,CHEMBL623836,,1,BAO_0000219,F,10029.0,U,Autocuration,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,,,
6953,Cricetulus griseus,22224,CHEMBL623837,,1,BAO_0000219,F,10029.0,U,Autocuration,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,,,
6954,Cricetulus griseus,80089,CHEMBL623838,,1,BAO_0000219,F,10029.0,N,Expert,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,,,
6955,,12675,CHEMBL623839,,1,BAO_0000019,F,,H,Autocuration,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,,
6956,,12675,CHEMBL623840,,1,BAO_0000019,F,,H,Autocuration,14837,Number of binding sites (n) of isolated serum protein AAG,,,,
6957,,22222,CHEMBL623841,,1,BAO_0000225,B,,M,Intermediate,16037,Association constant for binding to AATT duplex,,,,
6958,Homo sapiens,100090,CHEMBL623842,,1,BAO_0000219,F,9606.0,N,Expert,16597,Inhibition of ABAE human fibroblast cell proliferation,,,,
6959,Mus musculus,80668,CHEMBL623843,,1,BAO_0000218,F,10090.0,N,Intermediate,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,,,
6960,Oryctolagus cuniculus,102444,CHEMBL618669,,1,BAO_0000218,F,9986.0,D,Expert,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,,
6961,Oryctolagus cuniculus,102444,CHEMBL618670,,1,BAO_0000218,F,9986.0,D,Expert,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,In vivo,,,
6962,,69,CHEMBL618671,,1,BAO_0000357,B,,H,Autocuration,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,,
6963,,69,CHEMBL618672,,1,BAO_0000357,B,,H,Autocuration,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,,
6964,Homo sapiens,80669,CHEMBL618673,,1,BAO_0000219,F,9606.0,N,Intermediate,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,,,
6965,Homo sapiens,80669,CHEMBL618674,,1,BAO_0000219,F,9606.0,N,Intermediate,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,,,
6966,Human immunodeficiency virus 1,22224,CHEMBL618675,,1,BAO_0000219,F,11676.0,U,Autocuration,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,,,
6967,Human immunodeficiency virus 1,22224,CHEMBL618676,,1,BAO_0000219,F,11676.0,U,Autocuration,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,,,
6968,Human immunodeficiency virus 1,22224,CHEMBL618677,,1,BAO_0000219,F,11676.0,U,Autocuration,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,,,
6969,Homo sapiens,80025,CHEMBL618678,,1,BAO_0000219,F,9606.0,N,Intermediate,11843,Inhibition of growth of renal cancer ACHN cell line,,,,
6970,Homo sapiens,80025,CHEMBL618679,,1,BAO_0000219,F,9606.0,N,Intermediate,16939,Inhibition of growth of ACHN renal cancer cell line,,,,
6971,Homo sapiens,80025,CHEMBL618680,,1,BAO_0000219,F,9606.0,N,Intermediate,4782,Inhibitory concentration required against ACHN renal cancer cell line,,,,
6972,Homo sapiens,80025,CHEMBL618681,,1,BAO_0000219,F,9606.0,N,Expert,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,,,,
6973,Homo sapiens,80025,CHEMBL618682,,1,BAO_0000219,F,9606.0,N,Intermediate,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,,,
6974,Homo sapiens,80025,CHEMBL618683,,1,BAO_0000219,F,9606.0,N,Intermediate,12858,Cytotoxic activity against ACHN Renal cancer cell line,,,,
6975,Homo sapiens,80025,CHEMBL618684,,1,BAO_0000219,F,9606.0,N,Intermediate,17380,Cytotoxicity evaluation against ACHN renal cancer cells,,,,
6976,Homo sapiens,80025,CHEMBL618685,,1,BAO_0000219,F,9606.0,N,Intermediate,5858,In vitro antitumor activity against human renal ACHN cell line,,,,
6977,Homo sapiens,80025,CHEMBL876499,,1,BAO_0000219,F,9606.0,N,Intermediate,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,,
6978,Homo sapiens,80025,CHEMBL618686,,1,BAO_0000219,F,9606.0,N,Intermediate,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,,,
6979,Homo sapiens,80025,CHEMBL618687,,1,BAO_0000219,F,9606.0,N,Intermediate,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,,,
6980,Homo sapiens,80025,CHEMBL618688,,1,BAO_0000219,F,9606.0,N,Intermediate,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,,
6981,Homo sapiens,80025,CHEMBL618689,,1,BAO_0000219,F,9606.0,N,Expert,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,,,
6982,Homo sapiens,80025,CHEMBL618690,,1,BAO_0000219,F,9606.0,N,Intermediate,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,,,
6983,Homo sapiens,80025,CHEMBL618691,,1,BAO_0000219,F,9606.0,N,Intermediate,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,,,
6984,Homo sapiens,80025,CHEMBL619373,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,,
6985,Homo sapiens,80025,CHEMBL884008,,1,BAO_0000219,F,9606.0,N,Intermediate,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,,,
6986,Homo sapiens,80025,CHEMBL619374,,1,BAO_0000219,F,9606.0,N,Intermediate,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,,,
6987,Homo sapiens,80025,CHEMBL619375,,1,BAO_0000219,F,9606.0,N,Intermediate,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,,,
6988,Homo sapiens,80025,CHEMBL619376,,1,BAO_0000219,F,9606.0,N,Intermediate,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,,,
6989,Homo sapiens,80025,CHEMBL619377,,1,BAO_0000219,F,9606.0,N,Intermediate,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,,,
6990,Homo sapiens,80025,CHEMBL619378,,1,BAO_0000219,F,9606.0,N,Intermediate,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,,,
6991,Canis lupus familiaris,50588,CHEMBL872527,,1,BAO_0000218,A,9615.0,N,Intermediate,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,In vivo,,,
6992,Canis lupus familiaris,50588,CHEMBL876500,,1,BAO_0000218,A,9615.0,N,Intermediate,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,,
6993,Canis lupus familiaris,50588,CHEMBL619379,,1,BAO_0000218,A,9615.0,N,Intermediate,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,,
6994,Canis lupus familiaris,50588,CHEMBL619538,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Volume distribution after 15 mg/kg iv dose in Dogs,In vivo,,,
6995,Canis lupus familiaris,50588,CHEMBL619539,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Volume distribution after 30 mg/kg po dose in Dogs,In vivo,,,
6996,Canis lupus familiaris,50588,CHEMBL619540,,1,BAO_0000218,A,9615.0,N,Intermediate,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,In vivo,,,
6997,Canis lupus familiaris,50588,CHEMBL619541,,1,BAO_0000218,A,9615.0,N,Intermediate,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,In vivo,,,
6998,Canis lupus familiaris,50588,CHEMBL619542,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Volume of distribution was evaluated in dog,In vivo,,,
6999,Canis lupus familiaris,50588,CHEMBL619543,,1,BAO_0000218,A,9615.0,N,Intermediate,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,,,
7000,Canis lupus familiaris,50588,CHEMBL619544,,1,BAO_0000218,A,9615.0,N,Expert,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,,
7001,Canis lupus familiaris,50588,CHEMBL619545,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,The compound was tested for volume of distribution in dog,In vivo,,,
7002,Canis lupus familiaris,50588,CHEMBL619546,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,In vivo,,,
7003,Canis lupus familiaris,50588,CHEMBL619547,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Vd (1 mg/kg) was determined in dog (in vivo),In vivo,,,
7004,Canis lupus familiaris,50588,CHEMBL619548,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Vd in dog,In vivo,,,
7005,Canis lupus familiaris,50588,CHEMBL619549,,1,BAO_0000218,A,9615.0,N,Intermediate,4219,Volume distribution was determined,In vivo,,,
7006,Canis lupus familiaris,50588,CHEMBL619550,,1,BAO_0000218,A,9615.0,N,Intermediate,1696,Volume of distribution in dog,In vivo,,,
7007,Canis lupus familiaris,50588,CHEMBL876501,,1,BAO_0000218,A,9615.0,N,Intermediate,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,In vivo,,,
7008,Canis lupus familiaris,50588,CHEMBL619551,,1,BAO_0000218,A,9615.0,N,Intermediate,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,In vivo,,,
7009,Canis lupus familiaris,50588,CHEMBL619552,,1,BAO_0000218,A,9615.0,N,Intermediate,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,,
7010,Canis lupus familiaris,50588,CHEMBL619553,,1,BAO_0000218,A,9615.0,N,Intermediate,4727,Volume distribution at the dose of 2 mg/kg in dog,In vivo,,,
7011,Canis lupus familiaris,50588,CHEMBL618722,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Steady state volume of distribution was determined,In vivo,,,
7012,Canis lupus familiaris,50588,CHEMBL618723,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,In vivo,,,
7013,Canis lupus familiaris,50588,CHEMBL618724,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,,
7014,Canis lupus familiaris,50588,CHEMBL618725,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,,
7015,Canis lupus familiaris,50588,CHEMBL618726,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,,
7016,Canis lupus familiaris,50588,CHEMBL618727,,1,BAO_0000218,A,9615.0,N,Intermediate,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),In vivo,,,
7017,Canis lupus familiaris,50588,CHEMBL624233,,1,BAO_0000218,A,9615.0,N,Intermediate,4239,Pharmacokinetic property (vdss) was measured in dog,In vivo,,,
7018,Canis lupus familiaris,50588,CHEMBL624234,,1,BAO_0000218,A,9615.0,N,Intermediate,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,In vivo,,,
7019,Canis lupus familiaris,50588,CHEMBL624235,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,In vivo,,,
7020,Canis lupus familiaris,50588,CHEMBL624236,,1,BAO_0000218,A,9615.0,N,Intermediate,6057,Volume displacement was calculated in dog,In vivo,,,
7021,Canis lupus familiaris,50588,CHEMBL624237,,1,BAO_0000218,A,9615.0,N,Intermediate,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,,
7022,Canis lupus familiaris,50588,CHEMBL624238,,1,BAO_0000218,A,9615.0,N,Intermediate,5505,Volume distribution constant was determined,In vivo,,,
7023,Canis lupus familiaris,50588,CHEMBL624239,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,In vivo,,,
7024,Canis lupus familiaris,50588,CHEMBL875829,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,,
7025,Canis lupus familiaris,50588,CHEMBL624240,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,,
7026,Canis lupus familiaris,50588,CHEMBL624241,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Volume distribution (Vdss) was measured in dog,In vivo,,,
7027,Canis lupus familiaris,50588,CHEMBL624242,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Volume distribution (Vdss) was measured in dog,In vivo,,,
7028,Canis lupus familiaris,50588,CHEMBL624243,,1,BAO_0000218,A,9615.0,N,Intermediate,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,,
7029,Canis lupus familiaris,50588,CHEMBL624244,,1,BAO_0000218,A,9615.0,N,Intermediate,5145,Volume of distribution in steady state was determined in dog,In vivo,,,
7030,Canis lupus familiaris,50588,CHEMBL624245,,1,BAO_0000218,A,9615.0,N,Intermediate,6821,Volume of distribution of compound was determined in dog,In vivo,,,
7031,Canis lupus familiaris,50588,CHEMBL624246,,1,BAO_0000218,A,9615.0,N,Intermediate,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,In vivo,,,
7032,Canis lupus familiaris,50588,CHEMBL624247,,1,BAO_0000218,A,9615.0,N,Intermediate,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),In vivo,,,
7033,Canis lupus familiaris,50588,CHEMBL624248,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Volume of distribution (Vdss) was measured in dog,In vivo,,,
7034,Canis lupus familiaris,50588,CHEMBL624249,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,,
7035,Canis lupus familiaris,50588,CHEMBL624250,,1,BAO_0000218,A,9615.0,N,Intermediate,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
7036,Canis lupus familiaris,50588,CHEMBL624251,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
7037,Canis lupus familiaris,50588,CHEMBL624252,,1,BAO_0000218,A,9615.0,N,Intermediate,11659,Maximum rate of depolarization of the upstroke of the action potential,,,,
7038,Canis lupus familiaris,50588,CHEMBL624253,,1,BAO_0000218,A,9615.0,N,Intermediate,6448,Steady state volume distribution in dog,In vivo,,,
7039,Canis lupus familiaris,50588,CHEMBL624950,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,In vivo,,,
7040,Canis lupus familiaris,50588,CHEMBL624951,,1,BAO_0000218,A,9615.0,N,Intermediate,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,In vivo,,,
7041,Canis lupus familiaris,50588,CHEMBL875830,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,In vivo,,,
7042,Canis lupus familiaris,50588,CHEMBL624952,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Volume distribution in dog after administration of 1 mg/kg iv,In vivo,,,
7043,Canis lupus familiaris,50588,CHEMBL624953,,1,BAO_0000218,A,9615.0,N,Intermediate,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,In vivo,,,
7044,Canis lupus familiaris,50588,CHEMBL624954,,1,BAO_0000218,A,9615.0,N,Intermediate,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,,
7045,Canis lupus familiaris,50588,CHEMBL624955,,1,BAO_0000218,A,9615.0,N,Intermediate,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,In vivo,,,
7046,Canis lupus familiaris,50588,CHEMBL624956,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,Vss was determined,,,,
7047,Canis lupus familiaris,50588,CHEMBL625129,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,Vss in dog,,,,
7048,Canis lupus familiaris,50588,CHEMBL625130,,1,BAO_0000218,A,9615.0,N,Intermediate,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,In vivo,,,
7049,Canis lupus familiaris,50588,CHEMBL625131,,1,BAO_0000218,A,9615.0,N,Intermediate,4942,Volume distribution in dogs,In vivo,,,
7050,Canis lupus familiaris,50588,CHEMBL625132,,1,BAO_0000218,A,9615.0,N,Intermediate,17796,Volume of distribution in dog,In vivo,,,
7051,Canis lupus familiaris,50588,CHEMBL872263,,1,BAO_0000218,A,9615.0,N,Intermediate,4883,Tested for the oral bioavailability in dog,In vivo,,,
7060,Mus musculus,50594,CHEMBL624336,,1,BAO_0000218,A,10090.0,N,Intermediate,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,In vivo,,,
7061,Mus musculus,50594,CHEMBL624337,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,In vivo,,,
7062,Mus musculus,50594,CHEMBL624338,,1,BAO_0000218,A,10090.0,N,Intermediate,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,In vivo,,,
7063,Mus musculus,50594,CHEMBL624339,,1,BAO_0000218,A,10090.0,N,Intermediate,4239,Bioavailability was measured in mouse,In vivo,,,
7064,Mus musculus,50594,CHEMBL624340,,1,BAO_0000218,A,10090.0,N,Intermediate,17592,Bioavailability in mouse,In vivo,,,
7065,Mus musculus,50594,CHEMBL624341,,1,BAO_0000218,A,10090.0,N,Intermediate,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,In vivo,,,
7066,Mus musculus,50594,CHEMBL624342,,1,BAO_0000218,A,10090.0,N,Intermediate,2801,Bioavailability in mouse,In vivo,,,
7067,Mus musculus,50594,CHEMBL624343,,1,BAO_0000218,A,10090.0,N,Intermediate,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,In vivo,,,
7068,Mus musculus,50594,CHEMBL624344,,1,BAO_0000218,A,10090.0,N,Intermediate,17718,Oral bioavailability in mouse,In vivo,,,
7069,Mus musculus,50594,CHEMBL624345,,1,BAO_0000218,A,10090.0,N,Intermediate,5727,Oral availability at 50 mg/kg po in male mice,In vivo,,,
7070,Mus musculus,50594,CHEMBL624346,,1,BAO_0000218,A,10090.0,N,Intermediate,5302,Oral bioavailability in mouse (dose 10 mg/kg),In vivo,,,
7071,Mus musculus,50594,CHEMBL624347,,1,BAO_0000218,A,10090.0,N,Expert,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,In vivo,,,
7072,Mus musculus,50594,CHEMBL624348,,1,BAO_0000218,A,10090.0,N,Intermediate,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",In vivo,,,
7074,Mus musculus,50594,CHEMBL622754,,1,BAO_0000218,A,10090.0,N,Intermediate,6091,Oral bioavailability in mouse,In vivo,,,
7075,Mus musculus,50594,CHEMBL622755,,1,BAO_0000218,A,10090.0,N,Intermediate,6091,Oral bioavailability in vivo in mice;ND=Not determined,In vivo,,,
7076,Mus musculus,50594,CHEMBL622756,,1,BAO_0000218,A,10090.0,N,Intermediate,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,In vivo,,,
7077,Mus musculus,50594,CHEMBL622757,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),In vivo,,,
7078,Mus musculus,50594,CHEMBL622758,,1,BAO_0000218,A,10090.0,N,Intermediate,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),In vivo,,,
7079,Mus musculus,50594,CHEMBL622759,,1,BAO_0000218,A,10090.0,N,Intermediate,3802,Tested for bioavailability of the compound,In vivo,,,
7080,Mus musculus,50594,CHEMBL622760,,1,BAO_0000218,A,10090.0,N,Intermediate,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,In vivo,,,
7081,Mus musculus,50594,CHEMBL622761,,1,BAO_0000218,A,10090.0,N,Intermediate,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,,Plasma
7082,Mus musculus,50594,CHEMBL622762,,1,BAO_0000218,A,10090.0,N,Intermediate,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,,Plasma
7083,Mus musculus,50594,CHEMBL622763,,1,BAO_0000218,A,10090.0,N,Intermediate,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,,Plasma
7084,Mus musculus,50594,CHEMBL622764,,1,BAO_0000218,A,10090.0,N,Intermediate,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,,Plasma
7085,Mus musculus,50594,CHEMBL622765,,1,BAO_0000218,A,10090.0,N,Intermediate,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,,Plasma
7086,Mus musculus,50594,CHEMBL622766,,1,BAO_0000218,F,10090.0,N,Intermediate,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,,
7087,Mus musculus,50594,CHEMBL622767,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,,
7088,Mus musculus,50594,CHEMBL622768,,1,BAO_0000218,A,10090.0,N,Intermediate,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,,
7089,Mus musculus,50594,CHEMBL875948,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Blood
7090,Mus musculus,50594,CHEMBL622769,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Blood
7091,Mus musculus,50594,CHEMBL622770,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Blood
7092,Mus musculus,50594,CHEMBL622771,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Blood
7093,Mus musculus,50594,CHEMBL622772,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Blood
7094,Mus musculus,50594,CHEMBL622773,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Blood
7095,Mus musculus,50594,CHEMBL622774,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Blood
7096,Mus musculus,50594,CHEMBL621725,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Bone
7097,Mus musculus,50594,CHEMBL621726,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,,Bone
7098,Homo sapiens,81034,CHEMBL621727,,1,BAO_0000219,F,9606.0,N,Intermediate,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,,,
7099,Homo sapiens,81034,CHEMBL622413,,1,BAO_0000219,F,9606.0,N,Expert,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,,,
7100,Homo sapiens,81034,CHEMBL622414,,1,BAO_0000219,F,9606.0,N,Intermediate,2859,Compound was evaluated for cytotoxicity against A2780 cell line,,,,
7101,Homo sapiens,81034,CHEMBL622415,,1,BAO_0000219,F,9606.0,N,Expert,15688,Inhibition of A2780 cell clonogenic assay,,,,
7102,Homo sapiens,81034,CHEMBL884001,,1,BAO_0000219,F,9606.0,N,Expert,5642,Cytotoxic effect on ovarian cancer cell line (A2780),,,,
7103,Homo sapiens,81034,CHEMBL622416,,1,BAO_0000219,F,9606.0,N,Intermediate,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,,,
7104,Homo sapiens,81034,CHEMBL622417,,1,BAO_0000219,F,9606.0,N,Intermediate,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,,,
7105,Homo sapiens,81034,CHEMBL622590,,1,BAO_0000219,F,9606.0,N,Expert,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,,,
7106,Homo sapiens,81034,CHEMBL622591,,1,BAO_0000219,F,9606.0,N,Expert,17582,Antiproliferative activity against human A2780 cells,,,,
7107,Homo sapiens,81034,CHEMBL622592,,1,BAO_0000219,F,9606.0,N,Expert,17764,Inhibition of human A2780 cell proliferation,,,,
7108,Homo sapiens,81034,CHEMBL622593,,1,BAO_0000219,F,9606.0,N,Expert,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,,,
7109,Homo sapiens,81034,CHEMBL622594,,1,BAO_0000219,F,9606.0,N,Expert,17764,Inhibition of human A2780 cell proliferation (No data),,,,
7110,Homo sapiens,81034,CHEMBL622595,,1,BAO_0000219,F,9606.0,N,Intermediate,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,,,
7111,Homo sapiens,81034,CHEMBL622596,,1,BAO_0000219,F,9606.0,N,Intermediate,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,,,,
7112,Homo sapiens,81034,CHEMBL622597,,1,BAO_0000219,F,9606.0,N,Expert,17777,Growth inhibition against A2780 wild-type ovarian cell lines,,,,
7113,Homo sapiens,81034,CHEMBL622598,,1,BAO_0000219,F,9606.0,N,Intermediate,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,,,
7114,Homo sapiens,104766,CHEMBL622599,,1,BAO_0000019,F,9606.0,D,Autocuration,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,,
7115,Homo sapiens,81034,CHEMBL622600,,1,BAO_0000219,F,9606.0,N,Intermediate,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,,
7116,Homo sapiens,81034,CHEMBL622601,,1,BAO_0000219,F,9606.0,N,Intermediate,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,,
7117,Homo sapiens,81034,CHEMBL622602,,1,BAO_0000219,F,9606.0,N,Intermediate,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,,,
7118,Homo sapiens,81034,CHEMBL622603,,1,BAO_0000219,F,9606.0,N,Intermediate,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,,,
7119,Homo sapiens,81034,CHEMBL622604,,1,BAO_0000219,F,9606.0,N,Intermediate,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,,
7120,Homo sapiens,81034,CHEMBL622605,,1,BAO_0000219,F,9606.0,N,Intermediate,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,,,
7121,Homo sapiens,81034,CHEMBL622606,,1,BAO_0000219,F,9606.0,N,Expert,15069,In vitro inhibition of human ovarian cell line A2780,,,,
7122,Homo sapiens,81034,CHEMBL619463,,1,BAO_0000219,F,9606.0,N,Expert,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,,,
7123,Homo sapiens,81034,CHEMBL619464,,1,BAO_0000219,F,9606.0,N,Intermediate,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,,,
7124,Homo sapiens,81034,CHEMBL619465,,1,BAO_0000219,F,9606.0,N,Expert,14553,Concentration required to inhibit A2780-cell growth by 50%,,,,
7125,Homo sapiens,81034,CHEMBL619466,,1,BAO_0000219,F,9606.0,N,Expert,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,,,
7126,Homo sapiens,81034,CHEMBL619467,,1,BAO_0000219,F,9606.0,N,Expert,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,,,,
7127,Homo sapiens,81034,CHEMBL619468,,1,BAO_0000219,F,9606.0,N,Intermediate,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,,,
7128,Homo sapiens,81034,CHEMBL619469,,1,BAO_0000219,F,9606.0,N,Expert,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,,,
7129,Homo sapiens,81034,CHEMBL619470,,1,BAO_0000219,F,9606.0,N,Expert,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,,
7130,Homo sapiens,81034,CHEMBL619471,,1,BAO_0000219,F,9606.0,N,Intermediate,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,,,
7131,Homo sapiens,81034,CHEMBL619472,,1,BAO_0000219,F,9606.0,N,Intermediate,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,,,,
7132,Homo sapiens,81034,CHEMBL619473,,1,BAO_0000219,F,9606.0,N,Intermediate,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,,,
7133,Homo sapiens,81034,CHEMBL874368,,1,BAO_0000219,F,9606.0,N,Intermediate,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,,,
7134,Homo sapiens,81034,CHEMBL884003,,1,BAO_0000219,F,9606.0,N,Intermediate,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,,,
7135,Homo sapiens,81034,CHEMBL622690,,1,BAO_0000219,F,9606.0,N,Intermediate,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,,,
7136,Homo sapiens,81034,CHEMBL622691,,1,BAO_0000219,F,9606.0,N,Intermediate,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,,,
7137,Homo sapiens,81034,CHEMBL622692,,1,BAO_0000219,F,9606.0,N,Intermediate,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,,
7138,Homo sapiens,81034,CHEMBL623406,,1,BAO_0000219,F,9606.0,N,Intermediate,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,,,
7139,Homo sapiens,81034,CHEMBL884004,,1,BAO_0000219,F,9606.0,N,Intermediate,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,,,
7140,Homo sapiens,81034,CHEMBL623407,,1,BAO_0000219,F,9606.0,N,Intermediate,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,,,
7141,Homo sapiens,81034,CHEMBL623408,,1,BAO_0000219,F,9606.0,N,Intermediate,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,,,
7142,Homo sapiens,81034,CHEMBL623409,,1,BAO_0000219,F,9606.0,N,Expert,12989,In vitro antitumor activity against A2780 cell line.,,,,
7143,Homo sapiens,81034,CHEMBL623410,,1,BAO_0000219,F,9606.0,N,Intermediate,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,,,
7144,Homo sapiens,81034,CHEMBL623576,,1,BAO_0000219,F,9606.0,N,Expert,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,,,
7145,Homo sapiens,80025,CHEMBL623577,,1,BAO_0000219,F,9606.0,N,Intermediate,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,,,
7146,Homo sapiens,80025,CHEMBL623578,,1,BAO_0000219,F,9606.0,N,Intermediate,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,,,,
7147,Homo sapiens,80025,CHEMBL623579,,1,BAO_0000219,F,9606.0,N,Intermediate,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,,,
7148,Homo sapiens,80025,CHEMBL623580,,1,BAO_0000219,F,9606.0,N,Expert,17376,In vitro lethal concentration against most sensitive ACHN cell line,,,,
7149,Homo sapiens,80025,CHEMBL623581,,1,BAO_0000219,F,9606.0,N,Intermediate,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,,,,
7150,Homo sapiens,80025,CHEMBL857456,,1,BAO_0000219,F,9606.0,N,Intermediate,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,,,,
7151,Homo sapiens,80025,CHEMBL623582,,1,BAO_0000219,F,9606.0,N,Intermediate,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,,,
7152,Homo sapiens,80025,CHEMBL623583,,1,BAO_0000219,F,9606.0,N,Intermediate,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,,,
7153,Homo sapiens,80025,CHEMBL623584,,1,BAO_0000219,F,9606.0,N,Intermediate,2806,In vitro anticancer activity against ACHN renal cancer cell line,,,,
7154,Homo sapiens,80025,CHEMBL623585,,1,BAO_0000219,F,9606.0,N,Intermediate,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,,,
7155,Homo sapiens,80025,CHEMBL623586,,1,BAO_0000219,F,9606.0,N,Intermediate,16364,Percent selectivity was evaluated in renal ACHN cell lines,,,,
7156,Homo sapiens,80025,CHEMBL623587,,1,BAO_0000219,F,9606.0,N,Intermediate,13859,In vitro inhibitory activity against renal ACHN cancer cell line,,,,
7157,Homo sapiens,80025,CHEMBL875279,,1,BAO_0000219,F,9606.0,N,Intermediate,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,,,,
7158,Homo sapiens,80025,CHEMBL623588,,1,BAO_0000219,F,9606.0,N,Intermediate,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,,,
7159,Homo sapiens,80025,CHEMBL623589,,1,BAO_0000219,F,9606.0,N,Intermediate,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,,,
7160,Homo sapiens,80025,CHEMBL623590,,1,BAO_0000219,F,9606.0,N,Intermediate,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,,,
7161,Homo sapiens,80025,CHEMBL623591,,1,BAO_0000219,F,9606.0,N,Expert,12888,Cytotoxic effect on renal cancer line ACHN,,,,
7162,Homo sapiens,80025,CHEMBL623592,,1,BAO_0000219,F,9606.0,N,Intermediate,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,,,
7163,Homo sapiens,80025,CHEMBL623593,,1,BAO_0000219,F,9606.0,N,Intermediate,3381,In vitro inhibition of Renal Cancer ACHN cell lines,,,,
7164,Homo sapiens,80025,CHEMBL623594,,1,BAO_0000219,F,9606.0,N,Intermediate,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,,,,
7165,Homo sapiens,80025,CHEMBL621833,,1,BAO_0000219,F,9606.0,N,Expert,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,,,,
7166,Homo sapiens,80025,CHEMBL621834,,1,BAO_0000219,F,9606.0,N,Intermediate,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,,,
7167,Homo sapiens,80025,CHEMBL621835,,1,BAO_0000219,F,9606.0,N,Intermediate,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,,,
7168,Homo sapiens,80025,CHEMBL621836,,1,BAO_0000219,F,9606.0,N,Intermediate,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,,,
7169,Homo sapiens,80025,CHEMBL621837,,1,BAO_0000219,F,9606.0,N,Intermediate,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,,,
7170,Homo sapiens,80025,CHEMBL875280,,1,BAO_0000219,F,9606.0,N,Intermediate,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,,,
7171,Homo sapiens,80025,CHEMBL621838,,1,BAO_0000219,F,9606.0,N,Intermediate,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,,,
7172,Homo sapiens,80025,CHEMBL621839,,1,BAO_0000219,F,9606.0,N,Intermediate,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,,,
7173,,22224,CHEMBL621840,,1,BAO_0000019,A,,U,Autocuration,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,
7174,,10647,CHEMBL621841,,1,BAO_0000019,F,,H,Autocuration,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,,
7175,Cytomegalovirus,50529,CHEMBL622979,,1,BAO_0000218,F,10358.0,N,Expert,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,,,
7176,Cytomegalovirus,50529,CHEMBL876595,,1,BAO_0000218,F,10358.0,N,Intermediate,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,,
7177,,12159,CHEMBL620221,,1,BAO_0000357,B,,H,Autocuration,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,,
7178,,12159,CHEMBL620222,,1,BAO_0000357,B,,H,Autocuration,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,,
7179,Bos taurus,80670,CHEMBL620506,,1,BAO_0000219,F,9913.0,N,Intermediate,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,,,
7180,Mus musculus,80671,CHEMBL620507,,1,BAO_0000219,F,10090.0,N,Intermediate,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,,,
7181,Mus musculus,80671,CHEMBL620508,,1,BAO_0000219,F,10090.0,N,Intermediate,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,,,
7182,Mus musculus,80671,CHEMBL620509,,1,BAO_0000219,F,10090.0,N,Intermediate,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,,,
7183,Mus musculus,80671,CHEMBL620510,,1,BAO_0000219,F,10090.0,N,Intermediate,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,,,
7184,Mus musculus,80671,CHEMBL620511,,1,BAO_0000219,A,10090.0,N,Intermediate,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,,,
7185,Mus musculus,80671,CHEMBL620512,,1,BAO_0000219,F,10090.0,N,Intermediate,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,,,
7186,Mus musculus,22224,CHEMBL620513,,1,BAO_0000019,F,10090.0,U,Autocuration,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,,
7187,Mus musculus,22224,CHEMBL620514,,1,BAO_0000019,F,10090.0,U,Autocuration,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,,
7188,Mus musculus,22224,CHEMBL620515,,1,BAO_0000019,F,10090.0,U,Autocuration,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,,
7189,Bacillus subtilis,22224,CHEMBL620516,,1,BAO_0000218,A,1423.0,U,Autocuration,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),In vivo,,,
7190,Canis lupus familiaris,50588,CHEMBL620517,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,,,,Plasma
7191,Canis lupus familiaris,50588,CHEMBL620518,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,,,,Plasma
7192,Canis lupus familiaris,50588,CHEMBL620519,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,,,
7193,Canis lupus familiaris,50588,CHEMBL621386,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,In vivo,,,
7194,Canis lupus familiaris,50588,CHEMBL621387,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,In vivo,,,
7195,Canis lupus familiaris,50588,CHEMBL621388,,1,BAO_0000218,A,9615.0,N,Intermediate,3184,Compound was evaluated for its clearance when administered intravenously in dog,In vivo,,,
7196,Canis lupus familiaris,50588,CHEMBL621389,,1,BAO_0000218,A,9615.0,N,Intermediate,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,,
7197,Canis lupus familiaris,50588,CHEMBL621390,,1,BAO_0000218,A,9615.0,N,Intermediate,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,,,
7198,,22229,CHEMBL621391,,1,BAO_0000100,P,,U,Intermediate,4219,Calculated partition coefficient (clogP),,,,
7199,Canis lupus familiaris,50588,CHEMBL621392,,1,BAO_0000218,A,9615.0,N,Intermediate,3748,Half life in dog,,,,
7200,Canis lupus familiaris,50588,CHEMBL621393,,1,BAO_0000218,A,9615.0,N,Intermediate,3132,Time taken for EC90 was determined when tested in dog,,,,
7201,Canis lupus familiaris,50588,CHEMBL621394,,1,BAO_0000218,A,9615.0,N,Intermediate,4219,Half life (iv) was determined,,,,
7202,Canis lupus familiaris,50588,CHEMBL621395,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,,Liver
7203,Canis lupus familiaris,50588,CHEMBL621396,,1,BAO_0000218,A,9615.0,N,Intermediate,6057,Area under the curve was calculated in dog after iv administration,,,,
7204,Canis lupus familiaris,50588,CHEMBL621397,,1,BAO_0000218,A,9615.0,N,Intermediate,6057,Area under the curve was calculated in dog after peroral administration,,,,
7205,Canis lupus familiaris,50588,CHEMBL621398,,1,BAO_0000218,A,9615.0,N,Intermediate,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,,
7206,Canis lupus familiaris,50588,CHEMBL618818,,1,BAO_0000218,A,9615.0,N,Intermediate,3639,pKa was evaluated in dog,,,,
7207,Canis lupus familiaris,50588,CHEMBL618819,,1,BAO_0000218,A,9615.0,N,Intermediate,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,,
7208,Canis lupus familiaris,50588,CHEMBL618820,,1,BAO_0000218,A,9615.0,N,Intermediate,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,,
7209,Canis lupus familiaris,50588,CHEMBL873810,,1,BAO_0000218,A,9615.0,N,Intermediate,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,In vivo,,,
7210,Canis lupus familiaris,50588,CHEMBL876606,,1,BAO_0000218,A,9615.0,N,Intermediate,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,In vivo,,,
7211,Canis lupus familiaris,50588,CHEMBL618821,,1,BAO_0000218,A,9615.0,N,Intermediate,3624,Compound was evaluated for the half-life (t 1/2) in hours,,,,
7212,Canis lupus familiaris,50588,CHEMBL618822,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,In vivo,,,Blood
7213,Canis lupus familiaris,50588,CHEMBL618823,,1,BAO_0000218,A,9615.0,N,Intermediate,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,In vivo,,,Blood
7214,Canis lupus familiaris,50588,CHEMBL618824,,1,BAO_0000218,A,9615.0,N,Intermediate,4709,Half life after intravenous administration of 1 mg/kg in dog,In vivo,,,
7215,Canis lupus familiaris,50588,CHEMBL618825,,1,BAO_0000218,A,9615.0,N,Intermediate,15660,Half life was measured in dog,,,,
7216,Canis lupus familiaris,50588,CHEMBL618826,,1,BAO_0000218,A,9615.0,N,Intermediate,5302,Half life period in dog after 5 mg/kg dose,In vivo,,,
7217,Canis lupus familiaris,50588,CHEMBL618827,,1,BAO_0000218,A,9615.0,N,Intermediate,17791,Half life period was evaluated in dog; 4-4.8,,,,
7218,Canis lupus familiaris,50588,CHEMBL618828,,1,BAO_0000218,A,9615.0,N,Intermediate,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,In vivo,,,
7219,Canis lupus familiaris,50588,CHEMBL618829,,1,BAO_0000218,A,9615.0,N,Intermediate,4257,Half-life was determined in dog after a3 mg/kg of iv dose,In vivo,,,
7220,Canis lupus familiaris,50588,CHEMBL618830,,1,BAO_0000218,A,9615.0,N,Intermediate,3771,Half-life was determined,,,,
7221,Canis lupus familiaris,50588,CHEMBL618831,,1,BAO_0000218,A,9615.0,N,Intermediate,6305,Half life in dogs,,,,
7222,Canis lupus familiaris,50588,CHEMBL619489,,1,BAO_0000218,A,9615.0,N,Intermediate,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,In vivo,,,Plasma
7223,Canis lupus familiaris,50588,CHEMBL619649,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,In vivo,,,
7224,Canis lupus familiaris,50588,CHEMBL876607,,1,BAO_0000218,A,9615.0,N,Intermediate,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,In vivo,,,
7225,Canis lupus familiaris,50588,CHEMBL619650,,1,BAO_0000218,A,9615.0,N,Intermediate,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,In vivo,,,
7226,Canis lupus familiaris,50588,CHEMBL619651,,1,BAO_0000218,A,9615.0,N,Intermediate,4839,Compound was tested for half life in dog,,,,
7227,Canis lupus familiaris,50588,CHEMBL619652,,1,BAO_0000218,A,9615.0,N,Intermediate,4839,Compound was tested for its half life in dog,,,,
7228,Canis lupus familiaris,50588,CHEMBL619653,,1,BAO_0000218,A,9615.0,N,Intermediate,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,In vivo,,,
7229,Canis lupus familiaris,50588,CHEMBL619654,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Half life of compound in dog was determined,,,,
7230,Canis lupus familiaris,50588,CHEMBL619655,,1,BAO_0000218,A,9615.0,N,Intermediate,4219,Half life (iv) was determined,In vivo,,,
7231,Canis lupus familiaris,50588,CHEMBL619656,,1,BAO_0000218,A,9615.0,N,Intermediate,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,,Blood
7232,Canis lupus familiaris,50588,CHEMBL873812,,1,BAO_0000218,A,9615.0,N,Intermediate,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,,,Plasma
7233,Canis lupus familiaris,50588,CHEMBL621365,,1,BAO_0000218,F,9615.0,N,Intermediate,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,In vivo,,,Plasma
7234,Canis lupus familiaris,50588,CHEMBL621366,,1,BAO_0000218,A,9615.0,N,Intermediate,4453,Half life in dog,,,,
7235,Canis lupus familiaris,50588,CHEMBL621367,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Half life in dog plasma,,,,Plasma
7236,Canis lupus familiaris,50588,CHEMBL621368,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,In vivo,,,Plasma
7237,Canis lupus familiaris,50588,CHEMBL621369,,1,BAO_0000218,A,9615.0,N,Intermediate,6535,Half life in dog plasma after administration of 1 mg/kg iv,In vivo,,,Plasma
7238,Canis lupus familiaris,50588,CHEMBL621370,,1,BAO_0000218,A,9615.0,N,Intermediate,3132,Half life in dog plasma was determined at dose 10 mg/kg,In vivo,,,Plasma
7239,Canis lupus familiaris,50588,CHEMBL621371,,1,BAO_0000218,A,9615.0,N,Intermediate,5374,Half life in dog was determined,,,,
7240,Canis lupus familiaris,50588,CHEMBL621372,,1,BAO_0000218,A,9615.0,N,Intermediate,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),In vivo,,,
7241,Canis lupus familiaris,50588,CHEMBL621373,,1,BAO_0000218,A,9615.0,N,Intermediate,16907,Half life upon exposure to human plasma,,,,Plasma
7242,Canis lupus familiaris,50588,CHEMBL621374,,1,BAO_0000218,A,9615.0,N,Intermediate,6057,Half life was calculated in dog,,,,
7243,Canis lupus familiaris,50588,CHEMBL621375,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Half life was determined,,,,
7244,Canis lupus familiaris,50588,CHEMBL621376,,1,BAO_0000218,A,9615.0,N,Intermediate,5473,Half life was determined,,,,
7245,Canis lupus familiaris,50588,CHEMBL619624,,1,BAO_0000218,A,9615.0,N,Intermediate,4368,Half life by intravenous administration of 1.2 mg/kg in dog,In vivo,,,
7246,Canis lupus familiaris,50588,CHEMBL875840,,1,BAO_0000218,A,9615.0,N,Intermediate,6448,Half life in dog,,,,
7247,Canis lupus familiaris,50588,CHEMBL619625,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Half life in dog after intra venous administration of the compound,,,,
7248,Canis lupus familiaris,50588,CHEMBL619626,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,,,,
7249,Canis lupus familiaris,50588,CHEMBL619627,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Half life in dog after po administration of the compound,In vivo,,,
7250,Canis lupus familiaris,50588,CHEMBL873817,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Half life in dog after po administration of the compound; ND means Not determined,In vivo,,,
7251,Canis lupus familiaris,50588,CHEMBL619628,,1,BAO_0000218,A,9615.0,N,Intermediate,6265,Half life in dog at the single oral dose of 1 mg/kg,In vivo,,,
7252,Canis lupus familiaris,50588,CHEMBL619629,,1,BAO_0000218,A,9615.0,N,Intermediate,5006,Half life in dogs,,,,
7253,Canis lupus familiaris,50588,CHEMBL619630,,1,BAO_0000218,A,9615.0,N,Intermediate,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,In vivo,,,
7254,Canis lupus familiaris,50588,CHEMBL619631,,1,BAO_0000218,A,9615.0,N,Intermediate,405,Half life in rat,,,,
7255,Canis lupus familiaris,50588,CHEMBL619632,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),In vivo,,,
7256,Mus musculus,50594,CHEMBL619633,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Bone
7257,Mus musculus,50594,CHEMBL875841,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Bone
7258,Mus musculus,50594,CHEMBL619634,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Bone
7259,Mus musculus,50594,CHEMBL619635,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Bone
7260,Mus musculus,50594,CHEMBL619636,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Bone
7261,Mus musculus,50594,CHEMBL619637,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Gut
7262,Mus musculus,50594,CHEMBL619638,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Gut
7263,Mus musculus,50594,CHEMBL619639,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Gut
7264,Mus musculus,50594,CHEMBL619640,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Gut
7265,Mus musculus,50594,CHEMBL619641,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Gut
7266,Mus musculus,50594,CHEMBL619642,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Gut
7267,Mus musculus,50594,CHEMBL619643,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Gut
7268,Mus musculus,50594,CHEMBL619644,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Heart
7269,Mus musculus,50594,CHEMBL621112,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Heart
7270,Mus musculus,50594,CHEMBL621113,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Heart
7271,Mus musculus,50594,CHEMBL621114,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Heart
7272,Mus musculus,50594,CHEMBL621115,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Heart
7273,Mus musculus,50594,CHEMBL621116,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Heart
7274,Mus musculus,50594,CHEMBL621117,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Heart
7275,Mus musculus,50594,CHEMBL621118,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Kidney
7276,Mus musculus,50594,CHEMBL621119,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,,Kidney
7277,Mus musculus,50594,CHEMBL621120,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Kidney
7278,Mus musculus,50594,CHEMBL621757,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Kidney
7279,Mus musculus,50594,CHEMBL621758,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Kidney
7280,Mus musculus,50594,CHEMBL621759,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Kidney
7281,Mus musculus,50594,CHEMBL621760,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Kidney
7282,Mus musculus,50594,CHEMBL621761,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Liver
7283,Mus musculus,50594,CHEMBL621762,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Liver
7284,Mus musculus,50594,CHEMBL621763,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Liver
7285,Mus musculus,50594,CHEMBL624502,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Liver
7286,Mus musculus,50594,CHEMBL624503,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Liver
7287,Mus musculus,50594,CHEMBL624504,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Liver
7288,Mus musculus,50594,CHEMBL624505,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Liver
7289,Mus musculus,50594,CHEMBL624506,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Lung
7290,Homo sapiens,81034,CHEMBL624507,,1,BAO_0000219,F,9606.0,N,Intermediate,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),,,,
7291,Homo sapiens,81034,CHEMBL624508,,1,BAO_0000219,F,9606.0,N,Intermediate,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,,,
7292,Homo sapiens,81034,CHEMBL624509,,1,BAO_0000219,F,9606.0,N,Intermediate,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,,,
7293,Homo sapiens,81034,CHEMBL624510,,1,BAO_0000219,F,9606.0,N,Intermediate,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,,,
7294,Homo sapiens,81034,CHEMBL875956,,1,BAO_0000219,F,9606.0,N,Expert,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,,,
7295,Homo sapiens,81034,CHEMBL839885,,1,BAO_0000219,F,9606.0,N,Expert,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,,,
7296,Homo sapiens,81034,CHEMBL624511,,1,BAO_0000219,F,9606.0,N,Expert,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,,,
7297,Homo sapiens,81034,CHEMBL624512,,1,BAO_0000219,F,9606.0,N,Intermediate,17270,In vitro cytotoxicity against A2780 cell line,,,,
7298,Homo sapiens,81034,CHEMBL624513,,1,BAO_0000219,F,9606.0,N,Intermediate,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,,,
7299,Homo sapiens,81034,CHEMBL624514,,1,BAO_0000219,F,9606.0,N,Intermediate,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,,,
7300,Homo sapiens,81034,CHEMBL618547,,1,BAO_0000218,F,9606.0,N,Intermediate,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,,,
7301,Homo sapiens,81034,CHEMBL618548,,1,BAO_0000219,F,9606.0,N,Intermediate,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,,,
7302,Homo sapiens,81034,CHEMBL618549,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Inhibition of tubulin polymerization in analogy of ca.,,,,
7303,Homo sapiens,81034,CHEMBL618550,,1,BAO_0000219,F,9606.0,N,Intermediate,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,,,
7304,Homo sapiens,81034,CHEMBL618551,,1,BAO_0000219,F,9606.0,N,Expert,6181,Cytotoxic effect in ovarian cancer cell line (A2780),,,,
7305,Homo sapiens,81034,CHEMBL618552,,1,BAO_0000219,F,9606.0,N,Intermediate,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,,,
7306,Homo sapiens,81034,CHEMBL618553,,1,BAO_0000219,F,9606.0,N,Intermediate,4840,Tested for the cytotoxicity in A2780 ovarian cell line,,,,
7307,Homo sapiens,81034,CHEMBL618554,,1,BAO_0000219,F,9606.0,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,,,
7308,Homo sapiens,81034,CHEMBL618555,,1,BAO_0000219,F,9606.0,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,,,
7309,,80017,CHEMBL618556,,1,BAO_0000219,F,,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,,,
7310,,80017,CHEMBL618557,,1,BAO_0000219,F,,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,,,
7311,,80017,CHEMBL618558,,1,BAO_0000219,F,,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,,,
7312,,80017,CHEMBL618559,,1,BAO_0000219,F,,N,Intermediate,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,,,
7313,Homo sapiens,81034,CHEMBL618560,,1,BAO_0000218,F,9606.0,N,Intermediate,17753,In vivo log of cells killed after administration of compound in A2780 cell line,,,,
7314,Homo sapiens,81034,CHEMBL618561,,1,BAO_0000218,F,9606.0,N,Intermediate,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,In vivo,,,
7315,Homo sapiens,81034,CHEMBL618562,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,,,
7316,Homo sapiens,81034,CHEMBL618563,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,,,
7317,Homo sapiens,81034,CHEMBL618564,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,,,
7318,Homo sapiens,81034,CHEMBL618565,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,,,
7319,Homo sapiens,81034,CHEMBL618566,,1,BAO_0000218,F,9606.0,N,Intermediate,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,,,
7320,Homo sapiens,81034,CHEMBL618567,,1,BAO_0000219,F,9606.0,N,Intermediate,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,,,
7321,Homo sapiens,81034,CHEMBL618568,,1,BAO_0000219,F,9606.0,N,Expert,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,,,
7322,Homo sapiens,81034,CHEMBL618569,,1,BAO_0000219,F,9606.0,N,Expert,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,,,
7323,Homo sapiens,81034,CHEMBL621857,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,,,
7324,Homo sapiens,81034,CHEMBL621858,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,,,
7325,Homo sapiens,81034,CHEMBL621859,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,,,
7326,Homo sapiens,81034,CHEMBL621860,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,,,
7327,Homo sapiens,81034,CHEMBL621861,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,,,
7328,Homo sapiens,81034,CHEMBL621862,,1,BAO_0000219,F,9606.0,N,Expert,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,,,
7329,Homo sapiens,81034,CHEMBL621863,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,,
7330,Homo sapiens,81034,CHEMBL621864,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,,
7331,Homo sapiens,81034,CHEMBL621865,,1,BAO_0000219,F,9606.0,N,Intermediate,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,,,
7332,Mus musculus,81034,CHEMBL621866,,1,BAO_0000219,F,10090.0,N,Intermediate,17737,In vitro antiproliferative activity against A2780 cell line,,,,
7333,Mus musculus,81034,CHEMBL621867,,1,BAO_0000219,F,10090.0,N,Expert,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,,,
7334,Homo sapiens,81034,CHEMBL621868,,1,BAO_0000219,F,9606.0,N,Intermediate,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,,,
7335,Homo sapiens,81034,CHEMBL875282,,1,BAO_0000219,F,9606.0,N,Intermediate,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,,,
7336,Canis lupus familiaris,50588,CHEMBL621869,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,,,,
7337,Canis lupus familiaris,50588,CHEMBL621870,,1,BAO_0000218,A,9615.0,N,Intermediate,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,In vivo,,,
7338,Cercopithecidae,22224,CHEMBL621871,,1,BAO_0000019,A,9527.0,U,Autocuration,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,,
7339,Cercopithecidae,22224,CHEMBL621243,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Plasma
7340,Cercopithecidae,22224,CHEMBL621244,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Plasma
7341,Macaca fascicularis,22224,CHEMBL621245,,1,BAO_0000218,A,9541.0,U,Autocuration,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,,
7342,Macaca fascicularis,22224,CHEMBL621246,,1,BAO_0000218,A,9541.0,U,Autocuration,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,In vivo,,,
7343,Macaca fascicularis,22224,CHEMBL621247,,1,BAO_0000218,A,9541.0,U,Autocuration,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,In vivo,,,
7344,Rattus norvegicus,22224,CHEMBL618386,,1,BAO_0000218,A,10116.0,U,Autocuration,4256,Oral Bioavailability in rat,In vivo,,,
7345,Cercopithecidae,22224,CHEMBL618387,,1,BAO_0000218,A,9527.0,U,Autocuration,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,,
7346,Cercopithecidae,22224,CHEMBL618388,,1,BAO_0000218,A,9527.0,U,Autocuration,5302,Area under curve value in monkey at a dose of 5 mg/kg,,,,
7347,Cercopithecidae,22224,CHEMBL618389,,1,BAO_0000218,A,9527.0,U,Autocuration,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,,
7348,Cercopithecidae,22224,CHEMBL618574,,1,BAO_0000019,A,9527.0,U,Autocuration,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,,
7349,Cercopithecidae,22224,CHEMBL618575,,1,BAO_0000019,A,9527.0,U,Autocuration,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,,
7350,Cercopithecidae,22224,CHEMBL618576,,1,BAO_0000019,A,9527.0,U,Autocuration,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,,
7351,Cercopithecidae,22224,CHEMBL618577,,1,BAO_0000218,A,9527.0,U,Autocuration,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,,
7352,Cercopithecidae,22224,CHEMBL876487,,1,BAO_0000218,A,9527.0,U,Autocuration,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,,
7353,Cercopithecidae,22224,CHEMBL618578,,1,BAO_0000218,A,9527.0,U,Autocuration,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,,
7354,Cercopithecidae,22224,CHEMBL618579,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,,
7355,Cercopithecidae,22224,CHEMBL618580,,1,BAO_0000019,A,9527.0,U,Autocuration,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,,
7356,Cercopithecidae,22224,CHEMBL618581,,1,BAO_0000218,A,9527.0,U,Autocuration,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,,
7357,Cercopithecidae,22224,CHEMBL618582,,1,BAO_0000218,A,9527.0,U,Autocuration,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,,
7358,Cercopithecidae,22224,CHEMBL618583,,1,BAO_0000218,A,9527.0,U,Autocuration,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,,
7359,Cercopithecidae,22224,CHEMBL618584,,1,BAO_0000218,A,9527.0,U,Autocuration,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,,
7360,Cercopithecidae,22224,CHEMBL618585,,1,BAO_0000218,A,9527.0,U,Autocuration,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),In vivo,,,
7361,Cercopithecidae,22224,CHEMBL618586,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,,
7362,Cercopithecidae,22224,CHEMBL618587,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,,
7363,Cercopithecidae,22224,CHEMBL618588,,1,BAO_0000218,A,9527.0,U,Autocuration,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,In vivo,,,
7364,Cercopithecidae,22224,CHEMBL618589,,1,BAO_0000019,A,9527.0,U,Autocuration,17409,Binding towards monkey plasma protein at 10 uM,,,,
7365,Cercopithecidae,22224,CHEMBL618590,,1,BAO_0000019,A,9527.0,U,Autocuration,17409,Binding towards monkey plasma protein at 100 uM,,,,
7366,Cercopithecidae,22224,CHEMBL872262,,1,BAO_0000218,A,9527.0,U,Autocuration,1052,Apparent bioavailability in squirrel monkey was determined,In vivo,,,
7367,Cercopithecidae,22224,CHEMBL618591,,1,BAO_0000218,A,9527.0,U,Autocuration,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,In vivo,,,
7368,monkey,22224,CHEMBL618592,,1,BAO_0000218,A,9443.0,U,Autocuration,17509,Bioavailability in monkey (dose 2 mg/kg),In vivo,,,
7369,Cercopithecidae,22224,CHEMBL876488,,1,BAO_0000218,A,9527.0,U,Autocuration,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,In vivo,,,
7370,Cercopithecidae,22224,CHEMBL618593,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,In vivo,,,
7371,monkey,22224,CHEMBL618594,,1,BAO_0000218,A,9443.0,U,Autocuration,11219,Bioavailability in monkey (i.d. dosing),In vivo,,,
7372,Cercopithecidae,22224,CHEMBL618595,,1,BAO_0000218,A,9527.0,U,Autocuration,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,In vivo,,,
7373,Cercopithecidae,22224,CHEMBL621469,,1,BAO_0000019,A,9527.0,U,Autocuration,17796,Clearance of the drug was measured in cynomolgus,,,,
7374,Cercopithecidae,22224,CHEMBL621470,,1,BAO_0000218,A,9527.0,U,Autocuration,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,In vivo,,,
7375,Cercopithecidae,22224,CHEMBL621471,,1,BAO_0000218,A,9527.0,U,Autocuration,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,In vivo,,,
7376,Macaca mulatta,22224,CHEMBL621472,,1,BAO_0000218,A,9544.0,U,Autocuration,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,In vivo,,,Plasma
7377,Cercopithecidae,22224,CHEMBL621473,,1,BAO_0000218,A,9527.0,U,Autocuration,17267,Plasma clearance in rhesus monkey was determined,In vivo,,,
7378,Cercopithecidae,22224,CHEMBL621474,,1,BAO_0000218,A,9527.0,U,Autocuration,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,In vivo,,,
7379,Cercopithecidae,22224,CHEMBL621475,,1,BAO_0000218,A,9527.0,U,Autocuration,5922,Plasma clearance in cynomolgus monkey,In vivo,,,
7380,Cercopithecidae,22224,CHEMBL621476,,1,BAO_0000218,A,9527.0,U,Autocuration,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,In vivo,,,
7381,Cercopithecidae,22224,CHEMBL624290,,1,BAO_0000218,A,9527.0,U,Autocuration,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,In vivo,,,
7382,Cercopithecidae,22224,CHEMBL624291,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,In vivo,,,
7383,Cercopithecidae,22224,CHEMBL624292,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,In vivo,,,
7384,Cercopithecidae,22224,CHEMBL624293,,1,BAO_0000218,A,9527.0,U,Autocuration,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,In vivo,,,
7385,Cercopithecidae,22224,CHEMBL624294,,1,BAO_0000218,A,9527.0,U,Autocuration,4578,Tested for Clearance upon iv administration to african green monkey,In vivo,,,
7386,Cercopithecidae,22224,CHEMBL624295,,1,BAO_0000218,A,9527.0,U,Autocuration,17592,Clearance in monkey,In vivo,,,
7387,Canis lupus familiaris,50588,CHEMBL624296,,1,BAO_0000218,A,9615.0,N,Intermediate,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
7388,Canis lupus familiaris,50588,CHEMBL624297,,1,BAO_0000218,A,9615.0,N,Intermediate,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),In vivo,,,
7389,Canis lupus familiaris,50588,CHEMBL624298,,1,BAO_0000218,A,9615.0,N,Intermediate,16367,Half life was evaluated after intravenous administration to dogs,In vivo,,,
7390,Canis lupus familiaris,50588,CHEMBL624299,,1,BAO_0000218,A,9615.0,N,Intermediate,5472,Half life was evaluated in dog,,,,
7391,Canis lupus familiaris,50588,CHEMBL624300,,1,BAO_0000218,A,9615.0,N,Intermediate,5474,Half life was evaluated in dog,,,,
7392,Canis lupus familiaris,50588,CHEMBL624301,,1,BAO_0000218,A,9615.0,N,Intermediate,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,In vivo,,,
7393,Canis lupus familiaris,50588,CHEMBL624302,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),In vivo,,,
7394,Canis lupus familiaris,50588,CHEMBL876026,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,Half life period after intravenous administration in dog,In vivo,,,
7395,Canis lupus familiaris,50588,CHEMBL624303,,1,BAO_0000218,A,9615.0,N,Intermediate,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,In vivo,,,
7396,Canis lupus familiaris,50588,CHEMBL624304,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Half life period at a dose of 1 uM/kg in dog was determined,,,,
7397,Canis lupus familiaris,50588,CHEMBL624305,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Half life period was determine after peroral administration at 10 mpk in dog,In vivo,,,
7398,Canis lupus familiaris,50588,CHEMBL624306,,1,BAO_0000218,A,9615.0,N,Intermediate,5668,Half life period was determine after peroral administration at 5 mpk in dog,In vivo,,,
7399,Canis lupus familiaris,50588,CHEMBL624307,,1,BAO_0000218,A,9615.0,N,Intermediate,3854,Half life period was determined,,,,
7400,Canis lupus familiaris,50588,CHEMBL624308,,1,BAO_0000218,A,9615.0,N,Intermediate,5505,Half life period was determined,,,,
7401,Canis lupus familiaris,50588,CHEMBL624309,,1,BAO_0000218,A,9615.0,N,Intermediate,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,In vivo,,,
7402,Canis lupus familiaris,50588,CHEMBL624310,,1,BAO_0000218,A,9615.0,N,Intermediate,1918,Half life period was evaluated in dog,,,,
7403,Canis lupus familiaris,50588,CHEMBL625003,,1,BAO_0000218,A,9615.0,N,Intermediate,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,In vivo,,,
7404,Canis lupus familiaris,50588,CHEMBL625004,,1,BAO_0000218,A,9615.0,N,Intermediate,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),In vivo,,,
7405,Canis lupus familiaris,50588,CHEMBL625005,,1,BAO_0000218,A,9615.0,N,Intermediate,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,In vivo,,,
7406,Canis lupus familiaris,50588,CHEMBL873813,,1,BAO_0000218,A,9615.0,N,Intermediate,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,In vivo,,,
7407,Canis lupus familiaris,50588,CHEMBL625006,,1,BAO_0000218,A,9615.0,N,Intermediate,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,In vivo,,,
7408,Canis lupus familiaris,50588,CHEMBL625007,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,In vivo,,,
7409,Canis lupus familiaris,50588,CHEMBL876027,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,In vivo,,,
7410,Canis lupus familiaris,50588,CHEMBL625008,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,In vivo,,,
7411,Canis lupus familiaris,50588,CHEMBL625009,,1,BAO_0000218,A,9615.0,N,Intermediate,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,In vivo,,,
7412,Canis lupus familiaris,50588,CHEMBL625010,,1,BAO_0000218,A,9615.0,N,Intermediate,5210,Half-life of compound in plasma of dog was determined,,,,Plasma
7413,Canis lupus familiaris,50588,CHEMBL625011,,1,BAO_0000218,A,9615.0,N,Intermediate,5210,Half-life of compound was determined in dogs,,,,
7414,Canis lupus familiaris,50588,CHEMBL621553,,1,BAO_0000218,A,9615.0,N,Intermediate,2959,Half-life after administration of 4 mg/Kg oral dose in dog,In vivo,,,
7415,Canis lupus familiaris,50588,CHEMBL621554,,1,BAO_0000218,A,9615.0,N,Intermediate,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,In vivo,,,
7416,Canis lupus familiaris,50588,CHEMBL621555,,1,BAO_0000218,A,9615.0,N,Intermediate,5064,Half-life in Dog,,,,
7417,Canis lupus familiaris,50588,CHEMBL621556,,1,BAO_0000218,A,9615.0,N,Intermediate,5147,Half-life in Dog,,,,
7418,Canis lupus familiaris,50588,CHEMBL621557,,1,BAO_0000218,A,9615.0,N,Intermediate,5145,Half-life in dog,,,,
7419,Canis lupus familiaris,50588,CHEMBL621558,,1,BAO_0000218,A,9615.0,N,Intermediate,6123,Half-life in dog after oral administration at 1 mg/kg,In vivo,,,
7420,Canis lupus familiaris,50588,CHEMBL621559,,1,BAO_0000218,A,9615.0,N,Intermediate,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,In vivo,,,
7421,Canis lupus familiaris,50588,CHEMBL621560,,1,BAO_0000218,A,9615.0,N,Intermediate,4333,Half-life in dogs,,,,
7422,Canis lupus familiaris,50588,CHEMBL876028,,1,BAO_0000218,A,9615.0,N,Intermediate,4333,Half-life in dogs; ND indicates not determined,,,,
7423,Canis lupus familiaris,50588,CHEMBL621561,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,Half-life in plasma of dog,,,,Plasma
7424,Canis lupus familiaris,50588,CHEMBL621562,,1,BAO_0000218,A,9615.0,N,Intermediate,12500,Half-life in plasma of dog at dose of 3-10 mgkg,,,,Plasma
7425,Canis lupus familiaris,50588,CHEMBL621563,,1,BAO_0000218,A,9615.0,N,Intermediate,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,In vivo,,,
7426,Canis lupus familiaris,50588,CHEMBL621564,,1,BAO_0000218,A,9615.0,N,Intermediate,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,In vivo,,,
7427,Canis lupus familiaris,50588,CHEMBL621565,,1,BAO_0000218,A,9615.0,N,Intermediate,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,In vivo,,,
7428,Canis lupus familiaris,50588,CHEMBL621566,,1,BAO_0000218,A,9615.0,N,Intermediate,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,In vivo,,,
7429,Canis lupus familiaris,50588,CHEMBL621567,,1,BAO_0000218,A,9615.0,N,Intermediate,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,In vivo,,,
7430,Canis lupus familiaris,50588,CHEMBL622978,,1,BAO_0000218,A,9615.0,N,Intermediate,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,In vivo,,,
7431,Canis lupus familiaris,50588,CHEMBL873814,,1,BAO_0000218,A,9615.0,N,Intermediate,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,In vivo,,,
7432,Canis lupus familiaris,50588,CHEMBL623219,,1,BAO_0000218,A,9615.0,N,Intermediate,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,In vivo,,,
7433,Canis lupus familiaris,50588,CHEMBL624477,,1,BAO_0000218,A,9615.0,N,Intermediate,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,In vivo,,,
7434,Canis lupus familiaris,50588,CHEMBL624478,,1,BAO_0000218,A,9615.0,N,Intermediate,6227,t1/2 in dog,,,,
7435,Canis lupus familiaris,50588,CHEMBL624479,,1,BAO_0000218,A,9615.0,N,Intermediate,14541,Half-life period measured in dogs,,,,
7436,Canis lupus familiaris,50588,CHEMBL624480,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,In vivo,,,
7437,Canis lupus familiaris,50588,CHEMBL623595,,1,BAO_0000218,A,9615.0,N,Intermediate,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,In vivo,,,
7438,Canis lupus familiaris,50588,CHEMBL623596,,1,BAO_0000218,A,9615.0,N,Intermediate,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,In vivo,,,
7439,Canis lupus familiaris,50588,CHEMBL623597,,1,BAO_0000218,A,9615.0,N,Intermediate,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",In vitro,,,Plasma
7440,Canis lupus familiaris,50588,CHEMBL623598,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo half life period was calculated at 1 mg/kg in dog,In vivo,,,
7441,Canis lupus familiaris,50588,CHEMBL623599,,1,BAO_0000218,A,9615.0,N,Intermediate,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,In vivo,,,
7442,Canis lupus familiaris,50588,CHEMBL623600,,1,BAO_0000218,A,9615.0,N,Intermediate,17853,Longer half-life in dog (i.v.) at 0.5 mpk,In vivo,,,
7443,Canis lupus familiaris,50588,CHEMBL623601,,1,BAO_0000218,A,9615.0,N,Intermediate,4353,Oral bioavailability in dog (dose 5 uM/kg),In vivo,,,
7444,Canis lupus familiaris,50588,CHEMBL623602,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,In vivo,,,
7445,Canis lupus familiaris,50588,CHEMBL623603,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,In vivo,,,
7446,Canis lupus familiaris,50588,CHEMBL623604,,1,BAO_0000218,A,9615.0,N,Intermediate,16452,Bioavailability in dog (dose 1 mg/kg i.v.),In vivo,,,
7447,Mus musculus,50594,CHEMBL623605,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,,Lung
7448,Mus musculus,50594,CHEMBL623606,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Lung
7449,Mus musculus,50594,CHEMBL623607,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Lung
7450,Mus musculus,50594,CHEMBL623608,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Lung
7451,Mus musculus,50594,CHEMBL623609,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Lung
7452,Mus musculus,50594,CHEMBL623610,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Lung
7453,Mus musculus,50594,CHEMBL623611,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Muscle tissue
7454,Mus musculus,50594,CHEMBL623612,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,In vivo,,,Muscle tissue
7455,Mus musculus,50594,CHEMBL623613,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Muscle tissue
7456,Mus musculus,50594,CHEMBL623614,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Muscle tissue
7457,Mus musculus,50594,CHEMBL623615,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Muscle tissue
7458,Mus musculus,50594,CHEMBL623616,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Muscle tissue
7459,Mus musculus,50594,CHEMBL623617,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Muscle tissue
7460,Mus musculus,50594,CHEMBL875944,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Zone of skin
7461,Mus musculus,50594,CHEMBL623618,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Zone of skin
7462,Mus musculus,50594,CHEMBL623619,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Zone of skin
7463,Mus musculus,50594,CHEMBL623620,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Zone of skin
7464,Mus musculus,50594,CHEMBL623621,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Zone of skin
7465,Mus musculus,50594,CHEMBL623622,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Zone of skin
7466,Mus musculus,50594,CHEMBL623623,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Zone of skin
7467,Mus musculus,50594,CHEMBL623624,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Spleen
7468,Mus musculus,50594,CHEMBL618521,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Spleen
7469,Mus musculus,50594,CHEMBL618522,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Spleen
7470,Mus musculus,50594,CHEMBL618523,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Spleen
7471,Mus musculus,50594,CHEMBL618524,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Spleen
7472,Mus musculus,50594,CHEMBL618525,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Spleen
7473,Mus musculus,50594,CHEMBL624586,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Spleen
7474,Mus musculus,50594,CHEMBL624587,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,In vivo,,,Stomach
7475,Mus musculus,50594,CHEMBL624588,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,In vivo,,,Stomach
7476,Mus musculus,50594,CHEMBL624589,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,In vivo,,,Stomach
7477,Mus musculus,50594,CHEMBL624590,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,In vivo,,,Stomach
7478,Mus musculus,50594,CHEMBL624591,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,In vivo,,,Stomach
7479,Mus musculus,50594,CHEMBL624592,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,In vivo,,,Stomach
7480,Mus musculus,50594,CHEMBL624593,,1,BAO_0000218,A,10090.0,N,Intermediate,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,In vivo,,,Stomach
7481,Rattus norvegicus,50597,CHEMBL624594,,1,BAO_0000218,A,10116.0,N,Intermediate,4689,Oral bioavailability in rat,In vivo,,,
7482,Rattus norvegicus,50597,CHEMBL624595,,1,BAO_0000218,A,10116.0,N,Intermediate,4950,Tested for the bioavailability in rat,In vivo,,,
7483,Rattus norvegicus,50597,CHEMBL624596,,1,BAO_0000218,A,10116.0,N,Intermediate,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),In vivo,,,
7484,Rattus norvegicus,50597,CHEMBL624597,,1,BAO_0000218,A,10116.0,N,Intermediate,406,Bioavailability in rat,In vivo,,,
7485,Rattus norvegicus,50597,CHEMBL624598,,1,BAO_0000218,A,10116.0,N,Intermediate,12500,Bioavailability in rat,In vivo,,,
7486,Rattus norvegicus,50597,CHEMBL624599,,1,BAO_0000218,A,10116.0,N,Intermediate,12500,Bioavailability in rat (dose 3-10 mg/kg),In vivo,,,
7487,Rattus norvegicus,50597,CHEMBL875166,,1,BAO_0000218,A,10116.0,N,Intermediate,5247,Bioavailability in rat,In vivo,,,
7488,Rattus norvegicus,50597,CHEMBL624600,,1,BAO_0000218,A,10116.0,N,Intermediate,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,In vivo,,,Plasma
7489,Rattus norvegicus,50597,CHEMBL624601,,1,BAO_0000218,A,10116.0,N,Intermediate,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,In vivo,,,Plasma
7490,Rattus norvegicus,50597,CHEMBL624602,,1,BAO_0000218,A,10116.0,N,Intermediate,6647,Half life after oral administration was determined in rats at 6 mg/kg,In vivo,,,
7491,Rattus norvegicus,50597,CHEMBL624603,,1,BAO_0000218,A,10116.0,N,Intermediate,6484,Half life was determined,,,,
7492,Rattus norvegicus,50597,CHEMBL624604,,1,BAO_0000218,A,10116.0,N,Intermediate,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,In vivo,,,
7493,Rattus norvegicus,50597,CHEMBL624605,,1,BAO_0000218,A,10116.0,N,Intermediate,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,In vivo,,,Plasma
7494,Rattus norvegicus,50597,CHEMBL624606,,1,BAO_0000218,A,10116.0,N,Intermediate,3307,Half life in rats,,,,
7495,Rattus norvegicus,50597,CHEMBL624607,,1,BAO_0000218,A,10116.0,N,Intermediate,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,In vivo,,,Blood
7496,Rattus norvegicus,50597,CHEMBL624608,,1,BAO_0000218,A,10116.0,N,Intermediate,8833,Hill coefficient of the compound,,,,
7497,Rattus norvegicus,50597,CHEMBL624609,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,,Blood
7498,Rattus norvegicus,50597,CHEMBL624610,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,,Blood
7499,Rattus norvegicus,50597,CHEMBL624611,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,,Blood
7500,Rattus norvegicus,50597,CHEMBL624612,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,,Blood
7501,Rattus norvegicus,50597,CHEMBL875167,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,,Blood
7502,Rattus norvegicus,50597,CHEMBL624613,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,,Blood
7503,Rattus norvegicus,50597,CHEMBL624614,,1,BAO_0000218,A,10116.0,N,Intermediate,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,,Blood
7504,Rattus norvegicus,50597,CHEMBL624392,,1,BAO_0000218,A,10116.0,N,Intermediate,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,,
7505,Rattus norvegicus,50597,CHEMBL624393,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,,,Brain
7506,Rattus norvegicus,50597,CHEMBL624394,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,,,Brain
7507,Rattus norvegicus,50597,CHEMBL624395,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,,,Brain
7508,Rattus norvegicus,50597,CHEMBL624396,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,,,Brain
7509,Rattus norvegicus,50597,CHEMBL624397,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,,,Brain
7510,Rattus norvegicus,50597,CHEMBL624398,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,In vivo,,,Thyroid gland
7511,Rattus norvegicus,50597,CHEMBL624399,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,In vivo,,,Thyroid gland
7512,Rattus norvegicus,50597,CHEMBL624400,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,In vivo,,,Thyroid gland
7513,Rattus norvegicus,50597,CHEMBL624401,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,In vivo,,,Thyroid gland
7514,Rattus norvegicus,50597,CHEMBL624402,,1,BAO_0000218,A,10116.0,N,Intermediate,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,In vivo,,,Thyroid gland
7515,Rattus norvegicus,50597,CHEMBL624403,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,,Blood
7516,Rattus norvegicus,50597,CHEMBL624404,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,In vivo,,,Blood
7517,Rattus norvegicus,50597,CHEMBL624405,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,,Blood
7518,Rattus norvegicus,50597,CHEMBL624406,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,,Bone
7519,Rattus norvegicus,50597,CHEMBL624407,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,In vivo,,,Bone
7520,Rattus norvegicus,50597,CHEMBL624408,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,,Bone
7521,Rattus norvegicus,50597,CHEMBL618644,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,In vivo,,,Heart
7522,Rattus norvegicus,50597,CHEMBL618645,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,In vivo,,,Heart
7523,Rattus norvegicus,50597,CHEMBL618646,,1,BAO_0000218,A,10116.0,N,Intermediate,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,In vivo,,,Heart
